This page is an index of disclosures published in the ERJ between January 2007 and March 2013. Since then, disclosures have been published alongside the article to which they refer.
- Volume 29, 2007
- Volume 30, 2007
- Volume 31, 2008
- Volume 32, 2008
- Volume 33, 2009
- Volume 34, 2009
- Volume 35, 2010
- Volume 36, 2010
- Volume 37, 2011
- Volume 38, 2011
- Volume 39, 2012
- Volume 40, issue 1, July 2012
- Volume 40, issue 2, August 2012
- Volume 40, issue 3, September 2012
- Volume 40, issue 4, October 2012
- Volume 40, issue 5, November 2012
- Volume 40, issue 6, December 2012
- Volume 41, issue 1, January 2013
- Volume 41, issue 2, February 2013
- Volume 41, issue 3, March 2013
Volume 29, 2007
A Back to top
C. Advenier. This author's study was funded by Novartis Pharma. DOI: 10.1183/09031936.00032806
M.J. Abramson served on the Scientific Advisory Committee for the Australian Asthma Study, which was sponsored by GlaxoSmithKline. The author has also previously received travel assistance from AstraZeneca DOI: 10.1183/09031936.00080906.
A. Aliverti. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
S. Andreas received reimbursement for attending a symposium and received funds for research. He also received lecture fees from AstraZeneca, Boehringer-Ingelheim, Novartis, Weinmann and Respironics. The study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
S.M. Arend was invited as an expert by the Centers for Disease Control (Atlanta, GA, USA) to attend a meeting held in Atlanta in July 2005, during which guidelines on the use of QuantiFERON®-TB Gold were drafted. This included the presentation of studies in which the assay, as described in the manuscript that appears in the June 2007 issue of the European Respiratory Journal, was used. DOI: 10.1183/09031936.00117506
B Back to top
T.R. Bai has received fees for speaking and consulting. DOI: 10.1183/09031936.00112606
P.J. Barnes has received research funding from and given lectures on behalf of AstraZeneca and GlaxoSmithKline, both of which market combination inhalers. DOI: 10.1183/09031936.00080306
P.J. Barnes. The Exacerbations of COPD meeting (held in Como, Italy, in April 2005) summarised in the author's review article presented in the June issue of the European Respiratory Journal was sponsored by an educational grant from AstraZeneca. The sponsors had no input into the structure of the meeting or the preparation of that article. DOI: 10.1183/09031936.00109906
K.M. Beeh received compensation for serving on an advisory board for Novartis, Germany. The author has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies (Boehringer, Novartis, Pfizer, Fujisawa and Merck Sharpe & Dohme) in 2003, 2004 and 2005. K.M. Beeh has received fees for speaking at a conference symposium sponsored by Novartis in 2005. The institution at which the author is currently employed has received compensation for participating in multicentre clinical trials in 2004, 2005 and 2006 from several companies (AstraZeneca, Boehringer, Novartis, GlaxoSmithKline, Revotar Biopharmaceuticals, EpiGenesis, Corus Pharma, Allmirall Prodesfarma, Merck Sharp & Dohme and Fujisawa). The author also has been reimbursed for travel expenses by Novartis, Boehringer, Merck Sharpe & Dohme and Pfizer for attending several conferences. DOI: 10.1183/09031936.00060006
J. Behr has received fees for speaking and consulting from Actelion Pharmaceutics. The author has also received reimbursement for travel to the ERS congress from Actelion Pharmaceutics DOI: 10.1183/09031936.00149205.
M.G. Belvisi has received an educational grant from GlaxoSmithKline and Novartis. The author has also acted as a consultant for GlaxoSmithKline. DOI: 10.1183/09031936.00101006
T. Bernhardt has been employed by an organisation that may gain or lose financially from the results of this author's work. DOI: 10.1183/09031936.00047306.
J. Bion was President of the European Society of Intensive Care Medicine, declared European Union grants for CoBaTrICE and GenOSept projects, was chair of independent data and safety monitoring committees for Orion (Espoo, Finland) and for Alliance Pharmaceuticals (Chippenham, UK) and declared travel grants from Draeger (Luebeck, Germany), Pfizer (Tadworth, UK) and Wyeth (Maidenhead, UK). DOI: 10.1183/09031936.00010206
S.S. Birring is a co-author of the Leicester Cough Questionnaire. DOI: 10.1183/09031936.00101006
A. Blau. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
J. Boe has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author's manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
J. Boe has 135 B- shares in AstraZeneca PLC. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
J. Bögel. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
A.W.J. Bossink is a member of the advisory board of Oxford Immunotec Ltd, Oxford, UK. DOI: 10.1183/09031936.00117506
L-P. Boulet has received fees for attending symposia, speaking, organising education, research and consulting. Specifically, he has received: honoraria to attend Advisory Boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis; lecture fees from 3M, AstraZeneca, GlaxoSmithKline, Novartis and Merck Frosst; sponsorship for basic research from 3M, Altana, AstraZeneca and Merck Frosst; funding for participating in multicentre studies for the treatment of asthma from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, Merck Frosst, Novartis, Roche, Schering and Topingen; and support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst. DOI: 10.1183/09031936.00132406.
P.H. Brekke's travel to the American Thoracic Society Congress was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00106406.
V. Brusasco has received: €4,650 from GSK for a manuscript copyright; €11,625 in 2003, €11,625 in 2004 and €12,500 in 2005€2006 for serving on an advisory board for Altana; €5,000 in 2002, €5,000 in 2003, €3,000 in 2004 and €3000 in 2005 from Lofarma for consultancy; €5,750 in 2004 from MSD for consultancy; €960 in 2006 from GSK for consultancy; €1,000 in 2002 for speaking at a meeting organised by Sigma-Tau; €1,875 in 2002, €6,000 in 2004, €11,500 in 2005 and €3,325 for speaking at conferences sponsored by Boehringer Ingelheim; €2,500 for speaking at a meeting organised by Chiesi; and €2,500 for consultancy in a study sponsored by Chiesi. V. Brusasco's institution received €15,000 in 2003 as an unrestricted research grant from Altana and has participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00112606
C Back to top
P.M.A. Calverley. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
R. Cameron has been an employee of Novartis since April 1996. DOI: 10.1183/09031936.00060006
B. Celli received consultancy fees from Ortho Biotech. DOI: 10.1183/09031936.00137106
B.R. Celli. The Exacerbations of COPD meeting (held in Como, Italy, in April 2005) summarised in the author's review article presented in the June 2007 issue of the European Respiratory Journal was sponsored by an educational grant from AstraZeneca. The sponsors had no input into the structure of the meeting or the preparation of that article. DOI: 10.1183/09031936.00109906
N.I. Chaudhary was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
K.F. Chung has: received reimbursement from Altana and Novartis for attending respiratory conferences; received renumeration for attending advisory boards organised by GlaxoSmithKline, AstraZeneca and Novartis; has collaborated with Vivometrics for evaluation of LifeShirt as a cough monitor; and has obtained unrestricted research funds from GlaxoSmithKline. DOI: 10.1183/09031936.00101006
A. Connors declared being a Veterans Administration DSMB on a randomised controlled trial, a co-investigator on a National Institutes of Health (NIH) grant, having support from the National Heart, Lung and Blood Institute for the Acute Respiratory Distress Syndrome Network (ARDSNet), but having no support from industry. DOI: 10.1183/09031936.00010206
C. Cote received a consultant fee and a small research grant from Ortho Biotech. DOI: 10.1183/09031936.00137106
H.O. Coxson received CAN$11,000 in 2005 for serving on an advisory board for GlaxoSmithKline. In addition, H.O. Coxson is the co-investigator on two multicentre studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project. The author has three contract service agreements with GlaxoSmithKline to quantify the computed tomography scans in subjects with chronic obstructive pulmonary disease. A percentage of H.O. Coxson's salary between 2003 and 2006 (US$15,000 per year) derives from contract funds provided to a colleague, P. D. Pare, by GlaxoSmithKline, for the development of validated methods to measure emphysema and airway disease using computed tomography. H.O. Coxson is the co-investigator on a Canadian Institutes of Health & Industry (Wyeth) partnership grant. There is no financial relationship between any industry and the study that appears in the June 2007 issue of the European Respiratory Journal. DOI: 10.1183/09031936.00039807
D Back to top
R.L. Dellacà. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
E. Derom received $1,950 in 2002, $2,280 in 2003 and $2,495 in 2004 for serving on an advisory board for GlaxoSmithKline. The author also received $106,930 for the period 2003-2005 from Altana Pharma, $5,890 for the period 2003-2005 from GlaxoSmithKline, $100,280 in 2004 from SGSBiopharma and $163,400 in 2003 from Novartis as research grants for participating in clinical trials. E. Derom received a grant from AstraZeneca to allow him to attend the ATS 2004 congress and from Altana Pharma to attend the ERS 2005 congress. DOI: 10.1183/09031936.00060006
M. Dreher has been reimbursed by a local provider of home ventilators, Werner und Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation in 2003, 2005 and 2006, and for attending the 10th International Conference on Home Mechanical Ventilation 2005 in Lyon, France. DOI: 10.1183/09031936.00075806
H.W. Duchna. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
N. Duffy. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
F Back to top
L.M. Fabbri has received funds for research, consulting fees, lecture fees and reimbursements for travel expenses for attending symposiums/meetings from Chiesi Farmaceutici, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Pfizer, Roche, Altana, Novartis, Schering-Plough and Menarini DOI: 10.1183/09031936.00095906.
K.O. Fagerström has received fees for speaking and consulting, and reimbursement for attending symposia. He holds stocks in an organisation that may gain or lose financially: the company is called NicoNovum and it develops nicotine replacement products. DOI: 10.1183/09031936.00060806.
R.A. Fairhurst is an employee of Novartis Pharma UK Ltd and has stock in this organisation. DOI: 10.1183/09031936.00032806
I. Fietze. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
G Back to top
H-A. Ghofrani has received fees for speaking and consulting from Actelion Pharmaceutics DOI: 10.1183/09031936.00149205.
R.E. Girgis has received: consulting and speaker honoraria from Encysive Pharmaceuticals; consulting honoraria from Cotherix; speaker honoraria from Actelion; and clinical research support from Encysive, Pfizer, United Therapeutics, Myogen, Actelion and Lilly-ICOS. DOI: 10.1183/09031936.00081706
A. Günther has received lecture fees and reimbursement for attending a symposium by Actelion DOI: 10.1183/09031936.00149205.
H Back to top
I.P. Hall has received research support and travel cost supports (for the European Respiratory Society Congress 2006) from Novartis Pharma. The research support was provided for a project on novel long-acting beta-agonist. DOI: 10.1183/09031936.00088206
J.R. Harris has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author's manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
D. Hartl has been employed by an organisation that may gain or lose financially from the results of this author's work. DOI: 10.1183/09031936.00047306.
M. Herridge declared grants from the Physicians' Services Incorporated Foundation, the Ontario Thoracic Society and the NIH but no consulting fees. DOI: 10.1183/09031936.00010206
M. Higgins has been employed by Novartis since November 2001 and holds shares in the company. DOI: 10.1183/09031936.00060006
F. Hilberg was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
K Back to top
F. Kanniess received contributions for the conduct of clinical trials or educational grants from GSK, Epigenesis, ALTANA, AstraZeneca, Allmiral Prodesfarma, Boehringer Ingelheim, Schering-Plough, Astellas and ONO. DOI: 10.1183/09031936.00060006
J.A. Kastelik has received speaker honoraria or reimbursement for attending symposia for AstraZeneca, GlaxoSmithKline, Pfizer, Boehringer-Ingelhein and Schering Plough. The author has also received an educational grant from Altana Pharma. DOI: 10.1183/09031936.00101006
G.G. King has received, over the past 5 years, various travel sponsorships from AstraZeneca and GlaxoSmithKline for travel and accommodation to attend international scientific meetings. The value of these sponsorships is approximately from AUS$10,000 to AUS$15,000 per year. A proportion of G.G. King's research work is conducted at the Woolcock Institute of Medical Research, which receives unrestricted grants from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline and Vita Medical, and which also has a consultancy agreement with Pfizer, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline for which G.G. King provides consultancy services related to asthma and COPD. G.G. King's research group receives a proportion of the grants and monies that arise from those companies, as part of a general allocation of those funds for research purposes across all research groups of the Woolcock Institute of Medical Research. DOI: 10.1183/09031936.00112606
J. Kongerud has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author's manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
I. Koper. The author±s study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
M. Korppi is a member of the consultant board for respiratory syncitial virus infections in children of Abbott Oy, Finland. DOI: 10.1183/09031936.00001907
N.G. Koulouris. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
S.L. Kunkel has received a speaking fee from the University of Maryland (Maryland, MD, USA) and the University of California (USA). He has also consulted for Novartis and Pharmacopeia. DOI: 10.1183/09031936.00122806
L Back to top
I. Leconte is an Actelion employee who own stocks from this company DOI: 10.1183/09031936.00149205.
C-G. Löfdahl has: been paid for lectures by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; taken part in ad hoc advisory boards for the same companies; and has had institutional support from AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
M.B. Lund has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author's manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
M Back to top
F.J. Martinez has received funds for research. DOI: 10.1183/09031936.00122806
W. Mitzner has received fees for speaking, organising education, research and as a member of staff. DOI: 10.1183/09031936.00112606
S.H. Mody is currently an employee of Ortho Biotech Clinical Affairs, LLC and owns stock in Johnson & Johnson, its parent company. DOI: 10.1183/09031936.00137106
M. Molimard. The author's study was funded by Novartis Pharma. DOI: 10.1183/09031936.00032806
A.H. Morice has received research support from Profile Respiratory Systems Ltd, Altana Pharma, AstraZeneca, GlaxoSmithKline, Schering Plough Research and Novartis. The author has also received speaker honoraria from AstraZeneca, Altana Pharma, IVAX Pharmaceuticals, GlaxoSmithKline, ReckittBenckiser Healthcare and Novartis. Advisory committee honoraria have been received from Proctor and Gamble Healthcare and GlaxoSmithKline. Sponsorship to attend international meetings was also provided by IVAX Pharmaceuticals and Boehringer-Ingelheim. DOI: 10.1183/09031936.00101006
H. Müllerova has competing financial interests. The author is an employee of a pharmaceutical company: GlaxoSmithKline R&B. DOI: 10.1183/09031936.00092506
J. Müller-Quernheim received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG as a part of a research collaboration. DOI: 10.1183/09031936.00152106
T.M. Murphy has received educational grants from GlaxoSmithKline, AstraZeneca, Merck, Sepracor, Genentech and Novartis. The author has also received consulting fees from AstraZeneca and Merck, and speaking fees from AstraZeneca and Merck. DOI: 10.1183/09031936.00112606
N Back to top
H. Nakano has filed a patent entitled "System and method for automated detection of apnea and hypopnea" DOI: 10.1183/09031936.00091206.
E. Naline. The author's study was funded by Novartis Pharma. DOI: 10.1183/09031936.00032806
G. Nicolini is an employee of the company that was sponsor of the study (Chiesi Farmaceutici) DOI: 10.1183/09031936.00095906.
W. Nystad has received funds for research from the Norwegian Foundation for Health and Rehabilitation. This author's manuscript was submitted to the European Respiratory Journal in 2005. DOI: 10.1183/09031936.00044805.
O Back to top
T. Omland has received fees for speaking, research and consulting. He has received: honoraria from Roche Diagnostics, Bayer Diagnostics and Abbott Laboratories; consultancy fees from Roche Diagnostics; and research support from Roche Diagnostics and Abbott laboratories, manufacturers of assays for tropinin. DOI: 10.1183/09031936.00106406.
T.H.M. Ottenhoff received funds for a member of staff and has been an expert witness on the subject of the study presented in the June 2007 issue of the European Respiratory Journal. The author also obtained grants for standard research projects funded by the European Union or the Dutch Government. DOI: 10.1183/09031936.00117506
P Back to top
P.L. Paggiaro has received approximately €50,000 in the last 5 years as a fee for speaking for GSK, AstraZeneca, MSD, Novartis, Menarini, Boehringer Ingelheim and Pfizer. The author has also received €45,000 from Altana Pharma in the last 5 years for research. DOI: 10.1183/09031936.00095906.
A. Papi has received funds for research, fees for speaking, reimbursements for attending symposiums and fees for consulting from Chiesi Farmaceutici DOI: 10.1183/09031936.00095906.
P.D. Paré is the principle investigator of a project funded by GSK to develop CT-based algorithms to quantitative emphysema and airway disease in COPD. With collaborators, the author has received ~$300,000 to develop and validate these techniques. The funds have been applied solely to the research to support programmes and technicians. P.D. Paré is also PI of a Merck Frost-supported research programme to investigate gene expression in the lungs of patients who have COPD. He and collaborators have received ~$200,000 for this project. These funds have supported the technical personnel and expendables involved in the project. DOI: 10.1183/09031936.00112606
J.E. Park was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
I.D. Pavord has received lecture fees of less than €5,000 from GSK and AstraZeneca, and holds an industry-sponsored grant of €250,000 from GSK. DOI: 10.1183/09031936.00146306
R. Pearl was on the Advisory Board for Hutchinson Technology (Hutchinson, MN, USA) and declared an honorarium from Johnson and Johnson (New Brunswick, NJ, USA). DOI: 10.1183/09031936.00010206
A. Pedotti. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
P.P. Pompilio. The university at which the author's study was conducted (Politecnico di Milano University, Milan, Italy) owns a patent on the detection of expiratory flow limitation. DOI: 10.1183/09031936.00038006.
D.S. Postma has received grants for research purposes from AstraZeneca, GSK (two multicentre studies) and Altana, in local single centre research on asthma and COPD. This author received €10,000 in 2002-2004 for serving on an advisory board for Altana. D.S. Postma serves as a consultant to AstraZeneca, Altana, Centocor and GSK. The author has also been reimbursed to attend international meetings by AstraZeneca, Altana, Centocor and GSK. The author's institute has received an unrestricted educational grant from GSK. DOI: 10.1183/09031936.00124506
D.S. Postma received grants for research purposes from AstraZeneca, GlaxoSmithKline (for two multicentre studies) and Altana for local single-centre research on asthma and COPD. The author received ±10,000 in 2002±2004 for serving on an advisory board for Altana, and serves as a consultant to AstraZeneca, Altana, Centocor and GlaxoSmithKline. D.S. Postma has been reimbursed for attending international meetings by AstraZeneca, Altana, Centocor and GlaxoSmithKline. Her institute has received an unrestricted educational grant from GlaxoSmithKline. D.S. Postma has received: €10,000 for consultancy to Altana; €5,000 for serving on an advisory board for GlaxoSmithKline; and €5,000 for serving on the advisory board for AstraZeneca. The following industry-spondored grants have been received or are pending: €100,000 from AstraZeneca; €100,000 from GlaxoSmithKline; €100,000 from Altana. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
A. Prasse received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG as a part of a research collaboration. DOI: 10.1183/09031936.00152106
R. Prenzel. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
N.B. Pride has been a member of an advisory board for GlaxoSmithKline and has received fees for three related talks. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
R Back to top
K.F. Rabe received fees for consultancy. He is consultant to Hoffman La-Roche. DOI: 10.1183/09031936.00056206
J.H.C. Reiber received fees for consultancy. He is consultant to Medis Medical Systems, Leiden, the Netherlands. DOI: 10.1183/09031936.00056206
G.J. Roth was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
S. Roux is an Actelion employee who owns stocks from this company DOI: 10.1183/09031936.00149205.
S Back to top
M.J. Sanderson has received research, travel and educational funds from Sepracor Inc. DOI: 10.1183/09031936.00112606
S. Schädlich. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
J. Schmitt. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
A. Schnapp was, at the time of conducting the study, an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00152106
R. Schulz. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
W. Seeger received reimbursement: from Altana Pharma AG for participation in the ATS Congress in 2004; and from Schering AG for the Ventavis Launch Symposium (Madeira) in 2003. The author has also received speaking fees from Schering AG for taking part in an Expert Round Table in Pulmonary Hypertension and for taking part in the Ventavis Launch Symposium. W. Seeger has received: reimbursement from Pfizer AG for taking part in the 110th Annual Meeting of the German Society of Internal Medicine; and funds for research for clinical studies from Altana Pharma AG, Actelion, Schering AG, Myogen Inc. and Lung Rx. The author also received a fee from Altana Pharma AG for organising education for a graduate college and consulting fees from Altana Pharma AG, Lung Rx and Schering AG DOI: 10.1183/09031936.00149205.
H. Silverman was a member of DSMB, Broncus Technologies Inc. (Mountain View, CA, USA), declared an Ethics Consultant meeting travel grant from Boehringer Ingelheim Pharmaceuticals Inc. (Ingelheim, Germany) and a Research Ethics Training Grant from NIH. DOI: 10.1183/09031936.00010206
J.A. Smith is an inventor on a patent filed by South Manchester University Hospitals Trust (Manchester, UK), describing a novel method for automated cough detection. The Trust also has a licence agreement with a medical devices company to develop a commercial cough monitor. DOI: 10.1183/09031936.00101006
J. Solway has received, since 2001, consulting fees or honoraria for participating in expert or advisory panels from Tanox, Merck, Critical Concepts, Wyeth and Aventis Pharmaceutical Companies. The University of Chicago Asthma Center, which J Solway directs, has received educational grants from Glaxo, Merck and AstraZeneca. The author has received research funding from Glaxo, and has received travel support and honoraria to present at the Asthma and Smooth Muscle Symposia in Fukuoka, Japan, from Ono Pharmaceuticals. DOI: 10.1183/09031936.00112606
G. Stähler has received a fee for speaking. DOI: 10.1183/09031936.00149205.
M. Stanchina received grant support/honoraria from Respironics Inc. (Murrysville, PA, USA) and Boehringer Ingelheim Pharmaceuticals, Inc. DOI: 10.1183/09031936.00010206
N.L. Stephens has received an operating grant from the Philip Morris Extramural Research Foundation. DOI: 10.1183/09031936.00112606
A. Stewart received grants from the Tobacco Foundation of Australia in 1958. He is an employee and stockholder of Cryptopharma, a company with an interest in developing drugs to reduce airway and lung remodelling. DOI: 10.1183/09031936.00053506.
A.G. Stewart was the recipient of an Australian Tobacco Research Foundation Fellowship in 1984. DOI: 10.1183/09031936.00112606
B.C. Stoel received fees for consultancy. He is a consultant of BioImaging Technologies in Leiden, the Netherlands. He is also a consultant to Roche, Talecris and ZLB Behring concerning lung densitometry as the outcome parameter for testing drugs for emphysema. DOI: 10.1183/09031936.00056206
J. Stolk received fees for consulting and has acted as an expert witness on the subject of the study (published in the June 2007 issue of the European Respiratory Journal). The author is a consultant of BioImaging Technologies in Leiden, the Netherlands, and is involved in clinical trials in which lung densitometry is the primary outcome parameter of the study. J. Stolk is also a consultant for Hoffman La-Roche and Octapharma and gave advice on lung densitometry as the outcome parameter for detection of the effect of drugs for emphysema. DOI: 10.1183/09031936.00056206
J.H. Storre has been reimbursed from a local provider of home ventilators, Werner und Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation in 2003, 2005 and 2006, and for attending the 10th International Conference on Home Mechanical Ventilation 2005 in Lyon, France. The author also received a speaking fee of €500 in 2005 from Werner und Müller Medizintechnik. DOI: 10.1183/09031936.00075806
T Back to top
T. Tanigawa serves as CEO of the Somnonics Co. Ltd which aims to develop a screening for sleep apnoea syndrome in the general population and was established with the support of the University of Tsukuba DOI: 10.1183/09031936.00091206.
S. Tasci. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was supported by a grant from Respironics. DOI: 10.1183/09031936.00037106
M. Tatar has received a bronze sponsorship from the European Respiratory Society (ERS) to attend an Annual ERS Meeting. DOI: 10.1183/09031936.00101006
A. Thorén is a full-time employee of AstraZeneca. The author holds stocks or shares in an organisation that may in any way gain or lose financially from the results of the study. The author's study (which appears in the June 2007 issue of the European Respiratory Journal) was funded by a grant from AstraZeneca. DOI: 10.1183/09031936.00128806
P. Tønnesen has received fees for speaking and consulting, has acted as a consultant and has been paid for talks given for companies producing and selling smoking cessation drugs. DOI: 10.1183/09031936.00060806.
A. Trifilieff received reimbursement for attending a symposium and for research. This author had also acted as an expert witness on the subject of the study. A. Trifilieff is an employee of Novartis Pharma and has stock in Novartis. DOI: 10.1183/09031936.00032806
V Back to top
A. van As is a former employee of Novartis (until 31st August 2006) and owned Novartis stock until then. DOI: 10.1183/09031936.00060006
W Back to top
J.A. Wedzicha has received research grant funding and honoraria for attending meetings from GlaxoSmithKline. DOI: 10.1183/09031936.00092506
T. Welte has received fees totalling €300,000 for talks on national symposia from RESMED. The author has also received a research grant of ±100,000 from RESMED and a grant of €100,000 from Tyco Int. for organisation of an international multicentre study. DOI: 10.1183/09031936.00010206
R. West has received funds for research, consulting, members of staff, speaking and for organising education. He has worked for manufacturers of smoking cessation products, has been an expert witness on whether nicotine patches are VAT exempt and shares a patent for a novel nicotine-deliverable device. DOI: 10.1183/09031936.00060806.
W. Windisch was reimbursed by Breas Medical AB (Molnlycke, Sweden) for attending the annual ERS conferences between 2001 and 2005. This author has also been reimbursed from the local provider of home ventilators Werner and Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation between 2001 and 2006. W. Windisch received a speaking fee of €1,000 in 2005 from Werner und Müller Medizintechnik. DOI: 10.1183/09031936.00075806
Z Back to top
M.D. Zilberberg is an employee of Ortho Biotech, as well as a shareholder of Johnson & Johnson, its parent company. DOI: 10.1183/09031936.00137106
G. Zissel received a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG as a part of a research collaboration. DOI: 10.1183/09031936.00152106
Volume 30, 2007
A Back to top
A. Anzueto does not have a financial relationship with a commercial entity that has an interest in the subject of his manuscript. He has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: Boehringer Ingelheim, Bayer Pharma, Pfizer, GlaxoSmithKline, Wyeth Sanofi-Aventis and Altana. He has also beeen a consultant for Boehringer Ingelheim, Abbott Laboratories, Bayer Pharma, Pfizer, GlaxoSmithKliune, Wyeth Sanofi-Aventis and Altana. He has been the principal investigator for research grants and the University of Texas Health Science Center at San Antonio was paid for participating in multicentre clinical trials sponsored by Boehringer Ingelheim, Bayer Pharma, BARS, Lilly and the National Institutes of Health. DOI: 10.1183/09031936.00071607
H.G.M. Arets. The author has received, within the last 5 yrs, €1,000 from Chiron, €200 from MSD and €500 from Ivax Pharma for lectures. DOI: 10.1183/09031936.00051406
B Back to top
A. Baeza-Squiban. PM2.5 and PM organic extracts in the author's study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
B. Balbi's attendance at the 2006 ERS Congress was funded by Pfizer. The author also received funds as a member of staff, fees for speaking and funds for research. DOI: 10.1183/09031936.00112306
N.C. Barnes. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
M. Barron. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
E. Bathoorn has received sponsorship for attending symposia. The author also received an unrestricted grant from AstraZeneca (the Netherlands) for salary support. DOI: 10.1183/09031936.00163206
S. Bell. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
I.S.T. Bos. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
G.H. Bothamley has been employed by the UK NHS. DOI: 10.1183/09031936.00034007
J. Bourbeau. The author's study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
S. Bowler. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
H.C. Bucher. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
P. Bulpa has received fees for speaking from Pfizer, MSD and Zeneus Pharma. DOI: 10.1183/09031936.00062206
C Back to top
L. Caballero. The author's study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
J. Carlsen. The author has been on the Actelion Tracleer PMS committee, but has not received any funding in this capacity. DOI: 10.1183/09031936.00138706
P.A. Cattini. Funding support for the research described in the author's study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
A. Cayuela. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
Z-Q. Cheng. Funding support for the research described in the author's study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
M.P. Chung In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
P.N. Chhajed. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
D Back to top
C.W.H. Davies has been reimbursed for attending a working party group organised and paid for by LEO Pharma, the manufacturer of Innohep (tinzaparin), and for presenting this study to employees of LEO Pharma. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
J.C. de Jongste has, in the past 5 years, received travel grants and lectured on request at scientific meetings for GlaxoSmithKline, AstraZeneca, Merck, Sharp & Dohme, Altana Pharma, Chiron, Aerocrine and Roche. The author has also acted as scientific advisor for Aerocrine. Payments for these services went to the Dept of Pediatrics, Erasmus Medical Center Holding. The Dept of Pediatrics, Erasmus MC Holding, received research grants from GlaxoSmithKline, AstraZeneca, Aerocrine, Roche, Friesland Nutrition, Transave, Chiron and Pfizer. Medication for the author's study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
P.N.R. Dekhuijzen. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
G.C. Donaldson. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
H. Dressel has received two sensors for FeNO measurements for another study from Aerocrine. DOI: 10.1183/09031936.00023807
E.J. Duiverman has, in the past 5 years, received lecture fees and travel grants from AstraZeneca, GlaxoSmithKline, MSD, Altana Pharma, Chiron and UCB Pharma. The author was also a member of an MSD medical advisory board. The Dept of Paediatric Respiratory Diseases, University Medical Center Groningen, has received research grants from Numico Research, GlaxoSmithKline, MSD and UCB Pharma. Medication for the author's study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
E Back to top
O. Eickmeier. The author's study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
F Back to top
L.M. Fabbri reports having served as a consultant to Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer. The author has been paid lecture fees by Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer. L.M. Fabbri has also received grant support from Altana Pharma, AstraZeneca, Boehringer Ingelheim, Menarini, Miat, Schering Plough, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, UCB, Pfizer, the Italian Ministry of Health, and the Italian Ministry for University and Research. DOI: 10.1183/09031936.00067307
G. Ford. The author's study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
G. Freudenberg received reimbursement for attending a symposium and fees for speaking. Speeches on sleep-disordered breathing and mechanical ventilation were funded by ResMed, Airproducts and Heinen + Löwenstein. DOI: 10.1183/09031936.00073407
G Back to top
E. Gamble. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
B. Gaston holds shares in Respiratory Research, Inc., a company involved in studying airway acid base chemistry. DOI: 10.1183/09031936.00015507
J.P. Gawaziuk. Funding support for the research described in the author's study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
M.C.P. Geraedts. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
R. Gosens has received a lecture fee of €1,000 from Boehringer Ingelheim. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
R. Gosselink. The Erasmus MC, Sophia Children's Hospital (the cystic fibrosis centre used in the author's study) has received, in the past 5 years, research grants from Hoffman-La-Roche. The author's study was supported by Roche (the Netherlands); support with nebulisers was provided by Romedic (Meerssen, the Netherland); and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
E.S. Green has received financial support from LEO Pharma to attend educational meetings. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
D.C. Grootendorst. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
C. Gysin. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
H Back to top
M.P. Habib has received pharmaceutical grant support from Boehringer Ingelheim, Ortho McNeil, Pfizer, Bayer, Bristol-Meyers-Squibb, GlaxoSmithKline and Altana. He has also received honoraria for lectures from Daiichi Pharmaceuticals, Ortho McNeil, Pfizer and Bristol-Meyers-Squibb. DOI: 10.1183/09031936.00104606
T. Hafmans. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
M. Halank has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
A.J. Halayko. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
P.C. Hallal. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
R. Hamel. PM2.5 and PM organic extracts in the author's study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
M. Harris. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
K. Hattotuwa. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
L.M.A. Heunks. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
G. Hoeffken has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
M.M. Hoeper. The author is a member of Actelion's International Scientific Advisory Board and has received honoraria for speaking at conferences from Actelion Pharmaceuticals. The author has also received reimbursements for attending symposia and funds for research. DOI: 10.1183/09031936.00138706
M.M. Hoeper has received speaker's honoraria from Actelion Pharmaceuticals and Schering, and has served as an advisory board member for Actelion Pharmaceuticals. DOI: 10.1183/09031936.00032407
W.C.J. Hop's department provides regular statistical consultancies to GlaxoSmithKline. Medication for the author's study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
W.C.J. Hop. The Erasmus MC, Sophia Children's Hospital (the cystic fibrosis centre used in the author's study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author's study was supported by Roche (the Netherlands); support with nebulisers was provided by Romedic (Meerssen, the Netherland); and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
D. Horstkotte is a staff member funded by ResMed. DOI: 10.1183/09031936.00073407
M. Humbert has relationships with drug companies that include Actelion, Encysive, GlaxoSmithKline, Myogen, Schering, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, M. Humbert's other relationships with these companies include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00055407
M. Humbert. The author has relationships with drug companies including Actelion, GlaxoSmithKline, Schering, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00138706
J.F. Hunt has received funds for research. In the past 5 years, the author has been employed by and is a founder of Respiratory Research, Inc. He also holds stocks or shares in this company, which has an interest in airway pH, and has provided funds for his laboratory. J.F. Hunt owns intellectual property in methodology relevant to therapeutic airway alkalinisation. DOI: 10.1183/09031936.00015507
J Back to top
L.J. Janssen. The author's study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
J.R.B. Jardim. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
P.K. Jeffery. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
G.J. Jenniskens. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
P. Jones is a consultant statistician who is contracted to Boehringer-Ingelheim (among other companies). His affiliation is shown as Boehringer-Ingelheim on the author list. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
K Back to top
F. Kauffmann. The author received a grant of €720,000 from Merck, Sharp and Dohme in 2002 for the follow-up and genetic studies of the EGEA cohort (not including the present genome screen). DOI: 10.1183/09031936.00162206
H.A.M. Kerstjens has received sponsorship from AstraZeneca to travel to an ATS congress. The author has spoken at symposia organised by the company and the company also financed the study presented in the December 2007 issue of the European Respiratory Journal. The author's institution has received an educational grant to appoint a PhD fellow (E. Bathoorn). Competing arrangements apply with the competitors GlaxoSmithKline and Altana. DOI: 10.1183/09031936.00163206
S. Kesten is a full-time employee of Boehringer-Ingelheim. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
S. Kesten works for Boehringer Ingelheim Corporation, Ingelheim, Germany. DOI: 10.1183/09031936.00104606
P. Kesteven. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
M.A. Khan. The author's study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
S. Kianpour. The author's study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
D.G. Kiely. The author is a member of an Advisory Board for Actelion Pharmaceuticals and Pfizer, and has received fees for giving educational lectures for Scherring, Actelion, Pfizer and United Therapeutics. The author has also received reimbursements for attending symposia, fees for speaking, funds for research, funds for a member of staff and fees for consulting. DOI: 10.1183/09031936.00138706
J. Killen. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
E.J. Kim. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
H. Kim. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
S.Y. Kim. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
J.L.L. Kimpen received honoraria for organising educational events for Abbott International. The author has given unrestricted lectures at these educational events and was hired as a consultant by the same organisation. DOI: 10.1183/09031936.00031407
R. Kitz. The author's study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
W-J. Koh. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
A. Kotaniemi-Syrjänen. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author's study. DOI: 10.1183/09031936.00158106
C. Kroegel. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
O.J. Kwon. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
L Back to top
B. Lamp received fees for speaking, for organising education and for consulting from ResMed. The author also acted as an expert witness on the subject of the printed letter. DOI: 10.1183/09031936.00073407
J. Lee. The author's study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
S-H. Lee. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
J.D. Leuppi. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
B.D. Levy has received patent licensing fees from Berlex-Schering AG. DOI: 10.1183/09031936.00005807
M.V. Lopez. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
M Back to top
X. Ma. Funding support for the research described in the author's study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
M.J. Mäkelä. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author's study. DOI: 10.1183/09031936.00158106
A. Malhotra. The author has relationships with a number of companies for research grants (Respironics, Restore Medical), consulting (Inspiration Medical, Restore Medical) and speakers' bureaus (Sepracor, Respironics). DOI: 10.1183/09031936.00063406
L.P. Malmberg. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author's study. DOI: 10.1183/09031936.00158106
K. Malmström. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author's study. DOI: 10.1183/09031936.00158106
F. Marano. PM2.5 and PM organic extracts in the author's study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
J.J. Martín. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
J. McCormack. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
J.J.V. McMurray. The author's study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
I. Mehdi. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
A.M.B. Menezes. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. A.M.B. Menezes had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
H. Meurs. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
G. Michaud has received an honorarium from Denver Biomedical for a continuing medical education seminar to discuss the role of Pleurx catheters in malignant pleural effusion. DOI: 10.1183/09031936.00164706
D. Miedinger. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
M. Monreal. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
M. Montes de Oca. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
F. Morell. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
H. Muellerova. The author is an employee of GlaxoSmithKline, in the Research and Development Dept. DOI: 10.1183/09031936.00157906
A. Muiño. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
B. Müller has served as a consultant and received payments from Brahms AG to attend meetings. The author has also received research support and fulfilled speaking engagements. DOI: 10.1183/09031936.0166106
N.F. Murphy. The author's study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
N Back to top
D.E. Niewoehner has received research grants, consulting fees and speaking fees from Boehringer-Ingelheim, and speaking fees from Pfizer. DOI: 10.1183/09031936.00104606
E. Norrman received 49% of the costs for attending the European Respiratory Society Congress 2005 from AstraZeneca. DOI: 10.1183/09031936.00121705
M. Nuijsink was appointed as a clinical research fellow by GlaxoSmithKline and received lecture fees and travel support from that company. The author also received funds for research. Medication for the author's study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
O Back to top
O. Oldenburg has received travel grants and a fee for speaking from ResMed. DOI: 10.1183/09031936.00073407
W. Oldfield. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
T. O'Shaughnessy. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
R. Otero. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
P Back to top
K. Patel. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
I.D. Pavord. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
A.J. Peacock received fees for consulting and support for attending symposia and congresses from Pfizer, Actelion and Encysive. The author's study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
A.S. Pelkonen. An unrestricted grant was received from Merck Sharp & Dohme Ltd for the author's study. DOI: 10.1183/09031936.00158106
K. Pendry has been reimbursed by LEO Pharma, the manufacturer of tinzaparin, for attending a conference to present a paper on this work, entitled: "Outpatient treatment of patients with pulmonary embolism: results of a two phase observational study". The author's study (in the October issue of the ERJ) was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
R. Perez-Padilla has received fees for two conferences from GlaxoSmithKline and funding for travel to a congress. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
J. Pertuze. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
C.A. Piquette has been a member of the Boehringer-Ingelheim speakers' bureau and has received funds to support COPD research. The author also received sponsorship for attending a symposium. DOI: 10.1183/09031936.00104606
N. Pinsky. The author's study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
C. Pison. The author received grants/research support from Novartis, Encysive, GSK France, Boehringer Ingelheim France, AstraZeneca, Pfizer France, Bioproject, Astellas France, Numico and Nutricia France, Boston Scientific, LFB France and Bayer. The author has also consulted for Act'lion France and Nutricia, and is a member of Speakers' Bureau: Novartis, Act'lion, Boehringer Ingelheim France, Nutricia France, LFB France. DOI: 10.1183/09031936.00162206
D.S. Postma has received: reimbursement for attending symposia from AstraZeneca, GSK and Altana; funds for research from AstraZeneca, GSK and Altana; and consultant fees from Altana and GSK. DOI: 10.1183/09031936.00163206
D.J. Powrie has received sponsorship from Boehringer-Ingelheim for travel to academic meetings. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
Q Back to top
Y. Qiu. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
C.A.C. Ottenheijm. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
R Back to top
K.F. Rabe. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
F.S.F. Ram. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
K. Ramgolam. PM2.5 and PM organic extracts in the author's study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
J. Rello has served as a consultant for Bard (Murray Hill, NJ, USA), Wyeth (Madison, NJ, USA) and Intrabiotics (Carlsbad, CA, USA), and has received research grants from Bard. DOI: 10.1183/09031936.00048507
A.H. Remels. The author is supported by a grant from Numico Research (Wageningen, the Netherlands). Funding sources had no involvement in the collection, analysis and interpretation of data; in the writing of the report; or the decision to submit the paper for publication. The authors would like to disclose that there are no advisory board affiliations or financial or personal interests in any organisation sponsoring the research and accept full responsibility for conduct of the study and the decision to publish the present work. DOI: 10.1183/09031936.00144106
C. Rodríguez. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
M.A. Rose has, within the last 3 years, received honoraria for lectures from Merck Sharpe and Dohme. The author's study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
P. Rose has received financial support from LEO Pharma to attend educational meetings. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
M. Rosewich. The author's study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
B.H. Rowe has received financial support (research grants, consulting fees and lecture fees) in the past 5 years from Abbott Pharmaceuticals, AstraZeneca, GlaxoSmithKline and Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00119907
G. Ruberto. The author's study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
M. Rumelhard. PM2.5 and PM organic extracts in the author's study were supplied and chemically analysed by Renault (DIMAT). DOI: 10.1183/09031936.00085907
Y.J. Ryu. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
S Back to top
D. Schaafsma. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
C. Schindler. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
B. Schwierin is an employee of Actelion. DOI: 10.1183/09031936.00138706
K. Scrine has been an employee of Boehringer-Ingelheim since 1976. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
M.R. Sears holds the AstraZeneca Chair in Respiratory Epidemiology at McMaster University. DOI: 10.1183/09031936.00080007
E.S. Segal. The author is employed by Actelion Pharmaceuticals Ltd as VP and Head of Global Drug Safety. The author has also acted as an expert on the subject of the manuscript in presentations to the Drug Information Association and the EMEA. DOI: 10.1183/09031936.00138706
S. Senini. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
D. Serisier. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
H.J. Seyfarth has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
F. Sheikh. Funding support for the research described in the author's study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
E.K. Silverman has received grant support, consulting fees and honoraria from GlaxoSmithKline for studies of COPD genetics. The author has also received a speaker fee from Wyeth for a talk on COPD genetics and honoraria from Bayer. DOI: 10.1183/09031936.00009307
A. Spanevello's attendance to the 2006 ERS Congress was funded by Pfizer. He also received funds as a member of staff, fees for speaking and funds for research. DOI: 10.1183/09031936.00112306
M.R. Stämpfli. The author's study was supported by a grant-in-aid provided by AstraZeneca International. DOI: 10.1183/09031936.00025907
N.L. Stephens has received one operating grant from the External Research Fund of the Philip Morris Company. Funding support for the research described in the author's study was obtained from the Philip Morris External Research Program. DOI: 10.1183/09031936.00141805
P.J. Sterk has received honoraria and travel grants for speaking at meetings, not exceeding US$1,500 per year during the past 5 years. In addition, P.J. Sterk receives a honorarium as Chief Editor of the European Respiratory Journal. Medication for the author's study was donated by GlaxoSmithKline. Representatives of the company reviewed and commented on the protocol but made no other contributions to its design, conduct, interpretation or presentation. DOI: 10.1183/09031936.00111806
S. Stewart has previously acted as a research and educational consultant for Actelion Pharmaceuticals Ltd (Australia). The author's study was partially supported by an unrestricted research grant from Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00092306
D. Stolz. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
G.Y. Suh. In addition to the Korea Health 21 Research and Development Project, the author's study was also supported by a Samsung Biomedical Research Institute (Seoul, Korea) grant, number SBRI C-A6-402-1. DOI: 10.1183/09031936.00039507
J. Sültz has been paid by the Bavarian statutory accident insurance institutions for the agricultural sector for the time spent on the educational programme for the farmers involved in the author's study. DOI: 10.1183/09031936.00023807
C. Surber. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
T Back to top
C. Talamo. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
M. Tamm. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
V.F. Tapson has received research grants, and lecture and consulting fees from Sanofi Aventis. The author has also received consulting fees from Bayer and Eisai. V.F. Tapson does not own stock in any pharmaceutical or biotechnology company. DOI: 10.1183/09031936.00098007
H.A.W.M. Tiddens has received, within the last 3 years, honoraria and travel expenses for lectures and workshops from Hoffman-La-Roche and Genentech. The Erasmus MC, Sophia Children's Hospital (the cystic fibrosis centre used in the author's study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author's study was supported by Roche (the Netherlands), support with nebulisers was provided by Romedic (Meerssen, the Netherland) and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
C. Tiplady. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
M. Travaci. The author's study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
A. Tremblay has received speaker's honoraria for medical presentations on malignant pleural effusions/Pleurx catheter. DOI: 10.1183/09031936.00164706
J. Trujillo-Santos. The RIETE Registry was supported by an unrestricted educational grant from Sanofi-Aventis Spain. The Registry Coordinating Center, S&H Medical Science Service, provided logistic and administrative support. DOI: 10.1183/09031936.00071007
V Back to top
G. Valdivia. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
C.K. van der Ent. The author has received unrestricted grants, amounting to €200,000 from GlaxoSmithKline, €50,000 from Grönenthal and '20,000 from Roche Pharmaceuticals. DOI: 10.1183/09031936.00051406
L.J. van der Giessen has received, within the last 4 years, travel expenses for conferences from Roche. The Erasmus MC, Sophia Children's Hospital (the cystic fibrosis centre used in the author's study) has received, in the last 5 years, research grants from Hoffman-La-Roche. The author's study was supported by Roche (the Netherlands), support with nebulisers was provided by Romedic (Meerssen, the Netherland) and support with pulsoxymeters was provided by MTT (Wageningen, the Netherlands). DOI: 10.1183/09031936.00031107
T.H. van Kuppevelt. An unrestricted educational grant for the author's study was received from GlaxoSmithKline (Zeist, The Netherlands). DOI: 10.1183/09031936.00125106
D. Vethanayagam has received financial support (consulting and lecture fees) in the past 5 years from AstraZeneca, GlaxoSmithKline, Novartis and Nycomed. DOI: 10.1183/09031936.00119907
C.G. Victora. The PLATINO study was funded by Boehringer Ingelheim GmbH (Ingelheim, Germany). The funding source had no influence on the analyses or interpretation of the results presented in the paper. The corresponding author (A.M.B. Menezes) had full access to all the data in the study and had final responsibility for the decision to submit for publication. DOI: 10.1183/09031936.00083507
K. Viel is an employee of Boehringer-Ingelheim, the manufacturer of Tiotropium (Spiriva®), and has received reimbursements for attending symposia. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
A.M. Vignola†. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
W Back to top
C. Wainwright. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
K. Walmsley. Pfizer contributed some unencumbered funding to reduce some of the costs of the author's study. Pfizer supplied azithromycin for the author's study. Funding sources did not participate in the design or conduct of this study, data analysis, manuscript preparation or review. DOI: 10.1183/09031936.00163306
A-B. Wanzenried. The author's study was supported financially by a grant from Boehringer-Ingelheim GmbH, Basel, Switzerland. DOI: 10.1183/09031936.00015307
J.A. Wedzicha has received research funding for the published study and honoraria for speaking at meetings from Boehringer-Ingelheim and Pfizer. The author also received reimbursements for attending symposia. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
D. White. The author is a consultant for Respironics Inc, Alfred E. Mann Foundation, Aspire Medical, Itamar Medical, PAVAD and WideMed. The author occasionally consults for Cephalon, and Organon, and has research grants from Respironics Inc, Alfred E. Mann Foundation , Cephalon and WideMed. DOI: 10.1183/09031936.00063406
T.M.A. Wilkinson has received sponsorship from Boehringer-Ingelheim for travel to academic meetings. The author's study was funded by Boehringer-Ingelheim Ltd. DOI: 10.1183/09031936.00023907
J. Wimperis has received financial support from LEO Pharma to attend several conferences. The author's study was supported by a research grant from LEO Pharma to pH Associates to conduct the project. pH Associates were involved in the design of the author's study and provided assistance with data collation and reporting. DOI: 10.1183/09031936.00140506
H. Wirtz has received speaker's honoraria from Actelion Pharmaceuticals and Schering. DOI: 10.1183/09031936.00032407
P. Wrighton-Smith. The author is an employee of, and shareholder in, Oxford Immunotec. DOI: 10.1183/09031936.00145906
Z Back to top
J. Zaagsma has received an unrestricted educational grant from Boehringer Ingelheim. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
H. Zackon. The author's study was funded by AstraZeneca Canada Inc. DOI: 10.1183/09031936.00166606
J. Zhu. The author's study was funded, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00013006
S. Zielen has, within the last 3 years, received honoraria for lectures and attendance at Paediatric Advisory Boards from Merck Sharpe and Dohme. The author's study was supported by a research grant from Merck Sharpe and Dohme. DOI: 10.1183/09031936.00063106
A.B. Zuidhof. The author's study was supported by a grant from Boehringer Ingelheim. DOI: 10.1183/09031936.00004907
Volume 31, 2008
A Back to top
S.D. Aaron has received funds for speaking from GlaxoSmithKline and Boehringer Ingelheim. He has served on advisory boards for Boehringer Ingelheim and AstraZeneca. DOI: 10.1183/09031936.00098307
R. Aboutaam. The authors would like to thank W. Steinhilber from Nycomed (Zürich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
K.B. Adler has received research grants from AstraZeneca, Inc. and Sepracor, Inc. The author holds 150,000 founder's shares in a start-up Biotech firm, BioMarck, Inc. K.B. Adler has also served on the scientific advisory board of Sepracor, Inc. and has received consulting fees of approximately US$5,000 in the last 2 years. DOI: 10.1183/09031936.00103307
P. Albert has received speaker fees and conference travel grants from GSK, AstraZeneca and Pfizer. DOI: 10.1183/09031936.00116707
S. Aldington. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
N. Ambrosino has received a fee for organising education and funds for a member of staff. A congress organised by N. Ambrosino has been sponsored by Vivisol. The institution of N. Ambrosino has received an educational grant from Vivisol. DOI: 10.1183/09031936.00143507
S.D. Anderson is the inventor of the patent that covers the use of mannitol for bronchial provocations and clearance of mucus. The patent is owned by the Sydney South West Area Health Service (SSWAHS) and licensed to Pharmaxis Ltd. The author may benefit from royalties in the future. S.D. Anderson owns shares in Pharmaxis Ltd that the author purchased herself, but does not own any options. In her capacity as an employee of the SSWAHS, the author consults for Pharmaxis Ltd and is on the Scientific Advisory Board of the company. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
W. Anderson is a full-time employee of the sponsor of the study GlaxoSmithKline, and holds stocks or shares in the organisation. He has acted as an expert witness on the subject of his study, review. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
L. Annemans. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
B Back to top
T.R. Bai has received fees for speaking, funds for research and fees for consulting. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
S. Baldassarre. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00020407
J.A. Barberà. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
S. Baraldo. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, Boehringer Ingelheim and Nycomed, all of whom market drugs for respiratory diseases. DOI: 10.1183/09031936.00138707
E.D. Bateman has served on or currently serves on the advisory board for Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyowa Hakko, Merck, Novartis, Nycomed, Pfizer and Sanofi-Aventis. The author has also received honoraria for educational activities organised by Altana/Nycomed, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Pfizer. His institution has received funding for research from Almirall, Altana, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Kyowa Hakko, Lilly, Merck, Novartis, Nycomed, Pfizer, Sanofi-Aventis and Schering Plough. DOI: 10.1183/09031936.00138707
A. Bauer. The authors would like to thank W. Steinhilber from Nycomed (Zürich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
R.P. Baughman has received educational and research grants from Centocor; has been a consultant to Centocor, and has received funds for travel to symposium on inflammatory lung diseases from Centocor. DOI: 10.1183/09031936.00051907
N. Baxter. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
E. Bazzan. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
R. Beasley. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
B. Beck-Schimmer has received a research grant from Abbott AG, Baar, Switzerland (US$30,000). The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
L. Beckert. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
J. Behr. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
J. Behr has received fees for speaking and/or organising education from Actelion Pharamceutical, ALK Scherax, Altana, AstraZeneca, Bayer, Boehringer Ingelheim, GalxoSimthKline, Merck, NYCOMED, Schering, Zambon, Encysive, and ZLB Behring. He has received fees for consulting from Actelion Pharmaceutical, Bayer, GlaxoSmithKline, Pari, Pfizer, Schering, Zambon and has received research funds including funds for a member of staff from Actelion, Bayer, Mondobiotech, and Myogene. DOI: 10.1183/09031936.00171307
K. Blondeau. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
S. Blumenthal. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
H.M. Boezen has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
A. Boonstra has acted as an expert witness on the subject of the study featured in the April 2008 issue of the European Respiratory Journal. He has received a consulting fee from Pfizer. DOI: 10.1183/09031936.00114207
A.Boonstra's employer has received an unrestricted educational grant from Actelion and GlaxoSmithKline in the past 5 years exceeding €10.000. A. Boonstra has acted as a paid speaker for Actelion and United Therapeutics. A. Boonstra has attended symposia funded by Encysive, Pfizer and Actelion. DOI: 10.1183/09031936.00135407
C. Booy. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
C. Borland. British American Tobacco Ltd loaned Prof. Tim Higenbottam and Dr Colin Borland the original chemiluminescent nitric oxide analyser which was used for TLNO measurements in 1982'1985. DOI: 10.1183/09031936.00025108
L-P. Boulet is on the Advisory Boards of: AstraZeneca, Altana, GlaxoSmithKline, Merk Frosst and Novartis. He has received lecture fees from: 3M, AstraZeneca, Altana, GlaxoSmithKline, Merk Frosst and Novartis. He has received sponsorship for investigator-generated research from: AstraZeneca, GSK, Merck Frosst, Schering. Research funding for participating in multicentre studies has been given by: 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, Genentech, GlasxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen, Wyeth. He has also received support for the production of educational materials from: AstraZeneca, GlaxoSmithKline and Merck Frosst. L-P. Boulet is an Adviser for the Conseil du Médecadent du Québec and a member of the Quebec Workmen Compensation Board Respiratory Committee. He is also Chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee and co-leader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence. He currently holds the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI:10.1183/09031936.00104007
J. Bousquet has received funds for research and for consulting. He acted as an expert witness on the subject of the Global Guidelines presented. J. Bousquet has served on or currently serves on advisory boards for Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Stallergenes, Schering Plough, UCB and Uriach, and has received honoraria for educational activities organised by Altana/Nycomed, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Schering Plough, Stallergenes, UCB and Uriach. His institution has received funding for research from Almirall, Altana, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, Novartis, Nycomed, Schering Plough and Stallergenes. DOI: 10.1183/09031936.00138707
S. Bowler has received fees for consultation and or speaking from GSK, AstraZeneca, Boehringer Ingelheim and Altana Nycomed. DOI: 10.1183/09031936.00053107
P.H. Brekke's travel to the ATS congress was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00015807
C. Brouillard. The author's study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
R.A. Brown. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
G. Brusselle. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
G. Buesching. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
J. Buffels. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
R. Buhl. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
D. Burkhart is an employee of Boehringer Ingelheim (Ridgefield, CT, USA). The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
A. Bush has received expenses to travel to the ATS and ERS Congresses from GSK, AstraZeneca, MSD, Actelion and Altana. The author has also received fees for chairing (n=1) and speaking (n=1) at Evening Symposia at ERS, and he has received fees for lecturing and chairing meetings from GSK, AstraZeneca, MSD and Chiron (no single fee exceeding €2,000). In no case has he used, nor been asked to use, material provided by the sponsor. His department has benefited from travel grants for research fellows from Chiron and GSK, and received research grants, in all cases administered through the Royal Brompton Hospital Research Dept, from Pharmaxis Australia (support of a research fellow), Chiron and MSD. The Institutions that employ him (Royal Brompton Hospital, Imperial College) benefit from substantial pharmaceutical funding from multiple companies, declared in their own conflict of interest statements. DOI: 10.1183/09031936.00172207
C Back to top
P.M.A Calverley has sat on advisory boards for GSK, AstraZeneca, Pfizer, Roche, Altana and Novartis as part of clinical trials supervision and study development. He has spoken at meetings supported by GSK, AstraZeneca, Boehringer Ingelheim, Altana and British Oxygen. His department has received research funding from GSK, Altana, BOC and Chiesi. DOI: 10.1183/09031936.00116707
F. Capron has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
C. Cassino was an employee of Boehringer Ingelheim (Ridgefield, CT, USA) at the time the study was conducted. The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
M.G. Castel-Branco. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207.
B.R. Celli is a consultant and member of a speakers' bureau for Boehringer-Ingelheim and Pfizer, from whom he has received research grants. B.R. Celli has been on the advisory board of GlaxoSmithKline, Boehringer-Ingelheim, Dey Pharmaceutical, Sepracor, Altana, Almirall, AstraZeneca. The division he heads has grants from Boehringer-Ingelheim and GlaxoSmithKline. He has spoken for Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca and Almirall. The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
E.S. Chauliac. The Swiss Society of Paediatrics who provided funding for the author's study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
A.D. Chew. The author's study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
S.N. Christie. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
G.W. Clarke. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
J. Cohen. The author's study was funded by ALTANA Pharma (now part of the Nycomed Group). DOI: 10.1183/09031936.00082407
C. Compton is an employee of Pfizer Ltd. DOI: 10.1183/09031936.00033208.
J.E. Coote is employed by GlaxoSmithKline and holds a small number of their shares. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
G. Corvasce is a former employee of Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
U. Costabel. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
U. Costabel received consultancy fees from Centocor for advice on clinical trials and research grants from Centocor for participating in a clinical trial. DOI: 10.1183/09031936.00051907
M.R. Cowie has received research funding and speaking fees from ResMed. DOI: 10.1183/09031936.00048408
B. Cox. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
H.O. Coxson has received fees for speaking, funds for research, funds for a member of staff and fees for consulting. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
P.V. Coyle. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
C. Crim is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
D Back to top
F. Dalmay. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
C.W.H. Davies has been reimbursed for attending a working party group organised and paid for by LEO, the manufacturer of Innohep (tinzaparin), and also for presenting the study to employees of LEO. DOI: 10.1183/09031936.00156407
D.E. Davies is a co-founder and consultant of Synairgen, which has a programme involving a growth factor that shows some properties of EGF. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
E. Daviskas is employed by the Sydney South West Area Health Service (SSWAHS), the owner of the intellectual property of the use of mannitol for clearance of mucus, which has been licensed to Pharmaxis Ltd. The author may benefit from royalties in the future, owns shares in Pharmaxis Ltd that were purchased by the author herself, but does not own any options, and in her capacity as an employee of the SSWAHS, consults for Pharmaxis. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
F. Dawber is an employee and shareholder of GlaxoSmithKline, who is sponsoring ECLIPSE. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
J. de Blic. The authors would like to thank W. Steinhilber from Nycomed (Z'rich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
L. De Bolle. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
Y.P. de Visser. The piclamilast used in the author's study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
M. Decramer has received fees for speaking and consulting from Boehringer and Pfizer. He has also receivced funds for research from AstraZeneca. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
M. Decramer is a consultant and member of a speakers' bureau for Boehringer Ingelheim and Pfizer. The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
L. Delgado. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207.
M. Demedts has received consulting fees from Zambon, Wyeth and Roche, and lecture fees from GlaxoSmithKline, AstraZeneca and Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
J.C. Denyer is employed by GlaxoSmithKline and owns a small number of shares in GlaxoSmithKline. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
E. Derom received US$1,950 in 2002, US$2,280 in 2003 and US$2,495 in 2004 for serving on an advisory board for GlaxoSmithKline. The author received US$106,930 for the period 2003-2005 from Altana Pharma, US$5,890 for the period 2003-2005 from GlaxoSmithKline, US$100,280 in 2004 from SGS-Biopharma and $188,900 for the period 2003'2007 from Novartis, all as research grants for participating in clinical trials. The author has also received a grant from AstraZeneca to allow him to attend the ATS 2004, from Altana Pharma to attend the ERS 2005 Congress, and from AstraZeneca to attend the ERS 2006 Congress. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
R. Djukanović is a co-founder and consultant of Synairgen, which has a programme involving a growth factor that shows some properties of EGF. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
U. Domanski. The author's study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
W.R. Douma. The author's study was funded by ALTANA Pharma (now part of the Nycomed Group). DOI: 10.1183/09031936.00082407
L.J. Dupont. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
L.J. Dupont is a senior research fellow of the FWO Vlaanderen-Research Foundation-Flanders. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
J. Dupuis has received lecturer honorariums from Actelion Pharmaceuticals and Pfizer. He is also a member of scientific advisory boards for Actelion Pharmaceuticals and Encysive. DOI: 10.1183/09031936.00078207
E Back to top
S. Eberl is employed by the Sydney South West Area Health Service (SSWAHS), the owner of the intellectual property of the use of mannitol for clearance of mucus, which has been licensed to Pharmaxis Ltd. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
L. Edwards has been employed by an organisation that may gain or lose financially from the results of her study. She holds stocks or shares in an organisation that may gain or lose financially from the results of the study. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
J.S. Elborn. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
R. Ellis. The author's study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
P. Ernst has received speaker fees and/or has served on advisory boards for Altana, AstraZeneca, GlaxoSmithKline and Merck Frosst, Canada. He is also the recipient of a CDN$150,000 research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00098307
F Back to top
L.M. Fabbri has received funds for research, consulting fees, lecture fees and travel expense reimbursements for attending symposiums/meetings from Chiesi Farmaceutici, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKine, Pfizer, Roche, Altana, Novartis, Schering Pough and Menarini. DOI: 10.1183/09031936.00114307
L.M. Fabbri. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
J.M. Fitzgerald has received fees for speaking, for organising education, funds for research, funds for a member of staff and fees for consulting. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
M. FitzGerald has received fees for consulting on advisory boards and participated in speakers' bureaus for a number of pharmaceutical companies, which market asthma drugs. These include: AstraZeneca, Nycomed, GSK, Merck and Novartis. He has participated on scientific advisory boards to biotechnology companies, including Inflazyme, Topigen and OSIS. In addition, he has received research funds, paid into academic research accounts at UBC for the companies listed above, as well as Skye Pharma, Wyeth and Genentech. DOI: 10.1183/09031936.00138707
S. Flavin is an employee of the sponsor for this study. Except for the regular compensation (including salary, bonus and retirement fund), S. Flavin did not receive any other financial compensation from the company. The stock options held by S. Flavin are part of the regular compensation. DOI: 10.1183/09031936.00051907
C.D.R. Flower has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
K-J. Franke. The author's study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
M. Frey. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
G Back to top
N. Geudens. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
P. Gibson and his institution have received honoraria for educational activities organised by AstraZeneca, GlaxoSmithKline and Novartis. His institution has received funding for research from GlaxoSmithKline, Novartis and Pharmaxis. DOI: 10.1183/09031936.00138707
J-P. Giordanella. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
F.P. Gómez. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
M.M.E. Gosman. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
C. Grasemann. The author's study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
H. Grasemann. The author's study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
M. Griese. The authors would like to thank W. Steinhilber from Nycomed (Zurich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
H Back to top
T. Haahtela. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
G. Hagan has been employed by an organisation that may gain or lose financially from the results of the study. He holds stocks or shares in an organisation that may gain or lose financially from the results of the study. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
A. Hansell. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
M. Harwood. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
P.S. Hiemstra has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
T. Higenbottam is an employee of AstraZeneca Ltd. DOI: 10.1183/09031936.00033208
J.A. Hirota. The author's study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
M.M. Hoeper has received fees for speaking at conferences and/or consultations from Actelion Pharmaceuticals, Encysive, GlaxoSmithKline, Pfizer, United Therapuetics and Bayer-Schering. DOI: 10.1183/09031936.00134407
M.M. Hoeper has received lecturer honoraria from Actelion Pharmaceuticals, Schering, Pfizer and Encysive. He is also a member of scientific advisory boards for Actelion Pharmaceuticals, Pfizer, GSK and Encysive. DOI: 10.1183/09031936.00078207
J.C. Hogg's laboratory has, in the latter quarter of the last century, received support in the form of grants from the Canadian Tobacco Manufactures Council. This occurred both while J.C. Hogg was at McGill University in Montreal and for approximately 5 years after the author moved to Vancouver in 1977. The author also participated in a trial of the Eclipse cigarette, a 'smokeless' product developed for harm reduction because it heated the tobacco rather than burned it. Between approximately 1996 and 2000 the author and colleagues tested the hypothesis that this product would either prevent and/or reverse the elevation in blood leukocyte count that smokers experience because particulate count in the smoke generated by this product is markedly reduced. It was found that it did not but the author was not able to publish this result because the major respiratory journals developed a policy against publishing tobacco-sponsored research about the time that the work was finished. To the best of the author's recollection this study was complete in the year 2000 and he has received no funding from the tobacco industry since that time. DOI: 10.1183/09031936.00026208
Z. Hong is supported by an Actelion Young Investigators Award. DOI: 10.1183/09031936.00160407
G. Huchon received fees for speaking, organising education or consulting from Boehringer Ingelheim, GlaxoSmithKline and Pfizer. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
S.S. Hurd received reimbursement for speaking at a symposium and fees for speaking. The author also received travel reimbursement from the Asian Pacific Society for Respirology for speaking in an educational seminar during their national meeting in 2006. DOI: 10.1183/09031936.00138707
M.J. Hurle is an employee of GlaxoSmithKline and as a part of his remuneration package holds a small number of shares in that company. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
I Back to top
M.D. Inman. The author's study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
J Back to top
T. Jacinto. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
L.J. Janssen. The author's study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
M.A. Judson has received approximately $3000 USD consulting fees for Centocor, and has received research funding from Centocor to conduct this study. DOI: 10.1183/09031936.00051907
K Back to top
A. Kaplan has received speaking fees from the following companies: AstraZeneca, GlaxoSmithKline, Altana, Boehringer Ingelheim, Pfizer, Purdue, Ortho Janssen and Merck Frosst. The author has been on the advisory boards for Boehringer Ingelheim, Altana, AstraZeneca, Janssen Ortho, Merck Frosst, and Purdue. A. Kaplan has received funding for travel to report on proceedings of the ERS by AstraZeneca. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
M.S. Kavuru has received funds for research. DOI: 10.1183/09031936.00051907
S. Kesten is an employee of Boehringer Ingelheim (Ingelheim, Germany). The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
J.C. Kidney. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
K. Knobil is employed by GSK and holds stocks or shares in GSK. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
M. Kraft has: received research funding from Genentech and GSK; participated as a consultant for GSK, Merck and Genentech; and received honoraria as a speaker for GSK, Merck, Genentech and Novartis. The author has also organised research activities for GSK. DOI: 10.1183/09031936.00103307
C.E. Kuehni. The Swiss Society of Paediatrics who provided funding for the author's study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
C. Kuntz. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
L Back to top
Y. Lacasse. The author's study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
E.H. Laghmani. The piclamilast used in the author's study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
E. Lammers. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
C. Lange has received speaker's honoraria at symposia sponsored by Oxford Immunotec (manufacturer of T-SPOT.TB) and has served as a scientific advisor for Oxford Immunotec. DOI: 10.1183/09031936.00083707
I. Lankhorst has received consulting fees from Zambon and was formerly employed by Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
T.S. Lapperre. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
L.C. Lau. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
F. Laurent has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
M. Laviolette participated or participates in clinical trials for Altana, AstraZeneca, Boerinhger-Ingelheim, GlaxoSmithKline, Bayer, Merck, Asthmatx and Topigen. For the Asthmatx trials, M. Laviolette's institution, the Laval Hospital, received $182,000 in 2004, $115,000 in 2005, $151,000 in 2006 and $169,000 in 2007 (to date) for reimbursement for expenses related to clinical trials of bronchial thermoplasty. M. Laviolette gave lecture's sponsored by Altana, AstraZenenca, 3M, GlaxoSmithKline, Merck and Asthmatx. M. Laviolette received a medical research grant ($50,000) from Merck-Frosst in 2004 for a project that was published in JACI (2006; 118: 113-119). The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
C.L. Ledbetter. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
J.S-M. Lee has been employed by an organisation that may in any way gain or lose financially from the results of the study. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
M.L. Levy has received in the past 5 years reimbursement for attending a symposium, fees for speaking, fees for organising education and consulting, and funds for research. He has accepted sponsorship from the following for attending conferences: GlaxoSmithKline, AstraZeneca, Trinity-Cheisi, Merck Sharpe and Dohme, Merck, Altana Pharma, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, Schering Plough. He has accepted lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Alk-Abello. M.L. Levy has also been on advisory boards or provided consultancy for Schering Plough, Merck Sharp and Dohme, Trinity-Cheisi, Altana Pharma, Ranbaxy, AstraZeneca, 3M Pharmaceuticals and Novartis. DOI: 10.1183/09031936.00157507
G. Liistro. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
D. Liu is or has been an employee of Boehringer Ingelheim. The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
K.H. Lo is an employee of the sponsor for this study. Except for the regular compensation (including salary, bonus and retirement fund), K.H. Lo did not receive any other financial compensation from the company. The small amount of stocks held by K.H. Lo is part of the regular compensation. DOI: 10.1183/09031936.00051907
D.A. Lomas has received fees for speaking, funds for research and fees for consulting. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
C. Lopes. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
M Back to top
W. MacNee has received research grants to support work carried out in the author's laboratory from Pfizer, GlaxoSmithKline, Hoffmann La Roche, Telacris and Unilever. W. MacNee serves on an advisory board and expert panel for GlaxoSmithKline and SMB Pharmaceuticals. The author has received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings and travel to various meetings was funded by AstraZeneca, Zambon, Boehringer Ingelheim and GSK. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
P. Maestrelli. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
A. Malhotra has received consulting and/or research funds from Respironics, Inspiration Medical, Restore Medical, NMT Medical, Pfizer, Cephalon and speaking fees from Pfizer, Boehringer Ingelheim and Respironics. DOI: 10.1183/09031936.00067607
F. Maltais received fees for speaking at conferences sponsored by Boehringer Ingelheim, Pfizer and GlaxoSmithKline. He served on an advisory board for GlaxoSmithKline and Altana Pharma. He received research grants for participating in multicentre trials sponsored by GlaxoSmithKline, Boehringer Ingelheim, Altana Pharma and Merck. He received unrestricted researchs grant from Boehringer Ingelheim and GlaxoSmithKline. He has been reimbursed by AstraZeneca and Boehringer Ingelheim to attend two conferences. The author's study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
D.M. Mannino has received research funding from GlaxoSmithKline, Pfizer and Novartis and has served as a consultant or speaker for GlaxoSmithKline, Pfizer, Boerhringer-Ingelheim, Astra-Zeneca, Dey and Sepracor. DOI: 10.1183/09031936.00017008
H.A. Manrique. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
A-M. Marley. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
T.K. Marras has received an educational grant from Abbott, and speakers fees from Abbott and Bayer. DOI: 10.1183/09031936.00109007
S.A. Marsico. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
F.J. Martinez has received lecture honoraria from Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received reimbursement for attending advisory boards for Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received consultant fees from ALTANA Pharma, and received honoraria for organising education on behalf of Boehringer Ingelheim and Pfizer. Travel to the ERS Congress was funded by Pfizer. DOI: 01.1183/09031936.00099307
R. Maselli. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
T.E. McManus. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
E. Mehuys. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
V. Mertens. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
A. Michils. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00020407
J. Milot has received a research fund from GlaxoSmithKline. The author's study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
A. Moreira. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
P.A. Muñoz. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
R.D. Murdoch is an employee of GlaxoSmithKline, the sponsor of this research and holds stocks and shares. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
N Back to top
S.B. Neff. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
T.A. Neff. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
F. Neukirch. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
K. Nieuwland. The piclamilast used in the author's study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
A.G. Nicholson has received consulting fees from Zambon and lecture fees from AstraZeneca. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
G. Nilius. The author's study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
O Back to top
P. O'Byrne received fees for speaking from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed and Ono Pharma. The author has also received funds: for research from Altana, AstraZeneca, Biolipox, Boehringer Ingelheim, GlaxoSmithKline, IVAX, Medimmune, Merck, Pfizer, Topigen and Wyeth; and for consulting from AstraZeneca, Biolipox, GlaxoSmithKline, Nycomed, Resistentia and Topigen. P. O'Byrne has received consulting fees from AstraZeneca, Biolipox, GlaxoSmithKline, Nycomed, Resistentia and Topigen, and honoraria for speaking from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed and Ono Pharma. In addition, he has received grants-in-aid from AstraZeneca, Biolipox, Boehringer Ingelheim, GlaxoSmithKline, IVAX, Medimmune, Merck, Pfizer, Topigen and Wyeth. DOI: 10.1183/09031936.00138707
B.J. O'Connor. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
K. Ohta has: served on or currently serves on advisory boards for Abbott/Maruho, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Tanabe Mitsubishi and Taisho; and received honoraria for scientific lectures organised by AstraZeneca, GlaxoSmithKline, Merck, Ono, Schering-Plough and Teijin. K. Ohta's institution has received funding for research from AstraZeneca, GlaxoSmithKline and Otsuka. DOI: 10.1183/09031936.00138707
T. Omland has received: speaker's honoraria from Roche Diagnostics, Bayer Diagnostics and Abbott Laboratories; consultancy honoraria from Roche Diagnostics; and research support from Roche Diagnostics and Abbott Laboratories, manufacturers of assays for troponin. DOI: 10.1183/09031936.00015807
H.J. O'Neill. The authors' study was supported by nonrestricted grants from AstraZeneca, Boehringer Ingelheim and the Mater Hospital. DOI: 10.1183/1936.00107507
M. Oudkerk. The author's study was funded by ALTANA Pharma (now part of the Nycomed Group). DOI: 10.1183/09031936.00082407
P Back to top
C.P. Page is a member of the scientific advisory board for Endacea, Research Triangle Park, NC, USA, which is developing adenosine A1 receptor antagonists for the treatment of lung diseases. He holds stocks or shares. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
C. Palmares. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
A. Pamir. The authors would like to thank W. Steinhilber from Nycomed (Zurich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
J. Papassotiriou is an employee of BRAHMS AG, the manufacturer of the assay for procalcitonin. DOI: 10.1183/09031936.00054507
A. Papi. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
S.E. Pedersen has served on advisory boards for GlaxoSmithKline, AstraZeneca and Nycomed, and has received honoraria for educational activities organised by these three companies. His institution has received funding for research from AstraZeneca, GlaxoSmithKline, Merck and Nycomed. DOI: 10.1183/09031936.00138707
G. Pelaia. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
A.M. Peña. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
V. Pepin. The author's study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
T. Perez received funds for research from Boehringer Ingelheim France in 2003/2004. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
W. Phanprasit has received consulting fees for conducting air monitoring in the milk powder factory described in the manuscript. DOI: 10.1183/09031936.00106407
E. Pizzichini has served on or currently serves on advisory boards for AstraZeneca, GlaxoSmithKline and Nycomed, and has received honoraria for educational activities organised by Altana/Nycomed, AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00138707
A. Pritchard. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
D.S. Postma has received funding from GlaxoSmithKline, AstraZeneca and ALTANA Pharma (now part of the Nycomed Group) for research, speaking and consultancy. The author's study was funded by ALTANA Pharma (now part of the Nycomed Group). DOI: 10.1183/09031936.00082407
M. Puhan. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
R Back to top
K.F. Rabe reports having consulted, participated in advisory board meetings for and received lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Pfizer, Novartis, Altana Pharma, Merck Sharp & Dohme and GlaxoSmithKline. K.F. Rabe holds no stock or other equities in any pharmaceutical company. Between 2001-2006, the Dept of Pulmonology, of which the author is head, received grants from Altana Pharma, Novartis, Bayer, AstraZeneca, Pfizer, Merck Sharp & Dohme, Exhale Therapeutics, Boehringer Ingelheim, Roche and GlaxoSmithKline. DOI: 10.1183/09031936.00114307
F. Ratjen has received a fee for speaking at a symposium supported by Pharmacia. The author's study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
J.P. Remon. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
T. Renda. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
S.I. Rennard. In the last five years, S.I. Rennard has received financial support for speaking, consulting and/or to support research from Adams, Almirall, Altana, Array Biopharma, Astellas, AstraZeneca, Aventis, Bend Pharmaceuticals, Boehringer Ingelheim, Biolipos, Centocor, Critical Therapeutics, Dey Laboratories, GlaxoSmithKline, ICOS, Inspire Pharmaceuticals, Intermune, Johnson & Johnson, Lorillard, Merck, Nabi, Novartis, Ono, Otsuka, Parengenix, Pfizer, RJ Reynolds, Roche, Sankyo, Sanofi, Schering-Plough, Scios, Talecris and Wyeth. S.I. Rennard has also received fees for organising education. S.I. Rennard has in the past acted as a consultant to, and received grants from, the tobacco industry; these relationships ceased before January 1, 2008. DOI: 01.1183/09031936.00099307
E. Reutershahn. The author's study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
L. Reyes. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
G. Robinson. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
J. Roca. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
N. Roche received fees for speaking, organising education or consulting from Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Pfizer. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
R. Rodríguez-Roisin has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Pfizer; consulted with several pharmaceutical companies with relevance to the topics discussed in the present article (Altana, AstraZeneca, Aventis, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Esteve, Novartis, Pfizer and Chiesi); serves on advisory boards for Almirall, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Procter & Gamble and Chiesi; has been sponsored for several clinical trials; and has received laboratory research support from AstraZeneca, Almirall, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Esteve, and Pfizer. The authors are grateful to GSK for facilitating the placebo canisters. The study was supported by a grant-in-aid from Esteve and AstraZeneca (Peru). DOI: 10.1183/09031936.00116207
B. Roth Z'graggen. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
K-H. Ruhle has received research funding from Fisher & Paykel Healthcare, Heinen und Löwenstein, ResMed und Weinmann. This funding has gone into department funds. The author's study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
P. Rytilä. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
P. Rytilä. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
S Back to top
M. Saetta. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
M. Sardina is a current employee of Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
T.J. Savage is employed by GlaxoSmithKline and holds a small number of their shares. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
T. Schermer has received reimbursement from GlaxoSmithKline and Boehringer Ingelheim for travelling to scientific conferences in the respiratory field (ERS and IPCRG). He has also received compensation for serving on an advisory board for AstraZeneca. The author's institute has received unrestricted educational grants from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
E.R. Schmid has received a research grant from Abbott AG, Baar, Switzerland (US$30,000). The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
D. Schnabel has received grant support from Pfizer, and has been invited as a symposium speaker. He has participated in multi-site clinical studies for Pfizer. The author's study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
C. Schudt was fully employed by Altana Research and development. DOI: 10.1183/09031936.00002007
H.J. Schünemann received no personal payments from for-profit organisations. In the past 5 years, he has received research grants, fees and/or honoraria that were deposited into research accounts from the American Thoracic Society (fees), AstraZeneca (research grant, honoraria), Amgen (research grant), Chiesi Foundation (honorarium), Lily (honorarium), Pfizer (research grant, honorarium), Roche (honorarium) and UnitedBioSource (honorarium) for development or consulting regarding quality-of-life instruments for chronic respiratory diseases or as lecture fees related to the methodology of evidence-based practice guideline development and/or research methodology. McMaster University and the CLARITY Research Group at McMaster University have received licensing fees for use of the Chronic Respiratory Questionnaire. H.J. Schünemann is Documents Editor for the American Thoracic Society. Other institutions or organisations that the author is affiliated with may receive funding from for-profit sponsors that are supporting infrastructure and research that may serve the author's work. DOI: 10.1183/09031936.00163107
H.J. Schünemann. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
M.R. Sears has received research grants, consulting fees and speaker fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed (Altana), MerckFrosst Canada, Merck Sharp Dohme, Novartis and Schering-Plough and holds a Chair in Respiratory Epidemiology jointly endowed by AstraZeneca and McMaster University. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
W. Seeger has been reimbursed for participation in the ATS congress in 2004 by Altana Pharma AG and for participation in the Ventavis® Launch Symposium (Madeira) in 2003 by Schering AG. He received a fee for speaking from Schering AG for taking part in an Expert Round Table in Pulmonary Hypertension; from Schering AG for taking part in the Ventavis® Launch Symposium; from Pfizer AG for taking part in the 110. Annual Meeting of the German Society of Internal Medicine. He received funds for research for clinical studies funded by Altana Pharma AG, Actelion, Schering AG, Myogen Inc., Lung Rx. He received a fee for organising education for Graduate College financially supported by Altana Pharma AG. He received fees for consulting from Altana Pharma AG, Lung RX, Schering AG. Funding received in 2004: Schering Deutschland GmbH 12,000.00 Euro, Altana Pharma AG 40,000.00 Euro, Altana Pharma AG 12,811.00 Euro, Myogen Inc. Westminster 68,683.15 Euro, Lung Rx 351,368.23 Euro, Lung Rx $120,000.00, Altana Pharma AG 450,000.00 Euro. Funding received in 2005: Lung Rx $120,000.00, Encysive 77,414.23 Euro, Schering AG 5,000.00 Euro, Schering Deutschland GmbH 10,000.00 Euro, Altana Pharma AG 60,000.00 Euro, Altana Pharma AG 12,811.00 Euro, Schering Deutschland 40,000.00 Euro, Myogen Inc. Westminster 258,349.49 Euro, Altana Pharma AG 225,000.00 Euro. Funding received in 2006: Myogen Inc. Westminster/Gilead $120,000.00, Altana Pharma AG 12,811.00 Euro, Lung Rx $120,000.00, Schering AG 5,000.00 Euro. Funding received in 2007: Lung Rx $60,000.00, Schering AG 5,000.00 Euro, Gilead Colorado $34,125.00. DOI: 10/1183/09031936.00109407
G. Seumois. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
D. Sifrim. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
J.A. Silva. The author's study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
M. Silverman. The Swiss Society of Paediatrics who provided funding for the author's study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
E.K. Silverman has received: honorarium for a talk on COPD genetics in 2006, and grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics; honorarium from Wyeth for a talk on COPD genetics in 2004; honorarium from Bayer for a symposium at the ERS Meeting in 2005; honorarium from AstraZeneca for a talk at the Lund Symposium in 2007. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
D.E. Simcock has received travel awards by the American Thoracic Society and the British Lung Foundation to attend international respiratory conferences. The author's study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
A.K. Simonds has received research grants from Resmed Co and Breas Medical. DOI: 10.1183/09031936.00048408
N. Smiljanic-Georgijev was an employee of AstraZeneca and holds stocks or shares in an organisation that may in any way gain or lose financially from the results of the study. The author's study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author's study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
S. Smith has received funds for research. DOI: 10.1183/09031936.00053107
J.B. Snoeck-Stroband. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
J.B. Soriano received reimbursements for attending symposia, fees for speaking and fees for consulting. He was an employee of GlaxoSmithKline R&D up to 2005. DOI: 10.1183/09031936.00084507
D.R. Spahn. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
A. Spaar. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
D. Spina has received a grant to study adenosine receptor expression in the airways. This funding covered the cost of consumables and salary for a postdoctoral fellow to undertake the work presented in this manuscript. The study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
J.K. Sont has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
F. Stanzel. The authors would like to thank W. Steinhilber from Nycomed (Zürich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
P.J. Sterk has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
M. Steurer. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
R.A. Stockley has had unrestricted research funding from Talecris and AstraZeneca. He has provided consultancy for AstraZeneca, GSK, Boehringer, Schering Plough and Talecris. He has lectured for GSK and has been supported for attendance to ATS and ERS by Talecris and Boehringer. OI: 10.1183/09031936.00081707
M-P.F. Strippoli. The Swiss Society of Paediatrics who provided funding for the author's study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
S. Suissa has: participated in advisory board meetings (Boehringer Ingelheim, Pfizer, GlaxoSmithKline); given lectures (Boehringer Ingelheim, Pfizer); and received research grants from AstraZeneca. DOI: 10.1183/09031936.00098307
S.D. Sullivan has served on or currently serves on advisory boards for AstraZeneca, GlaxoSmithKline, Merck, Novartis, Sanofi-Aventis and Schering Plough, and has received honoraria for educational activities organised by AstraZeneca, Novartis and Genentech. DOI: 10.1183/09031936.00138707
P. Supply has received fees for consulting and is a consultant of Genoscreen. DOI: 10.1183/09031936.00053307
T Back to top
R. Tal-Singer is an employee and shareholder of GlaxoSmithKline who sponsored the ECLIPSE study. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
D.P. Tashkin is a consultant and member of a speakers' bureau for Boehringer Ingelheim and Pfizer, from whom he has received research grants. D.P. Tashkin has also received: fees for speaking from Boehringer-Ingelheim and Pfizer; a fee for organising education from a medical education company that received funding from Boehringer-Ingelheim and Pfizer; consulting fees from Boehringer-Ingelheim. The author's study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
N.H.T. ten Hacken has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
N.H.T. ten Hacken. The author's study was funded by ALTANA Pharma (now part of the Nycomed Group). DOI: 10.1183/09031936.00082407
M. Thomeer has received consulting fees from Zambon and InterMune, and lecture fees from Zambon, InterMune, AstraZeneca and GlaxoSmithKline. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
W. Timens has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
A. Torres was supported by CIBER of Enfermedades Respiratorias (CB06/060028). DOI: 10.1183/09031936.00073807
G. Turato. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
U Back to top
M. Uddin. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
V Back to top
B.A. Vanaudenaerde. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
B.M. Vanaudenaerde is a senior research fellow of the FWO Vlaanderen ' Research Foundation-Flanders. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
L. Van Bortel. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
A. Van Muylem. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00020407
E. vanOort. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
D.E. Van Raemdonck. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
D.E. Van Raemdonck. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
C.P. van Schayck has received funding from Pfizer, Boehringer Ingehlheim and GSK. DOI: 10.1183/09031936.00074307
I. Van Tongelen. GlaxoSmithKline Belgium provided the peak flow meters for the author's study. DOI: 10.1183/09031936.00112007
C. van Weel received the following unrestricted research and educational grants for the Dept of General Practice: less than US$10,000 from AstraZeneca, Bayer and NovoNordisk; and more than US$10,000 from Boehringer Ingelheim, GlaxoSmithKline and Novartis. The author has also received speaking fees. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
S. van Wijngaarden. The piclamilast used in the author's study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
A. Vatrella. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
E.K. Verbeken has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
A. Vergnenègre received fees for speaking or consulting from AstraZeneca, and GlaxoSmithKline and Pfizer. The present study was supported by a grant from Boehringer Ingelheim France (Reims, France). Logistical help, paid for by Boehringer Ingelheim, was provided by LOb Conseils (Cachan, France). DOI: 10.1183/09031936.00089607
G.M. Verleden. The author's study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
G.M. Verleden. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
J. Verschakelen has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
J. Vestbo has received research grants to support work carried out in the department where he works from GlaxoSmithKline. He has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingeheim and Pfizer for speaking in scientific meetings and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. Finally, his wife is an employee of AstraZeneca. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
U. Vester. The author's study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
J.M. Vonk. The author's study was funded by ALTANA Pharma (now part of the Nycomed Group). DOI: 10.1183/09031936.00082407
A.Vonk Noordegraaf received a $1200 lecture fee from Actelion. DOI: 10.1183/09031936.00135407
R. Vos is a research fellow of the FWO Vlaanderen-Research Foundation-Flanders. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
W Back to top
G.T.M. Wagenaar. The piclamilast used in the author's study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
F.J. Walther. The piclamilast used in the author's study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
J. Wattie. The author's study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
M. Weatherall. The author's study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
T. Welte received €4,000 in 2006 for speaking at conferences sponsored by BRAHMS AG. He also received €50,000 Euro in 2006 from BRAHMS AG as a research grant for participating in an investigator-initiated study. DOI: 10.1183/09031936.00054507
S.E. Wenzel has served on or currently serves on advisory boards for AstraZeneca, Boehringer Ingelheim, Isis, GlaxoSmithKline, Genetech, Merck and Novartis, and has received honoraria for educational activities organised by AstraZeneca, Critical Therapeutics and Merck. The author's institution has received funding for research from Amgen, Critical Therapeutics and Genetech. DOI: 10.1183/09031936.00138707
D.P. White organised symposia at the APSS meeting for Cephalon and Orphan Medical. D.P. White was paid for speaking by Cephalon. He received research support from Cephalon, Respironics Inc, WideMed, Itamar Medical. He received consulting fees from Cephalon, Respironics, WideMed, Itamar Medical, Aspire Medical, PAVAD. He is employed as chief Medical Officer for Respironics Inc. DOI: 10.1183/09031936.00067607
M. Woischnik. The authors would like to thank W. Steinhilber from Nycomed (Zurich, Switzerland) for the generous gift of polyclonal anti-human SP-B and SP-C antibodies. DOI: 10.1183/09031936.00081207
E. Wouters is a member of the scientific advisory boards for GSK, Boehringer Ingelheim, AstraZeneca and Numico, and has received lecture fees from GSK, AstraZeneca and Boehringer Ingelheim. Between 2004-2006, he received research grants from GSK, AstraZeneca, Boehringer Ingelheim, Centocor and Numico. The symposium upon which the author's review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
P. Wrighton-Smith is an employee of Oxford Immunotec, holds shares in Oxford Immunotec. P. Wrighton-Smith is an employee of, and shareholder in, Oxford Immunotec. DOI: 10.1183/09031936.00117207
Y Back to top
I.H. Young is employed by the Sydney South West Area Health Service (SSWAHS), the owner of the intellectual property of the use of mannitol for clearance of mucus, which has been licensed to Pharmaxis Ltd. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
T. Yue. The author's study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
Z Back to top
H.J. Zar has served on or currently serves on advisory boards for CiplaMedpro, Pfizer and Roche, and has received honoraria for educational activities organised by GlaxoSmithKline, Merck, Pfizer and Roche. The author's institution has received funding for research from AstraZeneca, Boehringer Ingelheim, BristolMyers Squibb, GlaxoSmithKline and Merck. DOI: 10.1183/09031936.00138707
J-P. Zellweger has been invited by Oxfordimmunotec in Oxford in 2004 and 2005 to attend workshops on Gamma-Interferon tests. DOI: 10.1183/09031936.00117207
R. Zuin. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
Volume 32, 2008
A Back to top
T. Abramidze. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
A. Agustí has received an educational grant from GlaxoSmithKline. This study has been supported by an unrestricted educational grant from GlaxoSmithKline (GSK). The fluticasone propionate was kindly provided by GlaxoSmithKline. DOI 10.1183/09031936.00020608
S Albertí has received an educational grant from GlaxoSmithKline. This study has been supported by an unrestricted educational grant from GlaxoSmithKline (GSK). The fluticasone propionate was kindly provided by GlaxoSmithKline. DOI 10.1183/09031936.00020608
H. Alkadhi. The author's study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
J.A. Anderson is a full-time employee of GlaxoSmithKline and holds shares in the company. DOI: 10.1183/09031936.00161507
J.A. Anderson is a full-time employee of GlaxoSmithKline (Uxbridge, UK) and holds shares in the company. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
S. Andreas was reimbursed for attendance at two workshops on smoking cessation funded by Pfizer® in 2006. DOI: 10.1183/09031936.00109607
I. Annesi-Maesano. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
N.R. Anthonisen. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University'Industry Partnership programme. DOI: 10.1183/09031936.00153207
D. Athanasopoulos. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
É. Azoulay has been a consultant for Pfizer and Gilead France. DOI: 10.1183/09031936.00142907
B Back to top
G. Bacher is an employee of mondoBIOTECH. The study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
C. Baezner. The author's study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
S. Baldassarre. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
M. Bando. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
E. Baraldi has received honoraria for lectures from Abbot, GlaxoSmithKline, Merck Sharp & Dohme and Valeas, and reimbursement for attending the ERS Congress from Merck Sharp & Dohme. E. Baraldi's institution received project funding from Aerocrine. DOI: 10.1183/09031936.00002108
M. Barbier. The author's study was been supported by an unrestricted educational grant from GlaxoSmithKline (GSK). The fluticasone propionate was kindly provided by GlaxoSmithKline. DOI 10.1183/09031936.00020608
N. Barlow. The author's study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
E.D. Bateman. In the last 3 years, E.D. Bateman has: provided consultancy services for Kyowa Hakko and GlaxoSmithKline; served on advisory boards for Almirall, Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman le Roche, Kyowa Hakko, Merck, Nycomed, Pfizer and Sanofi-Aventis; received lecture fees from Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Pfizer; served as an expert witness for GlaxoSmithKline; and received industry-sponsored grants from Almirall, Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman le Roche, Merck, Nycomed, Pfizer, Sanofi-Aventis and Lilly. DOI: 10.1183/09031936.00155307
R.A. Baumgartner. The author's study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
J. Behr. The author's study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
W. Berger. The author's study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
K.C. Bergmann. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Betsuyaku. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
D. Bevec is an employee of mondoBIOTECH. The author's study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
H. Bisgaard has been a consultant to and paid lecturer for Aerocrine, AstraZeneca, Altana, GlaxoSmithKline, Merck, MedImmune, NeoLab and Pfizer. The Danish Paediatric Asthma Centre has received unrestricted institutional grants from Aerocrine, AstraZeneca, GlaxoSmithKline, Merck and MedImmune. H. Bisgaard does not hold stock or options in any pharmaceutical company. DOI: 10.1183/09031936.00002108
H. Bisgaard has within the past 3 years been a consultant to, paid lecturer for and/or holds sponsored grants from AstraZeneca, GSK, Merck, MedImmune, Nycomed, NeoLab and Pfizer. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
L. Bjermer has been payed by AstraZeneca, GlaxoSmithKline and Merck for giving lectures in the field of asthma treatment and how to manage asthma. The topic of these lectures do not interfere with the author's study. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
B. Björkstén. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
P.N. Black. The author's study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
F. Blasi reports having received consulting fees from Pfizer, Sanofi-Aventis, and Altana; lecture fees from Bayer, Sanofi-Aventis, Pfizer, Abbott, Altana, and GlaxoSmithKline; and grant support from Pfizer and Altana. The study itself was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
K. Bloch. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
A.L. Boner has received fees for speaking from GlaxoSmithKline and Merck Sharp & Dohme, a research grant from Merck Sharp & Dohme, and consulting fees from GlaxoSmithKline and Merck Sharp & Dohme. Envicon, a company which produces encasing materials for house dust mite allergen avoidance, belongs to family members. DOI: 10.1183/09031936.00002108
S. Bonini has a research appointment at the Institute of Neurobiology and Molecular Medicine, Italian National Research Council (INMM-CNR, ARTOV), Rome, Italy. He is a member of the Research and Development Commission of the Italian Drug Agency (AIFA), Rome, Italy. He has received research grants, consultancies, editorial activity and honoraria from participation in speakers' bureaux from the following companies: Alcon, Allergopharma, Allergy Therapeutics, ALK, Almirall, Aventis, AstraZeneca, Bioallergy, Bioxell, GlaxoSmithKline, Lofarma, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Synthelabo, Schering-Plough, Stallaergens, UCB, and Zambon. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
R. Borie. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
L. Borish has received a medical school research grant from GlaxoSmithKline and consulting fees from Genentech/Novartis. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
L-P. Boulet. In the last 3 years, L-P. Boulet has: served on advisory boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis; received lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis; and received industry-sponsored grants from AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering, Boehringer Ingelheim, Asthma Tx, Ception, Topigen and Alexion. DOI: 10.1183/09031936.00155307
L-P. Boulet has been a member of advisory boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis. He has also received: lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis; sponsorship for investigator-generated research from AstraZeneca, GSK, Merck Frosst and Schering; research funding for participating in multicentre studies from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen and Wyeth; and support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst. L-P. Boulet has acted as: an advisor for the 'Conseil du Médicament du Québec' Member of the Quebec Workmen Compensation Board Respiratory Committee; Chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee; and co-leader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence. The author has also been the holder of the Laval University Chair on knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health, as well as a member of the asthma committee of the World Allergy Organisation. DOI: 10.1183/09031936.00109308
H.A. Boushey. In the last 3 years, H.A. Boushey has: served on advisory boards for GlaxoSmithKline; received lecture fees from GlaxoSmithKline, Genentech, Novartis and Boehringer Ingelheim; provided consultancy services for Altana, Sanofi-Aventis, Boehringer-Ingelheim, Novartis, Theravance, Nonomix and Sumitomo; and received an industry-sponsored grant from GlaxoSmithKline. DOI: 10.1183/09031936.00155307
P.L.P. Brand has received, between 2002 and 2007, grants and fees for organising, attending and speaking at symposia, research and consultancy, and employing junior staff members from AstraZeneca, GlaxoSmithKline, Merck and Altana. DOI: 10.1183/09031936.00002108
P.L.P. Brand. The author's study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, The Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
M. Brauer has served as an expert witness on behalf of an individual whose asthma was affected by exposure to smoke from agricultural burning. DOI: 10.1183/09031936.00097707
C.E. Brightling has received a total of '1 million research funding over the last 3 years (or is pending) from AstraZeneca, Cambridge Antibody Technology, GlaxoSmithKline. C.E. Brightling has also received <£10000 per annum from consultancy fees from Cambridge Antibody Technology, AstraZeneca, GlaxoSmithKline, Roche and Pfizer, and participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies (Boehringer Ingelheim, MSD, Pfizer). DOI: 10.1183/09031936.00056108
A.F.J. Brouwer. The author's study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, the Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
B. Brunekreef. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
H.P. Brunner-La Rocca. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
A. Bruno. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
V. Brusasco received: €11,625 for serving on an advisory board for Byk Goulden in 2003; €11,625 in 2004, €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €5,000 in 2003, €3,000 in 2004, and €3,000 in 2005 from Lofarma for consultancies; €812 in 2003 for speaking in a symposium and €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006 and €2,500 in 2007 for speaking at conferences sponsored by Boehringer Ingelheim; €960 in 2006 from GSK for participating in an advisory board; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board. V. Brusasco's institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00056808
M. Brutsche. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
G. Büchele. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
A. Bulfoni reports having received: consulting fees from Sanofi-Aventis and Pfizer; lecture fees from Guidoff; and grant support from Pfizer, Sanofi-Aventis and Wyeth-Lederle. The author's study was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
J.A. Burgers is a member of an advisory board of Roche Netherlands, and travel to the World Conference on Lung Cancer in Seoul was funded by Roche Netherlands. DOI 10.1183/09031936.00165607
P. Burney has received lecture fees from AstraZeneca and is currently advising GlaxoSmithKline on the design of a study. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
P. Burney has received speaking fees from AstraZeneca. DOI: 10.1183/09031936.00155607
D.M. Burns has testified against the tobacco industry in Litigation. DOI: 10.1183/09031936.00160007
A. Bush has received expenses to travel to the ATS and ERS congresses from GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, Actelion and Altana; he has received fees for chairing (n=1) and speaking (n=1) at ERS Evening Symposia and for lecturing and chairing meetings from GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme and Chiron (no single fee exceeded 2,000 Euros). His department has benefited from travel grants for research fellows from Chiron and GlaxoSmithKline, and received research grants, in all cases administered through the Royal Brompton Hospital Research Department, from Pharmaxis Australia (support of a research fellow), Chiron and Merck Sharp & Dohme. The institutions which employ him (Royal Brompton Hospital and Imperial College, London, UK) benefit from substantial pharmaceutical funding from multiple companies, declared in their own conflict of interest statements. DOI: 10.1183/09031936.00002108
W.W. Busse. In the last 3 years, W.W. Busse has: provided consultancy services for Genetech/Novartis, Isis, GlaxoSmithKline, Altanta, Wyeth, Pfizer, Dynavax, Centocor, Johnson & Johnson, CV Therapeutics, Hoffman-LaRoche, Ception, Amgen, Alza, Takeda, Mellenium, MAP Pharmaceuticals, Merck, Asthmatic, AstraZeneca, MedImmune, Memory Pharmaceuticals, Altair, PDL BioPharma, Schering Corporation, TEVA and Abbott Laboratories, received lecture fees from Novartis, Merck, AstraZeneca and GlaxoSmithKline, and received industry-sponsored grants from Novartis, Dynavax, Wyeth, Centocor, GlaxoSmithKline, Medicinova, Pfizer, Dey, Astellas, Inflazyme, Ception Therapeutics and Biowa/MedImmune. DOI: 10.1183/09031936.00155307
B.K. Butland (now B.K. Nicholas) owns shares in investment companies and unit trusts that are not restricted from holding shares in the tobacco industry.DOI: 10.1183/09031936.00077207
C Back to top
J. Callebert. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
P.M.A. Calverley has led studies supported by GSK, Altana, Roche and Chiesi, and has spoken at meetings supported by these companies and by AstraZeneca. He has served on advisory boards for Pfizer and GSK while his department has received non-product-related funding from GSK. DOI: 10.1183/09031936.00161507
P.M.A. Calverley has led studies supported by GSK, Altana, Roche and Chiesi, and has spoken at meetings supported by these companies and by AstraZeneca. He has served on advisory boards for Pfizer and GSK, while his department has received non-product-related funding from GSK. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
J.D. Campbell has received research grant support from Genentech, Inc. and a pre-doctoral fellowship from Genentech and Novartis. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
A. Carlucci has received reimbursement for attending some international meetings from Resmed. DOI: 10.1183/09031936.00000208
T.B. Casale. In the last 3 years, T.B. Casale has: provided consultancy services for Novartis, Genentech, OSI Pharmaceuticals, Zymo/Genetics; served on advisory boards for Novartis, Genentech, Allux and Capnia; received lecture fees from Merck; and received industry-sponsored grants from Dynavax, Novartis, NIH/NHLBI, Alcon Research, Allergy Therapeutics, Curalogic, Amgen, Allied Research, Genentech, Novartis, Pfizer, Schering and Capnia. DOI: 10.1183/09031936.00155307
B. Cassadei. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
J.A. Castro-Rodriguez has received honoraria as a lecturer and speaker in scientific meetings and courses under the sponsorship of Merck Sharp & Dohme, GlaxoSmithKline and Grunenthal, and as consultant for GlaxoSmithKline. DOI: 10.1183/09031936.00002108
M. Cazzola has received fees for speaking and consulting and/or financial support for attending meetings from Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, Encysive, GSK, Menarini Farmaceutici, Novartis, Nycomed, Pfizer and Sanovel Valeas. DOI: 10.1183/09031936.00056808
B.R. Celli. The division that B.R. Celli heads has received grant funding from Glaxo Smith Kline. In addition, B.R. Celli has received payments for speaking at symposiums and attending advisory boards for Glaxo Smith Kline, Boehringer Ingelheim, Almirall, Dey Pharmacautical and Astra Zeneca. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University'Industry Partnership program. DOI: 10.1183/09031936.00153207
P. Ceriana has received reimbursement for attending some international meetings from Fisher and Paykel and Resmed and fees for consulting from Airox. DOI: 10.1183/09031936.00000208
P. Chanez. In the last 3 years, P. Chanez has: provided consultancy services for Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough; served on advisory boards for Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough; received lecture fees from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough; and received industry-sponsored grants from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough. DOI: 10.1183/09031936.00155307
A. Chaouat has received fees for speaking at conferences and/or consultations from Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. DOI 10.1183/09031936.00015608
W. Chung is an employee of Schering Plough. DOI: 10.1183/09031936.00062307
S. Cogswell. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
J.E. Connett. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
W.O.C. Cookson. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
C.B. Cooper has received: fees for speaking from Boehringer Ingelheim, Pfizer, AstraZeneca and GlaxoSmithKline; research sponsorship from Boehringer Ingelheim, Forest and GlaxoSmithKline; and consulting fees from Boehringer Ingelheim, Dey and Pfizer. DOI: 10.1183/09031936.00030508
S. Corrao received lecture fees from GlaxoSmithKline and grant support from Pfizer. The author's study was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
S. Costantino. The author's study was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
H.O. Coxson has received honoraria, consultant fees and contract service agreements from GlaxoSmithKline for research studies involving quantitative computed tomography and COPD. H.O. Coxson received $11,000 in 2005 for serving on an advisory board for GSK. In addition HC is the co-investigator on two multi-centre studies sponsored by GSK and has received travel expenses to attend meetings related to the project. H.O. Coxson has three contract service agreements with GSK to quantify the CT scans in subjects with COPD and another contract service agreement with Spiration Inc for clinical trial involving an endobronchial valve. A percentage of his salary between 2003 and 2006 (US$ 15,000 per yr) derived from contract funds provided to a colleague (P.D. Paré) by GSK for the development of validated methods to measure emphysema and airway disease using computed tomography. H.O. Coxson is the co-investigator (D. Sin PI) on a Canadian Institutes of Health and Industry (Wyeth) partnership grant. The author's study was funded by a Research Grant with Spiration Inc. (Muller PI). The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC.). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
S. Craig. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
B. Crestani. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
N. Crosthwaite. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
A. Custovic has received grant support from Asthma UK, Moulton Charitable Trust, the UK Medical Research Council and GlaxoSmithKline, and is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, UCB Pharma, ALK and Phadia; travel to the American Academy of Asthma, Allergy & Immunology congress was funded by AstraZeneca. DOI: 10.1183/09031936.00002108
D Back to top
C. Das has received a fee for speaking from Actelion Pharmaceuticals. The author's study was supported by Actelion Pharmaceuticals UK. DOI: 10.1183/09031936.00069708
R.J.O. Davies. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
M. Decramer has received: fees for speaking from Boehringer Ingelheim and Pfizer; research sponsorship from AstraZeneca and GlaxoSmithKline; and consulting fees from Boehringer Ingelheim, Pfizer and GlaxoSmithKline. DOI: 10.1183/09031936.00030508
M. Dehoux. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J.C. de Jongste. In the last 3 years, J.C. de Jongste has served on advisory boards for GlaxoSmithKline, and has received industry-sponsored grants from Aerocrine, GlaxoSmithKline, Roche, AstraZeneca, Chiron, Transave, Pfizer and Friesland Nutrition. DOI: 10.1183/09031936.00155307
J.C. de Jongste's department (Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands) received project funding from Aerocrine, manufacturer of nitric oxide analysers, in 2005 and 2006. DOI: 10.1183/09031936.00132607
J.C. de Jongste has received funds for research. His employer (Dept of Paediatrics, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, the Netherlands) has accepted research funds from the following companies: Aerocrine, GlaxoSmithKline, Roche, AstraZeneca, Chiron, Transave, Pfizer and Friesland Nutrition. DOI: 10.1183/09031936.00002108
I. De Rudder. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
D.H. Dillard is an employee of Spiration Inc. and has stock options in this company. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
M. Di Valentino. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
N. Doughty has received reimbursement from Actelion Pharmaceuticals UK for attending a symposium. Actelion also funded the original research conducted by Galen Research and Papworth Hospital NHS Trust which led to the development of the CAMPHOR. The author's study was supported by Actelion Pharmaceuticals UK. DOI: 10.1183/09031936.00069708
E.J. Duiverman. The author's study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, the Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
E Back to top
E. Eber has received fees for speaking from AstraZeneca and Merck Sharp & Dohme, and for consulting from AstraZeneca and Merck Sharp & Dohme; travel to several congresses was funded by AstraZeneca, GlaxoSmithKline and Merck Sharp & Dohme. DOI: 10.1183/09031936.00002108
B. Eldh has stocks in excess of €13,000 in Swedisch Match, a global Group with a broad offering of brands in smokefree tobacco products, cigars, pipe tobacco and lights products. DOI: 10.1183/09031936.00121507
R. Ellis. The author's study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
P.L. Enright. In the last 3 years, P.L. Enright has provided consultancy services for Pfizer and InterMune. DOI: 10.1183/09031936.00155307
M.J. Epton. The author's study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
J. Eugen-Olsen. Copenhagen University, Hvidovre Hospital has applied for patents disclosing IP-10 and MCP-2 as biomarkers for M. tuberculosis infection. M. Ruhwald, P. Ravn and J. Eugen-Olsen are registered as co-inventors. DOI: 10.1183/09031936.00055508
M.L. Everard has received fees for speaking at meetings organised by GlaxoSmithKline, Merck Sharp & Dohme, Astra and Abbott. He has sat on advisory boards for GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, ML Laboratories, Abott and Novartis. M.L. Everard has received research funding from GlaxoSmithKline, Merck Sharp & Dohme and ML Laboratories. He has had his registration fees, travel and accommodation for attending ERS and ATS meetings paid for by AstraZeneca, Merck Sharp & Dohme, Novartis and GlaxoSmithKline. DOI: 10.1183/09031936.00002108
F Back to top
A. Fabre. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J. Fandrey has received travel reimbursement from the ERS for attending the 5th Lung Science Conference in Taormina, Italy. DOI: 10.1183/09031936.00013408
J.V. Fahy has received a fee for speaking, funds for research and fees for consulting from Gilead, Cytokinetics, Merck, Oxagen, Zymogenetics, Aerovance and Abgenix. DOI: 10.1183/09031936.00026808
C.L. Finger is an employee of and stockholder in Spiration Inc. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
A.J. Fisher received a clinical fellowship award from GlaxoSmithKline. DOI: 10.1183/09031936.00110807
W. Fokkens. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
F. Forastiere. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
F.M.E. Franssen. The author's study was supported by a research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00014008
U. Frey received reimbursement for travel arrangements to congresses and fees for talks, all of which were within the sponsorship laws of Switzerland. DOI: 10.1183/09031936.00002108
R. Frithiof. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
B.A. Fröhlich. The study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
T. Furukawa. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
G Back to top
G.D. Gamble. The author's study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
M. Gappa has received an unrestricted medical grant from GlaxoSmithKline and lecture fees (<GBP5,000) from Merck, Sharp & Dohme and GlaxoSmithKline, and is a member of an advisory board for GlaxoSmithKline. DOI: 10.1183/09031936.00002108
L. Garcia-Marcos has received reimbursement from GlaxoSmithKline, ALK-Abello and Merck Sharp & Dohme for attending scientific meetings and lecturing at scientific events organised by these industries. He has also consulted for GlaxoSmithKline, Merck Sharp & Dohme and ALK-Abello in the past. DOI: 10.1183/09031936.00002108
S.A. Gauw. The Dept of Pulmonology from the Leiden University Medical Center (Leiden, the Netherlands) received an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
F. Gejyo. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
J.E. Gern entered into a cooperative research agreement with EraGen Biosciences for the development of the Respiratory MultiCode Assay (viral diagnostic) used in this study. In addition, he has received honoraria for lectures and consulting fees from EraGen, and travel to the Association of Molecular Pathologists Annual Meeting in November 2005 was funded by EraGen. DOI: 10.1183/09031936.00161907
O. Georgiadou. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
L. Ghaly is an employee of Pharmacon, PLC, which consults for Schering Plough. DOI: 10.1183/09031936.00062307
H.A. Ghofrani has received educational grants from Pfizer, Actelion and Bayer Schering. H.A. Ghofrani has no stocks or other financial interest in companies that might have any interest or benefit from contents dealt with in this manuscript. H.A. Ghofrani has received lecture fees from: Actelion, Pfizer, Bayer Schering, Encysive and GSK. DOI: 10.1183/09031936.00124007
P.G. Gibson. In the last 3 years, P.G. Gibson has: received lecture fees from AstraZeneca, GlaxoSmithKline and Novartis; received industry-sponsored grants from Pharmaxis and GlaxoSmithKline; and has patents pending with CRC for Asthma, University of Newcastle. DOI: 10.1183/09031936.00155307
W. Gin-Sing has received honoraria from Actelion for speaking at educational meetings, attending nurse advisory board meetings, travel and accommodation grants for conferences. The information gathered for the author's study was funded through a research grant from Actelion and it has in the past sponsored staff posts within the Hammersmith Pulmonary Hypertension Service. DOI: 10.1183/09031936.00069708
M. Gjomarkaj. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
L. Gnatiuc. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
J. Godnic-Cvar. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Golemati. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
F. Grimminger has received educational grants from Pfizer, Actelion and Bayer Schering. F. Grimminger has no stocks or other financial interest in companies that might have any interest or benefit from contents dealt with in this manuscript. F. Grimminger has received lecture fees from: Actelion, Pfizer, Bayer Schering, Encysive and GSK. DOI: 10.1183/09031936.00124007
J.G. Grootens. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
H Back to top
S. Haag. The author's study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
T. Haahtela has received fees for speaking at meetings and consultation fees from AstraZeneca, Berlin Chemi, GlaxoSmithKline, MSD, OrionPharma and ScheringPlough. T. Haahtela has received an unrestricted grant from MSD for a clinical study. DOI: 10.1183/09031936.00062307
T. Haahtela has received lecture fees from AstraZeneca, Berlin Chemie, GSK, Meda, MSD, OrionPharma, and an academic grant in excess of €5000 for a clinical trial. He has served on the advisory board of MSD and OrionPharma. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
M. Hasegawa. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
T. Haselkorn has been a paid consultant to Genentech, Inc. since December 2002. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
J. Haughney has provided occasional consultancy, educational and speaker services for AstraZeneca, Merck, Sharpe and Dohme, Novartis and Teva, for which he has been paid. His University dept and the International Primary Care Respiratory Group (of which he is President) receive grants from most major pharmaceutical companies. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
B.A. Hay. The author's study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
Y.F. Heijdra. The anonymous disclosure of the data of the primary care diagnostic centre involved in the present study is supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
L. Heinzerling. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
P.B. Helli recieved a Student Fellowship Award from ALTANA Pharma (Nycomed). DOI: 10.1183/09031936.00054608
D. Hénin. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
H. Herwald. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
N. Hizawa. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
M.O. Hoekstra has received fees for speaking from GlaxoSmithKline and Mead Johnson, he received a research grant from GlaxoSmithKline, and travelled with Mead Johnson to the 2007 annual convention of the American Academy of Asthma, Allergy and Immunology. DOI 10.1183/09031936.00020108
M.M. Hoeper has received lecturer honoraria from Actelion Pharmaceuticals, GSK, Bayer-Schering, Pfizer and Encysive. The author is also a member of the scientific advisory boards for Actelion Pharmaceuticals, Bayer, Pfizer, GSK and Encysive. DOI: 10.1183/09031936.00091908
M.M. Hoeper has received a fee for speaking at a workshop from Novalung, Hechingen, Germany, the manufacturer of the pECLA device. DOI: 10.1183/09031936.00146408
S. Holgate. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
F. Holguin. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
J. Holme. The author's study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
R.J. Hopkins. The author's study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
R. Horne performs occasional consultancy duties for the pharmaceutical industry. Consultancy agreements include: GlaxoSnithKline, Gilead, Boehringer Ingelheim, Shire, Hayward Medical Communications, Oxford Pharmagensesis, Procter & Gamble, Servier and Merck, providing advice on design of patient surveys and research, and performing invited talks at national and international symposia of medication usage and adherence. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
T. Hosono. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
T. Howes was given a travel grant on two occasions to attend the ERS Congress by Novartis Pharma; was a consultant for Glaxo Welcome on a research programme for a fee of £500; and received fees for commercial research from Boehringer Ingelheim and Novartis Pharma. DOI 10.1183/09031936.00137008
M. Humbert has received consulting fees from Actelion, Myogen and Schering AG, and lecture fees from Actelion, Schering AG, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00009008
I Back to top
M.D. Inman. The author's study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
I. Iori reports having received consulting fees from Pfizer and lecture fees from GlaxoSmithKline and Sanofi-Aventis. The study itself was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
Y. Ishii. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
Y. Ito. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
J Back to top
C. Jansen. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
C. Janson. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
L.J. Janssen. The author's study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
L.J. Janssen received a consulting fee from GlaxoSmithKline, and operating grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00054608
C.J. Jolley has a 12-month contract with Glaxo Smith Kline, acting as a dyspnoea consultant. This is not a research post. Income £8,600. DOI: 10.1183/09031936.00018808
P. Jones has received, in the last 5 years, one grant of £100k from GSK, lecture and consulting fees from GSK, AstraZeneca, Boehringer, Spriation, Roche, Almirall and Bayer. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
P.W. Jones. Over the last 5 years, P.W. Jones has received a grant of £100,000 from GSK, and lecture and consulting fees from GSK, AZ, Boehringer, Spiration, Roche, Almirall and Bayer. DOI: 10.1183/09031936.00161507
G. Joos. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
U.R. Juergens. The author's study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
K Back to top
S. Kajikawa. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
O.N. Keene is a full-time employee of GlaxoSmithKline and owns shares in the company. DOI: 10.1183/09031936.00161507
O.N. Keene is an employee of GlaxoSmithKline (Uxbridge, UK) and holds shares in the company. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
S. Keshavjee. The author's study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
A. Kessel-Schaefer. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
C. Kitagawa. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
M. Kohler. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
M. Kohler. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
S. Konno. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
A. Koutsoukou. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
M.L. Kowalski. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
M. Kraft has received research funding from GlaxoSmithKline, Bronchus Technologies, Asthmatx and Genentech; speaking fees from GlaxoSmithKline, Merck and Genentech; and advisory board fees from Merck, Genentech, Novartis and Schering-Plough. DOI: 10.1183/09031936.00026808
S. Kriemler. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
L Back to top
A. Lalvani is lead inventor for patents underpinning T-cell-based diagnosis. The Lalvani ELISpot was commercialised by an Oxford University spin-out company (T-SPOT.TB®, Oxford Immunotec Ltd, Abingdon, UK) in which Oxford University and Professor Lalvani have minority shares of equity and to which Professor Lalvani acted as non-executive director from 2003-07. DOI: 10.1183/09031936.00148308
T.H. Lam has received free nicotine replacement therapy from Pfizer for research on smoking cessation. He is vice chairman of Hong Kong Council on Smoking and Health. DOI: 10.1183/09031936.00160007
C. Lange has received honoraria for speaking at symposia that were sponsored by Oxford-Immunotec, a manufacturer of an ELISPOT for the immunodiagnosis of tuberculosis. DOI: 10.1183/09031936.00059308
J. Langley works for, and holds stock in, Actelion Pharmaceuticals Ltd. The author's study was supported by Actelion Pharmaceuticals UK. DOI: 10.1183/09031936.00069708
P. Latzin's travel expenses to the ERS Infant Lung Function course in Nice 2007 were paid by EcoMedics. DOI: 10.1183/09031936.00073608
J-M. Launay. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J.H. Lee is an employee of Genetech Inc. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
D. Legnani reports having received consulting fees from Sanofi-Aventis, Bayer; lecture fees from Bayer, Sanofi-Aventis, Pfizer, Abbott, and GlaxoSmithKline. The study itself was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
W. Lenney has received an educational grant for research from GlaxoSmithKline and Abbott Laboratories, been on the Paediatric Advisory Boards of Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Novartis, Altana Pharma and Abbott Laboratories, and received travel funding to the ERS Congress from Novartis and Altana Pharma. In the last 5 years, W. Lenney has received speaker honoraria from Novartis, Altana Pharma, Merck Sharp & Dohme and GlaxoSmithKline. DOI: 10.1183/09031936.00002108
H.H. Leuchte has received a research grant from mondoBIOTECH. The author's study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
M.L. Levy. In the last 3 years, M.L. Levy has: provided consultancy services for Ranbaxy, Met Office and SCOPUS; served on advisory boards for Trinity Cheisi, Meda Pharmaceuticals and Merck Sharp & Dohme; received lecture fees from AstraZeneca, GlaxoSmithKline, Boehringer/Pfizer, Alk-Abello and Meda; received industry-sponsored grants from Trinity Cheisi, Meda Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Altana, MSD, Boehringer Ingelheim/Pfizer and TEVA Pharmaceuticals; and received royalties from Elsevier Publications. DOI: 10.1183/09031936.00155307
M.A. Lewis has received fees for speaking from GSK, J&J, Pfizer and Philips, fees for consulting from GSK and J&J, and fees for research from GSK, J&J, Pfizer and Philips. DOI: 10.1183/09031936.00096808.
L. Lindbom. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
A. Linka. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
A. Linka. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
D. Liu is an employee of Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, CT, USA). DOI 10.1183/09031936.00124108
M.C. Liu has received funding from Pfizer for technical training and assays performed in this trial. He has been a paid consultant and participant in advisory boards for Pfizer. He owns stock in Pfizer. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
C. Loureiro. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
A.E.M. Lucas. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
Y.M. Luo developed the multipair electrode used to record the diaphragm EMG. No patent is pending. DOI: 10.1183/09031936.00018808
M Back to top
X. Ma. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
H. Makita. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
J. Makowska. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S.F.P. Man has received support from GlaxoSmithKline (GSK) to attend a meeting organised by the company and has received unrestricted research grant support from Merck Frosst Canada, Inc and GSK of Canada. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
D.M. Mannino. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
J. Marchal-Sommé. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
S. Marchand-Adam. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J.G. Martin has received a medical school grant from Merck in support of this project. DOI 10.1183/09031936.00166907
F.J. Martinez has received lecture honoraria from Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received reimbursement for attending advisory boards for Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received consultant fees from ALTANA Pharma, and received honoraria for organising education on behalf of Boehringer Ingelheim and Pfizer. Travel to the ERS Congress was funded by Pfizer. DOI: 01.1183/09031936.00056808
S. Matthiesen. The author's study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
G. Mátyás. The author's study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
K. McGuinness is the inventor on a patent describing the novel methods for cough detection and monitoring, filed by the University Hospital of South Manchester (UK). K. McGuinness has an industrial collaboration and licence agreement with Vitalograph UK Ltd to develop a commercial cough monitoring system (Vitalojak). DOI: 10.1183/09031936.00052008
A. McIvor has received honoraria for speaking events and attending advisory board meetings of AstraZeneca, Abbot, Bayer, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Merck-Frosst and Pfizer pharmaceutical companies. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
S.P. McKenna works for Galen Research, who have received funding for the current research from Actelion Pharmaceuticals Ltd and have received other funding from Actelion in the past. The author has received funds from Actelion for symposium attendance and for consultancy. The author's study was supported by Actelion Pharmaceuticals UK. DOI: 10.1183/09031936.00069708
S. McKenzie has received departmental funds for travel from Allen and Hanburys. She has been an expert witness for both physicians and patients about issues concerning the treatment of asthma in preschool children. DOI: 10.1183/09031936.00002108
D.M. Meads works for Galen Research, which has received funding for the current research from Actelion Pharmaceuticals Ltd and have received other funding from Actelion in the past. The author's study was supported by Actelion Pharmaceuticals UK. DOI: 10.1183/09031936.00069708
S. Menjoge is an employee of Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, CT, USA). DOI 10.1183/09031936.00124108
A. Meyer. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
A. Michils. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
K. Millington is named inventor on patents relating to T-cell-based diagnosis. DOI: 10.1183/09031936.00148308
J. Mittendorf is a full-time employee at Bayer HealthCare. DOI: 10.1183/09031936.00114407
M. Mörgelin. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
K. Mori. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
A. Morice leads the development of the Hull Automated Cough Counter. DOI: 10.1183/09031936.00052008
Z. Mourid. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
J. Moxham has a 12-month contract with GlaxoSmithKline, acting as a dyspnoea consultant. This is not a research post. Income £8,600. DOI: 10.1183/09031936.00018808
N.L. Müller held a research grant from Spiration Inc. for the project reported in this manuscript. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
N Back to top
R. Naeije has received fees for speaking, reimbursements of travel expenses for attending meetings, and research funds from Actelion Pharmaceuticals, Encysive, Schering, Pfizer, Mondobiotech, and United Therapeutics. DOI 10.1183/09031936.00015608
K. Nagai. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
H. Nakano has filed a patent entitled 'System and method for automated detection of apnea and hypopnea'. The software used in the author's study was related to the patent. The study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
Y. Nasuhara. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
P.V. Nasute Fauerbach. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
S. Nava has received reimbursement for attending some international meetings from Draeger, Breas and Resmed, speaking fees from Respironics and Fisher Paykel and fees for consulting from Airox and Respironics. DOI: 10.1183/09031936.00000208
F. Neukirch has received an unrestricted educational grant from Boehringer Ingelheim. The author's study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry.DOI: 10.1183/09031936.00129507
C. Neurohr. The author's study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
M.S. Niederman received research grants from Nektor and Bayer. He received honoraria and consulting fees in excess of '10,000 from Schering, Bayer, Ortho-McNiel and Merck. DOI: 10.1183/09031936.00039908
S. Nishima. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
M. Nishimura. The author's study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
P. Norwood. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
O Back to top
P.M. O'Byrne. In the last 3 years, P.M. O'Byrne has: served on advisory boards for AstraZeneca, GlaxoSmithKline, Nycomed, Topigen and Resistentia; received lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed and Ono Pharma; and received industry-sponsored grants from AstraZeneca, Boehringer, Genentech, GlaxoSmithKline, Medimmune, Nycomed, Topigen and Wyeth. DOI: 10.1183/09031936.00155307
S. Oehmcke. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
T. Oei has received an educational grant from the ResMed Foundation. DOI: 10.1183/09031936.00127507
Y. Ohnishi. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
S. Ohno. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
M. Oki. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
P Back to top
E. Pace. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
M. Pai is an external consultant for the Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland), a nonprofit agency that collaborates with several industry partners (including Hain LifeScience, Nehren, Germany) for the development of new diagnostics for neglected infectious diseases. FIND had no role in the conduct of this meta-analysis and no industry partner was involved in the preparation of this manuscript. DOI 10.1183/09031936.00061808
S. Palkonen works as Executive Officer for the European Federation of Allergy and Airways Diseases Patients' Associations (EFA). EFA has unrestricted core funding for operational costs from GSK and Novartis (platinum sponsors: €50,000-60,000/company/year) and MSD ($12,000 silver sponsor). The author is a member of the GSK Health Advisory Board; EFA has received €500 consultancy fees/meeting fees, reasonable travel expenses and accommodation, provided by the GSK. S. Paldonen is a member of the EuropaBio Patient Advisory Board (no financial compensation for EFA). With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
P.D. Paré is the principal investigator of a project funded by GlaxoSmithKline to develop CT-based algorithms to quantify emphysema and airway disease in COPD. With collaborators, he has received ~$300,000 to develop and validate these techniques. The funds have been applied solely to the research to support programmes and technicians. P.D. Paré is also the principal investigator of a Merck Frosst supported research programme to investigate gene expression in the lungs of patients who have COPD. He and collaborators have received ~$200,000 for this project. These funds have supported the technical personnel and expendables involved in the project. Neither of these projects relates to the topic of the present article. DOI: 10.1183/09031936.00129107
M.R. Partridge. In the last 3 years, M.R. Partridge has: served on advisory boards for Novartis, AstraZeneca and Chiesi; and received lecture fees from AstraZeneca, Novartis, Merck, GlaxoSmithKline and Cipla. DOI: 10.1183/09031936.00155307
I.D. Pavord. In the last 3 years, I.D. Pavord has: received lecture fees from GlaxoSmithKline and AstraZeneca; has sat on advisory boards for GlaxoSmithKline, AstraZeneca, Merck and Novartis; and has received industry-sponsored grants from GlaxoSmithKline. DOI: 10.1183/09031936.00155307
R. Peché. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
J. Pepke-Zaba has received a fee for speaking from Actelion Pharmaceuticals. The author's study was supported by Actelion Pharmaceuticals UK. DOI: 10.1183/09031936.00069708
J.C.T. Pepperell. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
D. Perrotin has served on advisory boards, as speaker in scientific meetings and as study coordinator or investigator for E. Lilly. The author's study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry. DOI: 10.1183/09031936.00129507
G. Piacentini has received funding to attend the ERS Congress from Merck Sharp & Dohme and to attend a 3-day course on medical management at Bocconi University from AstraZeneca. He has received fees for speaking at national meetings and for contribution to educational programmes sponsored by GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, Valeas and Dompè Pharmaceuticals. DOI: 10.1183/09031936.00002108
R. Pistelli. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
D.S. Postma has received: fees for consulting for GSK, AstraZeneca and ALTANA Pharma; funds for research from ALTANA Pharma, AstraZenca and GSK; fees for speaking from ALTANA Pharma, AstraZeneca and GSK; and reimbursement for attending a symposium from AstraZeneca, ALTANA Pharma and GSK. DOI 10.1183/09031936.0101508
J. Potts. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
D.P. Price has consultant arrangements with Altana, Boehringer Ingelheim, GlaxoSmithKline, Merck Generics, Merck, Sharpe and Dohme, and Teva. He or his team have received grants and research support for research in asthma from the following organisations: UK National Health Service, Altana Pharma, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme, Novartis, Pfizer, Schering Plough and Teva. He has spoken for Altana Pharma, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme, and Pfizer. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
S. Provencher has received consulting and lecture fees from Actelion Pharmaceuticals Inc. and Encysive Canada Inc., and consultant fees from Unither Biotech Inc. DOI: 10.1183/09031936.00009008
M.A. Puhan received unrestricted research grants that were deposited into research accounts of the research groups that he belongs to from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca for development of quality of life instruments and respiratory rehabilitation trials. DOI: 10.1183/09031936.00140507
Q Back to top
C. Quesnel. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
R Back to top
K.F. Rabe has been consulting, participated in Advisory Board Meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceuticals, Pfizer, Novartis, AltanaPharma, MSD and GSK. K.F. Rabe holds no stock or other equities in pharmaceutical companies. The Dept of Pulmonology at Leiden University Medical Center (Leiden, the Netherlands), and thereby K.F. Rabe as head of the department, has received grants from AltanaPharma (US$222,616), Novartis (US$90,640), Bayer (US$61,762), AstraZeneca (US$113,155), Pfizer (US$406,000), MSD (US$118,000), Exhale Therapeutics (US$90,000), Boehringer Ingelheim (US$390,000), Roche (US$120,000) and GSK (US$299,495) in the years 2001 until 2006. The Dept of Pulmonology (Leiden University Medical Center) also received an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
K. Racké has received reimbursement for attending a symposium. The author's study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
H. Rasch. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
L. Rasouliyan is an employee of ICON Clinical Research, a company which receives research funding from Genentech, Inc. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
T. Raupach was reimbursed for attendance at two workshops on smoking cessation funded by Pfizer in 2006. DOI: 10.1183/09031936.00109607
P. Ravn has served as consultant on the formulation of clinical guidelines. The author received a single payment (€2,000) from Cellestis in 2006 and was an invited speaker at Cellestis-sponsored conferences in 2006 and 2007. DOI: 10.1183/09031936.00125607
P. Ravn has reviewed several papers on this topic. P. Ravn was a consultant for Cellestis Ltd. in 2006 to develop their clinical guidelines and received a single payment of €2000. She has been invited speaker by Abbott and Shering'Plough 2006, 2007, 2008 and has received grants from Abbott and Schering-Plough for research. Copenhagen University, Hvidovre Hospital has applied for patents disclosing IP-10 and MCP-2 as biomarkers for M. tuberculosis infection. M. Ruhwald, P. Ravn and J. Eugen-Olsen are registered as co-inventors. DOI: 10.1183/09031936.00055508
H.K. Reddel. In the last 3 years, H.K. Reddel has received consultancy payments from GlaxoSmithKline and AstraZeneca, has served on advisory boards for GlaxoSmithKline and AstraZeneca, and has received lecture fees from AstraZeneca. H.K. Reddel's employer has received funding from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pharmaxis. DOI: 10.1183/09031936.00155307
R.J. Riese. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
N. Roche has, in the past 5 years, received fees for speaking, organising education or consulting from Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Pfizer. The author's study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry.DOI: 10.1183/09031936.00129507
R.J. Roorda has been asked to give lectures at several symposia on paediatric pulmonology. On some occasions, he has received a small speaker's fee. The author's study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, The Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
G.A. Rossi has received educational grants and fees for speaking and consulting from Novartis, Merck Sharp & Dohme, Abbott, Altana and Valeas. DOI: 10.1183/09031936.00002108
M.D. Rossman has been a paid consultant both to industry and plaintiffs. In addition, he has been deposed as both an expert in chronic beryllium disease and also a treating physician. DOI: 10.1183/09031936.00098408
A.G. Rothfuchs. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
C. Roussos. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
C. Ruffié. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
M. Ruhwald. Copenhagen University, Hvidovre Hospital has applied for patents disclosing IP-10 and MCP-2 as biomarkers for M. tuberculosis infection. M. Ruhwald, P. Ravn and J. Eugen-Olsen are registered as co-inventors. DOI: 10.1183/09031936.00055508
E.W. Russi. The author's study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
E.P.A. Rutten. The author's study was supported by a research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00014008
P. Rytilä has received consultation fees and fees for speaking at meetings organised by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline and MSD. P. Rytilä has been employed by Orion Corporation Orion Pharma since January 2007. DOI: 10.1183/09031936.00062307
P. Rzehak. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
S Back to top
H. Saka. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
C. Sanjuas. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
H.P. Sauerwein has received a fee for speaking, funds for research and funds for a member of staff. The author's study was supported by a research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00014008
T. Schermer has received unrestricted research grants from several pharmaceutical companies and is a member of the International Primary Care Research Group speakers bureau. DOI: 10.1183/09031936.00088007
T.R.J. Schermer has received fees for attending and speaking at international conferences and several unrestricted grants for research from manufacturers of respiratory drugs (GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca). The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study is supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
A.M.W.J. Schols received lecture fees from Boehringer Ingelheim and received research grants between 2001 and 2004 from GlaxoSmithKline and Numico Research. The author's study was supported by a research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00014008
H.J. Schünemann received unrestricted research grants and honoraria that were deposited into research accounts or received by a research group that he belongs to from Pfizer, AstraZeneca and UnitedBiosource for development or consulting regarding quality of life instruments for chronic respiratory diseases. DOI: 10.1183/09031936.00140507
T. Schürmann. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
P.F. Schwartz. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
M.R. Sears. In the last 3 years, M.R. Sears has: received consultancies from AstraZeneca, GlaxoSmithKline and Merck Frosst; served on advisory boards for AstraZeneca, GlaxoSmithKline and Nycomed; received lecture fees from AstraZeneca, GlaxoSmithKline and Nycomed; served as an expert witness for AstraZeneca, GlaxoSmithKline and Nycomed; received industry-sponsored grants from AstraZeneca and Merck Frosst; and holds an endowed chair jointly supported by AstraZeneca and McMaster University. DOI: 10.1183/09031936.00155307
P. Seddon has received honoraria from Merck Sharp & Dohme for speaking at educational meetings and attending a medical advisory board. DOI: 10.1183/09031936.00002108
O. Selroos has received consultation fees and fees for speaking at meetings organised by AstraZeneca, and has stocks in excess of £5,000 in AstraZeneca. DOI: 10.1183/09031936.00062307
K. Senzaki. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
S. Shaheen. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Shimokata. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
E.K. Silverman received an honorarium for a talk on COPD genetics in 2006 as well as grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics. He has also received honoraria from Wyeth, Bayer, and Astra-Zeneca. DOI: 10.1183/09031936.00040208
M. Silverman has received consultancy fees from Merck Sharpe and Dohme, UK. DOI: 10.1183/09031936.00002108
G. Simonneau has serverd on the advisory committees for Actelion, Pfizer, Schering, United Therapeutics and GlaxoSmithKline. DOI: 10.1183/09031936.00009008
D.D. Sin. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
O. Sitbon has received consulting fees from Actelion, Myogen and GlaxoSmithKline, and lecture fees from Actelion, Schering AG and Pfizer. DOI: 10.1183/09031936.00009008
L. Skadhauge. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
I.J.M. Smeele. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
J. Smith is the inventor on a patent describing the novel methods for cough detection and monitoring, filed by the University Hospital of South Manchester (UK). J. Smith has an industrial collaboration and licence agreement with Vitalograph UK Ltd to develop a commercial cough monitoring system (Vitalojak). DOI: 10.1183/09031936.00052008
S. Smith has received an educational grant from the ResMed Foundation. DOI: 10.1183/09031936.00127507
O. Soehnlein. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
P. Soler. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. W'rch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J. Solway has received or benefitted from research funding from GlaxoSmithKline and from AstraZeneca, and has received consulting fees from Tanox, Merck, Wyeth, Cytokinetics, GlaxoSmithKline, AstraZeneca, Critical Therapeutics and Genentech. DOI 10.1183/09031936.00092908
I.J. Sørensen has received a fee for speaking from Wyeth and Abbott, who both make TNF-? blockers. She also received a fee from Abbott for arranging journal clubs for young doctors, funds for research from Abbott for multicentre studies of patients with spondyloarthritis, and fees for consulting from Abbot and BMS. DOI: 10.1183/09031936.00125607
D. Soussan. The author's study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry. DOI: 10.1183/09031936.00129507
D.S. Southam. The author's study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
S.C. Springmeyer is an employee of Spiration Inc. and has stock options in this company. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
J-P. Stasch has, in the past 5 years, been employed by an organisation that may in any way gain or lose financially from the results of his study or the conclusions of his review, editorial or letter. DOI: 10.1183/09031936.00114407
P.J. Sterk. The Dept of Pulmonology from the Leiden University Medical Center (Leiden, the Netherlands) received an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
P.J. Sterk. In the last 3 years, P.J. Sterk has: received lecture fees from GlaxoSmithKline Netherlands and AstraZeneca; received industry-sponsored grants from GlaxoSmithKline Netherlands; and receives royalties from Elsevier Scientific Publishing. DOI: 10.1183/09031936.00155307
A.G. Stewart has received grant support and been reimbursed conference attendance costs by GSK (UK). DOI: 10.1183/09031936.00119307
P.M. Stewart served as an expert witness on the Committee of Safety of Medicine on Inhaled Steroids 2004-2005. The author's study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
R.A. Stockley has received fees for consultancy as part of an advisory board from GSK, Roche and MSD. Lecture fees have been paid to R.A. Stockley by Talecris and GSK. R.A. Stockley has received industry sponsored grants from AZ, Altana and Talecris, to cover research costs and staff salaries. The author's study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
S.W. Stoloff. In the last 3 years, S.W. Stoloff: has received consultancy payments from Alcon, Altana, AstraZeneca, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, Sanofi-Aventis, Schering-Plough and Teva; serves on boards or advisory boards for Altana, Alcon, AstraZeneca, Dey, Genentech, GlaxoSmithKline, Novartis, Sanofi-Aventis and Schering-Plough; and has received lecture fees from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00155307
D. Stolz. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved: in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
C. Storness-Bliss. This study was funded by Spiration Inc. The funding source had no role in the quantitative CT study conception or design. All CT data analyses were conducted independently of the funding source at the Department of Radiology (Vancouver General Hospital, Vancouver, BC). The primary data are held at the James Hogg iCAPTURE Center. DOI: 10.1183/09031936.00056008
D. Strachan. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
J.R. Stradling. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit (Oxford, UK) in 1998. DOI: 10.1183/09031936.00026608
G. Stratakos. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
Y. Sugiyama. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
S. Suissa has participated in advisory board meetings, conferences and as a speaker in scientific meetings by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pirzer and Sepracor and received research grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00108308 and DOI: 10.1183/09031936.00103008
A.L. Sullivan has no financial interest in any company that may be affected by the published study. She has accepted financial assistance in attending national and international conferences and educational meetings from the following: GlaxoSmithKline, AstraZeneca, Altana Pharma (now Nycomed), Merck Sharp Dohme and Boehringer Ingelheim. A.L. Sullivan has received fees from GlaxoSmithKline for speaking at educational meetings. She also received fees for consultancy work from Altana Pharma, on a matter unrelated to the subject of the published study. The author's study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
B.E. Sullivan. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
S.D. Sullivan has received fees for speaking, research funds and consulting honorarium from Genentech, Inc. and Novartis. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
S.D. Sullivan. In the last 3 years, S.D. Sullivan: has received consultancy payments from Genentech, Novartis and Schering-Plough; has served on advisory boards for Merck, Schering-Plough, GlaxoSmithKline and Novartis; and has received industry-sponsored grants from Amgen, Genentech and Novartis. DOI: 10.1183/09031936.00155307
E. Suzuki. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
A. Swensen is an employee of Novartis Pharmaceuticals Corporation. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
S.J. Szefler. In the last 3 years, S.J. Szefler: has served on advisory boards for AstraZeneca, GlaxoSmithKline, Merck, Genentech, Novartis, Verus, MAP and Schering; has received lecture fees from Merck; and has received industry-sponsored grants from Ross, Division of Abbott. DOI: 10.1183/09031936.00155307
S.J. Szefler has served as a consultant and member of an advisory board for GlaxoSmithKline, Astra Zeneca and Aventis for the past 3 years and received approximately $6,000 per year from each company, and $5,000 per year for 2 years from Merck. He has also received research funds for clinical trial performance from AstraZeneca of $90,000 for 2002-2004 and from Ross Pharmaceuticals of $1,200,000 for 2004-2006. He has no stock ownership or commercial royalties in any of these companies. DOI: 10.1183/09031936.00026808
T Back to top
S. Tajima. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
T. Takada. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
M. Tamm. The author's investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved: in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
S. Tanaka. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
T. Tanigawa has filed a patent entitled 'System and method for automated detection of apnea and hypopnea'. The software used in the study was related to the patent. T. Tanigawa serves as CEO of the Somnonics Co. Ltd, to develop a screening for sleep apnea syndrome in general population, established by the support of the University of Tsukuba. This study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
D.P. Tashkin. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
D.R. Taylor. In the last 3 years, D.R. Taylor has received lecture fees and an industry-sponsored grant from Aerocrine AB, Solna, Sweden. DOI: 10.1183/09031936.00155307
T. Tazzeo. The author's study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
J.G. Teeter. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
M. Thomas has no shares in pharmaceutical companies. In the last 3 years, he has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: AstraZeneca, Boehringer Inglehiem, GSK, MSD, Schering-Plough and Teva. He has received honoraria for attending advisory panels for: Altana, AstraZeneca, BI, GSK, MSD, Merck Respiratory, Schering-Plough and Teva. M. Thomas has received sponsorship to attend international scientific meetings from: GSK, MSD and AstraZeneca. The author has also received funding for research projects from: GSK, MSD and AstraZeneca. He holds a research fellowship from Asthma UK. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
M.D. Thomas. In the last 3 years, M.D. Thomas: has served on advisory boards for GlaxoSmithKline, MSD, Merck Pharmaceutical, Ivax, Altana and Boehringer Ingelheim; has received lecture fees from GlaxoSmithKline, MSD, Merck Pharmaceutical, Ivax, Boehringer Ingelheim and AstraZeneca; and has received industry-sponsored grants from MSD, AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00155307
G. Thomsen. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
V.Ø. Thomsen is employed by the Statens Serum Institut (SSI). The SSI offers the QuantiFERON®-TB Gold analysis for clinical use, distributes the test within the region, and produces tuberculin and the BCG vaccine. V.Ø. Thomsen does not have any personal gain from any of the above. DOI: 10.1183/09031936.00125607
B.P.A. Thoonen. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
D. Thorn is an employee of Novartis Pharmaceuticals Corporation. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
A. Todo-Bom. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
J.W. Tomlinson. The author's study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
C. Tuor. The study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
U Back to top
H. Uemori. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
V Back to top
A. Valiulis has received travel grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Merck Sharp & Dohme for attending annual meetings of the ERS and ATS, as well as honoraria for lectures in satellite symposia of AstraZeneca, BerlinChemie, GlaxoSmithKline and Merck Sharp & Dohme. DOI: 10.1183/09031936.00002108
E. Valovirta. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
W.M.C. van Aalderen has received grants for attending symposia from GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, Altana Pharma, Novartis and Ooms Allergy. He has received speakers' fees from GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Ivax Pharma, Teva Pharma and Meda Pharma. W.M.C. van Aalderen has received fees for organisation of education from de Baar nascholingen, Benecke nascholingen, Nycomed and Scem Conference Services. He has received unrestricted research grants from GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Ivax Pharma, Teva Pharma and Numico. He has received fees for consulting from AstraZeneca, Merck Sharp & Dohme, Ivax Pharma and Teva pharma. DOI: 10.1183/09031936.00002108
T.J. van Boxem. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
Y. van Durme. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
K. Van Gundy has received funding for participating in a portion of the research used to obtain the data used for this publication. The author's study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
A. Van Muylem. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
N. van Rooijen. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
I.H. van Veen is supported by an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
C. van Weel has received <$10000 from AstraZeneca, Bayer and Novonordisk, and >$10,000 from Boehringer Ingelheim, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00088007
C. van Weel is a member of the GOLD Executive. He has received no personal benefits. C. van Weel has received unrestricted research and teaching grants for his university department from AstraZeneca, Bayer, NovoNordisk, Boehringer Ingelheim, GlaxoSmithKline and Novartis. He has no relation to, or income from, the tobacco industry. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
T. van Zele. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Varghese is an employee of Schering-Plough. DOI: 10.1183/09031936.00062307
G.M. Verleden is the present holder of the academic grant for Respiratory Pharmacology from the Katholieke Universiteit Leuven, Belgium which is funded by GlaxoSmithKline. DOI: 10.1183/09031936.00134307.
R. Vessey was an employee of GSK at the time this work was performed and is currently an employee of Merck. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
J. Vestbo has received support for research in COPD from GlaxoSmithKline. He has also received honoraria for advisory board activity and presenting at meetings from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer and Hoffmann-La Roche. J. Vestbo's wife works in the pharmaceutical industry (AstraZeneca) but neither the author nor his wife own shares in any pharmaceutical company. J. Vestbo received an unrestricted research grant from Scandinavian Tobacco Company of approximately 35,000 Euros in 1985. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
J. Vestbo has received support for research in COPD from GlaxoSmithKline; he has received honoraria for advisory board activities and presenting at meetings from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer, and Hoffmann-La Roche. J. Vestbo's wife works in the pharmaceutical industry (AstraZeneca) but neither he nor his wife own shares in any pharmaceutical company. DOI: 10.1183/09031936.00161507
J. Vestbo has received support for research in COPD from GlaxoSmithKline; he has received honoraria for advisory board activity and presenting at meetings from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Pfizer and Hoffmann-La Roche; his wife works in the pharmaceutical industry (AstraZeneca) but neither he nor his wife own shares in any pharmaceutical company. DOI: 10.1183/09031936.00160007
C.M. Villanueva. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
I. Vogiatzis. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
E. von Mutius. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
W Back to top
U. Wahn. With regard to the author's study which appears in the December 2008 issue of the ERJ, costs and expenses to hold a summit meeting and develop the Brussels Declaration discussed were covered with an unrestricted grant-in-aid from Merck. DOI: 10.1183/09031936.00053108
T.G. Walker is employed by and holds stock in GlaxoSmithKline. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University'Industry Partnership program. DOI: 10.1183/09031936.00153207
J. Wattie. The author's study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
E.J.M. Weersink. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Weiland†. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
G. Weinmayr. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
I. Weisman is employed by Pfizer Inc., New York, NY, USA. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
G. Wennergren has been a paid lecturer for AstraZeneca and Merck, and has received fees for helping AstraZeneca in organising an educational symposium for Swedish paediatric allergists. He does not hold stock or options in any pharmaceutical company. DOI: 10.1183/09031936.00002108
S.E. Wenzel has received consulting fees, advisory board fees and speaking fees from Genentech, Inc. Her total reimbursement for the past 5 years from Genentech was US$15,000. In addition, she has been reimbursed for consulting fees, advisory boards and speaking from Merck for a total of US$20,000 over 5 years. S.E. Wenzel has received consulting and speakers fees from Critical Therapeutics of US$20,000 over the past 5 years. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
S.E. Wenzel. In the past 3 years, S.E. Wenzel: has received consultancies from AstraZeneca, GlaxoSmithKline, Merck, Centocor, Genentech and Novartis; has served on advisory boards for AstraZeneca, GlaxoSmithKline, Merck, Novartis and Genentech; has received lecture fees from AstraZeneca, Merck and Critical Therapeutics; and has received industry-sponsored grants from Amgen. DOI: 10.1183/09031936.00155307
J. Wharton has received an educational grant, honoraria and funds towards travel expenses from Pfizer Global Research & Development. DOI: 10.1183/09031936.00124007
J.H. Wildhaber has given lectures for AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme and Nycomed, and has been a national and international advisor for Nycomed and Merck Sharp & Dohme. He has received research grants from AstraZeneca, GlaxoSmithKline and Merck Sharp & Dohme. DOI: 10.1183/09031936.00002108
M.R. Wilkins has received travel reimbursement, lecture fees and/or consulting fees from Pfizer, Actelion and Encysive. M.R. Wilkins has no stocks or other financial interest in companies that might have any interest or benefit from contents dealt with in the author's manuscript. DOI: 10.1183/09031936.00124007
J. Wilson received funding to attend scientific meetings from AstraZeneca Australia Pty Ltd and GlaxoSmithKline Australia Pty Ltd. DOI: 10.1183/09031936.00119307
W. Windisch. The study was supported by 'Werner und M'ller Medizintechnik®' (Bundesrepublik, Germany). DOI 10.1183/09031936.00066407
R.A. Wise. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
S. Wöhrl has received an educational grant from Merck Sharp & Dohme Austria, and fees for speaking from ALK-Abelló and AESCA Pharma. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
A. Woodcock is the inventor on a patent describing the novel methods for cough detection and monitoring, filed by the University Hospital of South Manchester (UK). A. Woodcock has an industrial collaboration and license agreement with Vitalograph UK Ltd to develop a commercial cough monitoring system (Vitalojak). DOI: 10.1183/09031936.00052008
E.F.M. Wouters is a member of the scientific advisory boards of GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Numico, and received lecture fees from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim. He received research grants between 2002 and 2004 from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Centocor and Numico. The author's study was supported by a research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00014008
X Back to top
L. Xing. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University'Industry Partnership program. DOI: 10.1183/09031936.00153207
Y Back to top
H. Yamasawa. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
D.H. Yates. The research group headed by D.H. Yates received the Actelion Endothelin Research Award for a research project into pulmonary hypertension in 2006. DOI: 10.1183/09031936.00160307
R.P. Young is Chief Scientific Officer for Synergenz Biosciences Ltd (Auckland, New Zealand), which part funded the author's study. The author also has stocks in Synergenz Bioscience Ltd. DOI 10.1183/09031936.00093908
S. Young is an employee of AstraZeneca and holds shares in the company. DOI: 10.1183/09031936.00125307
Z Back to top
S. Zakynthinos. The author's study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
M. Zehnder. The ultrasound equipment used in the author's study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
C. Zeitz received the Retinitis pigmentosa prize 2006. She received funds from VELUX and received funds for a member of staff from Hartmann Müller Foundation, Zurich. The author's study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
X. Zhang. The author's work was funded jointly by the Canadian Institutes of Health Research (CIHR; Ottawa, ON, Canada) and GlaxoSmithKline through a CIHR University-Industry Partnership program. DOI: 10.1183/09031936.00153207
Y. Zhang. The author's study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
J-P. Zock. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Zuberbier. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
M. Zureik has received an unrestricted educational grant from Boehringer Ingelheim. The author's study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry.DOI: 10.1183/09031936.00129507
Volume 33, 2009
A Back to top
I.M. Adcock has received educational grants from AstraZeneca, GlaxoSmithKline, Novartis and Pfizer; has received Travel Grants to attend the ERS and ATS from Boehringer-Ingelheim and GlaxoSmithKline; has received Speakers Fees from Novartis and Pfizer and has acted as a consultant for Chiesi, GlaxoSmithKline and Novartis. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
A.L.P. Albuquerque. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy) and licensed to BTS Spa company. DOI: 10.1183/09031936.00141607
A. Aliverti. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy) and licensed to BTS Spa company. DOI: 10.1183/09031936.00141607
J.A. Anderson is employed by and holds shares in GlaxoSmithKline. DOI: 10.1183/09031936.00169908
S.T. Anderson received equal sponsorship from both companies of £210 to present preliminary findings of this study at the Royal College of Paediatrics Spring meeting in York in April 2007. DOI: 10.1183/09031936.00153408
G. Armbrecht received fees for speaking from Procter and Gamble, Nycomed, Daiichi Sankyo and Lilly. DOI: 10.1183/09031936.00073908
G. Atkinson is employed by Pfizer. He receives a salary from Pfizer and holds Pfizer shares and share options. The study was funded by Pfizer. DOI: 10.1183/09031936.00068908
L. Ayers. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit in 1998 and 2006. DOI: 10.1183/09031936.00107408
É. Azoulay has received two research grants from the industry but not in relation to the topic of the current manuscript. DOI: 10.1183/09031936.00164208
B Back to top
J.C. Baird is scientific director of Psychological Applications, which holds the copyright of the computer program used to gather perceptual ratings in this research. DOI: 10.1183/09031936.00145208
A. Baldassarre. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00154008
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for asthma. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for COPD. DOI: 10.1183/09031936.00128008
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of which market treatments for COPD. DOI: 10.1183/09031936.00062708
E. Baró. The NEREA study was funded by an unrestricted grant from J. Uriach y Compañ'a. DOI: 10.1183/09031936.00087208
A. Bartoloni. The author's institution has received in 2007 an unrestricted educational grant (€5,000) from A.D.A. SRL, representative of Cellestis in Italy for the QuantiFERON-TB Gold Test. DOI: 10.1183/09031936.00107608
R.C. Basner. Sanko Junyaku and Eisai Co. Ltd (Tokyo, Japan) kindly performed the KL-6 assays. DOI: 10.1183/09031936.00150708
J. Batles-Garrido. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
R. Beasley has received fees for consulting and speaking and reimbursement for attending symposia from AstraZeneca, GlaxoSmithKline and Novartis. The author is currently undertaking a meta-analysis of the risk of asthma mortality with formoterol based on published Novartis studies and the summary AstraZeneca Safety Database, and a meta-analysis of the risk of asthma mortality with salmeterol based on the summary GSK Safety Database, both funded by MedSafe, Ministry of Health, New Zealand. R. Beasley's institute, the Medical Research Institue of New Zealand, has recieved research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00163408
M. Beau-Faller's travel to the CPLF Congress (Lyon 2007) was funded by Roche. DOI: 10.1183/09031936.00162307
L. Becker. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
Y. Beguin. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium®, Italy. DOI: 10.1183/09031936.00157707
P.Y. Berclaz is an employee of Eli Lilly and Co. and holds Eli Lilly and Co. stock. Eli Lilly and Co. has sponsored this study. Eli Lilly and Co. does not expect to benefit in any way from the results presented in this article. DOI: 10.1183/09031936.00091208
J. Bhattacharya. Sanko Junyaku and Eisai Co. Ltd (Tokyo, Japan) kindly performed the KL-6 assays. DOI: 10.1183/09031936.00150708
B. Björkstén. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
F. Blasi has, in the past 5 years, received reimbursement for attending a symposium. The author reports having received: consulting fees from Pfizer, Sanofi-Aventis, and Altana; lecture fees from Bayer, Sanofi-Aventis, Pfizer, Abbott, Altana, and GlaxoSmithKline; and grant support from Pfizer and Altana. DOI: 10.1183/09031936.00167707
T. Blenk has received fees for speaking from MSD, Procter and Gamble, and Sanofi Aventis. T. Blenk has received travel to congresses was funded by Procter and Gamble and Roche. DOI: 10.1183/09031936.00073908
W. Boersma has received financial compensation for educational activities for the Dutch Respiratory Society. He received a grant from GlaxoSmithKline for research activities performed at the Medical Centre Alkmaar (Alkmaar, the Netherlands). DOI: 10.1183/09031936.00166908
E.K.Borton has been partially funded via grants from ConAgra through the University of Cincinnati College of Medicine for his involvement in the medical surveillance program. E.K. Borton has received funding from ConAgra for conduction medical surveillance. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
A. Bosch. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
L-P. Boulet has sat on Advisory Boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis. He has received lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis; sponsorship for investigator-generated research from AstraZeneca, GSK, Merck Frosst, Schering; and research funding for participating in multicenter studies from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen, Wyeth. L-P. Boulet has received support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst; and in an adviser for the Conseil du Médicament du Québec Member of the Quebec Workmen Compensation Board Respiratory Committee. He is the Chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee, Co-leader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence and the holder of the Laval University Chair on knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. DOI: 10.1183/09031936.00120407
L-P. Boulet is on the advisory board for AstraZeneca, GlaxoSmithKline, Novartis and Schering-Plough. He has received lecture fees from Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst, Novartis and Medimmune and sponsorship for investigator-generated research from AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering-Plough and Novartis. L-P. Boulet has received research funding for participating in multicenter studies from Alexion, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Ception, GlaxoSmithKline, Genentech, IVAX, Medimmune, Novartis, Topigen and Wyeth. He has received support for the production of educational materials and initiatives from AstraZeneca, GlaxoSmithKline and Merck Frosst. He is the adviser for the Conseil du Médicament du Québec, Member of the Quebec Workmen Compensation Board Respiratory Committee. He is the Chair of the Canadian Thoracic Society Respiratory Guidelines Committee. Ex-officio member of the Board of Director of the Canadian Network of Centers of Excellence 'Allergen', Holder of the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. DOI: 10.1183/09031936.00121308
L-P. Boulet is on the advisory board for AstraZeneca, Altana, GlaxoSmithKline, Novartis and Merck Frosst. He has received lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst, and Novartis and sponsorship for investigator-generated research from AstraZeneca, GlaxoSmithKline, Merck Frosst and Schering-Plough. L-P. Boulet has received research funding for participating in multicenter studies from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, GlaxoSmithKline, Genentech, IVAX, Medimmune, Merck Frosst, Novartis, Roche Schering, Topigen and Wyeth. He has received support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst. He is the adviser for the Conseil du Médicament du Québec, Member of the Quebec Workmen Compensation Board Respiratory Committee. He is the Chair of the Canadian Thoracic Society Respiratory Guidelines Committee. Ex-officio member of the Board of Director of the Canadian Network of Centers of Excellence 'Allergen'', Holder of the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. DOI: 10.1183/09031936.00117708
D. Bölkow. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. DOI: 10.1183/09031936.00039808
L.P. Boulet has, within the past 5 yrs, been on advisory boards for AstraZeneca, GlaxoSmithKline, Novartis and Schering-Plough, and received lecture fees from Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst, Novartis and MedImmune. He has received sponsorship for investigator-generated research from AstraZeneca, GlaxoSmithKline, Merck Frosst, Novartis and Schering-Plough, and research funding for participating in multicentric studies from Alexion, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Ception, GlaxoSmithKline, Genentech, IVAX, MedImmune, Novartis, Topigen and Wyeth. L.P. Boulet has also received support for the production of educational materials and initiatives from AstraZeneca, GlaxoSmithKline and Merck Frosst. Governmentally, he has been an adviser to the Conseil du Médicament du Québec and Member of the Quebec Workmen Compensation Board Respiratory Committee. L.P. Boulet has also had the following organisational responsibilities: Chair of the Canadian Thoracic Society 'Canadian Respiratory Guidelines Committee'; Ex-officio member of the Board of Directors of the Canadian Network of Centers of Excellence 'AllerGen'; holder of the Laval University Chair on knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; consultant to the International Olympic Committee, the Quebec Workmen's compensation Board and the Quebec Government 'Conseil du medicament'; and Director of the Laval Hospital Center for evaluation of cardiorespiratory health of athletes. DOI: 10.1183/09031936.00169008
J. Bourbeau has received fees for speaking at conferences and for serving as an expert on advisory boards for AstraZeneca, BI, GSK and Pfizer. The author's MUHC Research Institute received research grants for investigator-initiated researches and unrestricted educational grants from AstraZeneca, BI, GSK and Pfizer. DOI: 10.1183/09031936.00001309
G. Bourg-Heckly. The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
L. Bråbäck. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
G. Braganza. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
P.L.P. Brand has received fees for lecturing, consultancy, and for research activities from GlaxoSmithKline, AstraZeneca, Nycomed, and Merck DOI: 10.1183/09031936.00166008
M. Brannigan. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
H. Bremer. The study has been partly sponsored by ResMed. DOI: 10.1183/09031936.00023408.
V. Brusasco has received €11,625 for serving on an advisory board for Byk Goulden in 2003. He also received€11,625 in 2004, €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana. He received €5,000 in 2003, €3,000 in 2004, and €3,000 in 2005 from Lofarma for consultancies. V. Brusasco received €2000 in 2007 from Valeas for consultancy. He received €812 in 2003 for speaking in a symposium and €3,750 in 2004 from MSD for consultancy. For speaking at conferences sponsored by Boehringer Ingelheim he received €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €9,200 in 2007 and €3,000 in 2008. He received £960 and €1300 in 2006 and €1200 from GSK for participating in a advisory boards. He received €6,000 in 2006 and €3000 in 2007 from Almirall for serving in an advisory board. V. Brusasco received €3,000 in 2006 from Forest Laboratories for serving in an advisory board. His institution received €20,000 in 2006 as unrestricted research grant from Boehringer Ingelheim as an unrestricted research grant from Boehringer Ingelheim, and participated in several multi-centre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031963.00165208
V. Brusasco has received: $9,300 as speaker's fee from Boehringer Ingelheim in 2008; $3,000 for serving on an advisory board for Altana in 2008; $3,000 for serving on an advisory board for Forest Laboratories in 2008. DOI: 10.1183/09031936.00183708
G. Büchele. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
C. Bussinger. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
C Back to top
P.M.A. Calverley. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy) and licensed to BTS Spa company. DOI: 10.1183/09031936.00141607
P.M.A. Calverley has spoken at meetings supported by GlaxoSmithKline (GSK), AstraZeneca and Chiesi. He has advised on trial design and research strategy for AstraZeneca, Boehringer Ingeheim, GSK, Roche, Nycomed, Almirall and Pfizer. His department has received research funding from GSK, Altana and Chiesi to conduct clinical trials and observational research in COPD. DOI: 10.1183/09031936.00169908
J-L. Canivet. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium, Italy. DOI: 10.1183/09031936.00157707
K-H. Carlsen has received, during the last five years: fees for speaking from Merck, GlaxoSmithKline AstraZeneca; and fees for consulting from GlaxoSmithKline and UCB during the last five years. DOI: 10.1183/09031936.00001209
K-H. Carlsen has received honoraria for giving presentations from Merck, GlaxoSmithKline and AstraZeneca. The author has also received honoraria for consultations from GlaxoSmithKline and UCB. DOI: 10.1183/09031936.00011909.
J.M. Cashman. Pulse oximeters were provided by Datex-Ohmeda, a GE Healthcare division in Louisville, CO, USA. DOI: 10.1183/09031936.00063108
B. Celli has been reimbursed by GlaxoSmithKline, Boehringer-Ingelheim, AstraZeneca and Almirall for participating in advisory boards, and speaking at various meetings. The Division he heads has been awarded research grants for different medication trials and for the discovery of new biomarkers in COPD. DOI: 10.1183/09031936.00169908
B. Chakrabarti. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy) and licensed to BTS Spa company. DOI: 10.1183/09031936.00141607
M. Chatwin. The AutoVPAP and VPAP III devices used in the study were provided by ResMed Co. DOI: 10.1183/09031936.00065008
R. Chaudhuri. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
Y-Z. Chen. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
D.W. Cockroft has, within the last 5 yrs, received research grant support from Wyeth, Genentech, MedImmune, IVAX, Topogen, Merck Frosst and Methapharm. He has received speaking fees from Astra Zeneca and GlaxoSmithKline, and travel support from Merck (ERS, 2008) and GlaxoSmithKline (ECACI, 2004). D.W. Cockroft has been on advisory boards for Astra Zeneca, Merck Frosst, Methapharm, Abbott and Novartis. DOI: 10.1183/09031936.00169008
J.G. Coghlan has provided consultancy services for Actelion and Encysive, as well as speaking at conferences and meetings sponsored by them. In addition 2 nurses in his unit are funded by Actelion and Encysive respectively. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
R. Condliffe has received funding for travel to symposia and conferences from Actelion and Encysive pharmaceuticals. He has also received an honorarium for speaking from Actelion. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
M. Connell. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
J-F. Cordier has received fees for speaking and organising education from Actelion, Pfizer and Glaxo. DOI: 10.1183/09031936.00161808
P.A. Corris has sat on advisory boards for Actelion and Pfizer and has received honoraria for speaking from Actelion and Encysive. He has acted as an expert witness for Pfizer. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
V. Cottin has received fees for lectures on pulmonary hypertension in 2006 and 2007 from Actelion Pharmaceuticals, Ltd. V. Cottin participates as investigator in clinical trials from Actelion Pharmaceuticals, United Therapeutics, and Pfizer. DOI: 10.1183/09031936.00161808
H.O. Coxson received CND$11,000 in 2005 for serving on an advisory board for GSK. In addition, the author is the co-investigator on two multi-centre studies sponsored by GSK and has received travel expenses to attend meetings related to the project. H.O. Coxson has three contract service agreements with GSK to quantify the CT scans in subjects with COPD. A percentage of the author's salary between 2003 and 2006 (US$15,000/year) derives from contract funds provided to a colleague, P.D. Pare, by GSK for the development of validated methods to measure emphysema and airway disease using computed tomography. H.O. Coxson is the co-investigator (D. Sin) on a Canadian Institutes of Health & Industry (Wyeth) partnership grant. There is no financial relationship between any industry and the current study. DOI: 10.1183/09031936.00106607
S. Craig. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit in 1998 and 2006. DOI: 10.1183/09031936.00107408
R. Crapo has received money from Lilly to review pulmonary function data. Eli Lilly and Co. has sponsored this study. Eli Lilly and Co. does not expect to benefit in any way from the results presented in this article. DOI: 10.1183/09031936.00091208
D Back to top
B. Dahlén. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
S-E. Dahlén has received research grants and been consulted by AstraZeneca. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
D. Damjanovic. The study has been partly sponsored by ResMed. DOI: 10.1183/09031936.00023408.
M. Dayer. The AutoVPAP and VPAP III devices used in the study were provided by ResMed Co. DOI: 10.1183/09031936.00065008
F.M. de Benedictis reports receiving research support and consulting fees from GlaxoSmithKline, MerckSharpDohme, Chiesi Fermaceutici, UCB; travel to the ERS congress was funded by GlaxoSmithKline. No other potential conflict of interest is reported. DOI: 10.1183/09031936.00177408
R. de Castellar. The NEREA study was funded by an unrestricted grant from J. Uriach y Compañ'a. DOI: 10.1183/09031936.00087208
M. Decramer. The activity monitors used in the author's study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
L. de Leval. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium®, Italy. DOI: 10.1183/09031936.00157707
R.L. Dellacà works at the Politecnico di Milano University, which owns a patent on the detection of Expiratory Flow Limitation by forced oscillation technique. DOI: 10.1183/09031936.00139608
C. Deng is an employee of Talecris Biotherapeutics, Inc. The author's study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00159408
E. Derom received $1,950 in 2002, $2,280 in 2003 and $2,495 in 2004 for serving on an advisory board for GlaxoSmithKline. He received $1,000 in 2008 for serving on an advisory board of AstraZeneca (Belgium). E. Derom received $106,930 for the period 2003-2005 from Altana Pharma, $5,890 for the period 2003-2005 from GlaxoSmithKline, $100,280 in 2004 from SGS-Biopharma and $188,900 in 2003-2007 from Novartis as research grants for participating in clinical trials. The author has also received a grant from AstraZeneca to allow him to attend the ATS Congress in 2004, a grant from Altana Pharma to attend the 2005 ERS Congress, a grant from GlaxoSmithKline to attend the 2006 ERS Congress, a grant from Boehringer Ingelheim to attend the 2007 ERS Congress and a grant from Nycomed to attend the ATS Congress. The author's study was funded by Nycomed Pharma. DOI: 10.1183/09031936.00079908
B. Dervaux. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
S.C. Dharmage. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
A. Dirksen. This study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). The randomised clinical trial was funded by Talecris, and presentation of results at scientific meeting by the authors was funded as well. DOI: 10.1183/09031936.00159408
R. Djukanovic has received educational grants from GlaxoSmithKline and AstraZeneca. He has shares in and consults for Synairgen. Travel to the ERS and ATS was funded by Boehringer Ingelheim. DOI: 10.1183/09031936.00163408
S. Dominique. The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
E. Donado. The NEREA study was funded by an unrestricted grant from J. Uriach y Compañ'a. DOI: 10.1183/09031936.00087208
I. Donnelly. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
L.E. Donnelly has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for COPD. DOI: 10.1183/09031936.00062708
F. Drobniewski has been reimbursed for travel costs for attending an IGRA symposium. DOI: 10.1183/09031936.00019709
L. Dupont. The activity monitors used in the author's study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
E Back to top
S. Ehlers has received a fee for presenting data at a satellite meeting and two investigator-initiated research grants from Amgen. DOI: 10.1183/09031936.00120908
T. Ekström. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
R. Engelstätter is an employee of Nycomed Pharma (Konstanz, Germnay). The author's study was funded by Nycomed Pharma. DOI: 10.1183/09031936.00079908
B. Erbas. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
P. Escourrou. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
S. Ewig has, in the past 5 years, received: reimbursement for attending a symposium; a fee for speaking; and a fee for organising education. The author has received fees from Bayer Vital, Wyeth, MSD, Pfizer, Novartis, Boehringer Ingelheim and Aventis. DOI: 10.1183/09031936.00004509
F Back to top
J.A. Falch has received lecture fees from Pfizer, Novartis, MSD, Sanofi-Aventis, Novo Nordisk, Roche, GSK, Eli Lilly, Nycomed and Pharmacia. J.A. Falch has also received funding for travel to congresses from MSD, Eli Lilly, GSK, Sanofi Aventis, Novartis and Amgen. DOI: 10.1183/09031936.00073908
K. Feldmann. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
G.T. Ferguson has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Schering Plough; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Altana, Boehringer-Ingelheim, Emphasys Medical Inc, Forrest, GlaxoSmithKline, Mannkind Corporation and Novartis. DOI: 10.1183/09031936.00169908
B. Ferry. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit in 1998 and 2006. DOI: 10.1183/09031936.00107408
C. Fiorelli. The author's institution has received in 2007 an unrestricted educational grant (€5,000) from A.D.A. SRL, representative of Cellestis in Italy for the QuantiFERON-TB Gold Test. DOI: 10.1183/09031936.00107608
A. Fluck. The study has been partly sponsored by ResMed. DOI: 10.1183/09031936.00023408.
R. Frey. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. R. Frey is an employee of Bayer HealthCare AG, Wuppertal, Germany. DOI: 10.1183/09031936.00039808
G Back to top
G. Garcia-Hernandez. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
A. Gazdar is a consultant/lectures for Astrazeneca, Genentech and Boehringer-Mannheim. Over 5 years ago, the author acted as a reviewer of grants for the Philip Morris Research Program and received payment at that time from Philip Morris for this role. DOI: 10.1183/09031936.00014009
B. Ghaye. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium®, Italy. DOI: 10.1183/09031936.00157707
H-A. Ghofrani. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. H-A. Ghofrani has received honoraria from Actelion, Pfizer, Bayer Schering, Encysive and Altana Pharma, and research grant support from Encysive, Pfizer, Ergonex and Altana Pharma. DOI: 10.1183/09031936.00039808
J.S.R. Gibbs has served on advisory boards for Actelion, Encysive, Pfizer and GSK pharmaceuticals. He has also received honoraria for speaking from Actelion. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
K. Goldsmith. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
D. Goletti has received a grant (€7,000) from Oxford Immunotec to pay a technician during 2007'2008. The author has a patent pending on immune assay for TB. However, it is not related to the matter of the present manuscript. DOI: 10.1183/09031936.00107608
H. Golpon has, in the past 5 years, received fees for consulting. DOI: 10.1183/09031936.00193309
R. Gosselink. The activity monitors used in the author's study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
F. Grimminger. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. F. Grimminger has received honoraria from Actelion, Pfizer and Altana Pharma, and research grant support from Bayer Schering, Actelion, Encysive, Pfizer, Aventis and Altana Pharma. DOI: 10.1183/09031936.00039808
F. Grimminger has received an educational grant from Pfizer, Actelion, Bayer, Schering and Novartis; has no stocks or other financial interest in companies that might have interest or benefit from contents dealt with in this manuscript. F. Grimminger has received lecture fees from: Actelion, Pfizer, Bayer, Schering, Encysive and GlaxoSmithKline. DOI: 10.1183/09031936.00109008
H Back to top
A. Hansen. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00140408
H. Harving. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00140408
J. Heinrich. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
E. Henriksson. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
T.J. Hilbert has been partially funded via grants from ConAgra through the University of Cincinnati College of Medicine for his involvement in the medical surveillance programme. T.J. Hillbert has received funding as a consultant to ConAgra, for the presentation of preliminary results of the medical surveillance program to various United States Federal agencies, and for conducting medical surveillance. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
M.M. Hoeper has received fees for consultations and lectures from Actelion Pharmaceuticals and Encysive Pharmaceuticals DOI: 10.1183/09031936.00193308
M.M. Hoeper has received fees for consultations and lectures from Actelion Pharmaceuticals and Encysive Pharmaceuticals. DOI: 10.1183/09031936.00193308
H. Hoffmann. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
S. Hofmann-Thiel. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
J.H. Huibers. The study was funded by a grant from Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00116308
M. Humbert has relationships with drug companies including Actelion, Bayer Schering, GSK, Novartis, Pfizer, and United Therapeutics. In addition to being investigators in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00094808
I Back to top
M. Idzko. ERS annual congress 2005, Copenhagen, oral presentation from the study sponsored by ResMed. The study has been partly sponsored by ResMed. DOI: 10.1183/09031936.00023408.
E. Ihre. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
M.S-M. Ip has received travel support from Resmed to attend a Task Force meeting of the International Diabetes Federation. DOI: 10.1183/09031936.00075408
A. Ishizaka. Sanko Junyaku and Eisai Co. Ltd (Tokyo, Japan) kindly performed the KL-6 assays. DOI: 10.1183/09031936.00150708
K. Ito. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
I. Izquierdo. The NEREA study was funded by an unrestricted grant from J. Uriach y Compañia. DOI: 10.1183/09031936.00087208
J Back to top
L.J. Janssen has, in the past 5 years, received: operating grant support from AstraZeneca and GlaxoSmithKline; and a consultancy fee from GlaxoSmithKline. DOI: 10.1183/09031936.00068508
W. Janssens. The activity monitors used in the author's study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
D. Jarvis. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
J. Jaye receives a salary from the ResMed. The AutoVPAP and VPAP III devices used in the study were provided by ResMed Co. DOI: 10.1183/09031936.00065008
S. Jelic. Sanko Junyaku and Eisai Co. Ltd (Tokyo, Japan) kindly performed the KL-6 assays. DOI: 10.1183/09031936.00150708
C.R. Jenkins has received fees for organising and speaking at educational symposia sponsored by GlaxoSmithKline; her institute receives predominantly project-based, but some untied funding for research. DOI: 10.1183/09031936.00169908
D.P. Jenkins. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
R. Jensen has received money from Lilly to review pulmonary function data. Eli Lilly and Co. has sponsored this study. Eli Lilly and Co. does not expect to benefit in any way from the results presented in this article. DOI: 10.1183/09031936.00091208
L. Jolly. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings, and received support for research from pharmaceutical companies, including GlaxoSmithKline. DOI: 10.1183/09031936.00169908
R.H. Jones. Pulse oximeters were provided by Datex-Ohmeda, a GE Healthcare division in Louisville, CO, USA. DOI: 10.1183/09031936.00063108
G.F. Joos has received funding from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, UCB, lecture fees from GlaxoSmithKline, AstraZeneca, Novartis, Almirall and has served on Scientific Boards for GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, MSD and Altana Pharma. The author's study was funded by Nycomed Pharma. DOI: 10.1183/09031936.00079908
L. Jörgensen. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
K Back to top
P. Kardos, in the past 3 years, has served on advisory boards for Chiesi, GlaxoSmithKline, Janssen-Cilag, and Novartis; received lecture fees from AstraZeneca, Boehringer Ingelheim, Cephalon, Chiesi, Janssen-Cilag, Novartis and Pfizer; participated in sponsored clinical trials (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Novartis) and has been reimbursed for attending scientific symposia from AstraZeneca, Chiesi, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00138808
J-M. Kaufman. The author's study was funded by Nycomed Pharma. DOI: 10.1183/09031936.00079908
O.N. Keene is a full-time employee of GlaxoSmithKline and holds shares in the company. DOI: 10.1183/09031936.00169908
L. Kheirandish-Gozal is partially supported by an investigator-initiated grant from Merck Company. DOI: 10.1183/09031936.00130608
D.G. Kiely has received consultancy and lecturing fees and been funded to attend conferences from Actelion, GSK, Pfizer, Encysive and Schering Pharmaceuticals. He has also received funding from Actelion for nursing staff. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
D. Kilpatrick has received research and administrative support from Actelion. Speaking honoraria from Actelion have been donated to a research fund DOI: 10.1183/09031936.00001208
K. Knobil is employed by GlaxoSmithKline and holds shares in GlaxoSmithKline. DOI: 10.1183/09031936.00169908
P.B. Koff. Pulse oximeters were provided by Datex-Ohmeda, a GE Healthcare division in Louisville, CO, USA. DOI: 10.1183/09031936.00063108
M. Kohler. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit in 1998 and 2006. DOI: 10.1183/09031936.00107408
D. Kotz. The study was funded by a grant from Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00116308
S.R. Kristiensen. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00140408
J-M. Kuhnigk is an employee of MeVis Research. DOI: 10.1183/09031936.00109808
W. Kummer has received a research grant from Boehringer Ingelheim Inc. DOI: 10.1183/09031936.00015108
L Back to top
S. Lachkar. The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
J. Lafferty. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
D.C-L. Lam has received reimbursement from Celki Company for attending a Refresher course in sleep medicine in Hong Kong. DOI: 10.1183/09031936.00075408
J.C-M. Lam attended the 2006 World Congress of Sleep (Montreal, Canada) and was funded by Respironics. DOI: 10.1183/09031936.00075408
C. Lange has received speaker's honoraria for attending scientific symposia/conferences that were supported by Cellestis and Oxford Immunotec during 2006-2008. DOI: 10.1183/09031936.00019709
D. Langer. The activity monitors used in the author's study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
A-S. Lantz. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
K. Larsson has, during the past 5 yrs, on one or more occasions served on an advisory board and/or served as speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MSD and Pfizer. K. Larsson has also received unrestricted research grants from Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca during the past 5 yrs. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
P. Latzin. Travel to the ERS infant lung function course in Nice 2007 was paid for by EcoMedics AG. DOI: 10.1183/09031936.00084008
P. Lavie is a consultant of Itamar Medical and received a grant, research equipment and travel support from Itamar Medical. P. Lavie has stocks in Itamar Medical and SLP. DOI: 10.1183/09031936.00086608
R. Lazor. The Swiss group for Interstitial and Orphan Lung Diseases (SIOLD) founded by R. Lazor receives financial support from Actelion. R. Lazor's travel to one ERS Congress was partially financed by Actelion. DOI: 10.1183/09031936.00161808
D. Lederer. Sanko Junyaku and Eisai Co. Ltd (Tokyo, Japan) kindly performed the KL-6 assays. DOI: 10.1183/09031936.00150708
G.K. LeMasters. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
X. Lenne. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
L.P. Levin. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
P. Lévy. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
M. Leyk is an employee of Eli Lilly and Co. and holds Eli Lilly and Co. stock. Eli Lilly and Co. has sponsored this study. Eli Lilly and Co. does not expect to benefit in any way from the results presented in this article. DOI: 10.1183/09031936.00091208
C. Llor. The NEREA study was funded by an unrestricted grant from J. Uriach y Compañia. DOI: 10.1183/09031936.00087208
J.E. Lockey has received funding as a consultant to ConAgra and for the presentation of preliminary results of the medical surveillance programme to various United States Federal agencies. J. Lockey has received grants from ConAgra through the University of Cincinnati College of Medicine for directing and analysing the data of the medical surveillance programme and for salary support of contributing faculty and support staff. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
H. Lode has in the past 5 years, received: reimbursement for attending a symposium; fees for speaking; fees for organising education; and funds for research. The author has worked as consultant and speaker for Pfizer, Bayer-Schering, Janssen, Sanofi-Aventis, Astellas and Wyeth. DOI: 10.1183/09031936.00004509
R. Louis. The author's study was funded by Nycomed Pharma. DOI: 10.1183/09031936.00079908
R. Louis. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00154008
C.M. Luna has received an Independent Research Grant from Pfizer for a study on experimental pneumonia in pigs. DOI: 10.1183/09031936.00046308
M Back to top
J. Maclay. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
W. MacNee has been reimbursed for travel by GlaxoSmithKline for attending conferences, has received honoraria from GlaxoSmithKline for participating as a speaker in scientific meetings and serves on an advisory board and expert panel for GlaxoSmithKline. Research grants to support work carried out in W. MacNee's laboratory come from Pfizer, GlaxoSmithKline and Unilever. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
N. Madershahian. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
H. Magnussen. The author's study was supported by an unrestricted research grant from AstraZeneca and by the Dr. Fritz Meyer Struckmann Foundation. The funding sources had no role in the study design, collection, analysis, or interpretation of the data or in the decision to submit the paper for publication. DOI: 10.1183/09031936.00024608
G. Mair. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
A. Mallart. The author's study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
A. Mantella. The author's institution has received in 2007 an unrestricted educational grant (€5,000) from A.D.A. SRL, representative of Cellestis in Italy for the QuantiFERON-TB Gold Test. DOI: 10.1183/09031936.00107608
F.D. Martinez has received: consultancy fees from MedImmune and GlaxoSmithKline; Advisory Board fees from Merck and MedImmune; and lecture fees from Merck and Genentech, Inc. DOI: 10.1183/09031936.00163408
D. McAllister. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
R.T. McKay was partially funded by ConAgra Foods for the design of a pulmonary surveillance and spirometry quality assurance programme. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
C. McSharry. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
B. Mennecier has served on an Advisory Board for Roche on Tarceva. The author's travel to ESMO Symposium on Chest Tumors (2005 Hambourg) was funded. DOI: 10.1183/09031936.00162307
T. Meyer. The author's study was supported by an unrestricted research grant from AstraZeneca and by the Dr. Fritz Meyer Struckmann Foundation. The funding sources had no role in the study design, collection, analysis, or interpretation of the data or in the decision to submit the paper for publication. DOI: 10.1183/09031936.00024608
E.D. Michelakis has received honoraria/consultancies from Pfizer, Encysive and Actelion to the total amount of less than US$10,000 over the past 5 years. DOI: 10.1183/09031936.00010609
A. Michils. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00154008
J.J. Miller. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
M. Miravitlles. The NEREA study was funded by an unrestricted grant from J. Uriach y Compañ'a. DOI: 10.1183/09031936.00087208
A. Molard's travel to the CPLF Congress (Lyon 2007) was funded by Roche. DOI: 10.1183/09031936.00162307
S. Moreno-Swirc. The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
D. Moro-Sibilot has received reimbursement for attending a symposium from Roche, Sanofi-Aventis, AstraZeneca and Lilly laboratories. He has received fees for speaking from Roche, Sanofi-Aventis, AstraZeneca and Lilly laboratories and a fee for organising education from Roche, Sanofi-Aventis and Lilly laboratories. D. Moro-Sibilot has received funds for research from Sanofi-Aventis laboratories and fees for consulting from Roche, Sanofi-Aventis and Lilly laboratories. DOI: 10.1183/09031936.00132008
M.J. Morrell has collaborated on the research grant from ResMed awarded to A.K. Simonds. The AutoVPAP and VPAP III devices used in the study were provided by ResMed Co. DOI: 10.1183/09031936.00065008
D. Muchmore is an employee of Eli Lilly and Co. and holds Eli Lilly and Co. stock. Eli Lilly and Co. has sponsored this study. Eli Lilly and Co. does not expect to benefit in any way from the results presented in this article. DOI: 10.1183/09031936.00091208
W. Mück. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. W. Mück is an employee of Bayer HealthCare AG, Wuppertal, Germany. DOI: 10.1183/09031936.00039808
C. Mühlfeld. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
T. Müller has received speaking fees of €500 from Novalung/Talheim, Germany for a lecture at a conference as well as €1000 for consultancies on High Frequency Oscillatory Ventilation from Novalung. DOI: 10.1183/09031936.00123608
J. Müller-Quernheim. The study has been partly sponsored by ResMed. DOI: 10.1183/09031936.00023408.
J. Mullol has received a fund for research from Uriach S.A and MSD, fees for consulting from Uriach S.A and Schering-Plough, and fees for speaking from Almirall Prodespharma, Uriach S.A and Schering-Plough. DOI: 10.1183/09031936.00017408
J.T. Murchison. The author's study was partially funded by Pfizer. DOI: 10.1183/09031936.00111808
G. Murmusaeva. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
N Back to top
G. Nagel. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
R. Nagib. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
D. Nicoll. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit in 1998 and 2006. DOI: 10.1183/09031936.00107408
D. Norbäck. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
W. Nystad. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
O Back to top
P.M. O'Byrne has been on advisory boards for AstraZeneca, Biolipox, GlaxoSmithKline, Merck, Nycomed, Topigen, Resistentia and Wyeth, and has received lecture fees from these and other pharmaceutical companies, including Chiesi and Ono Pharma. In addition, P.M. O'Byrne has received grants-in-aid for research studies from AstraZeneca, Boehringer, Genentech, GlaxoSmithKline, MedImmune, Merck, Pfizer, Schering and Wyeth. DOI: 10.1183/09031936.00169008
M. Ochs. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
K.M. Olsson has, in the past 5 yrs, received fees for consulting. DOI: 10.1183/09031936.00193309
C.F. Opitz is a consultant/investigator for Bayer-Schering. DOI: 10.1183/09031936.00033809
A. Ottosson is a full-time employee of AstraZeneca R&D, Lund, Sweden. The author has, in the past 5 years, received reimbursement for attending a symposium. DOI: 10.1183/09031936.00145006
P Back to top
D.G. Parr. This study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00159408
D. Payne has received lecture and consultancy fees from Astra Zeneca. He has also received lecture fees and assistance with travel/accomodation from Kyorin Pharmaceuticals. DOI: 10.1183/09031936.00172608
A.J. Peacock has received lecture fees, consultancy fees, advisory board fees and funding for staffing from Pfizer, Actelion, Encysive and GSK. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008 and DOI: 10.1183/09031936.00147608
A.J. Peacock has received compensation for advice to pharmaceutical companies (Actelion, Encysive, Pfizer, Myogen, United Therapeutics), but none of the advice related to the subject of this review. DOI: 10.1183/09031936.00139907
R. Peché . AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00154008
J. Pedersen. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00140408
A. Pedotti works at the Politecnico di Milano University, which owns a patent on the detection of Expiratory Flow Limitation by forced oscillation technique. DOI: 10.1183/09031936.00139608
J-L. Pépin. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
J. Pepke-Zaba has participated as a speaker in scientific meetings funded by Actelion, Schering, Pfizer and GSK. She has served on advisory boards for Actelion, Encysive and Pfizer. She has also received a joint educational grant from Actelion, LungRx, Pfizer and Schering. The author's study was supported by unrestricted educational grants from Actelion, LungRx, Pfizer and Schering. DOI: 10.1183/09031936.00092008
C. Picado has received funds for research from AstraZenecaa, GSK, Uriach S.A and MSD, fees for consulting from MSD, Uriach S.A and Stallergenes, and fees for speaking from AstraZeneca, GSK, Uriach and MSD. DOI: 10.1183/09031936.00017408
E. Piitulainen. This study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00159408
M.I. Polkey has received fees for lecturing or for advisory boards from GSK, AstraZeneca and Novartis. Through his hospital and university he holds grants from the Wellcome trust, PortAero and GSK, which entail measurement of daily physical activity. DOI: 10.1183/09031936.00176808
P.P. Pompilio works at the Politecnico di Milano University, which owns a patent on the detection of Expiratory Flow Limitation by forced oscillation technique. DOI: 10.1183/09031936.00139608
J-C. Preiser. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium®, Italy. DOI: 10.1183/09031936.00157707
Q Back to top
M. Quaranta. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy) and licensed to BTS Spa company. DOI: 10.1183/09031936.00141607
E. Quoix has served as an expert in two meetings of international experts for the development of Tarceva and Avastin. DOI: 10.1183/09031936.00162307
R Back to top
K.F. Rabe has consulted, participated in Advisory Board meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceuticals, Pfizer, Novartis, AltanaPharma, MSD and GSK. The author holds no stock or other equities in pharmaceutical companies. The Department of Pulmonology, and thereby K.F. Rabe as Head of the department, has received grants from AltanaPharma, Novartis, Bayer, AstraZeneca, Pfizer, MSD, Exhale Therapeutics, Boehringer Ingelheim, Roche and GSK in the years 2001-2006. DOI: 10.1183/09031936.00163408
K.F. Rabe has consulted, participated in Advisory Board Meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceuticals, Pfizer, Novartis, AltanaPharma, MSD and GSK. Professor Rabe holds no stock or other equities in pharmaceutical companies. The Department of Pulmonology, and thereby Professor K.F. Rabe as head of the department, has received grants from AltanaPharma, Novartis, Bayer, AstraZeneca, Pfizer, MSD, Exhale Therapeutics, Boehringer Ingelheim, Roche and GSK in the years 2001-2008. DOI: 10.1183/09031936.00176808
J-L. Racineux. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
M. Radermecker. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium®, Italy. DOI: 10.1183/09031936.00157707
F. Radner is a full-time employee of AstraZeneca R&D, Lund, Sweden. The author has, in the past 5 years, received reimbursement for attending a symposium. DOI: 10.1183/09031936.00145006
C. Raherison. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
P. Ravn was a consultant for Cellestis Ltd in 2006 to develop their clinical guidelines and received a single payment of €2000. P. Ravn has been invited as a speaker by Cellestis, Abbott and Schering-Plough and received funding for research from Abbott and Schering-Plough. P. Ravn is registered as inventor on a patent application disclosing IP-10 as marker for M. tuberculosis infection. DOI: 10.1183/09031936.00120908
S.E. Rees is a board member and shareholder of OBI APS. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00140408
D. Reid has received funding totalling $100,000 from Novartis Pharmaceuticals for a single centre investigator-driven research project. DOI: 10.1183/09031936.00001208
C.H. Rice. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
J. Richter. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
R. Rodriguez-Roisin has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Kyorin, Novartis and Pfizer; consulted with several pharmaceutical companies (Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, and Pfizer); serves on advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Pfizer, and Procter and Gamble; has been sponsored for several clinical trials by, and received laboratory research support from, Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Esteve, and Pfizer. DOI: 10.1183/09031936.00019009
L.J. Rubin has received reimbursement for attending a symposium, a fee for speaking, a fee for organising education, funds for a member of staff and is a consultant/investigator for Bayer-Schering and Actelion Pharmaceuticals. DOI: 10.1183/09031936.00033809
A-M. Ruppert's travel to the ESMO Symposium (Geneva 2007) was funded by Roche. DOI: 10.1183/09031936.00162307
P.H. Ryan. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
S Back to top
M. Salaün. The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
M. Sapene. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
Y. Saraclar. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
I-M. Schaefer. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
R.T. Schermuly. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. R.T. Schermuly has received honoraria from Actelion, Encysive and Bayer Schering, and research grant support from Bayer Schering, Actelion, Encysive, Pfizer and Ergonex. DOI: 10.1183/09031936.00039808
A. Schneider has, in the past 5 yrs, received fees for consulting. DOI: 10.1183/09031936.00193309
A.M.W.J. Schols has received a research grant from Numico Research and speaker fees from Numico Research and Nestlé in the past 5 years. DOI: 10.1183/09031936.00011209
M.R. Sears has participated in advisory board meetings for Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst Canada Ltd and Schering Plough. The author has given lectures for AstraZeneca, Merck Frosst Canada Ltd and Schering Plough, and has received research grants from AstraZeneca, GlaxoSmithKline, and Merck Frosst Canada. He holds an endowed chair in respiratory epidemiology, funded in part by a one-time endowment from AstraZeneca to McMaster University. This endowment from AstraZeneca provides less than 25% of his annual salary. DOI: 10.1183/09031936.00145006
J. Segers. The activity monitors used in the present study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
A.K. Simonds is in receipt of a research grant from ResMed Co. and from Breas Medical. The AutoVPAP and VPAP III devices used in the study were provided by ResMed Co. DOI: 10.1183/09031936.00065008
S.B. Shaker. The author's study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00159408
G. Simonneau has relationships with drug companies including Actelion, Bayer Schering, GSK, Pfizer, and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00094808
O. Sitbon has relationships with drug companies including Actelion, Bayer Schering, GSK, Pfizer, and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00094808
M. Skedinger. AstraZeneca Sweden supported the study. DOI: 10.1183/09031936.00095508
S. Sorichter. The study has been partly sponsored by ResMed. DOI: 10.1183/09031936.00023408.
M. Spears. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
P.J. Sterk has received honoraria from pharmacuetical industries for lectures on topics that were not directly related to drug therapy. The department of P.J. Sterk has received unrestricted research grants from pharmaceutical industries. DOI: 10.1183/09031936.00163408
R.A. Stockley has received noncommercial research funding from Talecris/Bayer Biological towards the UK database used for the submitted publication. In addition, he has acted in an advisory role to Baxter, Kamada and Aventis Behring, all of whom have α1-antitrypsin available as a therapeutic product. R.A. Stockley has lectured at scientific meetings on all aspects of α1-antitrypsin deficiency, including several symposia funded by Talecris/Bayer Biological. DOI: 10.1183/09031936.00061208
R.A. Stockley has received noncommercial research funding from Talecris/Bayer Biologicals towards the UK data base used for the submitted publication. In addition he has acted in an advisory role to Baxter, Kamada and Aventis Behring, all of whom have AAT available as a therapeutic product. R.A. Stockley has lectured at scientific meetings on all aspects of AAT deficiency including several symposia funded by Talecris/Bayer Biologicals. This study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00159408
D. Stolz has, in the past 5 years, received funds for research. DOI: 10.1183/09031936.00171408
J.R. Stradling. ResMed UK made an unconditional donation to support work in the Oxford Sleep Unit in 1998 and 2006. DOI: 10.1183/09031936.00107408
S. Suissa has participated in advisory board meetings, conferences and as a speaker in scientific meetings by various companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer and Sepracor), and has received research grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00189308
S. Suissa has served as a consultant or advisory board member for AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline. The author has given lectures for Boehringer Ingelheim and Pfizer; and has received a research grant from AstraZeneca. DOI: 10.1183/09031936.00145006
J. Sunyer. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
C. Svanes. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
T Back to top
L. Tan is employed by Pfizer. She receives a salary from Pfizer and holds Pfizer shares and share options. The study was funded by Pfizer. DOI: 10.1183/09031936.00068908
M. Thamm. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. DOI: 10.1183/09031936.00039808
L. Thiberville has been reimbursed by Mauna Kea Technologies for travel expenses, hosting and registration at the 2006 ACCP meeting (less than €1500, total). The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
D.R. Thickett received an educational grant from AstraZeneca to attend the ERS in 2007. He has acted in a consultancy role and been involved in an IPF trial for AstraZeneca. DOI: 10.1183/09031936.00060708
N.C. Thompson. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
C. Tiesler is an employee of Nycomed Pharma (Konstanz, Germany). The author's study was funded by Nycomed Pharma. DOI: 10.1183/09031936.00079908
M. Toftegaard is a board member and shareholder of OBI APS. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00140408
A. Torres has, in the past 5 years, received: a fee for speaking; funds for research; and fees for consulting. The author has received honoraria from Bayer, Wyeth, Astellas and Novartis. A. Torres has also received a grant from Pfizer. DOI: 10.1183/09031936.00004509
A. Torres has received a grant from Pfizer to study the effects of Linezolid versus Vancomycin in the animal model on VAP. DOI: 10.1183/09031936.00046308
T. Troosters. The activity monitors used in the present study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
L. Turaev. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
U Back to top
S. Unger. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. S. Unger is an employee of Bayer HealthCare AG, Wuppertal, Germany. DOI: 10.1183/09031936.00039808
G.T. Uzakova. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
V Back to top
R.W. Vandivier. Pulse oximeters were provided by Datex-Ohmeda, a GE Healthcare division in Louisville, CO, USA. DOI: 10.1183/09031936.00063108
J. van Ingen. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
A. Van Muylem. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00154008
O.C.P. van Schayck is an advisor and receives grants from Pfizer International for performing research projects. The study was funded by a grant from Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00116308
D. van Soolingen. Genotype MTBDR assays were provided free of charge by Hain Lifescience GmbH (Nehren, Germany). Drug susceptibility testing was performed with financial support from KfW Bankengruppe (Frankfurt, Germany) in the frame of the Drug Resistance Survey of Uzbekistan. DOI: 10.1183/09031936.00089808
J. Vestbo has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingeheim and Pfizer for speaking in scientific meetings and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. In 1985 J. Vestbo received 267,000 Dkr from Scandinavian Tobacco Company in support for a research project on exposure to cement dust, smoking, and respiratory disease. Research grants to support work carried out in the department where J. Vestbo works has come from GlaxoSmithKline. Finally, his wife, I. Vestbo, is an employee of AstraZeneca. The study was funded by Pfizer. DOI: 10.1183/09031936.00068908
J. Vestbo. Research grants to support work carried out in the department where J. Vestbo works have come from GlaxoSmithKline. J. Vestbo has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Pfizer for speaking in scientific meetings and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. Finally, his wife, Inge Vestbo, is an employee of AstraZeneca. DOI: 10.1183/09031936.00169908
C. Vever-Bizet. The Cellvizio®-Lung spectroscope prototype used for the clinical study was provided by Mauna Kea Technologies, Paris, France. DOI: 10.1183/09031936.00083708
S. Vicidomini. The author's institution has received in 2007 an unrestricted educational grant (€5,000) from A.D.A. SRL, representative of Cellestis in Italy for the QuantiFERON-TB Gold Test. DOI: 10.1183/09031936.00107608
V. Viot-Blanc. The study was sponsored by Cephalon, France. DOI: 10.1183/09031936.00016808
N.F. Voelkel. Pulse oximeters were provided by Datex-Ohmeda, a GE Healthcare division in Louisville, CO, USA. DOI: 10.1183/09031936.00063108
M. Vollroth. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
R. Voswinckel. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. DOI: 10.1183/09031936.00039808
B. Vrijsen. The activity monitors used in the present study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
W Back to top
T. Wahlers. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
H. Wang. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
J. Ward is employed by Pfizer. He receives a salary from Pfizer and holds Pfizer shares and share options. The study was funded by Pfizer. DOI: 10.1183/09031936.00068908
B. Waschki. The author's study was supported by an unrestricted research grant from AstraZeneca and by the Dr. Fritz Meyer Struckmann Foundation. The funding sources had no role in the study design, collection, analysis, or interpretation of the data or in the decision to submit the paper for publication. DOI: 10.1183/09031936.00024608
H. Watz. The author's study was supported by an unrestricted research grant from AstraZeneca and by the Dr. Fritz Meyer Struckmann Foundation. The funding sources had no role in the study design, collection, analysis, or interpretation of the data or in the decision to submit the paper for publication. DOI: 10.1183/09031936.00024608
S.K. Weiland. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
G. Weimann. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. G. Weimann is an employee of Bayer HealthCare AG, Wuppertal, Germany. DOI: 10.1183/09031936.00039808
G. Weinmayr. ALK (Hørsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. DOI: 10.1183/09031936.00075708
N. Weissmann. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. N. Weissmann has received honoraria from Actelion, Pfizer and Altana Pharma, and research grant support from Bayer Schering. DOI: 10.1183/09031936.00039808
M. Wencker is an employee of and holds company shares of Talecris Biotherapeutics, Inc. This study was sponsored by Talecris Biotherapeutics, Inc. (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00159408
G. Wennergren has received fees for lectures from AstraZeneca and for contributing to an advisory board, and fees for lectures from Merck Sharp & Dohme. He has received an unrestricted research grant amounting to €10,000 from AstraZeneca. He does not hold any stocks or shares in any pharmaceutical company. DOI: 10.1183/09031936.00177408
G. Wensing. The study was funded by a research grant from Bayer HealthCare AG, Wuppertal, Germany. C. Mulligan from Oxford PharmaGenesis™ provided editorial assistance funded by Bayer HealthCare AG. G. Wensing is an employee of Bayer HealthCare AG, Wuppertal, Germany. DOI: 10.1183/09031936.00039808
G. Wesseling is an advisor and receives grants from Pfizer International for performing research projects. The study was funded by a grant from Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00116308
K.L. White and others at IHI Environmental were hired by ConAgra to perform the industrial hygiene exposure assessments discussed in the paper. This work occurred between early 2005 and has continued to present. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
J.H. Wildhaber has received educational grants from Nycomed, GSK and MSD, and has served on their advisory boards. In the past 5 years, the author has also received reimbursement for attending a symposium, fees for speaking and fees for organising education. DOI: 10.1183/09031936.00116308
E. Willems. In the author's study, defibrotide was provided for compassionate use courtesy of Gentium®, Italy. DOI: 10.1183/09031936.00157707
T. Wittwer. Curosurf® was a kind gift from Nycomed Pharma GmbH, Linz, Austria. DOI: 10.1183/09031936.00024108
M. Wjst. The author's study was supported by Glaxo Wellcome AS (Bergen, Norway); Aventis (Montpellier, France); UCBPharma (Colombes, France); Aventis and GlaxoSmithKline France (both Paris, France); GlaxoSmithKline Italy (Pavia, Italy); Merck Pharmaceutical (Portland, USA); Glaxo Wellcome Spa (Verona, Italy); and GlaxoSmithKline Italy (Verona, Italy). DOI: 10.1183/09031936.00062907
S. Wood. GSK acted as sponsor for the trial. DOI: 10.1183/09031936.00158208
M.A. Woodhead has received fees for speaking and travel expense for congress attendance from Pfizer. DOI: 10.1183/09031936.00042208
M.A. Woodhead is serving on the data monitoring committee of a Wyeth sponsored study of pneumococcal vaccine, for which he will receive expenses. DOI: 10.1183/09031936.00075009
K. Wouters. The activity monitors used in the present study were a kind gift of BodyMedia, Pittsburgh, PA, USA. DOI: 10.1183/09031936.00091607
K. Woyda recieved a doctorial fellowship from Nycomed (Konstanz, Germany). DOI: 10.1183/09031936.00109008
Y Back to top
J.C. Yates is employed by GlaxoSmithKline and holds shares in GlaxoSmithKline. DOI: 10.1183/09031936.00169908
Z Back to top
R.T. Zamanian received a research grant from the Actelion Entelligence Young Investigator Award 2006 (San Francisco, CA, USA). DOI: 10.1183/09031936.00000508
Volume 34, 2009
A Back to top
M.J. Abramson served on the scientific advisory committee for the Australian Asthma Study, which was sponsored by GlaxoSmithKline, and has once received travel assistance for conference attendance from AstraZeneca and a speaker's honorarium from Boehringer Ingelheim. He is a co-investigator on a Reckitt-Benckiser-supported study of nonsteroidal anti-inflammatory drugs in asthma. DOI: 10.1183/09031936.00181608
G. Acuto has acted as an expert witness on the study topic. The author's study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
K.B. Adler has received honoraria for research presentations and consultations from various academic institutions and industry, totalling less than $10,000. The author has received research grants from Sepracor, Inc. and AstraZeneca, Inc., as well as from the National Institutes of Health and the US Environmental Protection Agency. K.B. Adler holds founders' shares of stock in BioMarck, Inc., valued at less than $1,000. DOI: 10.1183/09031936.00094109
M. Adner. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
S. Aldington. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
N. Ambrosino. Vivisol funded an annual position at University Hospital of Pisa for one member of staff. DOI: 10.1183/09031936.00182208
J.A. Anderson is employed by and holds shares in GlaxoSmithKline. The author's study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
J.A. Anderson is employed by and holds shares in GSK. DOI: 10.1183/09031936.00122608
J.M. Antó is principal investigator of a project that, in addition to competitive external multi-source funding, has been contributed to by AstraZeneca (€60,000 in 2008). DOI: 10.1183/09031936.00172908
J.G. Ayres was supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
A. Azzola. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
B Back to top
P.S. Bakke. This study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
J.A. Barbera has: received consultancy fees from Actelion, Bayer-Schering, Encysive, GSK and Pfizer; speaking fees from Actelion, Bayer-Schering, GSK and Pfizer; and unrestricted research grants from Actelion, Bayer-Schering, GSK and Pfizer. DOI: 10.1183/09031936.00139009
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for chronic obstructive pulmonary disease (COPD). DOI: 10.1183/09031936.00190908
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for COPD. DOI: 10.1183/09031936.00125909
B. Bausch. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. This grant paid for consumables and the salary of B. Bausch. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author's systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
B. Bausch. The author's work did not have specific funding, and was done in time made available by the authors' institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. DOI: 10.1183/09031936.00159108
R. Beasley has received fees for consulting and speaking and reimbursement for attending symposia from AstraZeneca, GlaxoSmithKline and Novartis. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
R. Beasley. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. R Beasley has received fees for consulting and speaking and reimbursement for attending symposia from AstraZeneca, GlaxoSmithKline and Novartis. The present study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
M-F. Beauchesne has received grant support from AstraZeneca Canada Inc and GlaxoSmithKline Canada Inc for the conduct of her research projects. She has also received consulting fees from GlaxoSmithKline Canada Inc and speaking fees from GlaxoSmithKline Canada Inc, Boehringer Ingelheim Canada Inc., AstraZeneca Inc, and Pfizer Canada Inc. She co-chairs the AstraZeneca Endowment Pharmaceutical Chair in Respiratory Health. DOI: 10.1183/09031936.00074608
M. Beghetti has served on advisory boards for Pfizer, Actelion, Bayer-Schering, Encysive, GlaxoSmithKline, INO therapeutics, Eli Lilly and Mondobiotech, and has received lecture fees from Actelion, Encysive and Bayer-Schering. DOI: 10.1183/09031936.00139009
P. Berry was employed by GlaxoSmithKline at the time of the study. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
L. Blais has carried out research contracts for AstraZeneca (Canada and USA) and Amgen Canada Inc., and co-chairs the AstraZeneca Endowment Pharmaceutical Chair in Respiratory Health. DOI: 10.1183/09031936.00074608
The BOLD study. Funding for the BOLD Operations Center was provided by unrestricted educational grants from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor and University of Kentucky. The Reykjavik BOLD site was funded by the Landspitali University Science Fund, Astra Zeneca in Iceland and GlaxoSmithKline in Iceland. The Norwegian BOLD site was funded by the Research Fund for Respiratory Medicine, Haukeland University Hospital and The Norwegian Association of Heart and Lung Patients and EXTRA funds from the Norwegian Foundation for Health and Rehabilitation. DOI: 10.1183/09031936.00166108
A.L. Boner travel to ERS congress was funded by GSK, he received fees for speaking from GSK and MSD, a research found of €5,000 from Pfizer, and he served once as a consultant in two international meetings, one organised by GSK and one by MSD. DOI: 10.1183/09031936.00166508
L. Bont received €12,000 from Abbott International for lectures and participation in Advisory Boards. DOI: 10.1183/09031936.00166508
A. Boonstra has acted as a paid speaker for Actelion and United Therapeutics. A. Boonstra has attended symposia funded by Encysive, Pfizer and Actelion. The employer of A. Boonstra has received an unrestricted educational grant from Actelion and GlaxoSmithKline in the past 5 years exceeding €10,000. DOI: 10.1183/09031936.00106008
E.K.Borton has been partially funded via grants from ConAgra through the University of Cincinnati College of Medicine for his involvement in the medical surveillance program. E.K. Borton has received funding from ConAgra for conduction medical surveillance. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
W.J. Boscardin. The author's study was funded by Eumedic, Ltd. DOI: 10.1183/09031936.00037409
O. Braendli. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. This grant paid for consumables. O. Braendli did not receive any salary support for his contribution to the paper. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author's systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
P. Brand was an employee of Inamed Research when the study was conducted. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
V. Brusasco received €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3,000 in 2005 and €3,500 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 for speaking at conferences sponsored by Boehringer Ingelheim; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3000 in 2007 from Almirall for serving on an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consusltancy. V. Brusasco's institution received €20,000 in 2006 from Boehringer Ingelheim as an unrestricted research grant, and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00103309
V. Brusasco received €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3000 in 2005 and €3,500 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 for speaking at conferences sponsored by Boehringer Ingelheim; €960 in 2006 and €1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consultancy. V. Brusasco's institution received €20,000 in 2006 as unrestricted research grant from Boehringer Ingelheim, and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00061509
V. Brusasco received: €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3,000 in 2005 and €3,500 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 for speaking at conferences sponsored by Boehringer Ingelheim; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consusltancy. VB's institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim, and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00074809
V. Brusasco has received: €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2004, €3000 in 2005 and €3,500 in 2008 from Lofarma for consultancies; €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 in 2008 for speaking at conferences sponsored by Boehringer Ingelheim; €960 in 2006 and 1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consusltancy. V. Brusasco's institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim, and participated in several multi-centre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00094109
G. G. Brusselle received lecture fees and honoraria for serving on advisory boards from Astra Zeneca, Boehringer Ingelheim, Glaxo Smith Kline, Pfizer, Novartis and UCB in 2004-2008. DOI: 10.1183/09031936.00150208
P.S. Burge funds, distributes and supports the Oasys-2 program for analysing serial PEF measurements for no financial gain to himself or his department. DOI: 10.1183/09031936.00150108
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD and GSK; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00166508
C Back to top
P.M.A. Calverley has spoken at meetings supported by GlaxoSmithKline, AstraZeneca and Chiesi. He has advised on trial design and research strategy for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche, Nycomed, Almirall and Pfizer. His department has received research funding from GlaxoSmithKline, Altana and Chiesi to conduct clinical trials and observational research in COPD. He has also received fees for consulting. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
P.M.A. Calverley has spoken at meetings supported by GSK, AstraZeneca and Chiesi. He has advised on trial design and research strategy for AstraZeneca, Boehringer Ingeheim, GSK, Roche, Nycomed, Almirral and Pfizer. His department has received research funding from GSK, Altana and Chiesi to conduct clinical trials and observational research in COPD. DOI: 10.1183/09031936.00122608
P. Calverley has received fees for consulting, a fee for speaking and funds for research. P. Calverley has spoken at meetings supported by GSK, AstraZeneca, Boehringer Ingelheim and Nycomed. He has also received research funding to conduct clinical trials for these companies and has advised them and Novartis, Roche and Chiesi on clinical trail design. DOI: 10.1183/09031936.00022809
K-H. Carlsen has received reimbursement for attending American Thoracic Society Annual Congress 2005 and 2006 from GlaxoSmithKline and American Academy of Asthma, Allergy and Immunology Annual Congress 2007 and 2008 from MSD, also received fees for speaking from GlaxoSmithKleine, MSD and Astra Zeneca. DOI: 10.1183/09031936.00166508
M. Cazzola has received honoraria for speaking and consulting and/or financial support for attending meetings from Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, GlaxoSmithKline, Kerios, Menarini Farmaceutici, Novartis, Nycomed (former Altana), Pfizer, Sanovel, Sigma Tau and Valeas, and is a member of the speaker bureau of Novartis. DOI: 10.1183/09031936.00013109
B. Celli has been reimbursed by GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Almirall for participating in advisory boards and speaking at different meetings. The Division he heads has been awarded research grants for different medication trials and for the discovery of new biomarkers in COPD. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
B.R. Celli has been reimbursed by GSK, BI, AZ and Almirall for participating in advisory boards and spoken at different meetings. The Division he heads has been awarded research grants for different medication trials and for the discovery of new biomarkers in COPD. DOI: 10.1183/09031936.00122608
H. Chen has been a consultant for EpiMetrix, Genentech, Gilead Science, Nektar Therapeutics, Novartis Pharmaceuticals, and United Therapeutics. DOI: 10.1183/09031936.00083909
W-H. Chen was employed by United BioSource Corporation at the time of the study. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
H.R. Collard has been a consultant for Actelion, Amira Pharmaceuticals, CV Therapeutics, Genzyme, Gilead Science, InterMune, Nektar Therapeutics, and Roche. DOI: 10.1183/09031936.00083909
J.R. Colthurst. The present study was funded by Eumedic, Ltd. J.R. Colthurst designed the Fenzian treatment system and founded Eumedic Ltd in which he has a shareholding. J.R. Colthurst works at Eumedic Ltd. DOI: 10.1183/09031936.00037409
C.B. Cooper. The present study was funded by Eumedic, Ltd. C.B. Cooper received financial support from Eumedic to attend an ATS annual meeting where an abstract relating to this study was presented and an investigator meeting held. C.B. Cooper has received an additional grant for a multi-centre clinical trial of the Fenzian device from Eumedic, Ltd. DOI: 10.1183/09031936.00037409
P. Corris has received fees for speaking and consulting from Actelion, Pfizer, Bayer, GSK and United Therapeutics. The author's department has received research funding from Pfizer. DOI: 10.1183/09031936.00139009
H.O. Coxson received $4800 in 2006 and 2007 for serving on the steering committee for the ECLIPSE project for GlaxoSmithKline. In addition, H.O. Coxson is the co-investigator on two multicenter studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project. He has three contract service agreements with GlaxoSmithKline to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc. to measure changes in lung volume in subjects with severe emphysema. A percentage of H.O. Coxson's salary between 2003 and 2006 (US$15,000 per year) derives from contract funds provided to a colleague, P.D. Pare, by GlaxoSmithKline for the development of validated methods to measure emphysema and airway disease using computed tomography. H.O. Coxson is the co-investigator (D. Sin Principal Investigator) on a Canadian Institutes of Health & Industry (Wyeth) partnership grant. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
H. Coxson received US$4,800 in 2006 and 2007 for serving on the steering committee for the ECLIPSE project for GSK. In addition HC is the co-investigator on two multi-centre studies sponsored by GSK and has received travel expenses to attend meetings related to the project. HC has three contract service agreements with GSK to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc to measure changes in lung volume in subjects with severe emphysema. A percentage of HC's salary between 2003 and 2006 (US$15,000/year) derives from contract funds provided to a colleague Peter D Pare by GSK for the development of validated methods to measure emphysema and airway disease using computed tomography. HC is the co-investigator (D Sin PI) on a Canadian Institutes of Health & Industry (Wyeth) partnership grant. DOI: 10.1183/09031936.00141808
C. Crim is an employee of GlaxoSmithKline, which sponsored the TORCH trial. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
D Back to top
S-E. Dahlén. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
F.M. de Benedictis has received research support and consulting fees, and has given lectures for Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp Dohme, UCB. DOI: 10.1183/09031936.00166508
C. de la Roza is an employee of Bayer Schering Pharma, the company sponsoring the study and manufacturing moxifloxacin. DOI: 10.1183/09031936.00195608
C. Delclaux has received a free NO analyser (price €30 000) from SERES Company for the development of the software dedicated to the multiple constant flow method. DOI: 10.1183/09031936.00164508
A. De Luisi has acted as an expert witness on the study topic. The author's study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
G. Deslee received grants for post-doctoral training from AstraZeneca (Paris, France). DOI: 10.1183/09031936.00123008
H.J. Dettmar is an employee of Technostics Ltd. DOI: 10.1183/09031936.00126908
P.W. Dettmar is a director of Selfnostics Ltd, which holds the rights to Cough Clinic, and is an employee of Technostics Ltd. DOI: 10.1183/09031936.00126908
A.T. Dinh-Xuan has received a reimbursement of €900 from Medisoft for attending the 5th International Meeting on NO in 2008, and a fee of €700 for chairing a session on pulmonary hypertension from Actelion in 2007. DOI: 10.1183/09031936.00094109
A. Dirksen. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
E Back to top
L.D. Edwards is an employee of GlaxoSmithKline. The author's study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
P. Eggimann. Funding obtained from Brahms AG (Hennigsdorf, Germany) used for assay material and logistics. DOI: 10.1183/09031936.00053209
G.E. Eide. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
P.L. Enright has received a total of about $25,000 from Pfizer during the period 2006-2008 for reviewing the quality of spirometry tests in a study of the effectiveness of varenicline for smoking cessation in patients with COPD. Pfizer and Boehringer co-market tiotropium for COPD, so increasing the spirometry abnormality rates amongst smokers would increase their profits. DOI: 10.1183/09031936.00164608
C. Esquinas. The author's study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
R. Ewert has received speaker fees from Bayer/Schering, Actelion and Encysive/Pfizer. DOI: 10.1183/09031936.00130408
F Back to top
G.T. Ferguson has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Schering Plough; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Altana, Boehringer-Ingelheim, Emphasys Medical Inc, Forrest, GlaxoSmithKline, Mannkind Corporation and Novartis. DOI: 10.1183/09031936.00122608
G.T. Ferguson has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Schering Plough; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Altana, Boehringer-Ingelheim, Emphasys Medical Inc, Forrest, GlaxoSmithKline, Mannkind Corporation and Novartis. This study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
A. Ferland. The author's study was supported by Abbott Pharmaceutical. DOI: 10.1183/09031936.00167308
B. Fleury is joint owner of a French patent for a hydraulic oral appliance titration system that is not marketed. DOI: 10.1183/09031936.00148208
M. Frankenberger is the holder of a patent for inhalative ATRA therapy. DOI: 10.1183/09031936.00105309
G Back to top
S. Gaine has received honoraria for speaking from a number of companies with interests in PAH, including Actelion, Pfizer, United Therapeutics and GSK. The author has served as an advisory board member of the same companies. DOI: 10.1183/09031936.00139009
S.P. Gaine has received speaker's honoraria and research support from companies involved in pulmonary arterial hypertension including Actelion, GSK, Pfizer/Encysive, and Lung Rx. DOI: 10.1183/09031936.00058408
N. Galiè has received fees for lecturing from Actelion, GSK, Pfizer and Bayer Schering. He has been involved in Steering Committee activities for Actelion, OSK, Pfizer and Bayer Schering. His Institute has received grants for conducting randomised controlled studies from Actelion, GSK, Pfizer and Bayer-Schering. DOI: 10.1183/09031936.00139009
M. García. The author's study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
J.S. Gibbs has received an educational grant from Actelion Pharmaceuticals; has received speakers fees from Actelion Pharmaceuticals, Bayer Schering, GSK and Lilly; and has been a member of an advisory board for Actelion Pharmaceuticals, Bayer Schering, GSK, Lilly, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00139009
H. A. Ghofrani has received lecturer honoraria from Actelion Pharmaceuticals, Bayer/Schering, GSK, Pfizer and Encysive. He is also a member of scientific advisory boards for Actelion Pharmaceuticals, Bayer, Encysive/Pfizer, GSK and LungRx. DOI: 10.1183/09031936.00130408
M.A. Gomez-Sanchez has received; research contacts (grants) from Pfizer, GSK, Bayer Schering, Schering, Actelion, Gilead, Lilly Icos, United Therapeutics and Lung Rx; and fees for speaking, organising education and consulting from Pfizer, GSK, Bayer Shering, Actelion and Lilly Icos. DOI: 10.1183/09031936.00139009
R. Gosens has received a research grant, lecture fees and travel reimbursement for the ATS 2007 conference from Boehringer Ingelheim Pharma GmbH & Co. DOI: 10.1183/09031936.00045209
K.I. Gourgoulianis has received an unrestricted grant from Pfizer Greece. (Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553:280-287.) DOI: 10.1183/09031936.00089407
A. Greenough has received education grants from Abbott Laboratories Ltd, research funds from Abbott Laboratories Ltd and MedImmune and fees for lecturing/chairing meetings from Abbott Laboratories Ltd. DOI: 10.1183/09031936.00166508
M. Griese has received one fee for speaking from Bayer Heath Care and a fee for consulting from CLS Behring. DOI: 10.1183/09031936.00029809
T.B. Grydeland. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
A. Gulsvik. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
H Back to top
M. Halank has received lecturer honoraria from Actelion Pharmaceuticals and Bayer/Schering. DOI: 10.1183/09031936.00175208
A.J. Halayko has received unrestricted operating research grants from Merck Frosst Canada, Inc., and GlaxoSmithKline. DOI: 10.1183/09031936.00045209
A. Hamilton. The author's study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
K. Hanna is an employee of Talecris Biotherapeutics. The author's study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
G. Harding is employed by the United BioSource Corporation, which provides consulting and other research services to pharmaceutical, device, government and nongovernment organisations. In this salaried position, G. Harding works with a variety of companies and organisations and receives no payment or honoraria directly from these organisations for services rendered. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
R.M. Harrison was supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
M. Harwood. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
A.A. Hatziefthimiou has received an unrestricted grant from Pfizer Greece. (Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553:280-287.) DOI: 10.1183/09031936.00089407
Z. He. The author's study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
D. Heederik received grants from the Produktschap Granen, Zaden en Peulvruchten, Den Haag, The Netherlands, for development and conduct and analysis of a surveillance system of occupational allergy and asthma in flour processing and bakery products industries of approx. 450000 euro. DOI: 10.1183/09031936.00164408
C.H. Herpich is an employee of Inamed Research. The author's study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
R. Hervás. The author's study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
P.S. Hiemstra has, as a member of the staff of The Department of Pulmonology, received grants from AltanaPharma, Novartis, Bayer, AstraZeneca, Pfizer, MSD, Exhale Therapeutics, Boehringer Ingelheim, Roche and GSK in the years 2001 until 2008. DOI: 10.1183/09031936.00045209
T.J. Hilbert has been partially funded via grants from ConAgra through the University of Cincinnati College of Medicine for his involvement in the medical surveillance programme. T.J. Hillbert has received funding as a consultant to ConAgra, for the presentation of preliminary results of the medical surveillance program to various United States Federal agencies, and for conducting medical surveillance. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
J. Hjoberg. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
M.M. Hoeper has speaker and consultant fees from Actelion, Bayer, Encysive, GSK, Lilly, LungRx, Novartis, and Pfizer. DOI: 10.1183/09031936.00056809
M.M. Hoeper has received speaking and/or consulting fees from Actelion, Bayer, Encysive, Gilead, GSK, Lilly, LungRx, Novartis and Pfizer. DOI: 10.1183/09031936.00094409
M.M. Hoeper has received lecturer honoraria from Actelion Pharmaceuticals, Bayer/Schering, GSK, Pfizer and Encysive. The author is also a member of scientific advisory boards for Actelion Pharmaceuticals, Bayer, Encysive/Pfizer, GSK and LungRx. DOI: 10.1183/09031936.00013309
M. M. Hoeper has received lecturer honorariums from Actelion Pharmaceuticals, Bayer/Schering, GSK, Pfizer and Encysive. He is also a member of scientific advisory boards for Actelion Pharmaceuticals, Bayer, Encysive/Pfizer, GSK and LungRx. DOI: 10.1183/09031936.00130408
M.M. Hoeper has received speaker's fees and/or honoraria for consultations from Actelion, Bayer, GSK, Gilead, Pfizer, LungRx and Novartis. DOI: 10.1183/09031936.00139009
D.H. Horstman is an employee of GlaxoSmithKline. The author's study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GlaxoSmithKline, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00006508
M. Humbert has, in the past 5 years, received: reimbursement for attending a symposium; fees for speaking; fees for organising education; funds for research; funds for a member of staff; fees for consulting. M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00102609
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00017809 and 10.1183/09031936.00139009
J Back to top
C. Jenkins has received fees for organising and speaking at educational symposia sponsored by GlaxoSmithKline; his institute receives predominantly project-based, but some untied funding for research. DOI: 10.1183/09031936.00122608
C. Jenkins has received fees for organising and speaking at educational symposia sponsored by GlaxoSmithKline; her institute receives predominantly project based, but some untied funding for research. The author's study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
S. Jonasson. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings and has received support for research from GlaxoSmithKline. The author's study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings, and received support for research from pharmaceutical companies, including GlaxoSmithKline. The author's study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings and received support for research from pharmaceutical companies, including GlaxoSmithKline. DOI: 10.1183/09031936.00122608
M. Jung has given a lecture at Merck and Co in 2006 for which a single fee was received. DOI: 10.1183/09031936.00084808
E.F. Juniper has, in the past 5 years, received fees for speaking, funds for research and fees for consulting. Consultant arrangements: GlaxoSmithKline, Astra Zeneca. Stock/other equity ownership: GlaxoSmithKline, Pfizer. Patent licensing arrangements: Copyright holder of the ACQ. Financial support (last 5 years): Johnson & Johnson, Schering Plough, Medpointe Pharma, CMP Therapeutics, Alterhealth, Pierre Fabre, GlaxoSmithKline, Munipharma, Ception Therapeutics, Sunten Phytotech, UCB Pharma, Activus Pharma, Novartis, Wyeth, Allergopharma, Airsonett, Embria Health Sciences, CV Technologies, Kalobios, Stallergens, AstraZeneca, Alk Abello, Medicinova, Artu Biologicals, Curalogic, IFE Europe, Genentech, Epigenesis, Merck, Cipla, Amgen, Rottapharma, Allergy Therapeutics, NovoNordisk, Inflazyme, Allergy Choices, Abbott Laboratories, Mitsubishi, Boehringher Ingelheim, Cytos Technologies, Wellpoint/Healthcore, Altanapharma, Capnia, Ivax Laboratories, Critical Therapeutics, Kyowa Hakko, Asthmatx, Neolab, Protein Design Laboratories, ClinPhone, Arriva, Schulman Ronca Bucuvals, Laboratories SMB, Vista Health Plan, Hal Allergy BV, Suburban Lung Associates, Galephar MF SA, Mannkind Corp, Prognostix, Formix Biosciences, Oxagen, SC Ellen Fast Comimpex SRL, Medimmune, Quintiles, PDL Biopharma, Bencard, Efficas, Pfizer, Alcon Lab, Aventis, Pahrmaxis, Assist Tech, Hoffmann LaRoche, Aerocrine, Dynavax, Medtap, Pharmaengine, Topigen, ClineDavis & Mann, Teikoku Pharma, NeoLab, KGK Synergise, AB Science.
K Back to top
H-U. Kauczor has received fees or speaking and organizing education as well as funds for research from Toshiba Medical, Siemens Medical Solutions, Altana Pharma, Bracco, Amersham, Bayer Schering and General Electric. He received fees for organizing education from Philips. He received funds for a member of staff from Toshiba Medical and Siemens Medical Solutions. He has been serving as an expert witness for several public funding agencies. DOI: 10.1183/09031936.00138508
O.N. Keene is a full-time employee of GlaxoSmithKline and holds shares in the company. DOI: 10.1183/09031936.00122608
S. Kesten. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
J. Kimpen received speakers fees over the years 2004-2006 from Abbott International for a total amount of €20,000. DOI: 10.1183/09031936.00166508
E.C. Kleerup. The author's study was funded by Eumedic, Ltd. E.C. Kleerup has received an additional grant for a multi-centre clinical trial of the Fenzian device from Eumedic, Ltd. DOI: 10.1183/09031936.00037409
J. Kleijnen. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author's systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
J. Kleijnen. The author's work did not have specific funding, and was done in time made available by the authors' institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. J. Kleijnen is an employee of Kleijnen Systematic Reviews Ltd. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the analyses or the writing of this article. DOI: 10.1183/09031936.00159108
G. Klein is an employee of Talecris Biotherapeutics The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
N. Kline Leidy is employed by, and holds stocks/shares in, the United BioSource Corporation, which provides consulting and other research services to pharmaceutical, device, government and nongovernment organisations. In this salaried position, N. Kline Leidy works with a variety of companies and organisations and receives no payment or honoraria directly from these organisations for services rendered. The present study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
L Back to top
T. Lahm has received a research grant from Pfizer, Inc ($16,800) to investigate the effects of sitaxsentan on pulmonary artery vasoreactivity in an animal model of endotoxinemia. This is not in relation to the topic of the current manuscript. DOI: 10.1183/09031936.00038909
Y-M. Lam. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
K. Larsson. The author's study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
T. A. Lee has received research funding for his contribution to the Burden of Obstructive Lung Disease (BOLD) Initiative, which has been funded in part by unrestricted educational grants to the Operations Center (www.boldcopd.org) from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor and University of Kentucky and has received past research grants from AstraZeneca, Boehringer-Ingelheim, Pfizer and GlaxoSmithKline and has participated in past advisory boards for AstraZeneca and Novartis. DOI: 10.1183/09031936.00166108
G.K. LeMasters. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
W. Lenney has received speaker fees from GSK and Novartis and has received educational grants for research projects from Abbott Laboratories and GSK. DOI: 10.1183/09031936.00166508
L.P. Levin. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
N.W. Locantore is an employee of GlaxoSmithKline. The author's study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
J.E. Lockey has received funding as a consultant to ConAgra and for the presentation of preliminary results of the medical surveillance programme to various United States Federal agencies. J. Lockey has received grants from ConAgra through the University of Cincinnati College of Medicine for directing and analysing the data of the medical surveillance programme and for salary support of contributing faculty and support staff. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
D. Lomas has received an educational grant, fees for speaking and acts as a consultant for GSK. DOI: 10.1183/09031936.00105309
D.A. Lomas has received an educational grant and fees for speaking and acts as a consultant for GlaxoSmithKline. The present study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
M Back to top
W. MacNee has been reimbursed for travel by GlaxoSmithKline, Zambon, AstraZeneca, Boehringer Ingelheim, Pfizer and Micromet for attending conferences, and has received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings. The author serves on advisory boards for GlaxoSmithKline, Pfizer, Almirall, Amgen, Bayer and Micromet, and serves as a consultant for Pfizer and SMB Pharmaceuticals. Research grants to support work carried out in W. MacNee's laboratory come from SMB, Pfizer, Ceremedix GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00155209
H. Magnussen received fees for speaking from Boehringer Ingelheim and funds for research from Boehringer Ingelheim. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
F. Maltais has received research funding support from BI/Pfizer, GSK and Novartis; and has served on speakers bureaus, consultation panels and advisory boards for GSK and BI/Pfizer. This study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
G. Mangialardi has acted as an expert witness on the study topic. The author's study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
A. Marín. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
S. Marsch. Funding obtained from Brahms AG (Hennigsdorf, Germany) used for assay material and logistics. DOI: 10.1183/09031936.00053209
S.E. Marsh. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
C. Martínez has received fees for organising education and consulting, and funds for research and a member of staff. DOI: 10.1183/09031936.00180708
M.G. Matera has received honoraria for consulting and/or financial support for attending meetings from Nycomed (former Altana), AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Pfizer. DOI: 10.1183/09031936.00013109
R.T. McKay was partially funded by ConAgra Foods for the design of a pulmonary surveillance and spirometry quality assurance programme. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
H. Meurs has received a research grant and grants for travel to the ATS from Boehringer Ingelheim Pharma GmbH &Co. KG. DOI: 10.1183/09031936.00045209
T. Meyer works for a contract research organisation that conducted the study on behalf of Talecris. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
L. Millares. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
B.E. Miller is an employee of GlaxoSmithKline. The author's study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
M. Miravitlles has received honoraria for lecturing from Bayer Schering Pharma and is member of the advisory board of the company. The current study was funded by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
T.J. Mitchell has received funding for research from Wyeth Vacccines and GlaxoSmithKline Biologicals. DOI: 10.1183/09031936.00007109
P-A. Molyvdas has received an unrestricted grant from Pfizer Greece. (Daenas C, Hatziefthimiou AA, Gourgoulianis KI, Molyvdas PA. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553:280-287.) DOI: 10.1183/09031936.00089407
E. Monsó has received research funding from Bayer Healthcare for participating in clinical trials promoted by the company. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
J. Morera has received research funding from Bayer Healthcare for participating in clinical trials promoted by the company. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
A.H. Morice is a director of Selfnostics Ltd, which holds the rights to Cough Clinic. DOI: 10.1183/09031936.00126908
B. Mueller. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
N Back to top
R. Naeije has received reimbursements of travel expenses to congresses and speakers' fees from Actelion, Encysive, Pfizer, Glaxo, Bayer, LungRX and Mondobiotech, and funds for research from Actelion and Encysive. DOI: 10.1183/09031936.00107108
D. Nathwani has received honoraria or fees for speaking at symposia or advisory boards organised by Wyeth, Astellas, J&J, Novartis, and Pfizer. All of these pharmaceutical companies produce anti-infectives. He has also received funds for undertaking research on behalf of Bayer. DOI: 10.1183/09031936.00122309
T. Neimert-Andersson. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
M.R. Nowitz. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
O Back to top
P.M. O'Byrne has been on advisory boards for AstraZeneca, GSK, Merck, Nycomed, Topigen, and Wyeth and has received lecture fees from these and other pharmaceutical companies including Chiesi and Ono Pharma. In addition, he has received grants-in aid for research studies from AstraZeneca, Boehrihger Genentech, GSK, Medimmune, Merck, Pfizer, Schering and Wyeth. DOI: 10.1183/09031936.00109409
D.E. O'Donnell has received research funding support from BI/Pfizer, GSK, Merck and Novartis; and has served on speakers bureaus, consultation panels and advisory boards for GSK and BI/Pfizer. The author's study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
K. Olsson has received speaker fees from Bayer/Schering. DOI: 10.1183/09031936.00130408
M. Olsson. This study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
C. Opitz has received lecture fees / honoraria from Actelion, Bayer Schering, Encysive/Pfizer and GlaxoSmithKline. DOI: 10.1183/09031936.00145708
C. Opitz has received speaker fees from Bayer/Schering, Actelion and Encysive/Pfizer. DOI: 10.1183/09031936.00130408
C. Opitz has received received speaking and/or consulting fees and/or travel support from Actelion pharmaceuticals, Bayer/Schering, OSK, Pfizer, Encysive, Lilly and LungRX. DOI: 10.1183/09031936.00139009
P Back to top
L. Palmberg. This study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
H. Pargger. Funding obtained from Brahms AG (Hennigsdorf, Germany) used for assay material and logistics. DOI: 10.1183/09031936.00053209
D.N.R. Payne has received lecture fees and consultancy fees from AstraZeneca and Kyorin pharmaceuticals and has received financial assistance for travel and accommodation from Kyorin pharmaceuticals. DOI: 10.1183/09031936.00186508
A. Peacock has received funds for travelling to meetings, consultancy work and attending advisory boards for Actelion, Pfizer, GlaxoSmithKline, Encysive, Eli Lilly and United Therapeutics. DOI: 10.1183/09031936.00107108
A. Peacock has received fees for speaking, membership of advisory boards and research funds from one or more of the following: Actelion, GSK, Pfizer, Lilly, United Therapeutics. DOI: 10.1183/09031936.00139009
K. Perrin. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
B. Pételle. is joint owner of a French patent for a hydraulic oral appliance titration system that is not marketed. DOI: 10.1183/09031936.00148208
S.G. Pillai is an employee of GlaxsoSmithKline. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
S.G. Pillai is a full-time employee of GlaxoSmithKline. DOI: 10.1183/09031936.00141808
P. Poirier. The author's study was supported by Abbott Pharmaceutical. DOI: 10.1183/09031936.00167308
M.I. Polkey has received honoraria for speaking on muscle dysfunction from Astra and Chiesi. His hospital and university have both received funding for research in this area from GSK. DOI: 10.1183/09031936.00074008
D.S. Postma is a member of an Advisory Board at GlaxoSmithkline, Boehringer Ingelhem and TEVA. She has received honoraria from Astra Zeneca and Nycomed and has received an Industry-Sponsored grant from Astra Zeneca, GalaxoSmithKline and Nycomed. DOI: 10.1183/09031936.00022809
S. Provencher has received lecture fees from Actelion Pharmaceuticals Canada Inc, Encysive Canada Inc and received consultant fees from Actelion Pharmaceuticals Canada Inc, Encysive Canada Inc, GlaxoSmithKline Canada Inc and Pfizer Canada Inc. DOI: 10.1183/09031936.00068009
M.A. Puhan. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. M.A. Puhan did not receive any salary support but put his honorarium into the general research account of the Horten Centre to support academic activities of the Centre. M.A. Puhan is supported by a career award of the Swiss National Science Foundation (3233B0/115216/1). Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author's systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
M.A. Puhan has received no personal payments from pharmaceutical industry, but has received unrestricted grants for investigator-initiated research that were deposited into research accounts of the research groups that he belongs to from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca for development of quality-of-life instruments and respiratory rehabilitation trials. DOI: 10.1183/09031936.00095408
M.A. Puhan. The author's work did not have specific funding, and was done in time made available by the authors' institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. M.A. Puhan did not receive any salary support but put his honorarium into the general research account of the Horten Centre to support academic activities of the Centre. DOI: 10.1183/09031936.00159108
R Back to top
K.F. Rabe has been consulting, participated in Advisory Board Meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceuticals, Pfizer, Novartis, AltanaPharma, MSD, and GSK. KR holds no stock or other equities in pharmaceutical companies. The Department of Pulmonology, and thereby K. Rabe as head of the department, has received grants from AltanaPharma, Novartis, Bayer, AstraZeneca, Pfizer, MSD, Exhale Therapeutics, Boehringer Ingelheim, Roche and GSK in the years 2001 until 2008. DOI: 10.1183/09031936.00045209
J. Rakic. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
S.E. Rees is a board member and shareholder of OBI APS. OBI APS is currently applying for a patent on the method presented in this manuscript. DOI: 10.1183/09031936.00105909
S. Rennard has received fees for consultancy from Abbot, Able consultancies, Almirall, Almirall/Forest, Altana, Anthera, APT Phram/Britnall, Aradign, AstraZeneca, Boehringer Ingelheim, Brtinall and Nicolini, Defined Health, Dunn Group, Eaton Associates, Gerson, GlaxoSmithKlein, Infomed, Johnson and Johnson, KOL Connection, Leerink Swan, Meda Corp, Mpex, Novartis, Otuska, Pfizer, Propagate, Pulmatrix, Quintiles, Roche, Scimed, TargeGen, Theravance, UBS, VantagePoint and VantagePoint Mgmt. He has served on the advisory boards of Abbot, Almirall, Boehringer Ingelheim, COPDForum, Dey, GlaxoSmithKline, Novartis, Nycomed, Nycomed/Strategicare, Pfizer, Pharmaxis, Schering-Plough, TargeGen. He has received lecture fees from ACCP, AstraZeneca, Creative Educational Concept, France Foundation, Network for Continuing Ed, Novartis, Pfizer and SOMA. He has received industry-sponsored grants from Almirall, AstraZeneca, Biomarck, Centocor, GlaxoSmithKlein, IFSH, Lorillard, Novartis, Pfizer, Phillip Morris and Roche. S. Rennard has received tobacco industry funding. Specifically, he has received funding from the tobacco industry for studies relating to harm reduction and to the impact of tobacco smoke on stem cells. He has also consulted with R.J. Reynolds without personal fee on the topic of harm reduction and received funding from R.J. Reynolds to evaluate the effect of a harm reduction product in normal smokers (1996) and in subjects with chronic bronchitis (1999) and to assess the effect of smoking cessation on lower respiratory tract inflammation (2000). He participated in a Philip Morris multi-center study to assess biomarkers of smoke exposure (2002) and received funding for a clinical trial from the Institute for Science and Health (2005), which receives support from the tobacco industry, to evaluate biomarkers in exhaled breath associated with smoking cessation and reduction. This study was supplemented with funding from Lorillard and RJ Reynolds. He has received a grant from the Philip Morris External Research Program (2005) to assess the impact of cigarette smoking on circulating stem cells in the mouse. He consulted with R.J. Reynolds on the topic of harm reduction until 2007, but did not receive personal remuneration for this. There are no active tobacco-industry funded projects. All ties with tobacco industry companies and entities supported by tobacco companies were terminated in 2007. DOI: 10.1183/09031936.00195809
R. Ria has acted as an expert witness on the study topic. The present study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
D. Ribatti has acted as an expert witness on the study topic. The present study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
C.H. Rice. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
L. Rubin has: received research grants from Actelion Pharmaceuticals, Gilead Sciences, Pfizer and United Therapeutics; served on advisory committees for Actelion, Gildean and Pfizer; served as a consultant for Actelion, Aires Pharmaceuticals, Bayer Schering Pharma, Cerulean Biosciences, Gilead, mondoGEN, Pfizer, Solvay Pharmaceuticals and United Therapeutics. L. Rubin owns stock in United Therapeutics. DOI: 10.1183/09031936.00139009
L.J. Rubin has served as an investigator and consultant for Actelion, Pfizer, United Therapeutics and Gilead in the development of treatments for pulmonary artery hypertension. DOI: 10.1183/09031936.00107108
M. Rutten-van Mölken is involved in the development and publication of the Dutch population-based life-time COPD model, which is financially supported by the Dutch Ministry of Health through the National Institute of Public Health and the Environment. She has also published a short-term COPD model to assess the cost-effectiveness of bronchodilator treatment in COPD, which was financially supported by Boehringer Ingelheim. She acts as a consultant on COPD modelling for Novartis and Nycomed. DOI: 10.1183/09031936.00108409
P.H. Ryan. The present study was supported by ConAgra. DOI: 10.1183/09031936.00050808
Å. Ryrfeldt. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
S Back to top
S.A. Sathyapala was previously funded for 6 months by GlaxoSmithKline. DOI: 10.1183/09031936.00074008
H.J. Schünemann has received no personal payments from pharmaceutical industry, but in the last three years he has received research grants and/or honoraria that were deposited into research accounts or received by a research group that he belongs to from AstraZeneca (research grant, honoraria), Chiesi Foundation (honorarium), Lily (honorarium), Pfizer (research grant, honorarium), and UnitedBioSource (honorarium) for development or consulting regarding quality of life instruments for chronic respiratory diseases and as lecture fees related to the methodology of evidence based practice guideline development and/or research methodology. Other institutions or organisations that he is affiliated with likely receive funding from for-profit sponsors that are supporting infrastructure and research that may serve his work. DOI: 10.1183/09031936.00095408
S. Semple was supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
F. Sériès. The author's study was supported by Abbott Pharmaceutical. DOI: 10.1183/09031936.00167308
H. J. Seyfarth has received lecturer honoraria from Actelion Pharmaceuticals and Bayer/Schering. DOI: 10.1183/09031936.00130408
S. Sharma is an employee of GlaxsoSmithKline. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00167908
P.M. Shirtcliffe. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
M. Shulte is an employee of Inamed Research. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
M. Siegemund. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
E.K. Silverman has received grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics. He has received consulting fees from Astra-Zeneca. He has also received honoraria from Wyeth, Bayer, GlaxoSmithKline, and Astra-Zeneca. DOI: 10.1183/09031936.00141808
E.K. Silverman has received grant support and consulting fees from GlaxoSmithKline for two studies of chronic obstructive pulmonary disease genetics. He has received consulting fees from AstraZeneca, and also honoraria from Wyeth, Bayer, GlaxoSmithKline and AstraZeneca. The author's study was sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00156508
T. Similowski has received honoraria from Atrotech (Finland) and Synapse Biomedical (USA) to translate from English to French the user's manuals of the two neurostimulator devices used in the patients in this study. DOI: 10.1183/09031936.00177708
G. Simonneau has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00139009
M. Singh is an employee of Lionex GmbH. DOI: 10.1183/09031936.00013409
O. Sitbon has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer and United Therapeutics, in addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00006508
O. Sitbon has received reimbursement for attending symposium and funds for research from Actelion, Pfizer, GSK and Bayer-Schering. He has received fees for speaking from Actelion, Pfizer, GSK, Bayer-Schering and United Therapeutics. He has received fees for consulting from Actelion, Pfizer and GSK. DOI: 10.1183/09031936.00068009
O. Sitbon has, in the past 5 years, received: reimbursement for attending a symposium; a fee for speaking; a fee for organising education; funds for research; funds for a member of staff; fees for consulting. O. Sitbon has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00102609
O. Sitbon has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00017809
F.W.J.M. Smeenk has received educational grants, and consulting and speaker fees from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.50130408
N. Smyrnios. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
A. Spaar. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. This grant paid for consumables and the salary of A. Spaar. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author's systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
A. Spaar. The author's work did not have specific funding, and was done in time made available by the authors' institutes. However, the study partly used data available from previous work. With relation to this previous work, the Horten Centre received a grant from Kleijnen Systematic Reviews Ltd for conducting systematic reviews in respiratory medicine. This grant paid for consumables and the salaries of B. Bausch and A. Spaar. DOI: 10.1183/09031936.00159108
R.A. Stockley. The authors are supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
D. Stolz. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
R. Strassmann. The Horten Centre (Zurich, Switzerland) received a grant from Kleijnen Systematic Reviews Ltd (York, UK) for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments and the methodology of randomised trials in respiratory medicine. R. Strassmann did not receive any salary support and performed all work as part of her medical thesis. Kleijnen Systematic Reviews Ltd received a grant from Pfizer Ltd for conducting systematic reviews about the effectiveness of pharmacological and nonpharmacological treatments in respiratory medicine. Pfizer did not, however, influence in any way the conduct of the author's systematic review or the writing of the article. DOI: 10.1183/09031936.00167708
V. Strugala is an employee of Technostics Ltd. DOI: 10.1183/09031936.00126908
S. Suissa has participated in advisory board meetings and conferences, and has acted as a speaker in scientific meetings for various companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer and Sepracor). The author has also received research grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00190908
B-M. Sundblad. This study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
L. Swedin. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
T Back to top
R. Tal-Singer is an employee of GlaxoSmithKline, the sponsor of the studies reported in the present manuscript. DOI: 10.1183/09031936.00156508
M. Tamm. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
N. Thakkar. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. DOI: 10.1183/09031936.00053209
R.K. Thomas has received research support from AstraZeneca, served as a consultant to Sequenom and received speaker honoraria by 454 Life Sciences and Infinity Pharmaceuticals. DOI: 10.1183/09031936.00042409
A. Torbicki has: served as a consultant for Actelion, Eli Lilly, GlaxoSmithKline and mondoBIOTECH; received honoraria from Bayer Schering, Eli Lilly and Sanofi Aventis; conducted research supported by Actelion, Bayer Schering, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, mondoBIOTECH and Pfizer. DOI: 10.1183/09031936.00139009
A. Torres has received fees for speaking from Astellas and Bayer, funds for research from Pfizer and fees for consulting from Wyeth, Astellas and Bayer. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
A. Torres has received payments for advisory board work from Astellas and Bayer, investigation grant from Pfizer and payment from Astella, Bayer and Sanofi to speak in sponsored symposia. DOI: 10.1183/09031936.00120009
J. Travers. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
J. Travers. The author's study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
V Back to top
A. Vacca has acted as an expert witness on the study topic. The present study was supported, in part, by Humanitas Mirasole. DOI: 10.1183/09031936.00165308
J-L. Vachiery has: received speaker's fees and travel grants from Actelion Pharmaceuticals, GlaxoSmithKline, Pfizer, United Therapeutics, BayerShering, Elli Lilly; and consultancy fees from GlaxoSmithKline, Pfizer, United Therapeutics, Elli Lilly. DOI: 10.1183/09031936.00139009
E.J.R. van Beek has received speaker's fee from Philips Medical Systems, and has consulted for a variety of pharmaceutical companies, but none of these are associated with the work presented. DOI: 10.1183/09031936.00138508
M. van Hage. The author's study was supported by funding from Astra Zeneca, EU (Contract No FOOD-CT-2004-506378). DOI: 10.1183/09031936.00030908
M. Venditti has received fee for speaking from Pfizer, GlaxoSmithKline, Novartis, Aventis, Bayer, Angelini, Gilead and Wyeth. DOI: 10.1183/09031936.00007709
J. Vestbo has received fees for speaking from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Pfizer; and funds for research and for a member of staff, from GlaxoSmithKline. He is a member of an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. His wife works for AstraZeneca in Copenhagen. He has, in 1985, received 267,000 Dkr from the Scandinavian Tobacco Company in support for a research project on exposure to cement dust, smoking, and respiratory disease. The present study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
J. Vestbo. Research grants to support work carried out in the department in which J. Vestbo works have come from GlaxoSmithKline. J. Vestbo has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingeheim and Pfizer for speaking in scientific meetings and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. Finally, his wife, Inge Vestbo, is an employee of AstraZeneca. In 1985 he received 267,000 Dkr from Scandinavian Tobacco Company in support for a research project on exposure to cement dust, smoking, and respiratory disease. DOI: 10.1183/09031936.00122608
S. Vilà. This study was funded by Bayer Schering Pharma. DOI: 10.1183/09031936.00195608
W.M. Vollmer has served on ad hoc advisory boards for Merck and Co., has participated in COPD workshops funded by Merck and GlaxoSmithKline, and is director of the Burden of Obstructive Lung Disease (BOLD) operations centre, funding for which includes unrestricted educational grants to the Kaiser Permanente Center for Health Research from Boehringer Ingelheim, Pfizer, Altana, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi and Merck. W.M. Vollmer is a past recipient of funding from Merck, which was associated with the validation work for the ATAQ instrument; however, he receives no royalties or other compensation from the use of ATAQ by others and does not hold any copyright privileges for the ATAQ instrument. DOI: 10.1183/09031936.00164608
A. Vonk-Noordegraaf received a $1,200 lecture fee from Actelion. DOI: 10.1183/09031936.00106008
I. von Scheele. The author's study was supported by a grant from the Research Department of AFA Insurance Company (Stockholm, Sweden). DOI: 10.1183/09031936.00105308
W Back to top
M. Weatherall. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
M. Weatherall. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
K.A. Webb. The author's study received financial support from Boehringer Ingelheim GmbH, Ingelheim, Germany. DOI: 10.1183/09031936.00168708
M. Wencker is employed by Talecris and holds company shares by Talecris. The study was sponsored by Inamed Research GmbH & Co. KG (Gauting, Germany) and was supported by a research grant from Talecris Biotherapeutics Inc, Research Triangle Park, NC, USA. DOI: 10.1183/09031936.00118408
K.L. White and others at IHI Environmental were hired by ConAgra to perform the industrial hygiene exposure assessments discussed in the paper. This work occurred between early 2005 and the present. The author's study was supported by ConAgra. DOI: 10.1183/09031936.00050808
M. Wijesinghe. The Medical Research Institute of New Zealand has received research grants from AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00159708
I. Wiklund was employed by GlaxoSmithKline at the time of the study. The study and the development of the COPD Assessment Test (CAT) were funded by GlaxoSmithKline. Support was provided by Innovex Medical Communications for the administration of the manuscript submission. This support was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00102509
M.V. Williams. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00174408
L.R. Willits is employed by and holds shares in GlaxoSmithKline. The author's study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
J. Winkler has received lecturer honoraria from Actelion Pharmaceuticals and Bayer/Schering. DOI: 10.1183/09031936.00130408
A.M. Wood. The authors are supported by a non-commercial grant from Talecris Biotherapeutics who had no involvement in study design or conduct, manuscript preparation or submission. DOI: 10.1183/09031936.00087908
M. Woodhead has received payment for lecturing from Pfizer and for being a member of a data monitoring committee from Wyeth. DOI: 10.1183/09031936.00120009
E.F.M. Wouters is a member of the scientific advisory boards for GSK, Boehringer Ingelheim, AstraZeneca and Numico, and he has and received lecture fees from GSK, AstraZeneca and Boehringer Ingelheim. The author has also received research grants between 2004 and 2007 from GSK, AstraZeneca, Boehringer Ingelheim, Centocor and Numico. DOI: 10.1183/09031936.50130408
Y Back to top
J.C. Yates is an employee of and owns shares in GlaxoSmithKline. The author's study was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00193908
Z Back to top
G. Zhu is a full-time employee of GlaxoSmithKline. DOI: 10.1183/09031936.00141808
L. Ziegler-Heitbrock is the holder of a patent for inhalative ATRA therapy. DOI: 10.1183/09031936.00105309
S. Zuyderduyn is sponsored by a research grant from Boehringer Ingelheim Pharma GmbH & Co. DOI: 10.1183/09031936.00045209
Volume 35, 2010
A Back to top
Y. Ahn. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
T. Aine. The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
N. Ambrosino. Vivisol funded an annual position at University Hospital of Pisa for one member of staff. DOI: 10.1183/09031936.00015910
S. Anders. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
S. Andreas has received fees for lectures and organising education of about €5,000 by Respironics, Resmed and Heinen & Lowenstein. He received consulting fees from Sanofi Synthelabo of about €1,000. DOI: 10.1183/09031936.00035310
I. Annila. The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
S.M. Arend. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
S.J. Arends. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
J.J. Armstrong is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
M. Arzt has received speaker fees from Respironics and Resmed of less than $10,000 in the past 5 years. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
E. Azoulay has received an educational grant from Pfizer (France), and has been a consultant for Pfizer and Gilead (France). DOI: 10.1183/09031936.00057509
A. Azuma received ¥750,000 in total for eight advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
B Back to top
D.M. Bailey. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
A. Baloira. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
R. Bals accepted a reimbursement from Talecris to attend a conference, received fees for speaking for Talecris, and fees for consulting Talecris; he and his staff members received funds for research. DOI: 10.1183/09031936.00069709
E. Baraldi received a research grant from Aerocrine (payment to Azienda Ospedaliera di Padova) and also received travel grants and lectured at scientific meetings for GlaxoSmithKline, Merck Sharp & Dohme, Abbott and Valeas. DOI: 10.1183/09031936.00074909
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for treating airway diseases. DOI: 10.1183/09031936.00051510
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of which market treatments for COPD. DOI: 10.1183/09031936.00036709
P. Bärtsch received a research grant of €10,000 from VIASYS Healthcare to support the present study. The study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
J. Behr was involved in the Bosentan Use in Interstitial Lung Disease (BUILD) programme as a member of the Steering Committee. The present study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
I. Belenkie. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
M.G. Belvisi has received an educational grant from GlaxoSmithKline and Novartis and has acted as a consultant for GlaxoSmithKline. Funding for the study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
R. Bhattacharjee is the recipient of a competitive unrestricted research fellowship from Jazz Pharmaceuticals. DOI: 10.1183/09031936.00075409
M.M. Berger. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
M.A. Birrell. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
H. Bisgaard has been a consultant to, paid lecturer for and holds sponsored grants from AstraZeneca, Altana, GSK, Merck, MedImmune, NeoLab and Pfizer. He does not hold stock or options in any pharmaceutical company in the respiratory field. The Danish Pediatric Asthma Center has received unrestricted institutional grants from AstraZeneca, GSK, Merck and MedImmune. DOI: 10.1183/09031936.00139508
A.L. Boner's travel to ERS congress was funded by GSK, he has received fees for speaking from GSK and MSD, and he served once as a consultant in two international meetings, one organised by GSK and one by MSD. DOI: 10.1183/09031936.00051509
K. Boomars. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
M. Boquete. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
M.W. Borgdorff. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
J. Bourbeau has received fees for speaking at conferences and for serving as an expert on advisory boards for AstraZeneca, BI, GSK, Novartis, Nycomed and Pfizer. The author's MUHC Research Institute received research grants for investigator-initiated researches and unrestricted educational grants from AstraZeneca, BI, GSK, Novartis and Pfizer. DOI: 10.1183/09031936.00079409
T.D. Bradley. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's groups has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
E. Brambilla acts as part of the Advisory Board at the ROCHE Laboratory. DOI: 10.1183/09031936.00018810
P. Brand. Between 2003 and 2008, P. Brand received fees for consulting, for attending symposia, for research endeavours, for speaking at symposia, and for junior staff, from GlaxoSmithKline, AstraZeneca, Merck Sharp and Dohme, and Nycomed. DOI: 10.1183/09031936.00139508
S.M. Brandenburg's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00065809
M-K. Breyer. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
A.H. Briggs has received honoraria, consulting fees, travel expenses and research grants from the sponsor of his study. He owns a minority (10%) shareholding in the company contracted to undertake the analysis. The contract gave full access to the data for the purposes of the analysis and freedom to publish the results subject to the consent of the trial steering committee. A. Briggs has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings. He has received support for research from pharmaceutical companies, including GlaxoSmithKline. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
B. Broers. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
K.K. Brown has participated on the Steering Committees of the Bosentan Use in Interstitial Lung Disease (BUILD)-1, -2 and -3 studies, and as a local principle investigator for multiple Actelion-sponsored trials. The present study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
V. Brusasco received: €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2005 and €3,500 in 2008 from Lofarma for consultancies; €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 in 2008 for speaking at conferences sponsored by Boehringer Ingelheim; €2,200 from Boehringer Ingelheim for consultancy in 2009; $1,500 from Deep Breeze for consultancy in 2009; €6,000 from Dompé for consultancy in 2009; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving on an advisory board; and €1,500 from Menarini for consusltancy in 2008. V. Brusasco's institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim, and participated in several multi-centre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00004510 and DOI: 10.1183/09031936.00005710
S. Burge acts as an expert witness for individual workers with a wide range of occupational lung diseases. DOI: 10.1183/09031936.00139409
O.C. Burghuber. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD and GSK; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00051509
A. Bush has received fees for speaking from GSK, Merck and AstraZeneca, in no case exceeding £1,500; he has received funding from Pharmaxis for a research fellow to perform a trial of inhaled mannitol in cystic fibrosis; he has had expenses to attend ATS paid by Altana. DOI: 10.1183/09031936.00139508
C Back to top
P.M.A. Calverley has spoken at meetings supported by GlaxoSmithKline, AstraZeneca and Chiesi. He has advised on trial design and research strategy for AstraZeneca, Boehringer Ingeheim, GlaxoSmithKline, Roche, Nycomed, Almirall and Pfizer. His department has received research funding from GlaxoSmithKline, Altana and Chiesi to conduct clinical trials and observational research in COPD. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
C. Canova. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
F. Carballada. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
V.P. Carnielli has received a fee for speaking for an educational event sponsored by Dey Laboratories, Napa, CA, USA and has received funds for research from Chiesi Pharmaceuticals, Parma, Italy. DOI: 10.1183/09031936.00074909
N. Carpenè. Vivisol funded an annual position at University Hospital of Pisa for one member of staff. DOI: 10.1183/09031936.00015910
S. Carraro received a research grant from Aerocrine, travel grants from Merck Sharp & Dohme and Chiesi and a fee for speaking from Merck Sharp & Dohme. DOI: 10.1183/09031936.00074909
T.P. Carroll has received a research grant from Talecris Biotherapeutics. DOI: DOI: 10.1183/09031936.00191908
C. Castell. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
O. Castro Añón. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
B. Celli. The division that this author heads has received grant funding from GlaxoSmithKline, Boehringer Ingelheim, Almirall and Pfizer. In addition, B. Celli has received payments for speaking at symposiums and attending advisory boards for GlaxoSmithKline, Boheringer Ingelheim, Almirall, Dey Pharmacautical, Astra Zeneca and Pfizer. The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00082909
E.J. Cetti. The Royal Brompton Hospital is reimbursed for a clinical trial unrelated to the study being published by Olympus. DOI: 10.1183/09031936.00148809
A.S.L. Chan. Support in-kind (mandibular advancement splints) was provided by SomnoMed Ltd. DOI: 10.1183/09031936.00077409
P. Chanez has received €105,000 from the following for regular paid consultancy work and lectures and education: Centocor; Astra Zeneca; Chiesi; GSK; Boehringer Ingelheim; Nycomed; Novartis; Almirall; and research grants and institutional research grants more than €20,000 from the following: Schering Plough; Centocor. DOI: 10.1183/09031936.00186109
M. Chatwin has participated in educational research projects that have been funded by Breas Medical. DOI: 10.1183/09031936.00073409
K.F. Chung has been paid for participating on Advisory Boards of several pharmaceutical companies to discuss treatments for asthma and COPD. He has also received funds for educational purposes, particularly for support for organising a conference on cough. He has also been renumerated for lecturing in courses organised by pharmaceutical companies, and been reimbursed travel expenses for attending international conferences. He has received research grants from such companies. DOI: 10.1183/09031936.00071309
P.A. Cistulli contributed to the development of the oral appliance used in the present study, which is being commercialised by SomnoMed Ltd. He previously served as a consultant and medical advisory board member (2004-2006, $AUD5,000 per annum), and has a pecuniary interest in the company. His department receives equipment (oral appliances) and financial support (2009 $AUD60,000) for research studies from SomnoMed Ltd. P.A. Cistulli is a chief investigator in a CPAP clinical trial funded by ResMed Inc, and his department receives equipment support (CPAP machines) for investigator-initiated studies. He is a board member of the ResMed Foundation, a non-profit charitable organisation. Support in-kind (mandibular advancement splints) was provided by SomnoMed Ltd. DOI: 10.1183/09031936.00077409
F.G.J. Cobelens. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
J.W. Cohen Tervaert. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
H. Collard has served as a consultant for Actelion ($11,000 in 2009) and Gilead ($5000 in 2009). H. Collard has previously served as a consultant for Amira Pharmaceuticals ($3,400 in 2009), CV Therapeutics ($2,400 in 2008), Nektar ($1,000 in 2008), Genzyme ($900 in 2007) and InterMune ($7,500 in 2006). DOI: 10.1183/09031936.00006610
H.R. Collard has been a consultant for Actelion, Amira Pharmaceuticals, CV Therapeutics, Genzyme, Gilead Science, InterMune, Nektar Therapeutics and Roche. DOI: 10.1183/09031936.00092309
M. Collins. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
J.F. Cordier has received fees for consulting, speaking at conferences, and travel for scientific congresses from Pfizer, Glaxo, Actelion. DOI: 10.1183/09031936.00076209
P. Corris has received fees for speaking and consulting from Actelion, Pfizer, Bayer, GSK and United Therapeutics. The author's department has received research funding from Pfizer. DOI: 10.1183/09031936.00160309
D Back to top
J. Damoiseaux has received a fee for speaking on an educational conference from Phadia and Abbott. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
M.A. Darendeliler's travel and expenses to the German Dental and Medical Sleep Meeting in Regensburg, Germany was sponsored by SomnoMed Company in 2006. Support in-kind (mandibular advancement splints) was provided by SomnoMed Ltd. DOI: 10.1183/09031936.00077409
J. De Alba. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
K. de Boeck. As head of the department of paediatric pulmonology, K. de Boeck has received €15,000 per year from Ast grant during the last 4 years; €5,000 per year from Glaxo and Solvay, €4,500 per year from Roche, and speaker's fees from Roche, Novartis and Gilead. She has acted as a consultant for Wyeth, Astra, Grune Boehringer and Vertex. Travel to research meetings has been funded by Glaxo, Solvay, MSD and Astra. DOI: 10.1183/09031936.00139508
L. Debrus-Palmans. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
M. Decramer has been part of Advisory Boards for Boehringer-Pfizer, GSK, Nycomed, and Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He has also received lecture fees from these companies. All of the above amounted to less than €10,000/year. He has received a research grant of €45,000/year from AstraZeneca. The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00082909
M. Decramer has been part of advisory boards for Boehringer-Pfizer, GSK, Nycomed and Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than €10,000 per annum. He received a research grant of €45,000 per year from AstraZeneca. DOI: 10.1183/09031936.00091108
C. Dehnert received funding for travel to the Annual Meeting of the American College of Sports Medicine from VIASYS Healthcare. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
J. de Jongste has received partial funding of travel to ERS and ATS annual conferences from Altana, GlaxoSmithKline and AstraZeneca. He has lectured at symposia sponsored by GlaxoSmithKline and MerckSharpDohme. All payments went to the Sophia Children's Hospital Pediatric Research Unit. AstraZeneca contributed to the funding of one of two junior staff members for the department of Pediatric Respiratory Medicine. The department has received research funding from GlaxoSmithKline, Roche, Pfizer, Chiron and MerckSharpDohme. DOI: 10.1183/09031936.00139508
A. Dekkak. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
P. Devillier has, in the past five years, received reimbursement for attending symposia, fees for speaking, funds for research, and fees for consulting. The author has received: consulting fees from GlaxoSmithKline, Nycomed, Schering-Plough, Astra Zeneca, Boehringer-Ingelheim; and research grants from Nycomed, Novartis, Boehringer-Ingelheim, Sanofi-Aventis, Servier, Pierre Fabre and Top Pharm. DOI: 10.1183/09031936.00139909
A.T. Dinh-Xuan has received a reimbursement of €900 from Medisoft for attending the 5th International Meeting on NO in 2008, and a fee of €700 for chairing a session on pulmonary hypertension from Actelion in 2007. DOI: 10.1183/09031936.00057509
A.T. Dinh-Xuan has received a reimbursement of €900 from Medisoft for attending the 5th International Meeting on NO in 2008, and a fee of €700 for chairing a session on pulmonary hypertension from Actelion in 2007. DOI: 10.1183/09031936.00060209
A.T. Dinh-Xuan has received a reimbursement of €900 from Medisoft for attending the 5th International Meeting on NO in 2008, and a fee of €700 for chairing a session on pulmonary hypertension from Actelion in 2007. DOI: 10.1183/09031936.00004510 and DOI: 10.1183/09031936.00005710
J.W. Dodd received a travel scholarship to the ATS congress in 2009 awarded by GSK. DOI: 10.1183/09031936.00125109
J. Domínguez participated in 2005 in the Oxford Immunotec (manufacturer of T-SPOT.TB) advisory board meeting. None of the Scientific Societies, neither Oxford Immunotec (Abingdon, UK) had a role in the study design, conduct, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript. DOI: 10.1183/09031936.00196608
C.E. Doneanu is an employee of Waters Corporation, Milford, MA, USA. DOI: 10.1183/09031936.00089409
L.E. Donnelly has received funding for lectures and research from AstraZeneca, Boehringer Ingelheim GlaxoSmithKline, Pfizer and Novartis, which market treatments for COPD. DOI: 10.1183/09031936.00036709
R.M. du Bois is/has been a paid consultant, Steering Committee member and/or co-chair of a Steering Committee for InterMune, Actelion, Centocor, Boehringer-Ingelheim, Novartis, Genzyme, and MondoBiotech. The author's study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
A. Duijvestijn. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
E Back to top
P.R. Eastwood is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
M. Ebina received ¥850,000 in total for nine advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
G. Edelmann. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
C. Erkens. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
S. Ewig has received fees for speaking and funds for research from BRAHMS company. DOI: 10.1183/09031936.00164909
F Back to top
V. Faoro. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
K.A. Ferguson reports receiving lecture fees from GlaxoSmithKline, Respironics Inc. and VitalAire, has received honoraria for talks from Pfizer and is a director of Critical Outcome Technologies Inc. This is a publicly traded company involved in early stage drug discovery. Involvement in this company has no bearing on the subject matter in K.A. Ferguson's study. The study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
I. Ferrarotti accepted a reimbursement from Talecris to attend a conference and received funds for research from Talecris. DOI: 10.1183/09031936.00069709
J. Fleetham. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
J.S. Floras. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
W.P.J. Franken. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
G-C. Funk. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
G Back to top
M. Gappa has received reimbursement of Travel expenses for attending a private workshop on lung function testing organized by ndd medical technologies. DOI: 10.1183/09031936.00159509
A. Gebhard. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
P. Gehr has received reimbursements and fees from different scientific societies and foundations for contributions to conferences and for research. He has also received fees for consulting with the Federal Office for the Environment of Switzerland. DOI: 10.1183/09031936.00159909
M. Gheradi. Vivisol funded an annual position at University Hospital of Pisa for one member of staff. DOI: 10.1183/09031936.00015910
H.A. Glick has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings. He has received support for research from pharmaceutical companies, including GlaxoSmithKline. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
R. Golpe. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
M. Gomberg-Maitland has received research grant support from Actelion, Encysive, Gilead, Lilly/Icos, Pfizer, Novartis, and United Therapeutics and has served as a consultant for Biomarin, Gilead, Medtronic, Millenium, and Pfizer. The author does not do any promotional speaking and has received honorarium from ABcomm and HealthmattersCME for CME-related events. M. Gomberg-Maitland has a patent filed entitled 'Compositions and Methods for Treating Pulmonary Hypertension' for the use of sorafenib in pulmonary hypertension (WO/2007/087575). DOI: 10.1183/09031936.00011110
M. Gomberg-Maitland has, in the past 5 yrs, received research grant support from Actelion, Co-Therix, Encysive, Gilead, Lilly/Icos, Pfizer and United Therapeutics, and has served as a consultant and/or on advisory boards for Alkermes, Biomarin, GlaxoSmithKline, Gilead, Medtronic, Millennium, Pfizer and United Therapeutics. She has received money for organising education from AB Communications, Inc. for CME symposia and reimbursement for attending an educational meeting from United Therapeutics. M. Gomberg-Maitland has a patent filed entitled, 'Compositions and Methods for Treating Pulmonary Hypertension' for the use of sorafenib in pulmonary hypertension (WO/2007/087575). DOI: 10.1183/09031936.00072709
D. Gozal serves on the National Speaker Bureau for Merck and has received honoraria for invited lectures on asthma. DOI: 10.1183/09031936.00075409
R.R. Grunstein's department has received funds from Somnomed, a manufacturer of mandibular advancement splints, to undertake research. Support in-kind (mandibular advancement splints) was provided by SomnoMed Ltd. DOI: 10.1183/09031936.00077409
H Back to top
G. Hahn. The present study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
P.J. Hanly reports having equity ownership in Tyco Healthcare and has received an honorarium for a CME talk from Respironics. Respironics have provided financial support to the University of Calgary for a training programme in Sleep Medicine, and have provided reimbursement for attending a scientific meeting. This study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
S. Hartl. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
N. Hart has received unrestricted research grants from both Resmed and Phillips-Respironics and travel and accommodation to both the ERS and ATS has been funded by GlaxoSmithkline and Phillips-Respironics. DOI: 10.1183/09031936.00167509
I.H. Heijink. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00065809
W. Heindl. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
D.R. Hillman is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
G. Hinterholzer. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
M.M. Hoeper has received speaker and/or consultant fees from Actelion, Bayer, Encysive, Gilead, GSK, Lilly, LungRx, Novartis, and Pfizer. DOI: 10.1183/09031936.00166409
C. Hogaboam. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
O. Holz. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
M. Hoogendoorn. The study was financially sponsored by Pfizer and Partners in Care Solutions (PICASSO) for COPD. DOI: 10.1183/09031936.00043309
M. Humbert has relationships with drug companies including Actelion, Bayer Schering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00175909
M. Humbert has relationships with drug companies, including Actelion, BayerSchering, GlaxoSmithKline, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00113009
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00070209.
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00038709
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00081009
M. Humbert has relationships with drug companies including Actelion, Altair, Astrazeneca, BayerSchering, Chiesi, GSK, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00035310
I Back to top
M. Ip has received sponsorships from Resmed, Respironics and Celki, Tyco for scientific conference travel (directly or indirectly through organizing committee). She has also received honorarium from Respironics (Philips) for lectures. DOI: 10.1183/09031936.00047709
J Back to top
X. Jais has relationships with drug companies including Actelion, Bayer Schering, GlaxoSmithKline, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00113009
M. Johnson is an employee of GlaxoSmithKline, which is developing GW865553 for the treatment of COPD. DOI: 10.1183/09031936.00071309
S.R. Johnson has acted as a consultant for Novartis regarding the use of mTOR inhibitors in LAM and TSC. DOI: 10.1183/09031936.00076209
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Almirall for speaking at meetings and participating in advisory board meetings and has received support for research from GlaxoSmithKline. DOI: 10.1183/09031936.00125109
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings. He has received support for research from pharmaceutical companies, including GlaxoSmithKline. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
G.F. Joos has received: funding from GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis and UCB; lecture fees from GSK, AstraZeneca, Boehringer Ingelheim, Almiral Prodespharma, UCB and Sanofi-Aventis; and scientific advisory board fees from GSK, AstraZeneca, Boehringer Ingelheim, Novartis and Nycomed. DOI: 10.1183/09031936.00051510
K Back to top
K. Kamio. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
M. Kamphorst. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
H. Kankaanranta has received reimbursement for attending an international conference and fees for speaking and consulting from GlaxoSmithKline. The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
S. Kawasaki. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
S. Kesten is a full time employee of Boehringer Ingelheim. The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00082908
S. Khalilieh is employed by Schering-Plough, which developed SCH527123. S. Khalilieh earns a salary from and owns stocks in Schering-Plough. The current research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
L. Kheirandish-Gozal is the recipient of an investigator initiated grant from Merck on treatment of pediatric sleep apnea with leukotriene modifiers. DOI: 10.1183/09031936.00075409
S.V. Kik. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
R.J. Kimoff has received honoraria for talks from Vitalaire and GlaxoSmithKline. This study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
T.E. King Jr has served on advisory boards for Actelion, InterMune and GlaxoSmithKline, and served as a consultant for Nektar, Alexza, AstraZeneca, Biogen, Centocor, Fibrogen, Genzyme; Human Genome Sciences, Johnson & Johnson, ImmuneWorks, Merck and CoTherix. DOI: 10.1183/09031936.00092309
T.E. King Jr has received reimbursement for attending a symposium; fees for speaking; and fees for consulting related to the treatment of interstitial lung diseases, including in idiopathic pulmonary fibrosis. T.E King Jr has also participated as an advisory board member or consultant to a number of pharmaceutical companies involved in the development of trials of novel therapies for interstitial lung disease, including Actelion, and has been paid for lecturing at a number of international meetings organised by the pharmaceutical industry, including Actelion. The present study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
R.G. Knowles is a full time employee of GlaxoSmithKline. Funding for the study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
R. Kohansal. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
Y. Kondoh. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
M. Korppi has been the member of the expert board for RSV infections organised by Abbott Finland Ltd in 2006'2007. DOI: 10.1183/09031936.00139508
S. Kudoh received ¥900,000 in total for nine advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
L Back to top
C. Lange has participated as a speaker in scientific meetings funded by Cellestis Ltd. and/or OxfordImmunotec Ltd. DOI: 10.1183/09031936.00045509
D. Langleben has served as an investigator, speaker and/or consultant for Actelion, Glaxo Smith Kline and Pfizer. DOI: 10.1183/09031936.00160309
I. Leconte. The author's study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
R.W.W. Lee. Support in-kind (mandibular advancement splints) was provided by SomnoMed Ltd. DOI: 10.1183/09031936.00077409
A. Leff is the principal investigator on this project, which was funded in part by Merck and Co. No part of the author's paper has been seen or reviewed by Merck and Co. The University of Chicago requires publication of results as a condition of acceptance of an industry grant without prior corporate review. The study was funded by a grant from Merck and Co. (USA). DOI: 10.1183/09031936.00009309
L. Lehtimäki has received reimbursement for attending a symposium and fees for speaking from GSK, and had a consultancy agreement 2007-2008 with a manufacturer of NO analysers (Aerocrine AB, Stockholm, Sweden). The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
F. Lioté has received fees for speaking from Roche, France, and travel to the EULAR Meeting 2009 was funded by Roche Chugai, France. DOI: 10.1183/09031936.00080209
A.G. Logan. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
G. Lorenzi-Filho has received a grant from Fisher and Paykel to conduct a study. DOI: 10.1183/09031936.00192008
M. Lotti. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
G. Lozano-Ortega is employed by the company contracted to undertake the analysis. The contract gave full access to the data for the purposes of the analysis and specified that the analysis would be published irrespective of the results. He has acted as a consultant and received honoraria, research grants and travel expenses to attend scientific meetings from a number of companies, including GlaxoSmithKline. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
A. Ludwig-Sengpiel. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
X.D. Lui. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
M. Luisetti accepted a reimbursement from Talecris to attend a conference, received fees for speaking for Talecris and Grisfols, and fees for consulting Talecris; he and his staff's members received funding for research. DOI: 10.1183/09031936.00069709
A.M. Luks. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
T. Lystig is a current employee of Boehringer Ingelheim Pharmaceuticals, a former employee of AstraZeneca, and has stock ownership in Affymetrix, Amgen, AstraZeneca, Medco Health Solutions, Merck, and Oncogenex Pharmaceuticals (no individual stock holding worth more than $10,000). The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00082909
M Back to top
P.T. Macklem is a paid consultant of Broncus Technologies which manufactures equipment for the bronchial bypass procedure, an experimental treatment for emphysema, a version of which was first proposed by P.T. Macklem in a 1978 editorial in the New Engl J Med. In 1970 the Canadian Tobacco Manufacturers Association provided 50% of the construction costs of the Meakins Christie Laboratories for Respiratory Research. The condition for accepting this donation was that there were no strings attached and that the industry had no influence whatsoever over the subject of the research performed or publications that resulted therefrom. P.T. Macklem became the founding Director of these Laboratories. DOI: 10.1183/09031936.00120609
P. Maestrelli. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
H. Magnussen. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
H. Mairbäurl. The present study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
S.F.P. Man. GSK/CIHR, C$128,700 (2005-2008), Principal Investigator. CIHR-Wyeth Pharmaceuticals, C$446,352 (2006-2008), co-investigator. DOI: 10.1183/09031936.00006710
R.A. McLaughlin is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
S. Mehra is a current employee of Pfizer Parmaceuticals. The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00082909
A.Y. Meliton. The author's study was funded by a grant from Merck and Co. (USA). DOI: 10.1183/09031936.00009309
L. Meliton. The author's study was funded by a grant from Merck and Co. (USA). DOI: 10.1183/09031936.00009309
E. Menold. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
M. Mensen. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
P.J. Merkus has been a paid lecturer for and holds sponsored unrestricted grants from Chiesi, Roche, MSD, Novartis and TEVA. He received a fee for organising education from SCEM Conference Services and the institution at which he was employed received unrestricted grants from Roche. DOI: 10.1183/09031936.00139508
M. Miravitlles has received honoraria for speaking at scientific meetings from Talecris and Grisfols, and fees for consulting and funding for research from Talecris Biotherapeutics. DOI: 10.1183/09031936.00069709
Y. Miyake was funded by Meiji Dairies Corporation (Tokyo, Japan). DOI: 10.1183/09031936.01006-2009.
E. Moilanen had a consultancy agreement 2007-2008 with a manufacturer of NO analysers (Aerocrine AB, Stockholm, Sweden). The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
D. Montani has relationships with drug companies including Actelion, Bayer Schering, GlaxoSmithKline, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00113009
D. Morrison has received an honorarium for a CME talk and equipment support from Vitalaire. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
N.M. Muñoz. The study was funded by a grant from Merck and Co. (USA). DOI: 10.1183/09031936.00009309
P. Murphy has received reimbursement for travel and attending the ERS Annual Congress 2007 from Boehringer Ingelheim pharmaceuticals. DOI: 10.1183/09031936.00167509
N Back to top
K. Nakata received ¥670,000 in total for seven advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
S. Nava has received reimbursement for attending symposia from ResMed, Draeger and Weinmann, fees for speaking from Respironics and ResMed, funds for research from Fisher and Paykel, Weinmann and Respironics, and fees for consulting from Respironics, Draeger and ResMed. DOI: 10.1183/09031936.00002410
B. Nemery. By the very nature of my research and clinical work in the field of occupational respiratory diseases, and through my position as an officer of the ERS, I anticipate gaining an academic benefit by participating in the publication of such a position paper. DOI: 10.1183/09031936.00139409
A.T. Nials. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
A.G. Nicholson has acted as a reviewer of slides and attended/lectured at symposia on subjects related to the IFIGENIA, BUILD 1, BUILD 3 and 1199.30 trials for Zambon Ltd, Actelion Ltd and Boeringher-Ingelheim Ltd between 2001 and 2008. DOI: 10.1183/09031936.00155108
R. Nieminen. The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
J.A. Noordhoek. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00065809
T. Nukiwa received ¥900,000 in total for nine advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
O Back to top
T. Ogura received ¥50,000 in total for three advisory boards from Shionogi & Co., Ltd. Travel to the ATS congress to present the result of this study was funded by Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
C.M. Osan. The study was funded by a grant from Merck and Co. (USA). DOI: 10.1183/09031936.00009309
P Back to top
L.A. Pérez-de-Llano has received honoraria from AstraZeneca and GSK for attending postgraduate meetings and giving talks. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
M. Pfeifer reports receiving grant support from Respironics. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
M.J. Phillips is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
M. Pizarro. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
M.I. Polkey was a guest of Respironics at their COPD forum April 28-30, 2009, Atlanta, GA. DOI: 10.1183/09031936.00073409
M.I. Polkey is employed by the Royal Brompton and Harefield NHS Trust which receives income from the UK National Health Service from the assessment and treatment of Type II respiratory failure in patients with MND (and other conditions). He attended an advisory board for Respironics in 2009 for which he was paid and has received research support which has been administered through the Guys and St Thomas Trust from Respironics and ResMed who make non-invasive ventilators. DOI: 10.1183/09031936.00167509
D.S. Postma. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00065809
D.S. Postma is a member of the Advisory Boards at GSK, Boehringer Ingelheim and TEVA. She has received honoraria from Astra Zeneca and Nycomed and has received industry-sponsored grants from GSK, Astra Zeneca and Nycomed. DOI: 10.1183/09031936.00044309
H. Proquitté was supported by common equipment and financial grants totalling €52,000 over the previous 3 years from Draeger (Luebeck, Germany). DOI: 10.1183/09031936.00058009
S. Provencher has received speaker fees from Actelion Pharmaceuticals Canada and Encysive Canada, and consultant fees from Actelion Pharmaceuticals Canada, Encysive Canada, Eli Lilly Canada, Glaxo-Smith-Kline Inc., and Pfizer Canada. DOI: 10.1183/09031936.00007110
R Back to top
K. Raemdonck. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
B. Raffestin has received reimbursement for attending a symposium from Resmed and GSK. DOI: 10.1183/09031936.00165509
G. Raghu has received an honorarium for ¥150,000 for giving an invited lecture on management on idiopathic fibrosis (key note speaker during the annual congress of the Japanese Respiratory Society - JRS, 2006). This was an invited lecture by the JRS and the honorarium, although paid by Shionogi & Co. Ltd, on behalf of the JRS was OKed by JRS for the invited lecture given by G. Raghu at the JRS meeting in Tokyo, Japan, in 2006. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
G. Raghu has received lecture fees from Actelion. His centre/university has received grants for patient-related costs associated with clinical studies sponsored by Actelion, Genzyme, InterMune and Wyeth. G. Raghu has also served as a consultant and steering committee member for clinical trials sponsored by Actelion, Centocor, Boerhinger-Ingelheim, Genzyme, Gilead and Wyeth, and was a consultant for a clinical trial sponsored by Shionogi. The present study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
F. Ratjen has acted as consultant and received research support from Inspire Inc., Roche, Novartis and Vertex; on the speaker's bureau of Genentech and Novartis. DOI: 10.1183/09031936.00139508
S.I. Rennard has had tobacco industry funding. Specifically, S.I Rennard has received funding from the tobacco industry for studies relating to harm reduction and to the impact of tobacco smoke on stem cells. He has also consulted with RJ Reynolds without personal fee on the topic of harm reduction. He received funding from RJ Reynolds to evaluate the effect of a harm reduction product in normal smokers (1996) and in subjects with chronic bronchitis (1999) and to assess the effect of smoking cessation on lower respiratory tract inflammation (2000); he participated in a Philip Morris multi-centre study to assess biomarkers of smoke exposure (2002); he received funding for a clinical trial from the Institute for Science and Health (2005), which receives support from the tobacco industry, to evaluate biomarkers in exhaled breath associated with smoking cessation and reduction. This study was supplemented with funding from Lorillard and RJ Reynolds. S.I. Rennard has received a grant from the Philip Morris External Research Program (2005) to assess the impact of cigarette smoking on circulating stem cells in the mouse. He consulted with RJ Reynolds on the topic of harm reduction until 2007, but did not receive personal remuneration for this. There are no active tobacco-industry funded projects. All ties with tobacco industry companies and entities supported by tobacco companies were terminated in 2007. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer.
S. Rich previously served as a part-time salaried employee at United Therapeutics; this concluded in January 2007. DOI: 10.1183/09031936.00072709
S. Roux is an employee of Actelion. The present study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
T. Rückle is an employee of Merck Serono International SA. DOI: 10.1183/09031936.00085509
M.P.M.H. Rutten-van Mölken has received previous research grants and speakers fees from Pfizer UK and Pfizer Netherlands, and was a board member of the foundation 'Stichting Astma Bestrijding' (SAB). The study was financially sponsored by Pfizer and Partners in Care Solutions (PICASSO) for COPD. DOI: 10.1183/09031936.00043309
C.M. Ryan has received an honorarium for a CME talk from Cephalon. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
S Back to top
S. Saarelainen has received reimbursement for attending a symposium and fees for speaking or consulting from GSK and Böehringer Ingelheim. The study medication was provided by GSK. DOI: 10.1183/09031936.00177508
J. Sadeh is employed by Schering-Plough, which developed SCH527123. J. Sadeh earns a salary from and owns stocks in Schering-Plough. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
D.D. Sampson is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
A. Sato received &yrn;900,000 for nine advisory boards and ¥1,125,000 for serving as a consultant (¥2,025,000 in total) from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
M.L. Scapellato. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
G. Schendler. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
A. Scherpereel received a travel grant and a fee for speaking at the 2008 IMIG Congress from CisBio. The author's research laboratory (INSERM U774) also received a research grant from CisBio (€20,000). DOI: 10.1183/09031936.00063109
G. Schmalisch was supported by common equipment and financial grants totalling €52,000 over the previous 3 years from Draeger (Luebeck, Germany). DOI: 10.1183/09031936.00058009
A.M. Schols. The author's study was financially sponsored by Pfizer and Partners in Care Solutions (PICASSO) for COPD. DOI: 10.1183/09031936.00043309
R. Schuster. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
F. Series. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
S. Sethi has received honoraria from Boehringer Ingelheim and Pfizer. In addition, the present article was based on discussion at a symposium sponsored by Boehringer Ingelheim Pharmaceuticals, Inc and Pfizer Inc. Responsibility for the content rests with the author, who originated and developed the intellectual content and performed substantive scientific revisions. The meeting, author participation, and manuscript preparation were supported by Boehringer Ingelheim and Pfizer. Boehringer Ingelheim and Pfizer did not review or edit the manuscript except to check it for medical misrepresentation. DOI: 10.1183/09031936.00081409
P.L.Shah. The Royal Brompton Hospital is reimbursed for a clinical trial unrelated to the study being published by Olympus. DOI: 10.1183/09031936.00148809
S.J. Shah was supported by an Actelion Entelligence Young Investigator Award. DOI: 10.1183/09031936.00072709
O. P. Sharma has received lecture fees of less than $5,000 from Pfizer. DOI: 10.1183/09031936.00150609
N.M. Siafakas has, in the past 5 years, received fees for speaking, funds for research and fees for consulting from Boehringer-Ingelheim GSK, Pfizer, Novartis, Nycomed, Chiesi, AstraZeneca and UCB. DOI: 10.1183/09031936.00177809
L. Simonato. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
A.K. Simonds has received a research grant from ResMed UK for £112,000 for a study unrelated to this paper, and also a research grant from Breas Medical, Sweden, for £50,000 for a study unrelated to this paper. DOI: 10.1183/09031936.00073409
G. Simonneau has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00070209.
G. Simonneau has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI: 10.1183/09031936.00113009.
D.D. Sin has received a research grant from AstraZeneca (AZ) and GlaxoSmithKline (GSK); has received honoraria for speaking engagements from AZ and GSK and has participated on advisory boards for both AZ and GSK. AZ covered expenses related to 2009 ERS participation for D.D. Sin. DOI: 10.1183/09031936.00006710
O. Sitbon has relationships with drug companies including Actelion, Bayer Schering, GSK, Lilly, Pfizer and United Therapeutics, in addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. He has received reimbursement for attending symposium and funds for research from Actelion, Pfizer, GSK, Lilly and Bayer Schering. He has received fees for speaking from Actelion, Bayer Schering, GSK, Lilly, Pfizer and United Therapeutics.. DOI: 10.1183/09031936.00070209.
O. Sitbon has relationships with drug companies including Actelion, Bayer Schering, GSK, Lilly, Pfizer and United Therapeutics, in addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. He has received reimbursement for attending symposium and funds for research from Actelion, Pfizer, GSK, Lilly and Bayer Schering. He has received fees for speaking from Actelion, Bayer Schering, GSK, Lilly, Pfizer and United Therapeutics.. DOI: 10.1183/09031936.00113009.
D-J. Slebos. The present study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00065809
M. Smilovitch. The author's study is partly funded by industry (Respironics, Resmed and Tyco approximately $200,000, as suppliers of the CPAP machines and equipment). The CIHR funding agency supplied approximately $1,000,000. In addition, the author's group has recently received a similar peer-reviewed grant from CIHR with Philips-Respironics Inc. as the industrial partner to support a clinical trial in heart failure patients with sleep apnoea. DOI: 10.1183/09031936.00070509
A.R. Smyth has received speaker's fees from Forest Laboratories (makers of Colistin) and Roche (Dornaise alfa) as well as support for his attendance at conferences and for educational events which he has organised (from both companies). He acts as a consultant to Biocontrol (bacteriophage therapy) and Boehringer Ingleheim. Forest Laboratories have provided an unrestricted educational grant that was used to fund research. He has acted as an expert witness regarding aminoglycoside nephrotoxicity. DOI: 10.1183/09031936.00139508
P. Soni is employed by Schering-Plough, which developed SCH527123. P. Soni earns a salary from and owns stocks in Schering-Plough. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
D. Spencer has received reimbursement for attending a symposium from Wyeth Pharmaceuticals. He has received fees for speaking from Wyeth Pharmaceuticals and GSK Biologicals. He is in receipt of unrestricted grants for conducting research from Wyeth Pharmaceuticals and GSK Biologicals, which fund staff. He has received fees from Wyeth Pharmaceuticals and GSK Biologicals for attending advisory boards. Both Wyeth Pharmaceuticals and GSK Biologicals are involved in the development and production of pneumococcal vaccines. DOI: 10.1183/09031936.00139508
M. Spencer was an employee of GlaxoSmithkline until 2006, and is now an employee of Janssen-Cilag, while retaining shares in GlaxoSmithkline. He has received consulting fees from GlaxoSmithKline, in which he is also a shareholder. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
V.K. Srinivasan. Support in-kind (mandibular advancement splints) was provided by SomnoMed Ltd. DOI: 10.1183/09031936.00077409
P. Stryszak is an employee of Schering-Plough and has shares in Schering-Plough. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
M. Suga received ¥850,000 in total for nine advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
H. Sugiura. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
E.R. Swenson. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messger'te. DOI: 10.1183/09031936.00185808
J. Swigris has participated as a Site Principle Investigator for Actelion and Intermune, and has received fees for consulting from Actelion. The present study was supported by a research grant from Actelion Pharmaceuticals for logistical support, monitoring, project management, data management, statistical analysis and reporting. Editorial assistance was provided by A. Gray (Elements Communications, Westerham, UK), supported by Actelion Pharmaceuticals (Allschwil, Switzerland). DOI: 10.1183/09031936.00188108
T Back to top
Y. Taguchi received ¥650,000 in total for seven advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
H. Takahashi received ¥550,000 in total for six advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
M. Takeuchi received ¥400,000 in total for three advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
K. Tanaka was funded by Japan Dairy Association (Tokyo, Japan). DOI: 10.1183/09031936.01006-2009.
H. Taniguchi has received ¥575,000 in total for six advisory boards from Shionogi & Co., Ltd. The author's study was sponsored by Shionogi & Co., Ltd. (Osaka, Japan). DOI: 10.1183/09031936.00005209
D.P. Tashkin has received consulting fees and grant support from Boehringer Ingelheim and Pfizer and is a member of the Speakers Bureau for Boehringer Ingelheim and Pfizer. The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00082909
D.R. Taylor has received lecture fees and funding for two research projects from Aerocrine AB, Sweden, a manufacturer of nitric oxide analysers. DOI: 10.1183/09031936.00003310
R. Tessari. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
A. Thomson was a member of the Paediatric Respiratory Advisory Board for Novartis Pharmaceuticals UK Ltd, June 2007, and has lectured for Astra Pharmaceuticals. DOI: 10.1183/09031936.00139508
S. Togo. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
A. Torres has received a grant from Pfizer for research in ventilator-associated pneumonia, and €1,500 from Bayer for speaking at a symposium. DOI: 10.1183/09031936.00198109
S. Torresan. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
M. Tsai is employed by Schering-Plough, which developed SCH527123. M. Tsai earns a salary from and owns stocks in Schering-Plough. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
V Back to top
A. Valentin. The author's study was supported by the Ludwig Boltzmann Institute (Linz, Austria) for COPD. DOI: 10.1183/09031936.00056909
P. van Houtte has received reimbursements from Eli Lily to organise, speak and chair local meetings. DOI: 10.1183/09031936.00063109
A.J.M. van Oosterhout. The author's study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00065809
P. van Paassen. The author's research was financially supported by Actelion Pharmaceuticals Nederland B.V. (Woerden, The Netherlands). DOI: 10.1183/09031936.00164209
C.R. van Wetering has received previous research and travel grants from Nutricia Netherlands. The study was financially sponsored by Pfizer and Partners in Care Solutions (PICASSO) for COPD. DOI: 10.1183/09031936.00043309
M. Vázquez Caruncho. GSK provided the exhaled nitric oxide analysers used in this work. The sources of funding did not participate in the collection, analysis and interpretation of the data, in the writing of the manuscript, nor in the decision to submit the manuscript for publication. DOI: 10.1183/09031936.00118809
G.M. Verleden is holder of the GSK Chair in respiratory medicine at the KUL, Belgium. DOI: 10.1183/09031936.00183509
S. Verver. T-SPOT.TB kits were kindly provided by Oxford Immunotec. The manufacturers and funders had no role in the study design, data collection, data analysis, decision to publish or preparation of the manuscript of this study. DOI: 10.1183/09031936.00098509
J. Vestbo. Research grants to support work carried out in the department in which J. Vestbo works have come from GlaxoSmithKline. He has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingeheim and Pfizer for speaking in scientific meetings, and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. Finally, his wife, I. Vestbo, is an employee of AstraZeneca. The present study was funded by GlaxoSmithKline under a contract that permitted the analysis and reporting of the results independently of the sponsor. The sponsor received and commented on the manuscript prior to submission. DOI: 10.1183/09031936.00153108
A. Visentin. QUBIsoft supplied the Piko-1 meters. DOI: 10.1183/09031936.00043709
P. Vock. The author's study received financial (research grant of €10,000) and technical support for body plethysmography from VIASYS Healthcare and technical support with the measurements of closing volume from ZAN Messgeräte. DOI: 10.1183/09031936.00185808
W.M. Vollmer has served on ad hoc advisory boards for Merck and Co.; has participated in COPD workshops funded by Merck and GlaxoSmithKline; and is Director of the Burden of Obstructive Lung Disease (BOLD) Operations Center, funding for which includes unrestricted educational grants to the Kaiser Permanente Center for Health Research from Boehringer Ingelheim, Pfizer, ALTANA, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi and Merck. W.M. Vollmer is a past recipient of funding from Merck associated with validation work for the Asthma Therapy Assessment Questionnaire (ATAQ) instrument; however, he receives no royalties or other compensation from the use of the ATAQ by others and does not hold any copyright privileges for the ATAQ instrument. Finally, W.M. Vollmer is employed by Kaiser Permanente, a health maintenance organisation that provides care to patients with COPD and obstructive sleep apnoea syndrome, and whose care for such patients could be influenced by the results of this study. DOI: 10.1183/09031936.00192008
H. Vyas has received £1000.00 for speaking at symposia. Funding from MSD and GSK. DOI: 10.1183/09031936.00087209
H. Vyas has received speaker's fees from GlaxoSmithKline, AstraZeneca, and Merck Sharp and Dohme. He has received financial support for attending conferences from AstraZeneca. DOI: 10.1183/09031936.00139508
W Back to top
D. Wagner has received a speaker's fee from Cellestis, Australia. DOI: 10.1183/09031936.00122109
X. Wang. The author's study was supplemented with funding in 2005 from Lorillard and RJ Reynolds. Funding was also provided by a grant from Pfizer. DOI: 10.1183/09031936.00134707
A. Warris has received funding for educational activities from Gilead and Pfizer and receives fees for consultancy activities from Pfizer. DOI: 10.1183/09031936.00139508
H. Watz. The author's research was funded by the Schering-Plough Research Institute. DOI: 10.1183/09031936.00048509
R.R. Wauer was supported by common equipment and financial grants totalling €52,000 over the previous 3 years from Draeger (Luebeck, Germany). DOI: 10.1183/09031936.00058009
A.U. Wells. The Royal Brompton Hospital is reimbursed for a clinical trial unrelated to the study being published by Olympus. DOI: 10.1183/09031936.00148809
J.P. Williamson is listed as an inventor on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. DOI: 10.1183/09031936.00041809
W. Windisch was reimbursed by Breas Medical AB (Molnlycke, Sweden) for attending the annual ERS conferences between 2001 and 2005 and by Werner and Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation between 2001 and 2007. W. Windisch received speaking fees: €2,000 in 2005 and €3,000 in 2008 from Dräger Medical, Germany; €2,000 in 2005, €1,000 in 2006, €1,000 in 2008 and €750 in 2009 from Heinen und Löwenstein, Germany; €1,000 in 2005 and €1,500 in 2007 from Werner und Müller Medizintechnik; €750 in 2006, 2007, 2008 and 2009 from VitalAire, Germany, respectively; €1,000 in 2006, €1,000 in 2007, €2,000 in 2008 and €3,500 in 2009 from Respironics, USA; €500 in 2006 and €500 in 2007 from Weinmann, Germany; €1,750 in 2008 and €1,750 in 2009 from ResMed, Germany; €500 in 2008 from MPV Truma, Germany; €1,000 in 2009 from Covidien, France. W. Windisch received funds for research: a research grant from Respironics, USA, in 2008 (US$100,000) and €60,000 for 2009 and 2010, respectively; €310,000 from Breas (1999-2009) and €75,000 for 2010. DOI: 10.1183/09031936.00177009
S. Wong. Funding for the author's study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00022908
Volume 36, 2010
A Back to top
M.G. Aabye received a travel grant sponsored by Cellestis Ltd in 2009. R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
S.D. Aaron has sat on advisory boards for GlaxoSmithKline, AstraZeneca and Boehringer-Ingelheim, and was paid $12,500 for these activities over the past 5 yrs. He received a nonrestricted research grant from Roche, Inc. for $200,000 in 2007. DOI: 10.1183/09031936.00165109
A.M. Abdelrahman The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
D. Abramowicz. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
M.R. Adams The study was funded in part by a grant from Actelion Pharmaceuticals Australia. The authors had full control over the design, execution, interpretation and presentation of the study. DOI: 10.1183/09031936.00083910
S. Ahlstedt was employed in 1981-2008 by PHADIA AB (Uppsala, Sweden), producer and manufacturer of IgE antibody tests. S. Ahlstedt has been retired from PHADIA AB since January 1, 2009: at present he only holds an academic position at Karolinska Institute, Stockholm, Sweden. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
A. Aliverti. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy), Institution of A. Aliverti, and licensed to BTS Spa company. DOI: 10.1183/09031936.00127310
J. Ancochea. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
A.B. Anderson. R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
R. Anderson was the recipient of a research grant from MSD, for the investigation of the anti-inflammatory mechanisms of montelukast. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
C. Angeletti. The author's study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
A. Anzueto has participated as a speaker in scientific meetings or courses organized and financed by various pharmaceutical companies including: Boehringer Ingelheim, Bayer Schering Pharma., Pfizer GlaxoSmithKline, Sanofi-Aventis. The author has being a consultant for Boehringer Ingelheim, Bayer Schering Pharma, Pfizer GlaxoSmithKline, Sanofi-Aventis, Altana. The author has being the principal investigator for research grants and the University of Texas Heath Science Center at San Antonio was paid for participating in multicentre clinical trials sponsored by: Boehringer Ingelheim, Bayer Pharma, BART, Lilly, Pfizer and National Institutes of Health. DOI: 10.1183/09031936.00077509
G. Armbrecht received fees for speaking from Procter&Gamble, Nycomed, Daiichi Sankyo, Lilly. This project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
H. Aschard. The author's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
J.D. Aubert has participated in advisory boards from Astellas, Novartis and GlaxoSmithKline. He has received travel sponsorship from Roche and Actelion to attend scientific meetings. DOI: 10.1183/09031936.00087809
J-D. Auberthas received sponsoring from Astellas, Novartis and Roche for attending an international conference. He has participated in advisory board from Astellas and Roche. DOI: 10.1183/09031936.00129810
M. Aubier has received reimbursement for attending scientific conferences, and/or fees for speaking and/or consulting from AstraZeneca, Boehringer Ingelheim, Novartis, Nycomed and Pfizer. The Pulmonary Department at Bichat University Hospital received financial compensation for services performed during participation in clinical trials organised by various pharmaceutical companies. DOI: 10.1183/09031936.00022010
B Back to top
P. Baas The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
C. Bachert. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
P.S. Bakke has received lecture fees totalling €1000 from GlaxoSmithKline and €1000 from AstraZeneca in the past 5 yrs. P.S. Bakke is a principal investigator of a study performed by GlaxoSmithKline. DOI: 10.1183/09031936.00186509
E. Baraldi received a research grant from Aerocrine (payment to Azienda Ospedaliera di Padova) and also received travel grants and lectured at scientific meetings for GlaxoSmithKline, Merck Sharp and Dohme, Abbott, and Valeas. DOI: 10.1183/09031936.00085510
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of which market treatments for COPD. DOI: 10.1183/09031936.00158008
F. Bartalesi has received a eimbursement for attending a symposium from A.D.A. srl, representative of Cellestis in Italy for the QuantiFERON-TB Gold test. DOI: 10.1183/09031936.00028510
P. Bärtsch's study was supported by a research grant of €10,000 from VIASYS Healthcare GmbH. Technical support was provided by H-J. Smith from CareFusion GmbH (Hoechberg, Germany), formerly VIASYS Healthcare GmbH. DOI: 10.1183/09031936.00092610
E.D. Bateman has received honoraria for consulting, speaking at scientific meetings, and participating in advisory boards for AstraZeneca. His institution has received grants for participation in clinical trials. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
A.K. Bauer. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
J. Behr has received fees for speaking and/or organising education from Actelion Pharamceutical, ALK Scherax, Altana, AstraZeneca, Bayer-Schering, Boehringer Ingelheim, GalxoSimthKline, Eli Lilly, Merck, Novartis, NYCOMED, Zambon. The author has received fees for consulting from Actelion Pharmaceutical, Bayer-Schering, Eli Lilly, GlaxoSmithKline, Pari, Pfizer. The author has also received research funds including funds for a member of staff from Actelion, Bayer, Mondobiotech, and Myogene. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
P. Berger has received fees for speaking or consulting from Novartis, GlaxoSmithKline, AstraZeneca and Chiesi. Travels to the ERS and ATS congress were funded by Novartis, GlaxoSmithKline and AstraZeneca. DOI: 10.1183/09031936.00019810
S.J. Bielinski's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
T. Bitter has received reimbursement of travel costs to the American Heart Association 2008 Scientific Sessions from Weinmann. DOI: 10.1183/09031936.00045609
R.A. Bond owns shares, and is scientific founder of, Inverseon. DOI: 10.1183/09031936.00003210
H. Boss was employed at Nycomed since more than 5 years. DOI : 10.1183/09031936.00172309
J. Bousquet reports having served as a consultant and/or received fees for lectures to Nycomed, AstraZeneca, Novartis, Chiesi , Schering Plough, Stallergènes, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche, Allmiral, Uriach, UCB. DOI: 10.1183/09031936.00012610.
J. Bousquet. The author's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
E. Bouzigon. The author's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
M.R. Bowman is an employee of, and possesses stock in, Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00097609
B. Brunekreef received a Center for Indoor Air Research grant in the mid 1990s. DOI: 10.1183/09031936.00081910.
G. Brusselle has, within the last 5 years, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, MerckSharp & Dohme, Novartis, Pfizer and UCB; he is a member of advisory boards for AstraZeneca, GlaxoSmithKline, Novartis and UCB. DOI: 10.1183/09031936.00140409
G.G. Brusselle has, within the past 5 yrs, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer and UCB; he is a member of advisory boards for AstraZeneca, GlaxoSmithKline, Novartis and UCB. DOI: 10.1183/09031936.00129509
V. Brusasco received: €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €3,000 in 2005 and €3,500 in 2008 from Lofarma for consultancies; €11,500 in 2005, €8,325 in 2006, €2,500 in 2007 and €6,600 in 2008 for speaking at conferences sponsored by Boehringer Ingelheim; €2,200 from Beohringer Ingelheim for consultancy in 2009; $1,500 from Deep Breeze for consultancy in 2009; €6,000 from Dompé for consultancy in 2009; £960 in 2006 and £1,200 in 2008 from GSK for participating in advisory boards; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving on an advisory board; and €1,500 from Menarini for consusltancy in 2008. V. Brusasco's institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim, and participated in several multi-centre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK and Novartis). DOI: 10.1183/09031936.00074210
R. Buhl has received reimbursement for attending scientific conferences, and/or fees for speaking and/or consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Nycomed and Pfizer. The Pulmonary Department at Mainz University Hospital received financial compensation for services performed during participation in clinical trials organised by various pharmaceutical companies. DOI: 10.1183/09031936.00022010
R. Buhl has received reimbursement for attending scientific conferences, and fees for speaking and consulting from AstraZeneca. The Pulmonary Department at Mainz University Hospital received financial compensation for services performed during participation in single- and multi-centre clinical phase I-IV trials organized by various pharmaceutical companies, including AstraZeneca. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
O. Burkhardt has received research grants from BRAHMS. He has also received a grant for travel to the American Thoracic Society international conference from BRAHMS. DOI: 10.1183/09031936.00163309
G. Burge has in the last 5 years received reimbursement for attending a symposium. DOI: 10.1183/09031936.00127110
P-R. Burgel. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
P.S. Burge received a grant from the Health Promotion Trust in the 1980s. This was a UK government organisation externally funded by the tobacco industry, to study the health consequences of indoor air (including environmental tobacco smoke). P.S. Burge wrote a legal report on this case in support of a common law claim. DOI: 10.1183/09031936.00075710
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD, GSK AstraZeneca, in no case exceeding £1,500; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00104809
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD, GSK AstraZeneca, in no case exceeding £1,500; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00064110
O. Butera. The author's study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
C Back to top
D. Caillaud. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
K-H. Carlsen has received fees for presentations from GlaxoSmithKline, Merck Sharp & Dohme and RespMed. He has acted as a consultant for GlaxoSmithKline and UCB. He has received reimbursement from GlaxoSmithKline for attending the American Thoracic Society annual congress and from Merck Sharp & Dohme for attending the annual congress of the American Academy of Allergy Asthma & Immunology. DOI: 10.1183/09031936.00104809
K-H. Carlsen has received fees for presentations from GlaxoSmithKline, Merck Sharp & Dohme and RespMed. He has acted as a consultant for GlaxoSmithKline and UCB. He has received reimbursement from GlaxoSmithKline for attending the American Thoracic Society annual congress and from Merck Sharp & Dohme for attending the annual congress of the American Academy of Allergy Asthma & Immunology. DOI: 10.1183/09031936.00064110
L. Carmona has received speaking fees under 4,000 €/ year from Abbott; and the organisation for which she works has received research grants from Abbott, Schering, Wyeth, UCB, Roche, and BMS. DOI: 10.1183/09031936.00028510
P. Carré. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
D.S. Celermajer Over the last 5 years, the author has attended PAH seminars and been sponsored to some of these events by Actelion, who have partially funded the current study. He has also received Speaker fees and received research support. The study was funded in part by a grant from Actelion Pharmaceuticals Australia. The authors had full control over the design, execution, interpretation and presentation of the study. DOI: 10.1183/09031936.00083910
B. Celli. The division that the author heads has received grant funding from GlaxoSmithKline, Boehringer Ingelheim, Forrest Pharmaceuticals and Aeris. In addition, B. Celli has received payments for speaking at symposia and attending advisory boards for GlaxoSmithKline, Boheringer Ingelheim, Almirall, Dey Pharmacautical and AstraZeneca. The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including D.P. Tashkin, B. Celli, M. Decramer and S. Kesten. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00127809
B. Celli. The division that B. Celli heads has received grant funding from GlaxoSmithKline, Boehringer Ingelheim, Almirall and Pfizer. In addition, B. Celli has received payments for speaking at symposia and attending advisory boards for GlaxoSmithKline, Boheringer Ingelheim, Almirall, Dey Pharmacautical, Astra Zeneca and Pfizer. DOI: 10.1183/09031936.00036110
F. Chabot. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
P. Chanez. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
J Changalucha. R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
A. Chaouat. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management and statistical analysis. DOI: 10.1183/09031936.00057010
H. Chen is an employee of, and possesses stock in, Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00097609
H-Y. Cho. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
R. Cockeran. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
J.-F. Cordier. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
J.-F. Cordier has received fees for speaking and reimbursement for attending congresses from Actelion Pharmaceuticals, Pfizer and Glaxo. DOI:10.1183/09031936.00004810
V. Cottin has received fees for speaking and for consultancy from Actelion Pharmaceuticals. DOI:10.1183/09031936.00004810
I. Court-Fortune. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
G.J. Criner. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
D Back to top
F.M. de Benedictis reports receiving research support and consulting fees from GlaxoSmithKline, MerckSharpDohme, Chiesi Fermaceutici, UCB; travel to the ERS congress was funded by GlaxoSmithKline. No other potential conflict of interest is reported. DOI: 10.1183/09031936.00104809
M. Decramer is a member of the speakers' bureau of Boehringer-Pfizer. He is also a member of the advisory board of these companies. In addition, he is a member of the advisory board of GSK and Nycomed. The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including D.P. Tashkin, B. Celli, M. Decramer and S. Kesten. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00127809
M. Decramer has received consulting fees from Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Nycomed, Altana and AstraZeneca, and lecture fees from Boehringer Ingelheim, Pfizer and Novartis, and grant support from AstraZeneca. DOI: 10.1183/09031936.00036110
C. Dehnert. The author's study was supported by a research grant of €10,000 from VIASYS Healthcare GmbH. Technical support was provided by H-J. Smith from CareFusion GmbH (Hoechberg, Germany), formerly VIASYS Healthcare GmbH. DOI: 10.1183/09031936.00092610
N.H. de Klerk. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
F. Demenais. The present study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
J. de Miguel has received funding from Boehringer and GSK to attend international respiratory conferences, fees (less than €2,000) for speaking in courses sponsored, but not organised, by these firms, and is currently investigator of one of the sites of the study EXACTT (205.368) by Boehringer. DOI: 10.1183/09031936.00011210
F. de Vries. The study was funded by AstraZeneca. GPRD is owned by the UK Department of Health and operates within the Medicines and Healthcare products Regulatory Agency (MHRA). GPRD is funded by the MHRA, Medical Research Council, various universities, contract research organisations and pharmaceutical companies. The department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. DOI: 10.1183/09031936.00124209
T. Derfuss is an employee of LEA Medizintechnik GmbH. DOI: 10.1183/09031936.00013809
R. Diel has received a fee for speaking at scientific symposia/conferences that were supported by Cellestis and Oxford Immunotec during 2006-2008. DOI: 10.1183/09031936.00028510
L.M. Diep. This project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
A.T. Dinh-Xuan has received a reimbursement of €900 from Medisoft for attending the 5th International Meeting on NO in 2008, and a fee of €700 for chairing a session on pulmonary hypertension from Actelion in 2007. DOI: 10.1183/09031936.00074210
J. Domínguez participated in 2005 in the Oxford Immunotec (manufacturer of T-SPOT.TB) advisory board meeting. DOI: 10.1183/09031936.00033510
L.E. Donnelly has received funding for lectures and research from AstraZeneca, Boehringer Ingelheim GlaxoSmithKline and Novartis, who market treatments for COPD. DOI: 10.1183/09031936.00158008
M. Dransfield. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
E.J. Duiverman's department has received research grants from GlaxoSK, MSD and TEVA Pharma. DOI: 10.1183/09031936.00185709
E. Duran. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
E Back to top
M.R. Edbrooke is employed by GlaxoSmithKline, the pharmaceutical company, and has stocks in excess of £5000 in said company. DOI: 10.1183/09031936.00026910
M.R. Edwards. In the present study, telithromycin was gifted by Sanofi Aventis. DOI: 10.1183/09031936.00095809
A. Eklund's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
T. Ekström is an employee of AstraZeneca and a shareholder. DOI: 10.1183/09031936.00022010
I. Ellingsen. This project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
E.F. Eriksen. This project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
G. Eriksson is a full time employee and shareholder for AstraZeneca. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
R. Escamilla. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
R. Ewert has received consultancy fees from Bayer Vital GmbH; participated in advisory boards for GSK and Lilly; has received honoraria from Actelion, Encysive, Bayer Vital, Lilly and AstraZeneca; has received travel grants from AstraZeneca; and has received research grant support from Encysive, Actelion and AstraZeneca. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
S. Ewig has received fees for lectures from BRAHMS. DOI: 10.1183/09031936.00163309
F Back to top
L.M. Fabbri reports having served as a consultant to Nycomed, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer; having been paid lecture fees by Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, Roche and Pfizer, having received grant support from Nycomed, Abbott, AstraZeneca, Boehringer Ingelheim, Menarini,, Novartis , Schering Plough, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, UCB, Pfizer, Italian Ministry of Health, and Italian Ministry for University and Research. DOI: 10.1183/09031936.00012610.
J.A. Falch has received lecture fees from Pfizer, Novartis, MSD, Sonofi-Aventis, Novo Nordisk, Roche, GSK, Eli Lilly, Nycomed and Pharmacia; funding for travel to congresses by MSD, Eli Lilly, GSK, Sanofi Aventis, Novartis, Amgen. This project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
V. Faoro has received reimbursements of travel expenses to congresses from Pfizer. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
D. Faurholt-Jepsen R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
M. Faurholt-Jepsen R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
C. Feldman has received honoraria for lecturing and/or acted on the advisory board and/or been given support for conference travel, and/or members of staff have received funding for conference travel from the following companies: Altana Madaus, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline and MSD. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
L. Fernández-Fau. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
A.R. Folsom's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
B.N. Francis's work was supported by BioMarin Pharmaceuticals. DOI: 10.1183/09031936.00188809
K.L.M.C. Franken. The author's study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
A.E. Franklin is an employee and shareholder in Inverseon, Inc. DOI: 10.1183/09031936.00003210
C. Feldman has received honoraria for lecturing and/or acted on the advisory board and/or been given support for conference travel, and/or members of staff have received funding for conference travel from the following companies: Altana Madaus, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline and MSD. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
H. Friis R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
D.E. Furst has received research grants from Abbott, Actelion, Amgen, BMS, Genentech, Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth and Xoma. He is also on the Advisory Board and consults for Abbott, Actelion, Amgen, BMS, Biogen Idec, Centocor, Genentech, Gilead, GSK, Merck, Nitec, Novartis, UCB, Wyeth and Xoma. D.E. Furst has received Honoraria from Abbott, Actelion, Amgen, BMS, Biogen Idec, Centocor, Genentech, Gilead, Merck and Xoma. He does CME only speaking for Abbott, Actelion and UCB. D.E. Furst is Director of Publications for CORRONA. DOI: 10.1183/09031936.00139809
G Back to top
R. Gaafar The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
N. Galiè has participated in advisory board activities for Actelion, Pfizer, United Therapeutics, Eli-Lilly, Bayer-Schering, Encysive and Glaxo-Smith-Kline, given paid lectures for Actelion, Pfizer, Bayer-Schering and Encysive. The Institute of Cardiology of the University of Bologna has received research grants from Actelion, Pfizer, United Therapeutics, Eli-Lilly, Bayer-Schering, Encysive and Glaxo-Smith-Kline. DOI: 10.1183/09031936.00038410
F. García-Río. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
W.J. Garner is a founder of Inverseon, Inc. and is a significant shareholder. DOI: 10.1183/09031936.00003210
H.A. Ghofrani has received consultancy fees from Bayer Schering Pharma AG, Actelion, Encysive, Pfizer, Ergonex, and Novartis; has participated in advisory board activities for Bayer Schering Pharma AG, Pfizer, GSK, Actelion, Ergonex, and Novartis; has received honoraria from Bayer Schering Pharma AG, GSK, Actelion, and Encysive/Pfizer; and has received grants from Bayer Schering Pharma AG, Aires, Encysive/Pfizer, and Novartis. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
H.P. Gideon. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
V. Gielen In the present study, telithromycin was gifted by Sanofi Aventis. DOI: 10.1183/09031936.00095809
S. Giersdorf is employed by BRAHMS, the manufacturer of the procalcitonin assay. DOI: 10.1183/09031936.00163309
E. Girardi received a travel reimbursement to go to an interferon-γ release assay symposium in Dubrovnik in May 2009 from Cellestis. The present study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
W. Gladwell. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
D. Goletti received a travel grant from Cellestis for the IGRA symposium held in Croatia in 2009. DOI: 10.1183/09031936.00028510
D. Goletti received a travel reimbursement to go to an interferon-γ release assay symposium in Dubrovnik in May 2009 from Cellestis. The present study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
J.J. Gomez-Reino is on the Advisory Boards of Abbott, BMS, Pfizer, Roche, Schering-Plough, and UCB, has received lectures fees from Abbott, BMS, Roche, Schering Plough and Wyeth, and research grants from Roche and Schering Plough. DOI: 10.1183/09031936.00028510
F. Gormand. The present study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
M. Gotfried. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
D. Gozal is on the National Speaker Bureau for Merck Company in the USA. DOI: 10.1183/09031936.00114209
C.M. Gravett has received an honorarium for speaking for MSD in the past. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
V. Gressin. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author is an employee of Actelion Pharmaceuticals France (a company promoting a drug for the treatment of PAH) as Medical Director and as such, own stocks. However, the author's study article relates to an epidemiology study with no consideration relating to therapeutic decisions. DOI: 10.1183/09031936.00057010
F. Grimminger has received honoraria from Actelion, Encysive and Pfizer and research grant support from Bayer Vital GmbH, Glaxo Smith Kline, Actelion Pharmaceutical Ltd., Quintiles GmbH, Ergo Nex Pharma GmbH, Pfizer Pharma GmbH, Encysive GmbH and GWT-TUD GmbH. DOI: 10.1183/09031936.00143308
F. Grimminger has Research Grants with Bayer Schering, Pfizer, Ergonex, and Encysive. The author has received honoraria payments from Bayer Schering, Pfizer, Actelion, Encysive, and Novartis Pharmaceuticals UK Limited. The author has also a consultancy and/or advisory board relationship to Nycomed (Altana Pharma). This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
F. Grimminger has research grants with Bayer Schering, Pfizer, Ergonex and Encysive; has received honoraria from Bayer Schering, Pfizer, Actelion, Encysive and Novartis Pharmaceuticals UK Ltd; and has a consultancy and advisory board relationship with Nycomed (Altana Pharma). DOI: 10.1183/09031936.00140309
K. Gruffydd-Jones. Financial support for the present study was provided by AstraZeneca. DOI: 10.1183/09031936.00117509
J. Grunewald's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
S. Günther. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
H Back to top
U. Haagen is employed by BRAHMS, the manufacturer of the procalcitonin assay. DOI: 10.1183/09031936.00163309
G. Habib A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has relationships with drug companies including Actelion, BayerSchering, GSK and Pfizer. Relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00057010
M. Halank has received honoraria from Actelion, Bayer Schering Pharma AG, Encysive, GlaxoSmithKline, Lilly and Pfizer; has received travel grants from Actelion, Bayer Schering Pharma AG, Lilly and Pfizer; and has participated in advisory board activities for GSK. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
B.J. Hales. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
J. Hankinson is affiliated with Hankinson Consulting Inc., a spirometry software company. DOI: 10.1183/09031936.00130010
T.W Harrison has received financial support to attend the ATS from Boehringer-Ingelheim, fees for speaking from Boehringer-Ingelheim, GlaxoSmithKline and AstraZeneca and fees for attending advisory boards from AstraZeneca. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
S. Hartl has received speakers fees from Böhringer Ingelheim and from GSK, her Department has received travel grants for members of staff from Nycomed, Böhringer and GSK.
S. Hartl is a scientific member of the Ludwig Boltzmann Institute, which has received grants from Nycomed , Böhringer and GSK. DOI: 10.1183/09031936.00046410
O. Hartmann is employed by BRAHMS, the manufacturer of the procalcitonin assay. DOI: 10.1183/09031936.00163309
B. Hasan The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
J. Haughney has received reimbursements for attending symposia, fees for speaking and organising educational events, funds for research, and fees for consulting from AstraZeneca the sponsors of this study. He has received support in some of these categories from other pharmaceutical companies: Boehringer-Ingelheim, Glaxo Smith Kline, Merck, Sharp and Dohme, Mundipharma, Novartis, Nycomed, Sanofi Aventis and Teva. DOI: 10.1183/09031936.00022010
C.A. Hewson is currently employed by and holds shares in Pfizer Inc. (less than �5000). DOI: 10.1183/09031936.00026910
Y. Hlombe. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
M.M. Hoeper has received consultancy fees and honoraria from Actelion, Bayer Schering Pharma AG, GSK, Lilly, LungRx, Novartis and Pfizer. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
E.M. Hollams. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
B.J. Holt. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
P.G. Holt received speaker's fee from Phadia AB for contribution to company-sponsored symposium at EAACI. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
C. Hollier's sleep laboratory has previously received an industry-sponsored project grant from ResMed, Australia, and PAP equipment for other research projects from Air Liquide Australia and MayoHealthcare, Australia. DOI: 10.1183/09031936.00115009
S. Huez has received reimbursements of travel expenses to congresses and speakers' fees from Actelion. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
M. Humbert. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00057010
M. Humbert's study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
M. Humbert has relationships with drug companies including AB Science, Actelion, Altair, Asmacure, Astrazeneca, BayerSchering, Chiesi, GSK, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00012610.
M. Humbert has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00052210
M. Humbert has relationships with drug companies including Actelion, Astrazeneca, BayerSchering, Chiesi, GSK, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00134210
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and memberhip of scientific advisory boards. DOI:10.1183/09031936.00004810
W. Huvenne. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
I Back to top
R. Ilsar has received speaker's fee of less than £1000 from Actelion Pharmaceuticals Pty Ltd. The study was funded in part by a grant from Actelion Pharmaceuticals Australia. The authors had full control over the design, execution, interpretation and presentation of the study. DOI: 10.1183/09031936.00083910
H. Imano's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
H. Iso's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
J Back to top
B.A. Jacobson is an employee of, and possesses stock in, Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00097609
X. Jaïs. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00057010
C.R. Jenkins has received speaker fees and fees for consultancy from AstraZeneca P/L. C.R. Jenkins manages the Education programme at the Woolcock Institute of Medical Research and AstraZeneca supports a position in this programme. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
K. Jeremiah R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
C.A. Jiménez-Ruiz. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
Z-C. Jing. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
M.K. Johnson. The project was supported by an unrestricted educational grant from Encysive/Pfizer. DOI: 10.1183/09031936.00155009
S.L. Johnston has received research grants from AstraZeneca, Centocor, GlaxoSmithKline, MedImmune, Sanofi-Pasteur & Synairgen; has share options in Synairgen and consults for AstraZeneca, Centocor, GlaxoSmithKline, MedImmune, Sanofi-Pasteur & Synairgen. DOI: 10.1183/09031936.00026910
S.L. Johnston. In the author's study, telithromycin was gifted by Sanofi Aventis. DOI: 10.1183/09031936.00095809
G.F. Joos has received departmental funding from the following companies: GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, UCB and Novartis; lecture fees received from GSK, AstraZeneca, Boehringer Ingelheim-Pfizer and Novartis; scientific advisory board fees received from GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Nycomed , Sanofi-Aventis, Almirall. DOI: 10.1183/09031936.00012610.
E.F. Juniper has acted as a consultant for GlaxoSmithKline and AstraZeneca, and has stock/ether equity ownership in GlaxoSmithKline and Pfizer. Over the last 5 years, E.F. Juniper has received financial support from: Johnson & Johnson, Schering Plough, Medpointe Pharma, CMP Therapeutics, Alterhealth, Pierre Fabre, GlaxoSmithKline, Munipharma, Ception Therapeutics, Sunten Phytotech, UCB Pharma, Activus Pharma, Novartis, Wyeth, Allergopharma, Airsonett, Embria Health Sciences, CV Technologies, Kalobios, Stallergens, AstraZeneca, Alk Abello, Medicinova, Artu Biologicals, Curalogic, IFE Europe, Genentech, Epigenesis, Merck, Cipla, Amgen, Rottapharma, Allergy Therapeutics, NovoNordisk, Inflazyme, Allergy Choices, Abbott Laboratories, Mitsubishi, Boehringher Ingelheim, Cytos Technologies, Wellpoint/Healthcore, Altanapharma, Capnia, Ivax Laboratories, Critical Therapeutics, Kyowa Hakko, Asthmatx, Neolab, Protein Design Laboratories, ClinPhone, Arriva, Schulman Ronca Bucuvals, Laboratories SMB, Vista Health Plan, Hal Allergy BV, Suburban Lung Associates, Galephar MF SA, Mannkind Corp, Prognostix, Formix Biosciences, Oxagen, SC Ellen Fast Comimpex SRL, Medimmune, Quintiles, PDL Biopharma, Bencard, Efficas, Pfizer, Alcon Lab, Aventis, Pahrmaxis, Assist Tech, Hoffmann LaRoche, Aerocrine, Dynavax, Medtap, Pharmaengine, Topigen, ClineDavis & Mann, Teikoku Pharma, NeoLab, KGK Synergise, AB Science. E.F. Juniper is the copyright holder of the Asthma Control Questionnaire. Financial support for the present study was provided by AstraZeneca. DOI: 10.1183/09031936.00117509
J. Just's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
K Back to top
M. Kabesch participates in speaking activities reimbursed by pharmaceutical companies (Roxall, GlaxoWellcome, Novartis, Sanofi Aventis, Allergopharma) and served on a scientific advisory board for Sanofi Aventis. He has received only public grant money in the past 5 yrs. He holds a patent share related to the use of ORMDL3 in asthma. DOI: 10.1183/09031936.00019310
H. Kankaanranta has received reimbursement for attending an international conference and fees for speaking and consulting from GlaxoSmithKline. DOI: 10.1183/09031936.00093510
N. Karlsson is a full-time employee of AstraZeneca and holds shares in the company. The present study was funded by AstraZeneca. DOI: 10.1183/09031936.00123709
R. Kast is a full-time employee at Bayer Schering Pharma. DOI: 10.1183/09031936.00140309
F. Kauffmann's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
P.R. Kemp has received support via his institution from GlaxoSmithKline. DOI: 10.1183/09031936.00032510
S. Kesten is a full-time employee of Boehringer-Ingelheim. The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including D.P. Tashkin, B. Celli, M. Decramer and S. Kesten. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00127809
S. Kesten is a full time employee of Boehringer Ingelheim. DOI: 10.1183/09031936.00036110
L. Kheirandish-Gozal is the recipient of an investigator-initiated grant on the treatment of paediatric sleep apnoea by Merck Company. DOI: 10.1183/09031936.00114209
A. Kitamura's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
M. Kiyama's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
A. Kjensli 's project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
S.R. Kleeberger. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
A. Klepczynska Nyström's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
H.M Klomp The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
K.P. Klugman has received honoraria for speaking and consulting from Wyeth and Sanofi Pasteur. DOI: 10.1183/09031936.00041210
M. Konishi's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
M.R. Kramer. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
M. Krasna. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
L. Kritharides has received unrestricted research and educational grants from Actelion Pharmaceuticals. The study was funded in part by a grant from Actelion Pharmaceuticals Australia. The authors had full control over the design, execution, interpretation and presentation of the study. DOI: 10.1183/09031936.00083910
A. Krug is an employee of LEA Medizintechnik GmbH. DOI: 10.1183/09031936.00013809
G.J. Kullman has relatives who work in management at Dupont Corp., partial owner of the company that operates the soy processing plant described in this study. This did not influence my work on this project. DOI: 10.1183/09031936.00151109
L Back to top
M. Lamotte. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
C. Lange's study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
C. Lange has received speaker's honoraria from Cellestis Ltd and Oxfordimmunotec Ltd, manufacturers of IGRAs, for attending symposia that were supported by these companies. The content of these presentations has not been influenced by these companies. DOI: 10.1183/09031936.00201609
C. Lange has received speakers honoraria at symposia/conferences that were supported by Cellestis Ltd. and /or Oxfordimmunotec Ltd., manufacturers of IGRAs. DOI: 10.1183/09031936.00028510
B-M. Larsson's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
M. Lathrop's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
F.N. Lauria's study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
W-T.N. Lee. The project was supported by an unrestricted educational grant from Encysive/Pfizer. DOI: 10.1183/09031936.00155009
W. Leeds. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
L. Lehtimäki has received reimbursement for attending a symposium and fees for speaking from GSK. LL had a consultancy agreement 2007-2008 with a manufacturer of NO analysers (Aerocrine AB, Stockholm, Sweden). DOI: 10.1183/09031936.00093510
N. Le Moual's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
J. Levitt The study was funded in part by a grant from Actelion Pharmaceuticals Australia. The authors had full control over the design, execution, interpretation and presentation of the study. DOI: 10.1183/09031936.00083910
A. Lo Mauro. Patents for optoelectronic plethysmography are owned by the Politecnico di Milano (Milan, Italy), Institution of A. Lo Mauro, and licensed to BTS Spa company. DOI: 10.1183/09031936.00127310
A.M. Luks. The author's study was supported by a research grant of €10,000 from VIASYS Healthcare GmbH. Technical support was provided by H-J. Smith from CareFusion GmbH (Hoechberg, Germany), formerly VIASYS Healthcare GmbH. DOI: 10.1183/09031936.00092610
A. Lundin's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
T. Lystig has the following conflicts of interest to report: current employee of Boehringer Ingelheim Pharmaceuticals, former employee of AstraZeneca; stock ownership in Affymetrix, Amgen, AstraZeneca, Medco Health Solutions, Merck, and Oncogenex Pharmaceuticals (no individual stock holding worth more than $10,000). The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including D.P. Tashkin, B. Celli, M. Decramer and S. Kesten. T. Lystig performed statistical analyses and participated in writing of the manuscript. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00127809
T. Lystig is a current employee of Boehringer Ingelheim Pharmaceuticals, a former employee of AstraZeneca, and has stock ownership in Affymetrix, Amgen, AstraZeneca, Medco Health Solutions, Merck and Oncogenex Pharmaceuticals (no individual stock holding worth more than $10,000). The author's study was supported by Boehringer Ingelheim and Pfizer. DOI: 10.1183/09031936.00036110
M Back to top
A.P. Maat The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
P.T. Macklem. In 1970 the Canadian Tobacco Manufacturers Association provided 50% of the construction costs of the Meakins Christie Laboratories for Respiratory Research. The condition for accepting this donation was that there were no strings attached and that the industry had no influence whatsoever over the subject of the research performed or publications that resulted therefrom. P.T. Macklem became the founding Director of these Laboratories. DOI: 10.1183/09031936.00059110
H. Magnussen received reimbursement for attending a symposium and a fee for speaking from Nycomed/former Altana in total not exceeding 5000 Euro in the past 5 years. The pulmonary research institute was funded by Nyocmed/former Altana for performing this study. DOI : 10.1183/09031936.00172309
A. Malhotra has received consulting and/or research income from the following companies: Respironics Philips, Restore Medtronic, Ethicon J&J, Apnex, NMT, Cephalon, Pfizer, Sepracor, Itamar DOI: 10.1183/09031936.00153809
S.S. Malhotra. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
S.F.P. Man has received educational grants from GlaxoSmithKline and AstraZeneca to support research. DOI: 10.1183/09031936.00082510
S.F.P. Man: GSK/CIHR, $(Can) 128,700 (2005-2008) principal investigator. CIHR-Wyeth Pharmaceuticals, $(Can) 446,352 (2006-2008) co-investigator. DOI: 10.1183/09031936.00097710
J.F. Masa. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
L. Mason is an employee of, and possesses stock in, Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00097609
S.A. McKenzie. A member of staff in S.A. McKenzie's department has received funding from Micromedical to attend the ERS Congress. DOI: 10.1183/09031936.00125009
G. McLennan. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
S. Mehra. At the time of conduct and publication of the manuscript, S. Mehra was a full-time employee of Pfizer Pharmaceuticals. The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including D.P. Tashkin, B. Celli, M. Decramer and S. Kesten. S. Mehra reviewed the data and participated in writing of the manuscript. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00127809
S. Mehra was a full-time employee of Pfizer Pharmaceuticals. DOI: 10.1183/09031936.00036110
C. Menadue's sleep laboratory has previously received an industry-sponsored project grant from ResMed, Australia, and PAP equipment for other research projects from Air Liquide Australia and MayoHealthcare, Australia. DOI: 10.1183/09031936.00115009
M. Mendelson. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
F.J. Meyer has received honoraria, fees for organising education, and travel grants from Bayer Schering Pharma AG. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
H.J. Milburn has received Elispot kits for research from Oxford Immunotec (UK). DOI: 10.1183/09031936.00028510
M. Miravitlles. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
M. Miravitlles has received honoraria: for speaking at scientific meetings from AstraZeneca, Boehringer Ingelheim, Pfizer and Bayer Schering; and for consulting from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Pfizer, Almirall and Bayer Schering. The present study was funded by AstraZeneca. DOI: 10.1183/09031936.00123709
E. Moilanen had a consultancy agreement 2007-2008 with a manufacturer of NO analysers (Aerocrine AB, Stockholm, Sweden). DOI: 10.1183/09031936.00093510
F. Monier's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
D. Montani. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00057010
D. Montani has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00052210
L. Muñoz. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
N Back to top
J.A. Nadel is named in a University of California San Francisco patent on epidermal growth factor receptor in mucous hypersecretion. DOI: 10.1183/09031936.00100610
R. Nadif's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
R. Naeije has received reimbursements of travel expenses to congresses and speakers' fees from Actelion, Pfizer, GlaxoSmithKline, Bayer, LungRX United Therapeutics and Mondobiotech, has participated to advisory boards for Actelion, Mondobiotech, United Therapeutics and LungRX, and has received funds for research from Actelion and Pfizer. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
H. Nakano's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
D. Natali. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
S.A. Natanek was funded by an unrestricted educational grant from GlaxoSmithKline. DOI: 10.1183/09031936.00104909
S. Nava has received reimbursement for attending a meeting from Weinmann, Draeger and Fisher and Paykel. Speaking fee not exceeding €1,000 from Resmed, Respironics and GE. Funds for research (free equipment use) from Fisher and Paykel, Resmed and Respironics. DOI: 10.1183/09031936.00123509
R. Nave is an employee of Nycomed GmbH (formerly ALTANA Pharma AG), Konstanz, Germany, who sponsored this study. DOI : 10.1183/09031936.00172309
S. Neupane. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
M.K.C. Ng The study was funded in part by a grant from Actelion Pharmaceuticals Australia. The authors had full control over the design, execution, interpretation and presentation of the study. DOI: 10.1183/09031936.00083910
O Back to top
P. O'Byrne has received consulting fees from Asmacure, AstraZeneca, GlaxoSmithKline, Nycomed, Resistentia, Topigen and honoraria for speaking from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed. In addition he has received grants-in-aid from AstraZeneca, Boehringer Ingelheim, Genentach, GlaxoSmithKline, Medimmune, Merck, Pfizer, Topigen, Wyeth. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
D.S. O'Callahan. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
T. Ohira's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
O. Oldenburg has received travel grants and a fee for speaking from ResMed. DOI: 10.1183/09031936.00045609
T. Oni. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
J. Ostinelli is a full time employee at AstraZeneca French subsidiary and has stocks in excess of €6000 in AstraZeneca. DOI: 10.1183/09031936.00022010
O. Östlund is an employee of AstraZeneca (Lund, Sweden). This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
T.H.M. Ottenhof. Leiden University Medical Center has filed a patent entitled Methods and means for diagnostics, prevention and treatment of Mycobacterium infections and tuberculosis disease, which has been licensed exclusively to the spin-off biotechnology company ISA Pharmaceuticals (Bilthoven, the Netherlands). T.H.M. Ottenhoff is one of the inventors of the patent and reports serving as an unpaid member of the steering committee of ISA Pharmaceuticals. He holds no financial interest in the patent. Leiden University Medical Center does not share financial benefits from this patent with its employees. The present study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
P Back to top
J-L. Paillasseur's work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
P.D. Paré was the principal investigator of a project that was funded by GSK to develop CT based algorithms to quantify emphysema and airway disease in COPD. With collaborators he received ~$300,000 to develop and validate these techniques. These funds he have been applied solely to the research to support programmers and technicians. Papers stemming from this work are still being published, although the financial arrangement has ended. P.D. Paré was also PI of a Merck Frosst-supported research programme to investigate gene expression in the lungs of patients who have COPD. He and collaborators have received ~$200,000 for this project. These funds have supported the technical personnel and expendables involved in the project. Papers stemming from this work are still being published, although the financial arrangement has ended. P.D. Paré has established a new contract with Merck to discover genetic predictors of gene expression in lung tissue. With collaborators, he will receive $95,000 over the next year to do this work. The funds will support personnel and buy supplies. P.D. Paré sits on an advisory board for Talecris Biotherapeutics who make anti-one antitrypsin replacement therapy. DOI: 10.1183/09031936.00136709
G.S. Parks is an employee of Amgen. DOI: 10.1183/09031936.00139809
F. Parent. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
F. Parsons. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
M.R. Partridge has received: fees for giving lectures and ad hoc consultancies from GlaxoSmithKline, AstraZeneca, Chiesi, Cipla, Teva and Novartis; departmental research funding from AstraZeneca; and help with publication of a history of asthma charities from Novartis. The present study was funded by AstraZeneca. DOI: 10.1183/09031936.00123709
J. Patel received travel expenses from Oxford Immunotec. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
J.Y. Paton has been the Treasurer of the European Respiratory Society for the past 3 years. He has also, in the last five years, received reimbursement for attending a symposium. DOI: 10.1183/09031936.00097410
A.J. Peacock. The project was supported by an unrestricted educational grant from Encysive/Pfizer. DOI: 10.1183/09031936.00155009
T. Perez's work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
S. Peterson is a full time employee for AstraZeneca and holds stocks of AstraZeneca. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
I. Pin's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
A.J. Piper has received travel reimbursement from Weinmann, Germany and has also been paid for speaking and organising educational activities on behalf of the following bilevel machine manufacturers: ResMed, Australia; Respironics, Australia; Weinmann, Germany; and Air Liquide, Australia. She has previously acted as a clinical consultant to ResMed. The sleep laboratory of A.J. Piper has also received an industry-sponsored project grant from ResMed, Australia, and PAP equipment for other research projects from Air Liquide Australia and MayoHealthcare, Australia. DOI: 10.1183/09031936.00115009
M.W. Pletz has received honoraria for speaking and consulting from Wyeth and Sanofi Pasteur. DOI: 10.1183/09031936.00041210
M.I. Polkey has received support via his institution from GlaxoSmithKline. DOI: 10.1183/09031936.00032510
M.I. Polkey has advised and received consulting fees from GlaxoSmithKline and AstraZeneca, on the topic of quadriceps dysfunction in COPD. DOI: 10.1183/09031936.00104909
C. Pousette's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
G. PrayGod R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
P. Princi has been funded via a grant from Respironics for web-survey designing and hosting. DOI: 10.1183/09031936.00123509
L. Puente-Maestú has received funding from Boehringer and GSK to attend international respiratory conferences, fees (less than €2,000) for speaking in courses sponsored, but not organised, by these firms and is currently IP of one of the sites of the study EXACTT (205.368) by Boehringer. DOI: 10.1183/09031936.00011210
K. Puri is employed by is employed by Calistoga Pharmaceuticals. DOI: 10.1183/09031936.00106609
Q Back to top
S. Quirce's study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
R Back to top
M.X. Rangaka. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
N. Range R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
P. Ravn is registered as co-inventors on a patent filed by Hvidovre Hospital disclosing IP-10 as a diagnostic marker for infection with M.tuberculosis. Has received 2000 Euro from Cellestis for a consultation on Guidelines 2005, and been invited to the 1 and 2 Global Conference on IGRA. DOI: 10.1183/09031936.00028510
P. Ravn was an invited speaker by Cellestis in 2009 and was reimbursed €2,000 for a consultation on Quanti-FERON guidelines in 2006. P. Ravn was a co-inventor on a pending patent on the use of IP-10 for diagnosis of TB. R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
H. Reddel's study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
S. Reddy. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
Y. Refaely. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
M.I. Restrepo does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. The author has participated in advisory boards for Ortho-McNeil-Janssen, Johnson & Johnson, and Novartis. Speaker's for Ortho-McNeil-Janssen, Johnson & Johnson, Pfizer, Covidien and BARD, Inc. Consultant for Wyeth and Theravan. MIR received supported by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant and a CTSA Award Number (KL2 RR025766). DOI: 10.1183/09031936.00077509
K. Retailleau. The study was supported by a grant from Pfizer. We are grateful to GE Healthcare Ultrasound (Diegem, Belgium) for the loan of the Vivid i. DOI: 10.1183/09031936.00024410
N. Roche. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
I. Rödin's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
E.A. Rondini. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
M. Ryg. This project has been financed, in part, with the aid of GSK via The Norwegian Thoracic Society. DOI: 10.1183/09031936.00148609
M. Ruhwaldhas applied for a patent disclosing IP-10 as marker for Mycobacterium tuberculosis infection and one disclosing MCP-2 as marker for M. tuberculosis infection. The author has registered as inventor on both pending applications. In 2009, he has received a travel grant sponsored by Cellestis Ltd. R. Wallis (Pfizer) made comments and critiques during the preparation of the manuscript. DOI: 10.1183/09031936.00039010
S Back to top
S. Saarelainen has received reimbursement for attending a symposium and fees for speaking or consulting from GSK and Boehringer Ingelheim. DOI: 10.1183/09031936.00093510
S. Saarelainen has received fees from GSK, AstraZeneca and Boehringer Ingelheim for speaking. His travel to the ERS Congress in Berlin was funded by Boehringer Ingelheim. DOI: 10.1183/09031936.00178109
S. Sakurai's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
G. Sánchez is an employee of GlaxoSmithKline S.A. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
G. Sánchez is an employee of GlaxoSmithKline S.A. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
S. Sato's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
L. Savale. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
P. Scheinmann. The present study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
R.T. Schermuly has received honoraria from Actelion, Encysive, Pfizer, Bayer Schering and Solvay, and research grant support from Bayer Schering, Actelion, Encysive, Pfizer, Solvay and Ergonex. DOI: 10.1183/09031936.00140309
R.T. Schermuly has received honoraria from Actelion, Bayer-Schering, Encysive, Pfizer and Solvay and research grant support from Actelion, Bayer-Schering, Encysive, Ergonex, Pfizer and Solvay. DOI: 10.1183/09031936.00143308
R.T. Schermuly's travel to the ERS congress in 2008 in Berlin and a speaking fee were funded by LungRX. DOI: 10.1183/09031936.00028009
H. Schirok is full-time employee at Bayer Schering Pharma and has stocks in this company. DOI: 10.1183/09031936.00140309
M. Sears has received research funding, consulting and speaking fees from AstraZeneca, and holds an endowed chair in Respiratory Epidemiology jointly endowed by AstraZeneca and McMaster University. This study was funded by AstraZeneca (Lund, Sweden). DOI: 10.1183/09031936.00124009
W. Seeger has received a fee for speaking/chairing the Ventavis Symposiums in 2006-2008 from BayerSchering AG, and a fee for speaking/chairing the PH Workshop in 2009 from Bayer Health Care. DOI: 10.1183/09031936.00140309
W. Seeger has received reimbursement for attending and fees for speaking/chairing at the ERS Congress 2008 funded by Lung RX, Ventavis Symposia 2004-2008 funded by Bayer Schering AG, PH update in 2007 and 2008 funded by Encysive. W. Seeger received fees for consulting from Lung RX and Bayer Schering AG. DOI: 10.1183/09031936.00028009
R. Seldon. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
O. Selroos drafted the manuscript for which he received financial support from AstraZeneca. The author has during the last five years received consultation fees from AstraZeneca and Galenica, fees for speaking at medical meetings organized by AstraZeneca and fees for drafting publications for AstraZeneca, Orion Pharma and Schering-Plough. DOI: 10.1183/09031936.00022010
M. Serralha. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
E. Setakis. The study was funded by AstraZeneca. GPRD is owned by the UK Department of Health and operates within the Medicines and Healthcare products Regulatory Agency (MHRA). GPRD is funded by the MHRA, Medical Research Council, various universities, contract research organisations and pharmaceutical companies. The department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. DOI: 10.1183/09031936.00124209
J.M. Seymour was funded by an unrestricted educational grant from GlaxoSmithKline. DOI: 10.1183/09031936.00104909
E. Shahar's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
N.M. Siafakas has, in the past 5 years, received fees for speaking, funds for research and fees for consulting from Boehringer-Ingelheim GSK, Pfizer, Novartis, Nycomed, Chiesi, AstraZeneca and UCB. DOI: 10.1183/09031936.00046410
G. Simmoneau. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00057010
D.D. Sin has, in the past 5 yrs, received honoraria for speaking engagements from GlaxoSmithKline (GSK) and AstraZeneca (AZ) and has served on an ad hoc basis on GSK and AZ's advisory board. D.D. Sin has also received research funding from AZ for unrestricted research grant. DOI: 10.1183/09031936.00082510
D.D. Sin has received a research grant from AstraZeneca (AZ) and GlaxoSmithKline (GSK); has received honoraria for speaking engagements from AZ and GSK and has participated on advisory boards for both AZ and GSK. AZ covered expenses related to 2009 ERS participation for D.D. Sin. DOI: 10.1183/09031936.00097710
V. Siroux's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
O. Sitbon. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00057010
C.M. Sköld's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
P.D. Sly. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
L.A.M. Smit. The present study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
V. Sobradillo-Peña. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
J. Solway is the principal investigator on a research grant to the University of Chicago from Astra-Zeneca, Inc. He has received a lecture fee from Eisai, and has received consulting fees from Tanox, Merck, Wyeth, Critical Therapeutics, AstraZeneca, Genentech, Sepracor, GlaxoSmithKline and Cytokinetics. DOI: 10.1183/09031936.00160209
J.B. Soriano. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
R. Souza. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. The author has received lecture and consultancy fees from Actelion, Pfizer and GlaxoSmithKline (GSK). DOI: 10.1183/09031936.00057010
G. Staehler has received honoraria from Bayer Schering Pharma AG. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
E. Ståhl is an employee of AstraZeneca and has shares in the company. The present study was funded by AstraZeneca. DOI: 10.1183/09031936.00123709
J-P. Stasch is a full-time employee at Bayer Schering Pharma. DOI: 10.1183/09031936.00140309
H.C. Steel. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
D.P. Steinfort has received payment of travel costs by Olympus, Australia, to attend a training course. DOI: 10.1183/09031936.00151809
K.P. Strohl has received and does receive funds for research from the Veterans Affairs Research Office (USA), the National Institutes of Health, and Inspire (hypoglossal nerve stimulation). He has also organised educational efforts (but none on this topic) for the American Thoracic Society, and for MedPartners. DOI: 10.1183/09031936.00174609
M. Svartengren's study was sponsored by the Swedish Rail Administration (Banverket). DOI: 10.1183/09031936.00099909
K. Svensson. Before retirement K. Svensson was an employee of AstraZeneca for 20 yrs. He has received funding from AstraZeneca for consultancy services. The author's study was funded by AstraZeneca. DOI: 10.1183/09031936.00123709
K. Svensson was formerly an employee of AstraZeneca. Financial support for the present study was provided by AstraZeneca. DOI: 10.1183/09031936.00117509
E.R. Swenson. The author's study was supported by a research grant of €10,000 from VIASYS Healthcare GmbH. Technical support was provided by H-J. Smith from CareFusion GmbH (Hoechberg, Germany), formerly VIASYS Healthcare GmbH. DOI: 10.1183/09031936.00092610
J. Swigris has, in the past 5 yrs, received consulting fees and a stipend for educational services from Actelion Pharmaceuticals to the amount of $5,500.00, and a consulting fee from Gilead Pharmaceuticals to the amount of $3,000.00. DOI: 10.1183/09031936.00071710
T Back to top
T. Tanigawa's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
D.P. Tashkin has received speaking fees, research funding and consultation fees from Boehringer Ingelheim. The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including D.P. Tashkin, B. Celli, M. Decramer and S. Kesten. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00036110
D.R. Taylor has received research funding of $25,000 from Aerocrine AB a manufacturer of nitric oxide analysers, and lecture fees of $3000 from the same source.
S. Tewari. Source of support for study: Aeris Therapeutics, Inc., Woburn, MA, USA. DOI: 10.1183/09031936.00106009
A.J. Theron. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
L. Thiberville is listed as a co-author of a patent related to confocal bronchoscopy of the airways. DOI: 10.1183/09031936.00194509
W.R. Thomas. Phadia Diagnostics (Uppsala, Sweden) provided the reagents for determination allergen-specific IgE antibody titres in the cohort. DOI: 10.1183/09031936.00184109
I. Tillie-Leblond. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI: 10.1183/09031936.00175109
G.R. Tintinger. This study was supported in part by a research grant from the Investigator Initiated Studies Programme, Merck. DOI: 10.1183/09031936.00157409
A. Torres has received a research grant from Pfizer. He is a consultant for Wyeth, Bayer, Astellas and Novartis. He is a speaker for Astellas Symposium. DOI: 10.1183/09031936.00022909
E.L. Travis. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
S. Trivedi. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
T. Troosters has served on advisory boards of the sponsors of the present study. The author has also received honoraria to speak in educational events organised or sponsored by Boehringer-Ingelheim and Pfizer. The author's study was funded by Boehringer Ingelheim and Pfizer. The design of the trial, monitoring of the trial conduct, approval of the statistical analysis, review of the data, and writing of the manuscript involved a joint advisory committee including the study authors. T. Troosters reviewed the data and participated in writing of the manuscript. Collection of the data and the statistical analyses were performed by employees of Boehringer Ingelheim. The decision to submit the manuscript involved all authors. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DOI: 10.1183/09031936.00127809
T. Troosters has received reimbursement as a speaker during congresses and post-graduate events of the European Respiratory Society. DOI: 10.1183/09031936.00127110
V Back to top
M. van de Pol The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
S.F. Van Eeden holds the GlaxoSmithKline Professorship in COPD. DOI: 10.1183/09031936.00082510
V. Vanini's study received financial support from ISA Pharmaceuticals. DOI: 10.1183/09031936.00140009
J. van Meerbeeck acknowledges receipt of speaker's and consulting fees, and unrestricted grants for research and education in the past 5 years from Eli Lilly. The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
G.R. van Pottelberge has received a travel grant for the ERS congress from Boehringer Ingelheim and travel to the EAACI congress was funded by Merck Sharp & Dohme DOI: 10.1183/09031936.00140409
C.P. van Schayck has received fees for speaking, consulting and organising education from AstraZeneca, GlaxoSmithKline, Pfizer and Boehringer Ingelheim. DOI: 10.1183/09031936.00022010
P.E. van Schil The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
T.P. van Staa. The study was funded by AstraZeneca. GPRD is owned by the UK Department of Health and operates within the Medicines and Healthcare products Regulatory Agency (MHRA). GPRD is funded by the MHRA, Medical Research Council, various universities, contract research organisations and pharmaceutical companies. The department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. DOI: 10.1183/09031936.00124209
D. Vervloet's study was supported by Merck, Sharp & Dohme (MSD). DOI: 10.1183/09031936.00154509
J.L. Viejo. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
C. Villasante. The IBERPOC study funding was obtained from Boehringer Ingelheim, Spain, SA. The EPI-SCAN study was funded by an unrestricted grant from GlaxoSmithKline Spain. DOI: 10.1183/09031936.00138409
E. von Mutius has received fees for consulting from Protectimmun. E. von Mutius is listed as an inventor on the following patents: publication number EP 1411977, composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases; publication number EP1637147, stable dust extract for allergy protection; and publication number EP 1964570, pharmaceutical compound to protect against allergies and inflammatory diseases. E. von Mutius is listed as inventor and has received royalties on the following patent: publication number EP2361632, specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders. DOI: 10.1183/09031936.00041410
C. von Plessen has received support for travel to scientific conferences from Ely Lilly, Astra, Roche, Glaxo, and research grants from the Regional Health Authority of Western Norway and from the University of Bergen. He chairs the protocol committee of a recently completed clinical trial that has received an unrestricted grant from Pierre Fabre, the manufacturer of Navelbine (vinorelbine). DOI: 10.1183/09031936.00171809
R. Voswinckelreceived a fee as a speaker on the topic of inhaled treprostinil for the treatment of pulmonary arterial hypertension at the ERS meeting 2008. He participated in the clinical development of inhaled treprostinil for PAH. DOI: 10.1183/09031936.00028009
W Back to top
C. Walker. Ozone exposures were conducted at the NIEHS Inhalation Facility under contract to Alion Science and Technology, Inc. DOI: 10.1183/09031936.00145309
R.S. Wallis has previously received research grant support and speaking fees from Wyeth and Amgen, and currently is an employee and shareholder of Pfizer. DOI: 10.1183/09031936.00028510
S. Ward. Financial support for the present study was provided by AstraZeneca. DOI: 10.1183/09031936.00117509
K. Wegscheider has received research grants from BRAHMS. He has also received fees from BRAHMS for participation in study design and evaluation. DOI: 10.1183/09031936.00163309
G. Weimann has been a full time employee of Bayer Schering Pharma AG for the past five years, and owns a small amount of stock from Bayer Schering Pharma AG. This study was supported by Bayer Schering Pharma AG, Berlin, Germany. C. Mulligan (Oxford PharmaGenesis Ltd, Oxford, UK) provided editorial assistance, supported by Bayer Schering Pharma AG, Germany. DOI: 10.1183/09031936.00182909
N. Weissmann has received honoraria from Actelion, Pfizer, Altana Pharma, and research grant support from Bayer Schering and Solvay Pharmaceuticals. DOI: 10.1183/09031936.00143308
N. Weissmann has received honoraria from Sanofi Aventis and Solvay, and research grant support from Bayer Schering, Sanofi Aventis and Solvay Pharmaceuticals. DOI: 10.1183/09031936.00140309
J. Welch The authors of the study are grateful to Eli Lilly Co. for supporting the trial through an educational grant. DOI: 10.1183/09031936.00039510
T. Welte has received a research grant from BRAHMS. He has also received fees for lectures from BRAHMS. DOI: 10.1183/09031936.00163309
T. Welte has received: fees for giving lectures and ad hoc consultancies from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Nycomed, MSD, Teva and Novartis; and departmental research funding from Novartis. The author's study was funded by AstraZeneca. DOI: 10.1183/09031936.00123709
T. Welte has received honoraria for speaking and consulting from Wyeth, MSD, GSK and Novartis. DOI: 10.1183/09031936.00041210
G. Wennergren has received fees for lectures from Merck Sharp & Dohme and GlaxoSmithKline. For lectures and for contributing to an advisory board, he has received fees from AstraZeneca and Novartis. He has received a research grant amounting to 10,000 Euros from AstraZeneca. G. Wennergren does not hold any stocks or shares in any pharmaceutical company. DOI: 10.1183/09031936.00104809
M.R. Wilkins has received a research grant from Biomarin Pharmaceuticals. This work is supported by BioMarin Pharmaceuticals. DOI: 10.1183/09031936.00188809
K.A. Wilkinson. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings.DOI: 10.1183/09031936.00171509
R.J. Wilkinson has acted as an unpaid member of expert panels of the Bill and Melinda Gates Foundation and the Foundation for Innovative Novel Diagnostics on the subject of diagnostic assays for tuberculosis. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings. DOI: 10.1183/09031936.00171509
S.F. Wolf is an employee of, and possesses stock in, Wyeth Pharmaceuticals. DOI: 10.1183/09031936.00097609
K.K. Wong's sleep laboratory has previously received an industry-sponsored project grant from ResMed, Australia, and PAP equipment for other research projects from Air Liquide Australia and MayoHealthcare, Australia. DOI: 10.1183/09031936.00115009
K. Wood. Oxford Immunotec provided funds and training to support a temporary member of staff for this project, and also the T-SPOT.TB kits without charge. Oxford Immunotec played no part in the design of this study or the decision to publish its findings.DOI: 10.1183/09031936.00171509
Y Back to top
A. Yaïci. A research grant from Actelion Pharmaceuticals France was obtained for the author's study for the logistical support, monitoring, project management, data management, and statistical analysis. DOI: 10.1183/09031936.00057010
K. Yamagishi's ancillary study received support from the Pfizer Health Research Foundation (Tokyo, Japan) and the ResMed Foundation (La Jolla, CA, USA). DOI: 10.1183/09031936.00118609
R.P. Young has received funds for his research programme from Synergenz BioScience Ltd. DOI : 10.1183/09031936.00033310
Z Back to top
J-P. Zellweger has received travel reimbursement from Oxford Immunotec for participating as a speaker in three international symposia during the last 5 years. DOI: 10.1183/09031936.00201609
B. Zhang. The study was funded by AstraZeneca. GPRD is owned by the UK Department of Health and operates within the Medicines and Healthcare products Regulatory Agency (MHRA). GPRD is funded by the MHRA, Medical Research Council, various universities, contract research organisations and pharmaceutical companies. The department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. DOI: 10.1183/09031936.00124209
L. Zhao's work was supported by BioMarin Pharmaceuticals. DOI: 10.1183/09031936.00188809
Volume 37, 2011
A Back to top
W.R. Addington has a share interest in Pneumoflex Systems, which devises methods that can be used in testing the risk of aspiration in stoke patients. However our letter compliments the authors (Ward et al.) for describing other methods, and does not make a value judgement on their relative merits. DOI: 10.1183/09031936.00083310
A.G.N. Agusti has received fees for research, speaking at scientific meetings and/or participating in advisory boards from Almirall, Astra-Zeneca, Boeheringer-Ingelheim, Chiessi, GlaxoSmithKline, Nycomed, Procter&Gamble and Roche. DOI: 10.1183/09031936.00091709
A. Ahmad. The present study was supported by Talecris Biotherapeutics. DOI: 10.1183/09031936.00033710
T. Alissafi. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
F.R. Almeida has a few grants but none of them is related to any commercial organisation, and no studies are related financially to any company. DOI: 10.1183/09031936.00194809
W.H. Anderson is a full time employee of GlaxoSmithKline. However, since this is a genetic study on susceptibility to COPD, it is not believed to present any conflict of interest. DOI: 10.1183/09031936.00091709
S. Andreas has received fees for lectures and organising education of about 5,000 euros by Respironics, Resmed and Heinen-Lowenstein. He received consulting fees from Sanofi Synthelabo of about 1,000 euros. DOI: 10.1183/09031936.00099710
N. Ambrosino has received reimbursement for attending a symposium: Boheringer Ingelheim, GSK, Menarini. He has also received a fee for speaking at Boheringer Ingelheim, Novartis, Astra Zeneca and for organising education at GSK. He has received funds for a member of staff from Boheringer Ingelheim, Pfizer. He also received fees for consulting for Boheringer Ingelheim. DOI: 10.1183/09031936.00131210
R. Amin. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
P. Aurora. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
G. Ayanoglu is an employee of Schering Plough Biopharma. DOI: 10.1183/09031936.00047410
B Back to top
P.S. Bakke is a national principle investigator of the ECLIPSE study. In 2007 I received 750 Euros in fee for speaking from GlaxoSmitKline, 1000 Euros in fee for speaking from Boehringer-Ingelheim. In 2008 I received 1000 Euros in fee for speaking from Boehringer-Ingelheim. DOI: 10.1183/09031936.00091709
S. Balkovec. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
E. Baraldi received a research grant from Aerocrine (payment to Azienda Ospedaliera di Padova) and also received travel grants and lectured at scientific meetings for GlaxoSmithKline, Merck Sharp & Dohme, Abbott, and Valeas. DOI: 10.1183/09031936.00091410
R.J. Barst has received funding for research and/or consulting from the following: Actelion, Gilead, Eli Lilly, Pfizer, Novartis, United Therapeutics, NHLBI, Ikaria. The present article was supported by Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00056110
C.M. Bastardo. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
M. Beghetti has served on advisory boards/consulting for Pfizer, Actelion Pharmaceuticals, Bayer Schering, Encysive Pharmaceuticals, GlaxoSmithKline, INO Therapeutics, Eli Lilly, and Mondobiotech and has received lecture fees from Actelion Pharmaceuticals, Encysive Pharmaceuticals, Pfizer and Bayer Schering. The present article was supported by Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00056110
S.D. Beevers. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
P.K. Bhavsar Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
L. Boeck. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
A. Boonstra has spoken at and received reimbursement for acting as an expert for GSK, Pfizer, Actelion, United Therapeutics up to €2,000. The author's employer has received unrestricted grants from these companies. DOI: 10.1183/09031936.00058410
A. Boonstra has spoken for and received reimbursement for acting as an expert for GSK, Pfizer, Actelion, United Therapeutics, of no more than 2,000 Euro. His employer has received unrestricted grants from these companies. DOI: 10.1183/09031936.00100510
A. Bossink received €1000 as a fee for speaking at a meeting organised by Biomerieux. DOI: 10.1183/09031936.00114810
A. Bossios. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
G. Bothamley
S. Brunelleschi in 2002 received grants from Philip Morris for two Research proposals "Effects of nicotinic agonists on the functional activity of monocyte and macrophage populations" and "Responsiveness of human monocytes and alveolar macrophages from smokers and patients with lung diseases to tachykinins and growth factors: a role for reactive oxygen species, tumour necrosis factor-? and NF-?B" DOI: 10.1183/09031936.00023310
C.D. Buckley. The present study was supported by Talecris Biotherapeutics. DOI: 10.1183/09031936.00033710
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD, GSK AstraZeneca, in no case exceeding £1,500; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00166010
A. Bush has been received expenses to travel to the American Thoracic Society from GSK, MSD and Altana, and speakers fees from MSD, GSK AstraZeneca, in no case exceeding £1,500; he has received a grant for a study of inhaled mannitol in cystic fibrosis from Pharmaxis, Australia. DOI: 10.1183/09031936.00044310
W. Busse This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
C Back to top
J. Cadranel In the last 5 yrs, the author has received fees for speaking and consulting from Boehringer-Ingelheim and Roche (less than $5,000 per year), and travel to the ASCO and/or IASLC congress was funded by Astra-Zeneca, Boehringer-Ingelheim, Merck Serono and Roche. Boehringer Ingelheim provided financial support for the assistance of Ogilvy Healthworld Medical Education. DOI: 10.1183/09031936.00179409
P.M.A. Calverley has received consulting fees from AstraZeneca, GlaxoSmithKline, Nycomed and Pfizer; speaking fees from GlaxoSmithKline and Nycomed; and grant support from Boehringer-Ingelheim and GlaxoSmithKline. DOI: 10.1183/09031936.00091709
K.H. Carlsen has received reimbursement for attending a symposium by Merck, and fees for speaking for Merck, GSK and Novartis, none of these in 2010. DOI: 10.1183/09031936.00091410
S. Catot. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
M. Cazzola has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies (Boehringer Ingelheim, GlaxoSmithKline, Sigma-Tau, Recordati, Abbott, Chiesi and AstraZeneca); served on an advisory board for Dey, GlaxoSmithKline, Novartis, AstraZeneca and Lallemand; served as a consultant to Almirall, Altana, Boehringer Ingelheim, and AstraZeneca; received fees from Keryos for serving as an expert witness; and been reimbursed by Novartis, Encysive, Altana, Pfizer and Menarini Farmaceutici for attending several conferences. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
S. Centanni received in the last five years honoraria for lectures from Boheringer Ingelheim, Menarini S.p:A., Merck Sharp and Dohme, Novartis and GlaxoSmithKline, for consulting from GlaxoSmithKline, Menarini S.p.A., Shering Plough. Research support and clinical trials from Boeringer Ingelheim, Novartis, GlaxoSmithKline, AstraZeneca. DOI: 10.1183/09031936.00045810
P. Chanez has provided consultancy services for Almirall, BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, and Schering Plough; has served on advisory boards for Almirall, BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, and Schering Plough, MSD; has received lecture fees from Almirall, BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, Schering Plough,MSD; and has received industry-sponsored grants from Almirall, BI, Centocor, GSK, AZ, Novartis, Teva, Chiesi, and Schering Plough. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
D. Choudat The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
M. Christ-Crain has received support from BRAHMS to attend meetings and fulfilled speaking engagements. DOI: 10.1183/09031936.00121510
M. Christ-Crain received speaking honoraria from Brahms. DOI: 10.1183/09031936.00035610
H. Chrystyn has no shares in any pharmaceutical companies. He has received sponsorship to carry out studies, together with some consultant agreements, reimbursement for conference attendance and honoraria for presentation, from several pharmaceutical companies whose portfolio includes inhaled products: Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Mundipharma, Orion, Teva, Truddell and UCB. Research sponsorship has also been received from grant awarding bodies (EPSRC and MRC). DOI: 10.1183/09031936.00166410
K.F. Chung Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
L. Clancy has received fees for speaking and consultancy, and funds for research from companies involved in making pharmaceuticals for treatment of Tobacco dependence. DOI: 10.1183/09031936.00020211
A.R. Clark Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
R. Colomer. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
J. Cohen The study was funded by Nycomed. DOI: 10.1183/09031936.00204109
J. Cortijo received a research grant from Almirall. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
D Back to top
R. Dahl has given lectures or sat on advisory boards at Nycomed, B-I, Pfizer, GSK, Novartis, Almirall, ALK, UCB, Airsonett, A-Z, MSD and TEVA, and has received research support from B-I, Pfizer, GSK, Novartis, A-Z, Airsonett, Stallergen and ALK. DOI: 10.1183/09031936.00045810
J. Davies is part of the UK CF Gene Therapy Consortium funded by a grant from the UK CF Trust; she has previously participated in Advisory Boards for Vertex Pharmaceuticals and is currently local PI on clinical trials for Vertex and PTC. DOI: 10.1183/09031936.00166010
P.L. Davies was funded by a grant from Arriva Pharmaceuticals (Alameda, CA, USA). DOI: 10.1183/09031936.00037810
M. Decramer has been part of Advisory Board for Boehringer-Pfizer, GSK, Nycomed, Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than 10,000 euro per annum. He received a research grant of 45,000 euro/year from AstraZeneca. M. Decramer is the President of the European Respiratory Society. DOI: 10.1183/09031936.00171210
M. Decramer has been part of Advisory Board for Boehringer-Pfizer, GSK, Nycomed and Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than 10,000 euro per annum. He received a research grant of 45,000 euro per year from AstraZeneca. DOI: 10.1183/09031936.00031810
M. Decramer has been part of Advisory Boards for Boehringer, Pfizer, GSK, Nycomed and Atlanta, and has performed consulting work for AstraZeneca, Boehringer-Pfizer, Nycomed, Dompe, Novartis and GSK. He also received lecture fees from these companies. All of the above amounted to less than €10,000 per annum. He received a research grant of €45,000 per year from AstraZeneca and has received grant supports from Boehringer-Pfizer, Chiesi, GSK, and UCB. DOI: 10.1183/09031936.00021110
D. DeMeo. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
D.W. Denning holds founder shares in F2G Ltd and Myconostica Ltd, both University of Manchester (Manchester, UK) spin-out companies and has received grant support from F2G as well as the Fungal Research Trust, the Wellcome Trust, the Moulton Trust, The Medical Research Council, The Chronic Granulomatous Disease Research Trust, the National Institute of Allergy and Infectious Diseases, National Institute of Health Research and the European Union, AstraZeneca and Basilea. He continues to act as an advisor/consultant to F2G and Myconostica as well as other companies over the last 5 years including Basilea, Vicuron (now Pfizer), Pfizer, Schering Plough, Nektar, Daiichi, Astellas, Gilead and York Pharma. He has been paid for talks on behalf of Schering, Astellas, Merck, Dainippon and Pfizer. DOI: 10.1183/09031936.00054810
F.M. de Benedictis reports receiving research support and consulting fees from GlaxoSmithKline, Merck Sharp Dohme, Chiesi Farmaceutici and UCB; travel to the ERS congress was funded by GlaxoSmithKline. No other potential conflict of interest is reported. DOI: 10.1183/09031936.00091410
A.H. De Boer The study was funded by Nycomed. DOI: 10.1183/09031936.00204109
J. de Castro. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
J.C. de Jongste has lectured on request for GlaxoSmithKline, Novartis, Abbott and MerckSharpeDohme, and received research grants from Aerocrine, GlaxoSmithKline, Roche, Friesland Nutrition and MerckSharpDohme. All payments were made to the ErasmusMC-Pediatrics Holding. DOI: 10.1183/09031936.00106109
F.H.C. de Jongh's travel and hotel costs to the ERS Congress in Barcelona 2010 were 50% funded by Teva Pharma NL. DOI: 10.1183/09031936.00166410
J.C. de Jongste received honoraria for lecturing on request of GSK and Novartis, and received funding for clinical research from GSK, Aerocrine, Friesland Nutrition, MSD and Roche. All payments were made to the institution. DOI: 10.1183/09031936.00091410
P. Delguste. The authors gratefully acknowledge five manufacturers who lent us the autoCPAP devices. DOI: 10.1183/09031936.00139510
P. de Pablo. The present study was supported by Talecris Biotherapeutics. DOI: 10.1183/09031936.00033710
A. De Soyza has received an educational grant from GlaxoSmithKline Pharmaceutical industries of £10,000 for an unrelated project in pulmonary hypertension. The author has also received speaker fees from GlaxoSmith Kline, AstraZeneca, Chiesi, Pfizer and for lectures. The author has also received advisory board fees from GlaxoSmithKline and Forrest laboratories. None of these are felt to represent conflict of interest to the manuscript but are included for transparency. DOI: 10.1183/09031936.00088410
B. Desai is an employee of Schering Plough Biopharma. DOI: 10.1183/09031936.00047410
S.G. Devadason has received funds for research from MAP Pharmaceuticals and fees for consulting from MAP Pharmaceuticals and Philips Respironics. DOI: 10.1183/09031936.00166410
R. Dhand has: received speaker fees from GSK and Pfizer; received consultancy fees from Dey, Aggenix and Bayer; and has been involved in clinical trials with GSK and Novartis. DOI: 10.1183/09031936.00166410
R. Diel has received a fee for speaking at symposia sponsored by Cellestis and Oxford Imunotec. DOI 10.1183/09031936.00114810 and DOI 10.1183/09031936.00115110
L. Dupont. The study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
M. Dury. The authors gratefully acknowledge five manufacturers who lent us the autoCPAP devices. DOI: 10.1183/09031936.00139510
A. D'Urzo has received funding from various pharmaceutical organizations to participate in educational and research events related to the management of asthma and chronic obstructive pulmonary disease. DOI: 10.1183/09031936.00136210
J.W. Dodd received a travel scholarship to ATS congress 2009 awarded by GSK. DOI: 10.1183/09031936.00170910
A. Dogra is an employee of Novartis Pharmaceutical Corporation. DOI: 10.1183/09031936.00045810
E. Donet. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
W.R. Douma The study was funded by Nycomed. DOI: 10.1183/09031936.00204109
R. de Waal Malefyt is an employee of Merck and holder of Merck Stock. DOI: 10.1183/09031936.00047410
O. Dumas The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
R. Dumitrascu The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
J. Dupuis has received speaker and consultant fees for Actelion and Pfizer. DOI: 10.1183/09031936.00053710
E Back to top
P. Eggimann. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
O. Eickelberg The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
G. Engström is employed as senior epidemiologist by AstraZeneca R&D, which is a manufacturer of drugs for respiratory diseases. DOI: 10.1183/09031936.00091110
P.L. Enright. and his wife were generously entertained by BIPI twice per year at four-star resorts, including a weekend at Euro-Disney for the first GOLD COPD guidelines promotional meeting. He was trained in developing persuasive presentations and effective public speaking as a member of the Boehringer speakers' bureau of key opinion leaders (KOLs). He has received six-figure consulting fees from Schering and from Pfizer for reviewing the quality of spirometry tests done for a study of mometasone for COPD and varenicline for smoking cessation in patients with COPD. He was provided with the services of medical writers and editors and has been generously reimbursed by continuing medical education (CME) corporations and professional societies for developing booklets, documents, presentations, webinars, and hands-on workshops promoting the use of spirometry by primary care providers for the detection of COPD and asthma. The financial sponsors of these CME programs included Glaxo, Astra-Zeneca, Pfizer, and Novartis, all of whom make or market inhalers for COPD. His travel expenses for advisory board meetings and international professional society meetings have been reimbursed by the COPD Foundation and the National Lung Health Education Program (NHLEP), both of which promote office spirometry for the detection of COPD and are generously funded by pharmaceutical companies which make COPD inhalers. His travel expenses and registration fees were paid by the Federation International Respiratory Societies (FIRS) to APSR meetings in Hong Kong, Beijing, Guangzhou, and Kyoto to serve on the writing group which provided recommendations for spirometry for the detection of COPD in developing countries. DOI: 10.1183/09031936.00135110.
S.I. Ertel has received fees from Actelion Pharmaceuticals Ltd for medical writing. The present article was supported by Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00056110
S. Ewig received funds for speaking at symposia organized on behalf of BRAHMS AG. DOI: 10.1183/09031936.00123610
M.L. Everard has, in the past 5 yrs: received fees for speaking at meetings organised by GSK, MSD, AZ, Profile, Orion and Abbott; sat on advisory boards for GSK, AstraZeneca, MSD, ML Labs, Abott, Novartis, MAP and Cheisi; and has had his registration fees, travel and accommodation for attending conferences by MSD, Novartis, GSK. DOI: 10.1183/09031936.00166410
F Back to top
T.L. Feenstra works for the Dutch Ministry of Health. The current research was funded by a grant from the Dutch Asthma Foundation. DOI: 10.1183/09031936.00043710
G. Ferrara received reagents for research from ADA srl, Italian distributor for Cellestis Ltd, to a value of €2,000. DOI: 10.1183/09031936.00115110
R.B. Fick Jr is an employee of Schering Plough Biopharma. DOI: 10.1183/09031936.00047410
A.J. Fisher has received speaker fees for educational meetings from Pfizer and research funding from Pfizer for investigator driven research using Sitaxsentan. DOI: 10.1183/09031936.00091610
A.J. Fisher is supported by a GlaxoSmithKline clinical fellowship award. DOI: 10.1183/09031936.00088410
U. Frey has received hardware support for infant lung function research from Ecomedics Systems, Dürnten Switzerland. DOI: 10.1183/09031936.00125510
G Back to top
M. Gaga has received honoraria, research and travel grants from AstraZeneca, GlaxoSmithKline, UCB, Novartis, S-P and Boehringer Ingelheim. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
N. Galiè has participated in advisory board activities for Actelion, Pfizer, United Therapeutics, Eli-Lilly, Bayer-Schering, Encysive and GlaxoSmithKline, and given paid lectures for Actelion, Pfizer, Bayer-Schering and Encysive. The Institute of Cardiology of the University of Bologna has received research grants from Actelion, Pfizer, United Therapeutics, Eli-Lilly, Bayer-Schering, Encysive and GlaxoSmithKline. DOI: 10.1183/09031936.00194810
A. Gavaldà is an employee of Almirall. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
J.E. Gern has stock options in EraGen BioSciences and 3V Biosciences; has worked as a consultant for GlaxoSmithKline, Synairgen, Biota, and Boehringer Ingelheim; is on the Scientific Advisory Board for 3V Biosciences; and has received research grants from Merck Inc. and Astra Zeneca. DOI: 10.1183/09031936.00092410
H.A. Ghofrani has received research grants from Ergonex Pharma GmbH and he is an advisor to Ergonex Pharma GmbH. The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
J.S.R. Gibbs is in receipt of research funds from United Therapeutics, has received speakers fees from Actelion, Bayer, GSK and Lilly, and has acted as a member of an advisory board for Actelion, GSK, Lilly, Novartis and Pfizer. DOI: 10.1183/09031936.00194810
E. Girardi has a patent pending on an immunological assay for diagnosing active tuberculosis. DOI: 10.1183/09031936.00114810
H. Gogos. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
D. Goletti had a travel reimbursement to go to the "2nd IGRA symposium" in Dubrovnik in May 2009 from Cellestis. DOI: 10.1183/09031936.00115110
J. Grein is an employee of Schering Plough Biopharma. DOI: 10.1183/09031936.00047410
F. Grimminger The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
V. Guillem. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
A. Gúrpide. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
P. Gustafsson. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
J. Grigg. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
K. Gruffydd-Jones has acted as a consultant for and spoken on behalf of GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim, Napp, Merck Sharpe & Dohme and Chiesi Pharmaceuticals. DOI: 10.1183/09031936.00005311
H Back to top
A. Hakulinen travelled to the ERS and EAACI Congress funded by ALK-Abello , GlaxoSmithKline and Boehringer Ingelheim. The author has given several lectures on asthma, allergy and COPD in Finland funded by AstraZeneca, GlaxoSmithCline, Boehringer Ingelheim, Schering Plough, ALK-Abello and Orion Pharma. The author has organised education on asthma and COPD funded by GlaxoSmithKline and Boehringer Ingelheim. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
J. Haughney has received reimbursements for attending symposia, fees for speaking and organising educational events, funds for research or fees for consulting from AstraZeneca, Boehringer-Ingelheim, Glaxo Smith Kline, Merck, Sharp and Dohme, Mundipharma, Novartis, Nycomed, Sanofi Aventis and Teva. DOI: 10.1183/09031936.00150910
N.N. Hansel has received reimbursement for attending a symposium from Astra Zeneca, and research funds ($100,000-200,000) and consulting funds ( <_3610000 from="from" pfizer.="pfizer." em="em">DOI: 10.1183/09031936.00063810
G. Hedlin has received funds (less than €10,000) for research by Phadia AB, Uppsala Sweden during 2008&endash;2010. The funding has been directed to a project concerning food allergy. DOI: 10.1183/09031936.00091410
D. Heederik The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
C. Hersh. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
M. Hery The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
E. Hoffman is a founder and share holder of VIDA Diagnostics Inc, a company which is commercialising lung image analysis software developed within Dr. Hoffman's laboratory, some of which was used in this data analysis. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
M.M. Hoeper has received fees for consultations and/or speaking at conferences from Actelion, Bayer, Gilead, GSK, Lilly, LungRx, Novartis and Pfizer. DOI: 10.1183/09031936.00194810
S.T. Holgate has lectured and served as a consultant for Synairgen, Amgen, Novartis, MSD, almiral, altair, he has stocks in excess of 5,000 GBP from Synairgen. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
I. Horvath has recieved: travel support for ERS, ATS and WAO congresses from AstraZeneca, Torrex Chiesi, MSD; and fees for speaking from GSK, AstraZeneca, MSD and Torrex-Chiesi. DOI: 10.1183/09031936.00166410
M. Humbert has relationships with drug companies, including Actelion, Bayer Schering, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188910
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer Schering, Chiesi,GSK, Lilly, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00028310
F. Hussain Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer Schering, Chiesi, GSK, Lilly, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00045710
I Back to top
D. Isla. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
D.D. Ivy has received an investigator initiated grant from Actelion and has received money as a consultant; received an investigator initiated grant from Gilead and has been paid as a grant reviewer; and has been a consultant for Pfizer. The present article was supported by Actelion Pharmaceuticals Ltd. DOI: 10.1183/09031936.00056110
J Back to top
A. Jabar. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
X. Jaïs has relationships with drug companies, including Actelion, Bayer Schering, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188910
R. Jensen. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
H.M. Janssens has accepted sponsorship from TEVA for attending conferences. She has received lecture fees from TEVA. She has also provided incidental consultancies for Philips Respironics, Vectura, TEVA and AstraZeneca. H.M. Janssens has received funding for research from AstraZeneca and Philips Respironics. DOI: 10.1183/09031936.00166410
M.K. Johnson has received speaker fees from Pfizer. DOI: 10.1183/09031936.00091610
N. Johnston owns non-voting shares in HealthDiary, a company which provides data management services for clinical research. DOI: 10.1183/09031936.00141310
P. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Almirall for speaking at meetings and participating in advisory board meetings and has received support for research from GlaxoSmithKline. DOI: 10.1183/09031936.00170910
E.F. Juniper holds the copyright for the Asthma Control Questionnaire. All commercial organisations are asked to pay a one-time user fee which covers consultation time, use of the questionnaire and the administrative costs of providing the questionnaire to clinicians and academics free of charge. DOI: 10.1183/09031936.00005311
K Back to top
B. Kampmann has received a reagent discount to the same value for a comparative side-by-side study of IGRA in children from both Oxford Immunotec and Cellestis. DOI: 10.1183/09031936.00115110
F. Kauffmann The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
S. Kerrigan. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
F.J. Kelly. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
S.V. Kemp has worked as an investigator on a study sponsored by Broncus. DOI: 10.1183/09031936.00100110
R. Kessler has received reimbursement for attending symposia, fees for speaking, and fees for organising education from AstraZeneca, GSK and Boehringer Ingelheim, funds for research from Roche, and funds for consulting from Novartis and AstraZeneca. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
W.J. Kim. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
N. Kirkham carried out the autopsy on behalf of HM Coroner, Newcastle upon Tyne and gave evidence at the Inquest held into the death, for which he received a fee. DOI: 10.1183/09031936.00091610
L. Koenderman is partner in a private&endash;public partnership between the Dutch government, the universities of Maastricht, Utrecht and Groningen, and GSK, Nycomed, AstraZeneca and Danone. The author has received a grant from GSK to travel to the ATS congress. DOI: 10.1183/09031936.00170409
F. Kolar The study partially was funded by CV Therapeutics (Palo Alto, CA, USA) to A. Zaza. DOI: 10.1183/09031936.00066710
X. Kong is an employee of GlaxoSmithKline. DOI: 10.1183/09031936.00091709
M. Köningshoff The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
O. Kornmann has, within the last five years, received honaria for lectures from Astra Zeneca, Boehringer Ingelheim, Novartis, Meda Pharma, for consulting from Pfizer, Novartis, for conducting clinical studies from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Bayer. DOI: 10.1183/09031936.00045810
F. Kouri The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
B. Kramer is employed by Novartis. DOI: 10.1183/09031936.00045810
H. Kromhout The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
C. Kulcke The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
L Back to top
I.M. Lang has relationships with drug companies including AOPOrphan Pharma, Actelion, Bayer Schering, GSK, Novartis, Pfizer, AstraZeneca, MSD, Servier, Böhringer Ingelheim and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. I.M. Lang was the recipient of a Californian Tobacco Industry Research Fellowship grant in 1991. DOI: 10.1183/09031936. 00033611
C. Lassen was emplyed by Novartis. DOI: 10.1183/09031936.00045810
A. Lalvani is named inventor for patents underpinning T cell-based diagnosis, some of which are licensed to Oxford Immunotec Ltd. The interferon-? ELISpot assay the author developed and validated for diagnosis of TB infection was commercialised by an Oxford University spin-out company (T-SPOT.TB®, Oxford Immunotec Ltd) in which the author and Oxford University have minority shares of equity, from which they are entitled to receive royalties and to which he acted as non-executive director from 2003-07. DOI: 10.1183/09031936.00105810
P. Latzin The author's travel expenses to the ERS infant lung function course in Nice 2007 were paid by EcoMedics AG. DOI: 10.1183/09031936.00125510
W-T.N. Lee has received unrestricted research support and travel grants from Pfizer. DOI: 10.1183/09031936.00091610
N. Le Moual The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
R.D. Levy has served on advisory and speaker boards in the past five years for Abbott, Actelion, AstraZeneca, Bayer, Boehringer-Ingelheim, Encysive, GlaxoSmithKline, Lily and Pfizer. DOI: 10.1183/09031936.00091709
D. Leynaud is employed by AstraZeneca in France as Scientific Project Leader. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
F. Li Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
P. Lianes. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
K.C. Lødrup Carlsen has given lectures to the following medical pharmaceutical companies; MSD, GSK and Astra Zeneca, and received public grants for PhD fellows, as well as grants from Kloster Foundation, Research grants in terms of analytes from Phadia as well as from EU-funding (Ga2LEN and MeDALL). DOI: 10.1183/09031936.00026311
D.A. Lomas has received an educational grant from GSK and MSD, fees for speaking from GSK and Novartis and acts as a consultant for GSK, Novartis and Amicus Therapeutics. DOI: 10.1183/09031936.00091709
W. Lou. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
A.A. Lowe received a MITACS operating grant of CAD 30,000.00 to support a postdoctoral fellow; this grant is not related to this study and has no commercial interest with any organization. DOI: 10.1183/09031936.00194809
J.L. Lordan has been a speaker at Pfizer sponsored hospital educational meetings. DOI: 10.1183/09031936.00091610
J. Lötvall. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
V. Lucchini The study partially was funded by CV Therapeutics (Palo Alto, CA, USA) to A. Zaza. DOI: 10.1183/09031936.00066710
F. Lurman is an employee of Sonoma Technology Inc., Petaluma, CA, USA. DOI: 10.1183/09031936.00081410
M Back to top
MJ.K. Marthin. In the present study NIOX® equipment was sponsored by The Lundbeck Foundation, Denmark. DOI: 10.1183/09031936.00032610
S. Marsch. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
B. Massutí. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
M. Mata is an employee of Almirall. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
T.K. Marras has received speakers' fees from Bayer pharmaceuticals, totalling CA$3,000. During the past three years, the author has received payment for speaking at CME events regarding mycobacterial infections (sponsored by Astra-Zeneca, Bayer, Glaxo Smith Kline) and consulting for Novartis regarding omalizumab use. The author has acted as a site-investigator for pharmaceutical industry-sponsored trials in pulmonary fibrosis (Intermune, Actelion) without personal reimbursement. DOI: 10.1183/09031936.00055010
J. Mattson is an employee of Schering Plough Biopharma. DOI: 10.1183/09031936.00047410
C. Mayo. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
T. McClanahan is an employee of Schering Plough Biopharma. DOI: 10.1183/09031936.00047410
D. Menzies has received reimbursement for attending symposia and honoraria for speaking from GSK. DOI: 10.1183/09031936.00062210.
J. Milara. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
M. R. Miller. received reimbursement of travel and lecture fee for presenting a talk on the errors concerning COPD staging in the GOLD classification to a meeting in Denmark on March 13th sponsored by GlaxoSmithKline. DOI: 10.1183/09031936.00135110.
M. Miralpeix is an employee of Almirall. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
M. Miravitlles has received honoraria from AstraZeneca for speaking at intenational and national meetings. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
G. Miserocchi The study partially was funded by CV Therapeutics (Palo Alto, CA, USA) to A. Zaza. DOI: 10.1183/09031936.00066710
D. Montani has relationships with drug companies, including Actelion, Bayer Schering, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188910
D. Montani has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00028310
D. Montani has relationships with drug companies including AB Science, Actelion, Bayer Schering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00033611 and DOI: 10.1183/09031936.00148409 and DOI: 10.1183/09031936.00045710
E.J. Morcillo received a research grant from Almirall. The present work was supported by Almirall S.A., Barcelona, Spain. DOI: 10.1183/09031936.00182009
N. Morrell The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
B. Mueller has received support from BRAHMS to attend meetings and fulfilled speaking engagements and also served as a consultant for and received research support from BRAHMS. DOI: 10.1183/09031936.00121510
B. Mueller received support from Brahms and bioMérieux to attend meetings and fulfilled speaking engagements, consultancy fees and for research projects. DOI: 10.1183/09031936.00035610
G.B. Mwenge. The authors gratefully acknowledge five manufacturers who lent us the autoCPAP devices. DOI: 10.1183/09031936.00139510
N Back to top
R. Nadif The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
K.G. Nielsen. In the present study NIOX® equipment was sponsored by The Lundbeck Foundation, Denmark. DOI: 10.1183/09031936.00032610
S. Nava has received: reimbursement for attending a meeting from Weinmann, Draeger, and Fisher and Paykel; speaking fees not exceeding €1,000 from Resmed, Respironics and GE; and funds for research (free equipment use) from Fisher and Paykel, Resmed and Respironics. DOI: 10.1183/09031936.00003211
H. Nelson was an investigator on the study and therefore his employer, National Jewish Health, received a research grant from Wyeth, now Pfizer Inc. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
M. Noonan presented study results in abstract at ACCP meeting 2008; received funds to recruit patients and do study protocol; received consultation fees of $300 for teleconference. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
O Back to top
J. Ostinelli is employed by AstraZeneca France as medical adviser, and has stocks in excess of 6,000 euro in AstraZeneca. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
P Back to top
P. Paggiaro has received in the last 5 years grants from AstraZeneca, Abbott, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini, MerckSharp&Dohme, Novartis, Shering-Plough,UCB, for lectures and educational activities; and from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Menarini, MerckSharp&Dohme, Novartis for support to institutional research activities and fellowships. DOI: 10.1183/09031936.00023310
F. Palazzo The study partially was funded by CV Therapeutics (Palo Alto, CA, USA) to A. Zaza. DOI: 10.1183/09031936.00066710
S. Palkonen The European Federation of Allergy and Airways Diseases Patients Associations (EFA), which the author works for and receives salary from, received a 2010 sustainable corporate partnership fee for core operations from: Novartis (€55,000), GSK (€55,000), BoehringerIngelheim (€30,000), Chiesi (€30,000), Merck (€30,000), ALK-Abelló (€15,000). Updated list of funders: http://www.efanet.org/about/index.html. EFA sustainable corporate partnership framework: http://www.efanet.org/about/documents/FinalSustainableCorporatePartnershipArrangementsEFAJune09.doc In addition, EFA recieves project funding from Merck: (€15,000) and in-kind support from Chiesi of the value of €10,000, and BI and GSK jointly €7,000. The author is a member of the GSK Health Advisory Board and EFA receives €500/meeting as honorarium and expenses. The author is also representing EFA at the THINK TANK of the EFPIA and Patient Advisory Board of the EuropaBio. There is no financial remuneration. DOI: 10.1183/09031936.00150910
A. Papi has served as a consultant to Chiesi Farmaceutici, GlaxoSmithKline, AstraZeneca, Dompè Farmaceutici, Nycomed; has been paid lecture fees by AstraZeneca, Chiesi Farmaceutici, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck Sharp & Dohme, Novartis, Gentili, Schering-Plough, UCB, Janssen-Cilag; has received grant support from AstraZeneca, Chiesi Farmaceutici, Boehringer Ingelheim, Merck Sharp & Dohme, GlaxoSmithKline, Novartis and Italian Ministry for University and Research. DOI: 10.1183/09031936.00150910
H. Pargger. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
L. Paz-Ares. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
V. Panoutsakopoulou. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
L. Paolozzi At the time the study was conducted, the author was an employee of Wyeth, which was acquired by Pfizer Inc. in October 2009. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
P.D. Paré was the principle investigator of a project that was funded by GSK to develop CT based algorithms to quantify emphysema and airway disease in COPD. With collaborators he received ~ $300,000 to develop and validate these techniques. These funds he have been applied solely to the research to support programmers and technicians. Papers stemming from this work are still being published although the financial arrangement has ended. The author was also PI of a Merck Frosst supported research program to investigate gene expression in the lungs of patients who have COPD. He and collaborators have received ~$200,000 for this project. These funds have supported the technical personnel and expendables involved in the project. Papers stemming from this work are still being published although the financial arrangement has ended. The author has established a new contract with Merck to discover genetic predictors of gene expression in lung tissue. With collaborators he will receive $95,000 US over the next year to do this work. The funds will support personnel and buy supplies. The author sits on an advisory board for Talecris Biotherapeutics who make anti-one antitrypsin replacement therapy. DOI: 10.1183/09031936.00091709
M.R. Partridge has received lecture fees and sponsorship to attend ERS and ATS meetings from GSK, TEVA, AstraZeneca, Chiesi, CIPLA and Dr Reddys Laboratories, and research funding from the Astra Foundation and help with the publication of a history of asthma charities from Novartis. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
I. Pavord has received payments for talks, support for attending educational meetings and financial support for research projects from GSK, Astra Zeneca and from MSD. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
A.J. Peacock has received speakers fees, honoraria to attend advisory boards, travel grants and unrestricted research support from Actelion, Bayer, Lilly, Pfizer, GSK and United Therapeutics, and gave evidence at the Inquest held into the death. DOI: 10.1183/09031936.00091610
G. Piacentini has received reimbursement for attending symposia and fee for speaking from Merck Sharp and Dohme, GlaxoSmithKline, Chiesi Farmaceutici and Valeas. DOI: 10.1183/09031936.00091410
S.G. Pillai is full-time employee of Glaxo SmithKline. DOI: 10.1183/09031936.00091709
I. Pin The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
M.I. Polkey has performed consultancy ( <_1000 for="for" broncus="broncus" and="and" portaero="portaero" received="received" research="research" funding="funding" from="from" portaero.="portaero." em="em">DOI: 10.1183/09031936.00100110
E. Polo. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
R. Porta. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
D.S. Postma has acted as a consultant to AZ, Boehringer Ingelheim, GSK, Nycomed and TEVA. The author received grants from AZ, NYcomed and GSK. The study was funded by Nycomed. DOI: 10.1183/09031936.00204109
D.S. Postma has acted as a consultant to AZ, Boehringer Ingelheim, GSK, Nycomed and Teva. The author has received grants from AZ, GSK and Nycomed. DOI: 10.1183/09031936.00106109
A. Pradas. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
D. Price has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis and Teva. The author or his research team have received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer and Teva. He has spoken for: Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Pfizer and Teva. He has shares in AKL Ltd, which produces phytopharmaceuticals. He is the sole owner of Research in Real Life Ltd. DOI: 10.1183/09031936.00150910
T. Puig. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
S.S. Pullamsetti The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
P. Princi has been funded via a grant from Respironics for web-survey design and hosting. DOI: 10.1183/09031936.00003211
Q Back to top
C. Queralt. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
R Back to top
K.F. Rabe is the President-Elect of the European Respiratory Society. DOI: 10.1183/09031936.00171210
G. Raghu. During the last five years, GR has received research grant from the National Institutes of health,(NIH), Bethesda, MD, USA to conduct NIH sponsored clinical studies and clinical trials for IPF through IPFnet sites; GR has provided services as a consultant for pharmaceutical/biotech industries (Actelion, Amira, Arresto, Amgen, Bayer, Boerhinger-Ingelheim, Centocor/Johnson and Johnson),Celgene, Gilead, GeNO, Stromedix)
G. Raghu. The author's instituition has received research grants to meet patient related costs associated with participation in clinical trials and to support research nurse coordinator/s to conduct clinical trials in accordance with approved Instituition Review Board(IRB) protocols. DOI: 10.1183/09031936.00017711
J. Rakic. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
F. Ratjen has spoken at symposia sponsored by Roche and received 5000 Euro in honoraria. He also received a grant from Roche Canada that covered the medication costs for this study. DOI: 10.1183/09031936.00072510
D. Raible At the time the study was conducted, the authors was an employee of Wyeth, which was acquired by Pfizer Inc. in October 2009. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
F. Ratjen has received a consulting fee of US$1,500 from North American Centre for Continuing Medical Education a consulting fee of US$2,000 US from Inspire Pharmaceuticals and Medical Exchange International, A speaking fee of CHF 4,000.00 from Novartis and a consulting fee of US$2,000 from Pharmaxis. DOI: 10.1183/09031936.00026311
P. Ravn is one of three registered as inventors on patents filed by Hvidovre University Hospital Denmark, disclosing IP-10 as a diagnostic marker for infection with M.tuberculosis.He has been an invited speaker at the 1 and 2 Global Conference on IGRA sponsored by Cellestis. He has also served as consultant on development of clinical guidelines by Cellestis in 2006. DOI: 10.1183/09031936.00114810
N. Reguart. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
J. Reilly. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
R. Reiter is an employee of Ergonex Pharma GmbH, which is undertaking clinical development of terguride for pulmonary arterial hypertension. The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
J. Rello has served on advisory boards for Johnson and Johnson, Pfizer and Wyeth. DOI: 10.1183/09031936.00093010
S.I. Rennard has received fees for consulting from Abbott, Almirall, Altana, Anthera, Aradigm, AstraZeneca, Biolipox, Boehringer-Ingelheim, Centocor, Critical Therapeutics, Defined Health, Easton Associates, GlaxoSmithKline, Johnson & Johnson, MedaCorp, Novartis, Otsuka, Mpex, Paragenix, Pfizer, Pulmatrix, Quintiles, Roche, Sanofi, Schering, TargeGen, Theravance, United Bioscience, Uptake Medical, Vantage Point; the author received lecture fees from American College of Chest Physicians, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Network for Continuing Education, Pfizer, SOMA; SR received fees for attending advisory boards from Abbott, Almirall, Altana, Boehringer-Ingelheim, Dey, GlaxoSmithKline, Novartis, Nycomed, Pfizer; SR received industry grants from Almirall, Astellas, AstraZeneca, Biomarck, Centocor, GlaxoSmithKline, IFSH, Lorillard, Nabi Novartis, Pfizer, Philip Morris, Roche. He has had tobacco industry funding. Specifically, he received funding from the tobacco industry for studies relating to harm reduction and to the impact of tobacco smoke on stem cells. He have also consulted without personal fee on the topic of harm reduction. He received funding from RJ Reynolds to evaluate the effect of a harm reduction product in normal smokers (1996) and in subjects with chronic bronchitis (1999) and to assess the effect of smoking cessation on lower respiratory tract inflammation (2000); he participated in a Philip Morris multi-center study to assess biomarkers of smoke exposure (2002); he received funding for a clinical trial from the Institute for Science and Health (2005), which receives support from the tobacco industry, to evaluate biomarkers in exhaled breath associated with smoking cessation and reduction. The Instutite for Science and Health study was supplemented with funding from Lorrilard and RJ Reynolds; he consulted with RJ Reynolds on the topic of harm reduction until 2007, but did not receive personal remuneration for this; I have received a grant from the Philip Morris External Research Program (2005) to assess the impact of cigarette smoking on circulating stem cells in the mouse. There are no active tobacco-industry funded projects. DOI: 10.1183/09031936.00091709
I. Rivolta The study partially was funded by CV Therapeutics (Palo Alto, CA, USA) to A. Zaza. DOI: 10.1183/09031936.00066710
M. Rocchetti The study partially was funded by CV Therapeutics (Palo Alto, CA, USA) to A. Zaza. DOI: 10.1183/09031936.00066710
N. Roche In the past 5 years, the author has received fees for attending scientific meetings, speaking, organising research, consulting or research from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Hoffman la Roche, Mundipharma, MEDA, Novartis, Nycomed/Altana, Pfizer, TEVA. DOI: 10.1183/09031936.00150910
R. Rosell. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
D. Rodenstein. The authors gratefully acknowledge five manufacturers who lent us the autoCPAP devices. DOI: 10.1183/09031936.00139510
M. Ruhwald has received a travel grant by Cellestis to attend a congress in 2009. DOI: 10.1183/09031936.00115110
S Back to top
I. Saarikko is an employee of Genolyze, Turku, Finland. DOI: 10.1183/09031936.00043310
P. Salinas. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
K. Samitas was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
J.M. Sánchez. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
R.T. Schermuly The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
R.T. Schermuly's travel to the ERS congress in 2008 in Berlin and a speaking fee were funded by LungRX. He has received honoraria from Actelion, Encysive, Pfizer, Bayer Schering and Solvay, and research grant support from Bayer Schering, Actelion, Encysive, Pfizer, Solvay and Ergonex. DOI: 10.1183/09031936.00043310
P. Schuetz has received support from BRAHMS to attend meetings and fulfilled speaking engagements. DOI: 10.1183/09031936.00121510
P. Schuetz received support from BRAHMS to attend meetings and fulfilled speaking engagements. DOI: 10.1183/09031936.00035610
W. Seeger The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
R. Segal is an employee of Discovery Laboratories, Inc. and currently holds both direct shares (8,635) and restricted shares (3,930) in Discovery Laboratories, Inc. These have been acquired over the past 10 years of employment at the Company, both as Company matching contributions to the 401k retirement plan or as a component of my compensation package. The author has also, as part of my compensation package, been granted annual "Incentive" and "Non-qualified" stock options at various "strike prices" and vesting periods (the total of which is 66,734) over the past 10 years. DOI: 10.1183/09031936.00020810
M. Semitekolou. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
L. Sequist. The author's institution has received research funding to support research staff from Astra Zeneca, Genentech and Boehringer Ingelheim. The author did not personally receive any salary support. The author has received a consulting fee from Genentech. Boehringer Ingelheim provided financial support for the assistance of Ogilvy Healthworld Medical Education. DOI: 10.1183/09031936.00179409
P.L. Shah has received research funding from Asthmatx, Olympus, Broncus and PneumRx. DOI: 10.1183/09031936.00100110
N.M. Siafakas is the Past President of the European Respiratory Society. DOI: 10.1183/09031936.00171210
M. Siegemund. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
E.K. Silverman has received grant support for two studies of COPD genetics and consulting fees from GlaxoSmithKline. He has received consulting fees from Astra-Zeneca. He has also received honoraria from Wyeth, Bayer, GlaxoSmithKline, and Astra-Zeneca. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
E.K. Silverman has received grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics. He has received consulting fees from Astra-Zeneca. He has also received honoraria from Wyeth, Bayer, GlaxoSmithKline, and Astra-Zeneca. DOI: 10.1183/09031936.00091709
A. Simonds has received research grants from ResMed Ltd and Breas Medical. DOI: 10.1183/09031936.00020211
G. Simonneau has relationships with drug companies, including Actelion, Bayer Schering, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188910
G. Simonneau reports serving as a consultatnt for Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli-Lilly, Pfizer, United Therapeutics and Novartis, and has received lecture fees and grants from Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli-Lilly and Pfizer. DOI: 10.1183/09031936.00194810
G. Simonneau reports serving as a consultant for Actelion Pharmaceuticals Ltd, BayerSchering, GlaxoSmithKline, Eli-Lilly, Pfizer, United Therapeutics and Novartis, and has received lecture fees and grants from Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli-Lilly and Pfizer. DOI: 10.1183/09031936.00028310
V. Siroux The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
O. Sitbon has relationships with drug companies, including Actelion, Bayer Schering, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188910
L.A.M. Smit The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
I. Smith has received fees for speaking for Cephalon, and has a funded research project from grants from Resmed and B and D medical. DOI: 10.1183/09031936.00099710
N. Smyrnios. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
R. Souza has received lecture and consultancy fees from Actelion, Pfizer and GlaxoSmithKline. DOI: 10.1183/09031936.00188910 and DOI: 10.1183/09031936.00028310
D.P. Steinfort has received reimbursement to attend a symposium; he received payment of travel costs by Olympus, Australia, to attend a training course. DOI: 10.1183/09031936.00075310
G. Simonneau reports serving as a consultant for Actelion Pharmaceuticals Ltd, BayerSchering, GlaxoSmithKline, Eli-Lilly, Pfizer, United Therapeutics and Novartis, and has received lecture fees and grants from Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli-Lilly and Pfizer. DOI: 10.1183/09031936.00045710
S. Sonnappa. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
A.G. Stewart has received grant support and been re-imbursed conference attendance costs by GSK (UK). DOI: 10.1183/09031936.00008109
R.A. Stockley has received a grant from Talecris Biotherapeutics. The present study was supported by Talecris Biotherapeutics. DOI: 10.1183/09031936.00033710
D. Stolz was supported by grants from the Swiss National Foundation, the Liechtenstein Foundation and the "Freiwillige Akademische Gesellschaft Basel". Additional funding was granted by the Clinic of Pulmonary Medicine, University Hospital Basel, Switzerland. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
B.A. Stuck has received grants exceeding 5,000 euros from Aspire Medical Fisher-Payket Healthcare, Celon AG Medical instruments and Sutter Medizintechnik. He has received fees for speaking exceeding 1,500 euros from Celon AG Medical Instrument Sutter Medizintechnik ung Neuwirth Medical Products. He has furthermore received consulting fees from Sutter Medizintechnik and Passion for Life Health Care exceeding 1,500 euros. DOI: 10.1183/09031936.00099710
P. Subbarao. A grant from Roche Canada covered the medication costs for this study. DOI: 10.1183/09031936.00072510
T Back to top
M. Tamm. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
M. Tarón. In the present study the TargeT trial was sponsored by Roche Farma, S.A. (Spain). DOI: 10.1183/09031936.00195609
N.H.T. ten Hacken The study was funded by Nycomed. DOI: 10.1183/09031936.00204109
N. Thakkar. The study was funded by Brahms (Hennigsdorf, Germany) and funding was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis and interpretation of the data or in the preparation, review and approval of the manuscript. DOI: 10.1183/09031936.00023810
K. Triantaphyllopoulos Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
S. Tsuiki has received grants from Japan Society for Promotion of Science (20592422, 21406033). DOI: 10.1183/09031936.00194809
V Back to top
R. Valenta is consultant for Biomay, Vienna, Austria and has received research grants from Biomay. DOI: 10.1183/09031936.00149109
D. Valeyre has been an investigator and sometimes a member of the steering committees in the following trials: INSPIRE (Intermune), CAPACITY (Intermune), BUILD I and III (Actelion), BIBF (Bohringer Ingelheim) and Centocor. Travel to ATS, ERS and CPLF could be funded for some of them by GlaxoSmithKline, Astra Zeneca and Bohringer. DOI: 10.1183/09031936.00086410
M.R. Van Scott was a co-investigator on a grant to East Carolina University from the PhillipMorris Foundation from 2005 to 2008. The funds were awarded to study the effects of automobile exhaust on myocardial infarctions. DOI: 10.1183/09031936.00047410
G.M. Verleden receives an annual research grant from GlaxoSmithKline (GSK) Belgium of 10.000 EUR, and is holder of the GlaxoSmithKline Chair in Respiratory Pharmacology at the Katholieke Universiteit Leuven, Leuven, Belgium. DOI: 10.1183/09031936.00068310
R. Vermeulen The study was partially funded by Merck, Sharpe and Dohme. DOI: 10.1183/09031936.00057610
T. Verse has received reimbursement for attending a symposium, fees for speaking, funds for research, and fees for consulting from the following companies: Celon AG (Germany), Aspire Medical (USA), Apneon Medical (USA), Resmed GmbH (Germany) and MPV Truma GmbH (Germany). DOI: 10.1183/09031936.00099710
J. Vestbo received 267,000 Dkr from Scandinavian Tobacco Company in 1985 in support for a research project on exposure to cement dust, smoking, and respiratory disease. DOI: 10.1183/09031936.00043710
J.C. Virchow has served on the speakers' bureau for Asche-Chiesi, AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer-Ingelheim, Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck, MSD, Munidpharma, Novartis, Nycomed/Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, TEVA, UCB/Schwarz-Pharma, Zydus/Cadila and has participated in advisory boards for Asche-Chiesi, Avontec, Boehringer-Ingelheim, Essex/Schering-Plough, GSK, Janssen-Cilag, MSD, Mundipharma, Novartis, Revotar, Sandoz-Hexal and UCB/Schwarz-Pharma. DOI: 10.1183/09031936.00150910
S. Vittorakis. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
C. Vogelmeier. The authors thank Brian Jepson, from Fishawack Communications Ltd, Abingdon, UK, who provided medical writing support funded by AstraZeneca. The operational conduct of the study including physician recruitment, patient interview, data collection and management was co-ordinated by Mapi Group, Lyon, France, a contract research organisation; the statistical analysis was performed by Sami Boussetta (Mapi Group). The study was funded by AstraZeneca. DOI: 10.1183/09031936.00051110
J.M. Vonk The study was funded by Nycomed. DOI: 10.1183/09031936.00204109
A. Vonk-Noordegraaf has received lecture fees from Actelion, Bayer, GlaxoSmithKline and Pfizer and has served on steering committees for Actelion, Bayer and Pfizer. DOI: 10.1183/09031936.00145910
W Back to top
J. Wadjula At the time the study was conducted, JW was an employee of Wyeth, which was acquired by Pfizer Inc. in October 2009. JW holds shares of Pfizer stock. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
D. Wagner has received a speaking fee of €500 from Cellestis in 2008 at a symposium. DOI: 10.1183/09031936.00115110
G. Washko. Funding for this study was provided by GlaxoSmithKline. DOI: 10.1183/09031936.00173009
N. Weissmann The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
G. Wennergren has received fees for lectures from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme and Novartis. He does not hold any stocks or shares in any pharmaceutical company. DOI: 10.1183/09031936.00091410
N. Westerhof received euro 250 for a talk on pulmonary hypertension in 2007. DOI: 10.1183/09031936.00100510
D. Whyatt. The present study was supported by Smiths Medical. DOI: 10.1183/09031936.00181910
J.G. Widdicombe has a share interest in Pneumoflex Systems, which devises methods that can be used in testing the risk of aspiration in stoke patients. However our letter compliments the authors (Ward et al.) for describing other methods, and does not make a value judgement on their relative merits. DOI: 10.1183/09031936.00083310
A.M. Wood. The present study was supported by Talecris Biotherapeutics. DOI: 10.1183/09031936.00033710
X Back to top
G. Xanthou. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
Y Back to top
X. Yang The study was partially funded by an unrestricted research grant from Ergonex Pharma GmbH, Appenzell, Switzerland. DOI: 10.1183/09031936.00126010
Z Back to top
G. Zalcman received fees for speaking and consulting from Roche France and travel to ASCO meeting 2009 was funded by Merck Serono France. Boehringer Ingelheim provided financial support for the assistance of Ogilvy Healthworld Medical Education. DOI: 10.1183/09031936.00179409
C. Zang At the time the study was conducted, the author was an employee of Wyeth, which was acquired by Pfizer Inc. in October 2009. This study was sponsored by Wyeth, which was acquired by Pfizer Inc. in October 2009. Wyeth was responsible for the collection and analysis of data. The authors and the sponsor were involved with study design, interpretation of data, manuscript preparation and decision to publish. All statistical analyses were done by the biostatistical group at Wyeth. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the report for publication. Medical writing support for this manuscript was provided by C. Bradley (Precise Publications LLC, Pluckemin, NJ, USA) and was funded by Wyeth. DOI: 10.1183/09031936.00063510
A. Zaza The study was partially funded by CV Therapeutics (Palo Alto, CA, USA) to the author. DOI: 10.1183/09031936.00066710
E. Zervas has received fees from pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Nycomed, Novartis and UCB, for speaking at meetings and participating in advisory board meetings. He has received support for research from several pharmaceutical companies, including GlaxoSmithKline. The present study was funded by an unrestricted research grant from GlaxoSmithKline (GSK Greece). DOI: 10.1183/09031936.00017810
M. Zhang Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
X. Zhou Pfizer Pharmaceuticals UK and Bristol-Myers Squibb provided materials for the study. DOI: 10.1183/09031936.00021110
G Zhu is an employee of GlaxoSmithKline. DOI: 10.1183/09031936.00091709
Volume 38, 2011
A Back to top
R.E. Aarnoutse. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
L. Adamek is an employee of GlaxoSmithKline. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
T. Ajayi has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
J.W.C. Alffenaar. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
C. Amos is a paid employee of Novartis, the sponsor of the study, and holds shares in Novartis. DOI: 10.1183/09031936.00191810
I.K. Anderson is an employee of MedImmune and has shares in Astra Zeneca in excess of $5000. DOI: 10.1183/09031936.00076210
S. Andreas Fees for speaking by Heinen & Löwenstein, Respironics. DOI: 10.1183/09031936.00095111
K. Andries is a Tibotec employee and holds Johnson and Johnson stock in excess of £5,000. DOI: 10.1183/09031936.00005610
J.M. Anto. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
A. Antón Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
A. Anzueto has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies, including Astra-Zeneca, Boehringer Ingelheim, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline and Sanofi-Aventis. The author has been a consultant for Astra-Zeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Sanofi-Aventis and Bayer-Schering Pharma. He has been the principal investigator for research grants and the University of Texas Heath Science Center at San Antonio and was paid for participating in multi-center clinical trials sponsored by GlaxoSmithKline, Bayer-Schering Pharma, BARD, Lilly and the National Institutes of Health. DOI: 10.1183/09031936.00028711
A. Anzueto has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: Astra-Zeneca, Boehringer Ingelheim, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline, Sanofi-Aventis. The author has been a consultant for Astra-Zeneca, Boehringer Ingelheim; Pfizer, GlaxoSmithKline, Sanofi-Aventis and Bayer-Schering Pharma. The author has also been the principal investigator for research grants and the University of Texas Heath Science Center at San Antonio, and was paid for participating in multi-center clinical trials sponsored by: GlaxoSmithKline, Bayer-Schering Pharma, BARD, Lilly, National Institutes of Health. DOI: 10.1183/09031936.00141110
G. Arcidiacono. Free supplies of PAIPO were provided for the study by Echos Srl (Milan, Italy). DOI: 10.1183/09031936.00109610
S. Armoni has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
B.M. Assael has in the past 3 yrs received honoraria and travel expenses for participation in expert panels and/or board memberships of Gilead and Inspire. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
R. Atun is an employee of The Global Fund to Fight AIDS, TB and Malaria (Geneva, Switzerland). The organisation works as a partnership between governments, civil society and the private sector. DOI: 10.1183/09031936.00041211
M. Aviram. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
P. Aurora. The study was funded, in part, by Smiths Medical. DOI: 10.1183/09031936.00164910
B Back to top
P.S. Bakke. has received lecture fees totalling 1,000 Euros from GlaxoSmthKline and 1,000 Euros from AstraZeneca the last 5 years. P.S. Bakke is a principle investigator of a study performed by GlaxoSmthKline. DOI: 10.1183/09031936.00193809
E.M. Bakker. Roche Netherlands B.V. supported the PhD research of E.M. Bakker with an unrestricted research grant. In addition, the PhD studies of E.M. Bakker were supported by a grant from the “Stichting Vrienden van het Sophia” (Friends of Sophia Children’s Hospital foundation). Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
N. Banik is an employee of GlaxoSmithKline GmbH & Co. KG, Germany. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
E. Baraldi has been received travel grants for the ERS annual meeting and speakers fees from GlaxoSmithKline, Merck Sharp & Dohme, Abbott, Chiesi and Valeas. DOI: 10.1183/09031936.00030711
F. Barbé. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
B.P. Barna. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
X. Basagaña. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
C.M. Bastardo. The study was funded, in part, by Smiths Medical. DOI: 10.1183/09031936.00164910
E.D. Bateman has received honoraria from Nycomed for speaker activities and membership of advisory boards, and his institution has received payments for his participation in clinical trials sponsored by Nycomed. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710.
E.D. Bateman. The author's study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
J. Bayona has received fees for acting as consultant for an Otsuka Pharmaceutical trial in Peru. J. Bayona declared that in the work performed for Otsuka Pharmaceutical Co Ltd. he abstained from discussions relating to the recommendations on drug regimens. DOI: 10.1183/09031936.00073611
F. de Benedictis has received research support and consulting fees from GlaxoSmithKline, Merck Sharp & Dohme, Chiesi Fermaceutici and UCB. DOI: 10.1183/09031936.00030711
A. Bergamaschi. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
D. Bilton has received £2,000 total for consultancy work regarding design of studies in cystic fibrosis and non-cystic fibrosis bronchiectasis. D. Bilton has received fees for chairing an advisory board for Pharmaxis. The institution to which D. Bilton is affiliated received standard clinical trial support from Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
H. Blau. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
R.M. du Bois has served as a consultant, study steering committee member, or chairman of a steering committee for Actelion, Boehringer Ingelheim, Bayer, Genzyme, InterMune Inc. and MondoBiotech. DOI: 10.1183/09031936.00068611
J.F. Bonfanti is a Janssen-Cilag employee (a Johnson and Johnson company). DOI: 10.1183/09031936.00005610
V. Bonneterre. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
M. Bonsignore. Travel to the ERS congress was funded by Weinmann and Boehringer. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
P. Borger. The study was supported by the Novartis Research Foundation. HDM extract was gifted by ALK-Abello, Hørsholm, Denmark. DOI: 10.1183/09031936.00068010
I.S.T. Bos. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
A. Bossink has received €1,000 for consultation from Oxford Immunotec Ltd. DOI:: 10.1183/09031936.00071111
A.W.J. Bossink received €1,000 as a fee for speaking at a Biomerieux meeting. DOI: 10.1183/09031936.00170010
A. Boudier. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
L-P. Boulet has served on advisory boards for AZ, GSK, Merck Frosst and Novartis, and received lecture fees from 3M, AZ, GSK, Merck Frosst and Novartis, sponsorship for investigator-generated research from AZ, GSK, Merck Frosst and Schering, research funding for participating in multicentre studies from Altair, Asmacure, AZ, BI, genentech, GSK, Pharmaxis, Schering and Wyeth, and support for the production of educational materials from AZ, GSK and Merck Frosst. The author is an adviser for the Conseil du Médicament du Québec and AETVIS, and a member of the Quebec Workmen Compensation Board Respiratory Committee. He is Chair of the Canadian Thoracic Society Guidelines Committee and Chair of GINA Guidelines Dissemination and Implementation Committee, and holder of the Laval University Chair on the Knowledge Translation (KT Canada), supported by CIHR. DOI: 10.1183/09031936.00114511
H.J.L. Brackel has received fees for consulting and for speaking from GlaxoSmithKline Pharma Europe. DOI:: 10.1183/09031936.00173710
E. Brambilla. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
M. Brauner. is a consultant for Actelion, Intermune and Johnson & Johnson. DOI: 10.1183/09031936.00187410
D. Bredenbröker is an employee of Nycomed GmbH. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710
P.Y. Brichon. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
M. Brose is an employee of Nycomed GmbH. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710
V. Brusasco received €3,800 in 2006 for serving on an advisory board for Altana; €3,500 in 2008 from Lofarma for consultancies; €8,325 in 2006, €2,500 in 2007, €6,600 in 2008 and €3,290 in 2010 for speaking at conferences sponsored by Boehringer Ingelheim; €2,200 from Boehringer Ingelheim for consultancy in 2009; USD $1,500 in 2009 and USD $1,000 in 2010 from Deep Breeze for consultancy; €3,000 in 2009 and €3,100 in 2010 from Dompé for consultancy; £960 in 2006 and €1,200 in 2008 from GSK for participating in advisory boards; €1,000 for speaking at a symposium sponsored by GSK; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board; €1,500 from Menarini for consultancy in 2008; €3,000 from Novartis for consultancy and meeting organization; €3,000 in 2010 from Nycomed for consultancy. V. Brusasco's institution received €20,000 in 2006 as unrestricted research grant from Boehringer Ingelheim as an unrestricted research grant from Boehringer Ingelheim, and participated in several multicentre clinical trial financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00055711
G. Brusselle has, within the past 5 yrs, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, MerckSharp&Dohme, Novartis, Pfizer and UCB; he is a member of advisory boards for AstraZeneca, GlaxoSmithKline, Novartis and UCB. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
G.G. Brusselle has, within the last 5 years, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, MSD, Novartis, Pfizer and UCB; the author is a member of advisory boards for AstraZeneca, GlaxoSmithKline and Novartis. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
R. Buhl has received reimbursement for attending scientific conferences, and/or fees for speaking and/or consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Nycomed and Pfizer. The Pulmonary Department at Mainz University Hospital received financial compensation for services performed during participation in clinical trials organised by various pharmaceutical companies. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
R. Buhl has received reimbursement for attending scientific conferences, and/or fees for speaking and/or consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Nycomed and Pfizer. The Pulmonary Department at Mainz University Hospital received financial compensation for services performed during participation in clinical trials organised by various pharmaceutical companies. The present study was sponsored by Novartis. DOI: 10.1183/09031936.00191810
C. Bullen's salary is paid by The University of Auckland and his research is supported by grants from the New Zealand Health Research Council (HRC), the University of Auckland and the NZ Heart Foundation. He has previously undertaken tobacco control research supported by the New Zealand Ministry of Health, and by Niconovum, (Helsingborg, Sweden), prior to the purchase of this company by RJ Reynolds in December 2009. Work on these studies was completed in May 2007, and the results were published in Nicotine & Tobacco Research in June 2009 and in Addiction in July 2010. C. Bullen is currently an investigator on a study involving reduced nicotine cigarettes in which the products were purchased by the University of Auckland from Vector Group Ltd (Miami, FL, USA). The author has no other connection with Vector Group Ltd. C. Bullen has previously undertaken research on electronic nicotine delivery systems (ENDS) funded by HealthNZ, in which the study products were supplied by Ruyan (Hong Kong, China); and he is the principal investigator on an HRC-funded efficacy trial of ENDS that will use products provided by a New Zealand-based ENDS retailer. DOI: 10.1183/09031936.00066011
A. Bush. The study was funded, in part, by Smiths Medical. DOI: 10.1183/09031936.00164910
C Back to top
P.M.A. Calverley has advised GSK, Nycomed, Boehringer Ingelheim and Roche about study design and conduct. The author has sat on advisory boards convened by these companies and also AstraZeneca, Bayer and Novartis. He has spoken at meetings supported in whole or in part by GSK, Nycomed, AstraZeneca and Boehringer Ingelheim. He has acted as an expert witness for Forest/Nycomed. He has no shares in any company or any connections with the tobacco industry. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710
D. Campagna. Free supplies of PAIPO were provided for the study by Echos Srl (Milan, Italy). DOI: 10.1183/09031936.00109610
P. Caponnetto. Free supplies of PAIPO were provided for the study by Echos Srl (Milan, Italy). DOI: 10.1183/09031936.00109610
K.L. Carlsen has in the last five years given lectures to the following medical pharmaceutical companies: MSD, GSK and Astra Zeneca. He has received public grants for PhD fellows, grants from the Kloster Foundation, and research grants in terms of analytes from Phadia as well as from EU-funding (Ga2LEN and MeDALL). DOI: 10.1183/09031936.00030711
L.M.S. Carlsson. has received a research grant from Ethicon. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
B. Charlton is the Medical Director of and holds stock options in Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
H. Chen has received consultancy fees from Genentech and United Therapeutics, and has received $100K in grant funding from Pfizer for investigator-initiated research. DOI:: 10.1183/09031936.00161410
F. Cibella. Free supplies of PAIPO were provided for the study by Echos Srl (Milan, Italy). DOI: 10.1183/09031936.00109610
C. Cillóniz Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
E. Clini has received an unrestricted research grant from Boheringer Ingelheim Italia and MPR Research (I). DOI: 10.1183/09031936.00039011
E.S. Cohen is an employee within the MedImmune AstraZeneca Group and owns share in excess of $2000. DOI: 10.1183/09031936.00076210
M. Cohen has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
M. Cohen-Cymberknoh has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
M. Colonna. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
P. Comba has been a consultant to the Italian Courts (i.e. the author has written documents requested by the Judge or by the Prosecutor, not by the defendants nor by the plaintiffs) in a number of trials concerning asbestos-related disease associated with occupational and environmental exposures. DOI: 10.1183/09031936.00084611
R. Condliffe has received honoraria for lecturing from Actelion and GSK. The author has also received funding to attend conferences from Pfizer, Actelion and GSK, and has sat on advisory boards for Bayer-Schering. DOI:: 10.1183/09031936.00027911
P. Cooper has taken part in a Pharmaxis advisory committee meeting in 2011 and holds Pharmaxis shares worth less than $6,000 in total. The institution to which P. Cooper is affiliated received standard clinical trial support from Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
V. Cottin has participated as investigator to a clinical trial, is a member of Advisory Board, has given lectures, and has been reimbursed for attending a symposium by Intermune Inc. DOI: 10.1183/09031936.00039011
A.J. Coyle is an employee of and has shares in Astra Zeneca/Medimmune in excess of $5,000. DOI: 10.1183/09031936.00076210
D Back to top
R.W. Dal Negro. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
C.L. Daley has received compensation from Otsuka as Chair of the Data Monitoring Committee for clinical trials of a new antituberculosis drug. C.L Daley declared that in the work performed for Otsuka Pharmaceutical Co Ltd. he abstained from discussions relating to the recommendations on drug regimens. DOI: 10.1183/09031936.00073611
H. Dalrymple. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
N. Davie is an employee of Pfizer Limited and receives an annual compensation package made up of salary and Pfizer stock. DOI: 10.1183/09031936.00167010
N.H.E. Davis is an employee of MedImmune and has share options in Astra Zeneca/Medimmune in excess of $2000. DOI: 10.1183/09031936.00076210
W. DeBacker. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
M. Decramer has been part of advisory boards for Boehringer, Pfizer, GSK, Nycomed and Altana. He has performed consulting work for Boehringer, Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than 10,000 Euro per annum. He received a research grant of 45,000 Euro/year from AstraZeneca. DOI: 10.1183/09031936.00093511
M. Decramer has been part of advisory boards for Boehringer-Pfizer, GSK, Nycomed and Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than 10,000 euro per annum. He received a research grant of 45,000 euro/year from AstraZeneca. DOI:: 10.1183/09031936.00079111 and DOI: 10.1183/09031936.00097111
M. Decramer has been part of Advisory Boards for Boehringer-Pfizer, GSK, Nycomed and Altana. The author has performed consulting work for Boehringer-Pfizer and GSK. The author has also received lecture fees from these companies. All of the above amounted to less than €10,000 per year. He received a research grant of €45,000 per year from AstraZeneca. DOI: 10.1183/09031936.00187110
B.M. de Jong. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
B.G.J. Dekkers. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
N.H. de Klerk. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
L. Delling. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
T. De Marco has received fees for speaking and consulting from Actelion, Gilead, United Therapeutics, and research funding from United Therapeutics and Novartis. DOI:: 10.1183/09031936.00161410
M. De Meulder is a Johnson and Johnson employee. DOI: 10.1183/09031936.00005610
C.P. Denton has acted as a consultant and received research grants from Actelion pharmaceuticals, Encysive pharmaceuticals and Pfizer Inc. DOI: 10.1183/09031936.00010910
K. Dheda has undertaken consulting work for and received research grants from Cellestis and Oxford Immunotec. DOI::10.1183/09031936.00071111
G. Dhillon The analysis was funded by W.R. Grace & Co., but the data upon which the analyses were based were independently collected by the Agency for Toxic Substances and Disease Registry (ATSDR), an agency of the US Department of Health and Human Services. DOI: 10.1183/09031936.00050210
R. Diel has received fees for speaking at symposia sponsored by Oxford Immunotec and Cellestis. DOI::10.1183/09031936.00071111
R. Diel has received fees for speaking at symposia sponsored by Oxford Immunotec and Cellestis. DOI: 10.1183/09031936.00099111
C. Disdier has received fees from Novartis: for lectures, for one Advisory Board meeting last year for less than €2,000, and travel to the Spanish RS congress. C. Disdier has participated as a chairman in symposiums organised by Esteve (€1,200), GSK (€1,200) and for teaching advanced bronchoscopy techniques by SIM-Pentax (€2,000) in the last 2 years. Travel to the ERS Congress was funded by Chiesi. The present study was sponsored by Novartis. DOI: 10.1183/09031936.00191810
K. Donnelly has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
Y. Dotan. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
T.M. Doyle. The present study was supported by a grant from GlaxoSmithKline-CIRF. DOI:: 10.1183/09031936.00133210
L.J. Dunn has received reimbursement from the ACCP 2010 for presentation of the Intensity Study. The author also received research funds as Principal Investigator of the Intensity Study. The present study was sponsored by Novartis. DOI: 10.1183/09031936.00191810
E Back to top
S. Eberle is an employee of GlaxoSmithKline (Munich, Germany). CAPNETZ received funding from GlaxoSmithKline for this study. DOI: 10.1183/09031936.00133510
W. Eduard. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
O. Eickelberg has received: consultancy fees and funds for research from Hoffmann La Roche; lecture fees from Bayer, AstraZeneca and Böhringer Ingelheim; and funds for research from Ergonex Pharma. DOI:: 10.1183/09031936.00103211
G.L. Elfring has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
R. Ellis. The present study was supported by a grant from GlaxoSmithKline-CIRF. DOI:: 10.1183/09031936.00133210
P.L. Enright has received during the past 5 years about $50,000 in consulting fees from Schering for reviewing the quality of spirometry tests done for a study of mometasone for COPD and about $50,000 from Pfizer for reviewing the quality of spirometry tests for a study of varenicline for smoking cessation in patients with COPD. His travel expenses and registration fees were paid by the Federation International Respiratory Societies (FIRS) to meetings in Hong Kong, Beijing, Guangzhou, and Kyoto to serve on the writing group which provided recommendations for spirometry for the detection of clinically important COPD in developing countries (but the recommendations were ignored). He has a deep personal conviction that when making medical decisions, the interests of patients should be given more weight than the financial interests of pharmaceutical companies. DOI: 10.1183/09031936.00063111 and DOI: 10.1183/09031936.00063211
G.S. Eriksson is employed by AstraZeneca and own shares in AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
P. Escourrou. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
J-F. Etter's salary is paid by the University of Geneva. He has served as an expert consultant for the World Health Organization regarding electronic nicotine delivery systems. He consulted for Pfizer, a manufacturer of smoking cessation medications, in 2006–2007 (on the Swiss varenicline advisory board), and received medications for a clinical trial from Pfizer in 2006. He has no competing interests since then. DOI: 10.1183/09031936.00066011
S. Ewig has received a reimbursement for attending a symposium on pneumococcal vaccine funded by Pfizer. He has also received fees from Pfizer SE for speaking. DOI: 10.1183/09031936.00125910
S. Ewig has received fees for research and speaking from Brahms (now Thermofisher). DOI: 10.1183/09031936.00039411
F Back to top
L. Fabbri reports having served as a consultant to Nycomed, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer; having been paid lecture fees by Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, Roche and Pfizer, having received grant support from Nycomed, Abbott, AstraZeneca, Boehringer Ingelheim, Menarini, Novartis , Schering Plough, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Italian Ministry of Health, and Italian Ministry for University and Research. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710
A.K.M. Fell. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
M. Ferrer. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
I. Fietze. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
J.M. FitzGerald is a member of the GINA Executive and also Chair of its Science Committee. The author is also a member of the Canadian Thoracic Society Asthma Committee, which is responsible for Canadian Asthma guidelines. He has received fees for lectures and advisory committees from AZ, GSK and Merck (all >$10,000), Nycomed, BI and Novartis (all < $10,000). He has received research grants from GSK, BI, Wyeth, Genentech, Topigen, the Canadian Institute for Health Research, Medimmune, Pharmaxis, Novartis and AllerGen NCE (all >$10,000). DOI: 10.1183/09031936.00114511
G. Flik. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
H. Foster has had expenses covered by Actelion to attend an annual conference on pulmonary hypertension; has been paid an honorarium to speak at an annual nurses meeting by Actelion. DOI: 10.1183/09031936.00053510
C. Fournier has received a fee from Olympus France for organising an education session in Lille on EBUS-TBNA. DOI: 10.1183/09031936.00182210
H. Fox is Chief Medical Officer of and holds stock options in Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
C.R. Frei is supported by a National Institutes of Health Grant KL2 RR025766, has received salary support from The University of Texas at Austin College of Pharmacy, has received research grant support, served as an advisor, and served as a consultant from Ortho-McNeil Janssen, and has received research grant support from AstraZeneca and Elan Pharmaceuticals. DOI: 10.1183/09031936.00141110
L. Freyder. The analysis was funded by W.R. Grace & Co., but the data upon which the analyses were based were independently collected by the Agency for Toxic Substances and Disease Registry (ATSDR), an agency of the US Department of Health and Human Services. DOI: 10.1183/09031936.00050210
G Back to top
L. Gaitini. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
C.G. Gallagher. The institution to which C.G. Gallagher is affiliated received standard clinical trial support from Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
J. Garcia-Aymerich. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
P.G. Gibson has participated in the development of educational material and as a speaker in educational symposia sponsored by GlaxoSmithKline, Pharmaxis, Novartis, AstraZeneca, and Boehringer Ingelheim. DOI:: 10.1183/09031936.00139810 and DOI: 10.1183/09031936.00170110
P.G. Gibson has received funds for preparing educational material, speaking in educational symposia, and related travel from GlaxoSmithKline, Pharmaxis, Novartis, AstraZeneca and Boerhinger Ingelheim. DOI: 10.1183/09031936.00076011
H. Glindmeyer. The analysis was funded by W.R. Grace & Co., but the data upon which the analyses were based were independently collected by the Agency for Toxic Substances and Disease Registry (ATSDR), an agency of the US Department of Health and Human Services. DOI: 10.1183/09031936.00050210
U.M Goehring is an employee of Nycomed GmbH. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710
D. Goletti has received grants from Cellestis to go to a scientific meeting in Croatia in 2009 and from ADA as a partial travel reimbursement to go to the ATS meeting in Canada in 2008. D. Goletti's institution received a grant from Oxford Immunotec, as part of the salary for a laboratory technician in 2007. DOI: 10.1183/09031936.00099111
T. Golibroda. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
R. Gosens has received lecture fees and research funding from Boehringer Ingelheim Pharma GmbH & Co. KG. The study was supported, in part, by Boehringer Ingelheim. DOI: 10.1183/09031936.00146610
L. Grote. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
R.R. Grunstein. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
P. Guillem. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
B. Gushulak is affiliated with Migration Health Consultants, Inc. B. Gushulak and Migration Health Consultants, Inc. received no funding or support from any source in connection with this project. DOI: 10.1183/09031936.00196610
H Back to top
T. Haahtela has received speakers fees from Abdi Ibrahim, Astellas, AstraZeneca, Leiras, MSD, and ALK-Abello, and is on the advisory boards of MSD and Orion. DOI: 10.1183/09031936.00114511
A.J. Halayko has received an educational grant from Merck Frosst and has received competitive funding for investigator-initiated research from Merck Frosst and from GlaxoSmithKline. DOI: 10.1183/09031936.00125010
T. Harrison has received honoraria from AstraZeneca for advisory work and presentations. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
P.H. Hart. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
S.G. Haworth has received an educational grant from Actelion Pharmaceuticals, consultation fees from GSK, Pfizer and Actelion, and reimbursement for travelling to speak at meetings from Bayer. DOI: 10.1183/09031936.00167010
M. Hayot participates in the scientific committee of Fontavie, a pulmonary rehabilitation institution. DOI: 10.1183/09031936.00167110
J. Hedner. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
J. Hedner. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
M. Henley is a paid employee of Novartis, the sponsor of the study. DOI: 10.1183/09031936.00191810
P.S. Hiemstra The Dept of Pulmonology, and thereby the author as a member of the staff of the department, has received grants from AltanaPharma, Novartis, Bayer, AstraZeneca, Pfizer, MSD, Exhale Therapeutics, Boehringer Ingelheim, Roche and GSK in the years 2001 until 2008. DOI: 10.1183/09031936.00013111
S. Hirawat has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
A.A. Hislop While collecting the information for this paper, the author was funded by a grant from Actelion for part of their salary. DOI: 10.1183/09031936.00053510
E.M. Hollams. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
B.J. Holt. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
P.G. Holt. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
W.C.J. Hop. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
R.J. Hopkins has received consultant fees from Synergenz BioScience Ltd. DOI:: 10.1183/09031936.00041711
S.G. Howarth Actelion markets bosentan and the author has been on their advisory board, spoken at symposia organised by them and received support funding to pay A.A. Hislop's salary. DOI: 10.1183/09031936.00053510
P. Howden-Chapman received a grant from Contact Energy Ltd and LPG Association to pay part of the cost of the heaters in the intervention arm of the Housing, Heating and Health Study. DOI: 10.1183/09031936.00115409
I. Huizar. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer Schering, Chiesi, GSK, Lilly, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI:: 10.1183/09031936.00075211
M. Humbert has relationships with drug companies including AstraZeneca, Chiesi, GlaxoSmithKline, MSD, Novartis, Nycomed and Pfizer. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
A.A. Humbles is an employee of MedImmune and has share options in excess of $5000. DOI: 10.1183/09031936.00076210
I Back to top
M.D. Inman. The present study was supported by a grant from GlaxoSmithKline-CIRF. DOI:: 10.1183/09031936.00133210
G. Ispas is a Tibotec employee. DOI: 10.1183/09031936.00005610
J Back to top
A. Jaques is the clinical development manager of and holds shares and stock options in Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
D. Jarvis. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
C. Jenkins has received reimbursement for advisory board membership, consultancy and speakers fees from Altana, AstraZeneca, GlaxoSmithKline, Hunter Immunology, Novartis, Nycomed and Tyrian Diagnostics. Her institute has received funding for its education and research programmes from AstraZeneca and GlaxoSmithKline, and from the Co-operative Research Centre for Asthma, a collaborative research programme funded jointly by the Australian Government and industry partners. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
P.W. Jones has received fees from pharmaceutical companies, including GlaxoSmithKline, for speaking at meetings and participating in advisory board meetings, and has received support for research from pharmaceutical companies, including GlaxoSmithKline. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
G.F. Joos has received funding from the following companies: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis and UCB; lecture fees received from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Almiral Prodespharma, UCB and Sanofi-Aventis; scientific advisory board fees received from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis and Nycomed. DOI:: 10.1183/09031936.00097111
K Back to top
K. Karason. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
P. Kardos has, in the past 5 yrs, served on advisory boards for Chiesi, GlaxoSmithKline, Janssen-Cilag, and Novartis; received lecture fees from AstraZeneca, Boehringer Ingelheim, Cephalon, Chiesi, Janssen-Cilag, Novartis and Pfizer; participated in sponsored clinical trials (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Novartis); and has been reimbursed for attending scientific symposia from AstraZeneca, Chiesi, GlaxoSmithKline, Janssen-Cilag and Novartis. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
R. Karnekar. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
F. Kauffmann. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
M.S. Kavuru. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
E. Kerem has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
J.L.L. Kimpen. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
G.G. King. Between 2005-9, G.G. King has received various travel sponsorships from Boehringer Ingelheim, Pfizer, AstraZeneca and GlaxoSmithKline for travel and accommodation to attend international, local and interstate meetings that include pharmaceutical industry-sponsored meetings and independent society scientific meetings. The values of these sponsorships (registration, cash, flights and accommodation) were approximately $AUS2,000 to $AUS15,000/year. A proportion of G.G. King's research work is conducted at the Woolcock Institute of Medical Research, which receives unrestricted grants from Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline, and which also has current and past consultancy agreements with Pfizer, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline. G.G. King provides consultancy services related to asthma and COPD, which include sitting on advisory boards and providing talks at local and national meetings. His research group receives a proportion of the grants and monies that arise from those companies, as part of a general allocation of those funds for research purposes across all research groups of the Woolcock Institute of Medical Research. G.G. King's research group is supported by competitive grants arising from local research foundations, the National Health & Medical Research Council of Australia, Cooperative Research Centre for Asthma and Airways and The Australian Lung Foundation. DOI: 10.1183/09031936.00018311
H. Kjuus. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
T. Klein. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
H.H. Knobel. is an employee of Philips Research. DOI: 10.1183/09031936.00032911
J. Kolbe has been involved in other pharmaceutical studies in the area of cystic fibrosis but does not regard those studies as being impacted, positively or negatively, by this study. The institution to which J. Kolbe is affiliated received standard clinical trial support from Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
R. Kolbeck is a full employee of MedImmune, LLC and has stock in excess of $10,000 in AstraZeneca Inc. DOI: 10.1183/09031936.00076210
J. Kongerud. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
M. Koopmans. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
G.H. Koppelman has received a research grant from GSK ( DOI: 10.1183/09031936.00194710 and DOI: 10.1183/09031936.00182410
J.G.W. Kosterink. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
A. Koul is a Tibotec employee. DOI: 10.1183/09031936.00005610
B. Kramer is a paid employee of Novartis, the sponsor of the study, and holds shares in Novartis. DOI: 10.1183/09031936.00191810
J.A. Kvamme. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
L Back to top
S. Lantuejoul. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
C. Lassen is a paid employee of Novartis, the sponsor of the study, and holds shares in Novartis. DOI: 10.1183/09031936.00191810
P. Lavie. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
J. Lefante. The analysis was funded by W.R. Grace & Co., but the data upon which the analyses were based were independently collected by the Agency for Toxic Substances and Disease Registry (ATSDR), an agency of the US Department of Health and Human Services. DOI: 10.1183/09031936.00050210
M.L. Levy has accepted sponsorship from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Trinity-Cheisi, Merck Sharpe and Dohme, Merck, Altana Pharma, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals and Schering Plough for attending conferences. He has accepted lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Cheisi and Alk-Abello. He has been on advisory boards or provided consultancy for GlaxoSmithKline, Schering Plough, Merck Sharp and Dohme, Cheisi, Altana Pharma, Ranbaxy, AstraZeneca, 3M Pharmaceuticals and Novartis. He has had research grants from Boehringer Ingelheim, Pfizer and GSK. He is a member of the ADMIT Group, which receives an unrestricted educational grant from MEDA pharmaceuticals. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
M.L. Levy has accepted sponsorship from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Trinity-Cheisi, Merck Sharpe and Dohme, Merck, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, TEVA, and Schering Plough for attending conferences. The author has accepted lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Cheisi and Alk-Abello. He has been on advisory boards or provided consultancy for GlaxoSmithKline, Schering Plough, Merck Sharp and Dohme, Cheisi, Altana Pharma, Ranbaxy, AstraZeneca, TEVA, and Novartis. He has had research grants from Boehringer Ingelheim, Pfizer and GSK. He is a member of the ADMIT Group, which receives an unrestricted educational grant from MEDA pharmaceuticals. Data Safety Monitoring Board (DSMB) for the FORWARD Study number CCD-0906-PR-0016. DOI: 10.1183/09031936.00114511
J.K. Liao has served as a consultant for Asahi-Kasei Pharma, Inc. DOI: 10.1183/09031936.00125010
C. Lombardi. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
B. Lundbäck has received fees for speaking from GSK, AstraZeneca and MSD during the past 5 years not exceeding €25,000 in total. The author has received research grants from GSK for studies of clinical epidemiology during the past 5 years not exceeding €200,000 in total and from AstraZeneca for studies of health economics not exceeding €60,000 in total. DOI: 10.1183/09031936.00143710
M Back to top
H. Maarsingh. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
H. Maarsingh. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
M.A. Mall is listed on a patent application filed by the University of North Carolina at Chapel Hill, USA, describing the βENaC-transgenic mouse. The βENaC-transgenic mouse has been deposited at The Jackson Laboratory for general disposition. DOI: 10.1183/09031936.00149810
A. Malur. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
S. Mancuso. Free supplies of PAIPO were provided for the study by Echos Srl (Milan, Italy). DOI: 10.1183/09031936.00109610
M.A. Marcos Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
O. Marrone. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
I. Marshall. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
N.S. Marshall. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
E. Martinez Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
J.F. Masa. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
S.C. Mathai has received an educational grant from Gilead Sciences and has received consulting fees from Bayer HealthCare Pharmaceuticals and United Therapeutics Corporation. DOI: 10.1183/09031936.00148310
D.F. McAuley has received consultancy fees and served on the advisory board for GlaxoSmithKline and received lecture fees from AstraZeneca. DOI: 10.1183/09031936.00032111
W. McNicholas. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
M.H. Menzen. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
P.J.F.M. Merkus. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
H. Meurs has received an unrestricted educational grant from MSD (Oss, The Netherlands). The study was financially supported by Merck Sharpe and Dohme. DOI: 10.1183/09031936.00057710
H. Meurs has received unrestricted educational grants from Boehringer Ingelheim and MSD; the author's travel to ATS meetings was supported by Boehringer Ingelheim, AstraZeneca and Novartis. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
H. Meurs has received unrestricted educational grants from Boehringer Ingelheim and MSD; the author's travel to ATS meetings was supported by Boehringer Ingelheim, AstraZeneca and Novartis. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
M. Meziane. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
N. Miglino. The study was supported by the Novartis Research Foundation. HDM extract was gifted by ALK-Abello, Hørsholm, Denmark. DOI: 10.1183/09031936.00068010
L.L. Miller has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
M.R. Miller oversees a research fund that has received payment from BioMedSys Ltd for his lecturing on how best to undertake spirometry in a research setting. This covered the technical aspects of performing spirometry, what data needs to be stored and how to choose the best format for access. DOI: 10.1183/09031936.00063111 and DOI: 10.1183/09031936.00063211
N.L. Miller has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
C.D. Mitnick serves on the Scientific Advisory Board of Otsuka Pharmaceuticals for the development of OPC-67683. C.D. Mitnick declared that in the work performed for Otsuka Pharmaceutical Co Ltd. she abstained from discussions relating to the recommendations on drug regimens. DOI:: 10.1183/09031936.00073611
S. Moledina has received expenses from Actelion for attending conferences and a fee for speaking at a conference organised by Actelion. DOI: 10.1183/09031936.00053510
J.M. Montserrat. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
A. Moreno Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
D. Moro-Sibilot. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
E.M. Mortensen has been the principal investigator for research grant awarded to the University of Texas Heath Science Center at San Antonio by the National Institutes of Health. DOI: 10.1183/09031936.00028711
B. Mueller received support from BRAHMS to attend meetings and fulfilled speaking engagements. The author has served as a consultant and received research support. DOI: 10.1183/09031936.00056811
N Back to top
H. Nagy-Mignotte. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
S.D. Nathan has served as a consultant for InterMune Inc., Gilead, Bayer, United Therapeutics, Actelion and GeNO. He has also received research funding from InterMune Inc., Gilead, Bayer, United Therapeutics and Actelion. DOI: 10.1183/09031936.00068611
A. Netzer. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
A.G. Nicholson has received fees and travel expenses for giving lectures and roles on advisory boards for Glaxo Smith Klein Ltd, Astra Zeneca Ltd, Eli Lilly Ltd and Oncimmune Ltd in relation to management of patients with lung cancer. DOI: 10.1183/09031936.00026711
R. Nielsen has received research grants from GlaxoSmithKline SA (USD 13,269) and Yara Praxair (USD 4,423) and has received lecture honoraria from Boehringer Ingelheim (USD 1,189) and Astra Zeneca (USD 885). DOI: 10.1183/09031936.00146310
K-C. Nordby. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
V.J. Northcutt has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
H. Notø. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
M.E. Numans. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
O Back to top
P.M. O'Byrne has been on advisory boards for AstraZeneca, GSK, Merck, Nycomed, Topigen, and Wyeth and has received lecture fees from these and other pharmaceutical companies including Chiesi, and Ono Pharma. In addition, he has received grants-in aid for research studies from AstraZeneca, Genentech, GSK, Medimmune, Merck, Pfizer, Topigen, and Wyeth. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
P.M. O'Byrne has received consulting fees from Asmacure, AstraZeneca, GlaxoSmithKline, Nycomed, Resistentia, and Topigen, and honoraria for speaking from AstraZeneca, Chiesi, GlaxoSmithKline and Nycomed. In addition, the author has received grants-in-aid from AstraZeneca, Boehringer Ingelheim, Genentach, GlaxoSmithKline, Medimmune, Merck, Pfizer, Topigen and Wyeth. DOI: 10.1183/09031936.00033811
D.E. O'Donnell has served on advisory boards for Boehringer Ingelheim, Pfizer, GSK, Novartis, and Nycomed (ö1,001-5,000), has received lecture fees from Boehringer Ingelheim, Astra Zeneca, Pfizer, and GSK (ö1,001-5,000), and has received industry-sponsored grants from Boehringer Ingelheim, GSK, and Merck Frost Canada (ö100,001 or more) and from Novartis and Pfizer (ö50,001-100,000). DOI:: 10.1183/09031936.00029411
A-C. Olin has chaired one symposium organised by Aerocrine and given two lectures on seminars organised by Aerocrine, and received lecture fees of around €3,000. DOI: 10.1183/09031936.00143710
V. Olivé Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
A. Oliven. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
R. Oliven. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
P. Openshaw holds a Tibotec-sponsored research grant. DOI: 10.1183/09031936.00005610
O. Östlund is employed by AstraZeneca and own shares in AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
P Back to top
A.I. Pack has received up to $1,000 from Taylor & Francis Group LLC, $5,001-10,000 from McGraw Hill Companies and $100,001 or more in NIH grants. DOI: 10.1183/09031936.00119210
M. Pai serves as a consultant for the Bill & Melinda Gates Foundation (BMGF). BMGF had no involvement with this research study or publication. DOI:: 10.1183/09031936.00181610
G. Parati. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
H.J. Park. The present study was supported by a grant from GlaxoSmithKline-CIRF. DOI:: 10.1183/09031936.00133210
F. Parsons. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
S. Pedersen has received honorarium for speaking and consulting from Nycomed and GlaxoSmithKline and his institution has received unconditional research grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00030711
M. Peltonen. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
T. Penzel. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
T. Pera. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
T. Perez. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
T. Perez. received fees for speaking at congresses in France from Chiesi, Novartis and Nycomed; received a fee for workshops by Chiesi and Nycomed; received funding for academic research from Nycomed and Novartis; is a consultant for Nycomed, Novartis and Pierre Fabre; and the author’s travel to the ERS and CPLF congresses were funded by Chiesi, Nycomed, Boehringer Ingelheim and Astra Zeneca. DOI: 10.1183/09031936.00067711
S. Peterson is employed by AstraZeneca and own shares in AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
I. Pin. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
A. Plagens is an employee of University Hospital Giessen and Marburg GmbH. DOI: 10.1183/09031936.00123809
R. Polosa. Free supplies of PAIPO were provided for the study by Echos Srl (Milan, Italy). DOI: 10.1183/09031936.00109610
D.S. Postma has received funding for research from AstraZeneca, GSK and Nycomed. The autho's travel to ERS or ATS congresses has been partially funded by AstraZeneca, GSK, Chiesi and Nycomed. She has acted as a consultant to AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and TEVA. DOI: 10.1183/09031936.00194710 and DOI: 10.1183/09031936.00182410
A.D. Pranger. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
M. Pretl. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
C. Préfaut is president of the medical committee of Fontalvie, a pulmonary rehabilitation institution, and is involved with Boehringer Ingelheim and AstraZeneca industries. DOI: 10.1183/09031936.00167110
T. Pugatch has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
T. Pumarola Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
Q Back to top
P.H. Quanjer received €11,000 from Novartis for over-reading spirometry tests performed in a clinical intervention study into the effectiveness of omalizumab in the treatment of allergic bronchopulmonary aspergillosis. DOI: 10.1183/09031936.00063111 and DOI: 10.1183/09031936.00063211
I. Quelapio. The Tropical Disease Foundation, which was I. Quelapio's employer until June 2010, received funds for research on a new anti-TB drug. I. Quelapio declared that in the work performed for Otsuka Pharmaceutical Co Ltd. she abstained from discussions relating to the recommendations on drug regimens. DOI: 10.1183/09031936.00073611
S. Quirce has been on advisory boards for and has received speaker's honoraria from AstraZeneca, GlaxoSmithKline, MSD, Novartis, Almirall, Altana, Chiesi and Pfizer. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
R Back to top
K.F. Rabe Although not employed by ERS, the author regards his function as an officer of this organisation an interest that he wishes to state. The trials analysed in the author's study were funded by Nycomed GmbH (Konstanz, Germany). DOI:: 10.1183/09031936.00178710
P.P. Ramon has received a fee from Olympus France for organising an education session in Lille on EBUS-TBNA. DOI: 10.1183/09031936.00182210
S. Ramón Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
W. Randerath receives scientific grants, talk fees and travel grants from companies, which are working in the field of sleep medicine (Weinmann, Respironics, Linde, Resmed). DOI:: 10.1183/09031936.00095111
P. Ravn Hvidovre Hospital has filed patents on the use of IP-10 as a marker for infection with Mycobacterium tuberculosis. The author is one of the registered co-inventors. The author has also been an invited speaker for Cellestis and has received QFT-IT kits at a reduced price for nonprofit research. DOI:: 10.1183/09031936.00071111
H.K. Reddel has been on advisory boards for AstraZeneca, GlaxoSmithKline and Novartis, has received speaker's honoraria from GlaxoSmithKline, AstraZeneca, Merck and Getz Pharma, has provided consultancy services for Biota and GlaxoSmithKline, and has received research funding from GlaxoSmithKline and AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
A. Reha has been an employee of and holds financial interests in PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
M.I. Restrepo has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies, including Pfizer, Ortho-McNeil-Janssen (Johnson & Johnson) and BARD. The author has being a consultant for Theravan, Trius and Pfizer. He has being the principal investigator for research grants awarded to the University of Texas Heath Science Center at San Antonio by the National Institutes of Health. DOI: 10.1183/09031936.00028711
M.I. Restrepo has served on advisory boards for Ortho-McNeil-Janssen, Johnson & Johnson, and Pfizer, received speaker's fees from Ortho-McNeil-Janssen, Johnson & Johnson, Pfizer, Covidien and BARD, Inc., and acted as a consultant for Wyeth. DOI: 10.1183/09031936.00141110
R. Riha. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
J. Rivlin. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
C. Robalo Cordeiro is a member of and received a fee from Intermune European Advisory Board. DOI: 10.1183/09031936.00039011
P. Robinson participated in a medical advisory committee to Pharmaxis Pharmaceuticals on the subject of dry powder inhaled mannitol and received an honorarium of less than €10,000 for the one day meeting. P. Robinson has received fees for chairing an advisory board for Pharmaxis. The institution to which P. Robinson is affiliated received standard clinical trial support from Pharmaxis Ltd. The study received funding from Pharmaxis Ltd. This study sponsor participated in the study design, data collection, data analysis, data interpretation and writing of the report. Following completion of the trial, the data were held and analysed by the sponsor. DOI: 10.1183/09031936.00187510
D. Rodenstein As head of the Dept of Pneumology, the author received in 2007 a grant for a research project in relation to COPD from AstraZeneca. D. Rodenstein gave a talk on the TORCH clinical trial (COPD) and received a fee from GSK. None of these were related to my contribution to the ERJ. DOI: 10.1183/09031936.00177010
D. Rodenstein. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
R. Rodriguez-Roisin has no conflict of interest with the current manuscript. In the past he participated, always as a lecturer and speaker in scientific meetings and courses under the sponsorship of Almirall, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Kyorin, Novartis, Pfizer, and Union Chimique Belge; consulted with several pharmaceutical companies (Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmith-Kline, Novartis, Nycomed, and Pfizer); serves on advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp Dome, Novartis, Nycomed, Pearl Therapeutics, Pfizer, Procter & Gamble; has been sponsored for several clinical trials by, and received laboratory research support from, Almirall, AstraZeneca, Boehringer Ingelheim, Glaxo-SmithKline, Esteve, and Pfizer. DOI: 10.1183/09031936.00042411
M. Roth The study was supported by the Novartis Research Foundation. HDM extract was gifted by ALK-Abello, Hørsholm, Denmark. DOI: 10.1183/09031936.00068010
D. Roymans is an employee of Tibotec-Virco Virology BVBA. DOI: 10.1183/09031936.00005610
G. Ruppel received honoraria from Medical Graphics Inc. and Biomedical Systems Inc. for speaking at educational seminars, and consulting fees from GSK and Gilead for over-reading of pulmonary function tests. DOI: 10.1183/09031936.00063211
S Back to top
T. Saaresranta. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
M. Saetta has received: honoraria from Farmaindustria, AstraZeneca, GlaxoSmithKline, Abbott Labs, Boehringer Ingelheim and Merck Sharpe & Dome; industry-sponsored grants from GlaxoSmithKline, AstraZaneca, Nycomed and Chiesi Farmaceutici. DOI:: 10.1183/09031936.00168210
S. Saglani. The study was funded, in part, by Smiths Medical. DOI: 10.1183/09031936.00164910
E. Salonini. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
G.V. Scagliotti has received honoraria from Eli Lilly, Roche, Sanofi Aventis and Astra Zeneca. DOI: 10.1183/09031936.00026711
T. Schaberg has received fees for speaking and for attending Advisory Boards from GSK, Pfizer, Bayer, Novartis and Sanofi. CAPNETZ received funding from GlaxoSmithKline for this study. DOI: 10.1183/09031936.00133510
T. Schaberg has received fees for speaking and attending Advisory Boards from GSK, Pfizer, Novartis, Sanofi and Bayer. DOI: 10.1183/09031936.00133910
T. Schaberg has received several consultant fees and fees for speaking from GSK, Bayer, Pfizer, Wyeth, Agnelli and Novartis. DOI: 10.1183/09031936.00145810
R. Schmidt-Ott is an employee of GlaxoSmithKline (Munich, Germany). CAPNETZ received funding from GlaxoSmithKline for this study. DOI: 10.1183/09031936.00133510
R.G. Schoemaker. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
I. Schultze-Neick has received unrestricted educational grants and funds for members of staff; and he has received fees for consulting, speaking at meetings, and organizing educational sessions, both from Pfizer and Actelion. DOI: 10.1183/09031936.00053510
P. Schuetz received support from BRAHMS to attend meetings and fulfilled speaking engagements. DOI: 10.1183/09031936.00056811
R. Schulz. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
R.J. Schwab has received fees for consulting from Ethicon (Johnson and Johnson; $1,001-5,000 (completed) and Medtronics ($1,001-5000), fees for speaking from Nuvigil (~$15,000), fees for organising education (AASM Board review course, $1,001-5,000), royalties from a commercial entity ($1,001-5000), and NIH grants ($100,001 or more). DOI: 10.1183/09031936.00119210
M.R. Sears holds an Endowed chair in Respiratory Epidemiology jointly endowed by AstraZeneca and McMaster University. He has received research funding from pharmaceutical companies including MSD and AstraZeneca. He has acted as a consultant or advisory board member to MSD, Novartis and AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
R. Sehmi. The present study was supported by a grant from GlaxoSmithKline-CIRF. DOI:: 10.1183/09031936.00133210
C. Seifart is an employee of University Hospital Giessen and Marburg GmbH. DOI: 10.1183/09031936.00123809
M. Serralha. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
S.A. Shore has received a speaker's fee from Merck Pharmaceuticals and consulting fees from Schering Plough. DOI: 10.1183/09031936.00125010
D. Shoseyov has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
A. Simonds has received research grants from ResMed for £303,000 and Breas Medical for £45K for studies unrelated to topic of editorial. DOI:: 10.1183/09031936.00106511
A.K. Simonds has received research grants from ResMed for £303,000 and Breas Medical for £45K for studies unrelated to the topic of the editorial. DOI:: 10.1183/09031936.00095111
G. Simonneau has relationships with drug companies including Actelion, Bayer Schering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI:: 10.1183/09031936.00075211
C.J.J.C.M. Sintnicolaas. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
V. Siroux. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
U. Sjöbring is employed by AstraZeneca and own shares in AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
C.D. Sjöström. is currently employed by AstraZeneca and has previously received lecture and/or consulting fees from Sanofi-aventis, Ethicon and MSD. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
L. Sjöström. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
M. Skogstad. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
R. Slama. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
M.A. Sleeman is an employee of MedImmune and has share options in excess of $5000 in Astrazeneca Grp. DOI: 10.1183/09031936.00076210
P. Sliwinski. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
P.D. Sly. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
M. Smit. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
J.J. Soler Cataluña has no conflict of interest regarding the current manuscript. He has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Esteve, GlaxoSmithKline, Nycomed and Pfizer; serves on advisory board for AstraZeneca, Boehringer Ingelheim and Pfizer; and has received laboratory research support from Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Esteve and Pfizer. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
S. Sonnappa. The study was funded, in part, by Smiths Medical. DOI: 10.1183/09031936.00164910
M.R. Stämpfli has received funds for research from MedImmune Inc. and AstraZeneca. DOI: 10.1183/09031936.00076210
K. Stenlöf. The Swedish Obese Subjects study was supported, in part, by grants from Hoffmann–La Roche, AstraZeneca, Cederroth, Ethicon and Sanofi-Adventis. DOI: 10.1183/09031936.00022111
J. Sunyer The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
T Back to top
M. Tamm The study was supported by the Novartis Research Foundation. HDM extract was gifted by ALK-Abello, Hørsholm, Denmark. DOI: 10.1183/09031936.00068010
D.R. Thickett. has consulted with a pharmaceutical company that has MMP inhibitors in development but not in relation to IPF treatment. DOI: 10.1183/09031936.00024711
M.J. Thomassen. The study was supported, in part, by Genentech (San Francisco, CA, USA). DOI: 10.1183/09031936.00197710
Y. Thomassen. The present study was funded, in part, by the European Cement Association (CEMBUREAU). DOI: 10.1183/09031936.00007711
A. Thorén is employed by AstraZeneca and own shares in AstraZeneca. The study was supported by AstraZeneca AB (Lund, Sweden). J. Brennan (MediTech Media Ltd) provided medical writing assistance on behalf of AstraZeneca AB. DOI:: 10.1183/09031936.00186510
H.A.W.M. Tiddens. The research organisation “BV Kindergeneeskunde” of the Erasmus MC – Sophia Children’s Hospital has in the past 3 yrs received research grants from Novartis and Roche, and honoraria and travel expenses for lectures and for participation in expert panels by H.A.W.M. Tiddens from Novartis, Gilead, Roche, Inspire and Bayer. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
I. Tillie-Leblond. has received fees for speaking, organising education, research and consulting from Novartis, AstraZeneca, GlaxoSmithKline, Chiesi and Boehringer Ingelheim. DOI: 10.1183/09031936.00127311
J.F. Timsit.. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
R. Tkacova. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
A.C. Toffart. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
A. Torres has received speaking fees from Astellas, MSD and Pfizer, and research grants from Pfizer and is on the advisory board for Astellas, MSD, Sanofi Pasteur. DOI: 10.1183/09031936.00133910
A. Torres has received research grants from Pfizer and Covidien. He has participated in the advisory boards of Astellas, Sanofi-Aventis. DOI: 10.1183/09031936.00145810
A. Torres has received speaking fees from Astellas, MSD and Pfizer, and research grants from Pfizer and Covidien. He is on the advisory boards of Astellas, MSD and Sanofi Pasteur. DOI: 10.1183/09031936.00125910
A. Torres has received research grants from Pfizer and Covidien. He has participated in the advisory boards of Astellas and Sanofi-Aventis. DOI: 10.1183/09031936.00070011
A. Torres Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
A. Toubi. The present study was supported by Inspire Medical Systems. DOI: 10.1183/09031936.00125810
U Back to top
D.R.A. Uges. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
C.S.P.M. Uiterwaal. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
V Back to top
A.A.P.H. Vaessen-Verberne received an unrestricted research grant from GlaxoSmithKline Pharmaceuticals and Consumer Healthcare (Zeist, the Netherlands). The grant was given for development of the web-based versions of the C-ACT and ACT (by an external office) and was used for hosting the website on the Internet during the study. Furthermore, this external office provided support throughout the study in case of unexpected problems. These web-based versions were used for study purposes only. No direct fees or gifts have been received by A.A.P.H. Vaessen-Verberne from GSK. DOI:: 10.1183/09031936.00173710
J. Valadas. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
D. Valeyre. is a consultant for Actelion, Intermune, and Sanofi and has been reimbursed for attending a symposium (travel and accommodation) by AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Nycomed. DOI: 10.1183/09031936.00187410
R. van Altena. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
T. Van de Casteele is a Tibotec employee. DOI: 10.1183/09031936.00005610
A.A.J.M. van de Ven. was supported by a non-restricted educational grant of Baxter Bioscience (Deerfield, IL, USA). DOI: 10.1183/09031936.00173410
C.K. van der Ent. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
T. van der Molen. Funding for this study was provided by GlaxoSmithKline (study number 111749). DOI: 10.1183/09031936.00177210
T.S. van der Werf. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
E.C. van der Wiel-Kooij. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
B. Van Kerckhove is a Tibotec-Virco employee. DOI: 10.1183/09031936.00005610
E. Van Miert. was an employee of the Philip Morris Research Laboratories BVBA between 1998 and June 2009. DOI: 10.1183/09031936.00000911
N. van Putte-Katier. The present study was supported by an unrestricted grant from GlaxoSmith Kline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
P. Van Remoortere is a Tibotec employee and holds Johnson and Johnson stock in excess of £5,000. DOI: 10.1183/09031936.00005610
D. van Soolingen. In the present study moxifloxacin was provided by Bayer. DOI: 10.1183/09031936.00176610
M. Vanstockem is a Tibotec employee. DOI: 10.1183/09031936.00005610
F. Van Velsen is a Tibotec employee and holds Johnson and Johnson stocks in excess of £5,000. DOI: 10.1183/09031936.00005610
G. Varoneckas. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
T. Verheij is involved in a project that has received unrestricted grant from GSK and in a study that is financed by Pfizer (funding for trial). DOI: 10.1183/09031936.00133910
T. Verheij is involved in a project which has received an unrestricted grant from GSK and in a study which is financed by Pfizer (fund for trial). DOI: 10.1183/09031936.00145810
T.J.M. Verheij. The present study was supported by an unrestricted grant from GlaxoSmithKline, Zeist, the Netherlands. DOI:: 10.1183/09031936.00034210
R. Verloes is employed by Tibotec, a Johnson and Johnson Company, and is holding company stocks in excess of £5,000. Tibotec funds the author's participation to scientific congresses. DOI: 10.1183/09031936.00005610
A. Vesin. The EGEA study was supported in part by a grant from Merck Sharp and Dohme. DOI: 10.1183/09031936.00120810
A. Vesin. Translation and critical editing of this manuscript was supported by Eli Lilly laboratories (Suresnes, France). DOI: 10.1183/09031936.00191710
J. Vestbo. has, in 1985, received 267,000 Dkr from the Scandinavian Tobacco Company in support of a research project on exposure to cement dust, smoking and respiratory disease. DOI: 10.1183/09031936.00193809
J. Vestbo has received fees for presenting and advising from the following companies: GSK, AstraZeneca, Nycomed, Chiesi, Pfizer, Boehringer-Ingelheim, Talecris, Hoffman - la Roche and Novertis. J. Vestbo has a research grant from GSK for HP-He MRI imaging in COPD and has recently received funding for taking part in the ECLIPSE study. His wife, I. Vestbo, worked in the pharmaceutical industry until 2009. In 1985 J. Vestbo received a grant of 276,000 DKK from the gift fund of the Scandinavian Tobacco Company. DOI: 10.1183/09031936.00042411
A. Vilella Luminex-Abbott Molecular Diagnostics (Wiesbaden, Germany) assisted with the laboratory investigation. DOI:: 10.1183/09031936.00168610
T.J. Vink. is an employee of Philips Research. DOI: 10.1183/09031936.00032911
A. Vitols. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
C. Vogelmeier is an employee of University Hospital Giessen and Marburg GmbH. DOI: 10.1183/09031936.00123809
S. Volpi. Activaero GmbH supplied Akita2® APIXNEB devices and technical support. DOI: 10.1183/09031936.00006211
H. Vrints. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
W Back to top
W.A.H. Wallace has had travel costs covered to attend Practical Management of Thoracic Tumours meetings in November 2009 and 2010 by Lilly. The author has also had the cost of registration to attend BTOG in Dublin in 2011 by Lilly. The author has acted as an expert for the Scottish Medicines Consortium advising on the ability of pathology samples to accurately classify non-small cell carcinomas as part of their evidence gathering prior to deciding to permit prescribing of pemitrexed. No financial reward was given for this advice. DOI: 10.1183/09031936.00176410
D. Weill was retained as a compensated consulting expert witness on behalf of W.R. Grace in legal matters. The author was compensated for performing a variety of data analyses, some of which were reported in this study. The analysis was funded by W.R. Grace & Co., but the data upon which the analyses were based were independently collected by the Agency for Toxic Substances and Disease Registry (ATSDR), an agency of the US Department of Health and Human Services. DOI: 10.1183/09031936.00050210
T. Welte has received fees for lectures from GlaxoSmithKline, is member of the GlaxoSmithKline advisory board and has received research grants from GlaxoSmithKline. CAPNETZ received funding from GlaxoSmithKline for this study. DOI: 10.1183/09031936.00133510
T. Welte has received fees for lectures from BRAHMS AG. The author has received grants for research from BRAHMA AG. DOI: 10.1183/09031936.00039411
J.B. Wempe. has received fees for speaking from Nycomed and research grants from the Netherlands Asthma Foundation and Boehringer Ingelheim. DOI: 10.1183/09031936.0011191
G. Wennergen has received fees for lectures from Novartis, Merck Sharp & Dohme, AstraZeneca and GlaxoSmithKline. The author does not hold any stocks or shares in any pharmaceutical company. DOI: 10.1183/09031936.00143710
P.J. Wijkstra. has received research grants and fees for speaking from Philips/Respironics.DOI: 10.1183/09031936.00111911
N.P. Willard. is an employee of Philips Research. DOI: 10.1183/09031936.00032911
M. Wilschanski has received reimbursement for travel to scientific meetings, research funding, funds for a member of staff, and consulting fees from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
M. Woodhead. has received financial support for travel and accommodation to attend the ERS in 2010, has acted as a paid Consultant to Astellis and is a paid member of a data monitoring committee for an ongoing clinical trial run by Pfizer. DOI: 10.1183/09031936.00105211
M. Woodhead is a paid member of a data monitoring committee for an ongoing clinical trial run by Pfizer. He is also an unpaid member of the ethical monitoring unit of one of the GRACE clinical trials and is chair of the ERS/ESCMID LRTI Guidelines Taskforce. DOI: 10.1183/09031936.00020111
YBack to top
Y. Yaakov has received funding support for the conduct of this study and has also received compensation for time, effort, and travel expenses related to data discussions and presentations from PTC Therapeutics, Inc. Drug supply and study funding were provided by PTC Therapeutics, Inc, South Plainfield, NJ, USA. DOI: 10.1183/09031936.00120910
W.W. Yew has received indirect sponsorship from GlaxoSmithKline and Pfizer to participate in international conferences. DOI: 10.1183/09031936.00186310
R.P. Young has received funding for research from Synergenz BioScience Ltd. DOI:: 10.1183/09031936.00041711
Z Back to top
J. Zaagsma has received an unrestricted educational grant from MSD (Oss, The Netherlands). The study was financially supported by Merck Sharpe and Dohme. DOI: 10.1183/09031936.00057710
J. Zaagsma received grant support from Boehringer Ingelheim Pharma GmbH & Co. KG and Organon, advisory board or consultancy fees from AstraZeneca, Boehringer Ingelheim and Astellas, lecturing fees from Boehringer Ingelheim, AstraZeneca and Nycomed, and fees for attending symposia by himself and/or staff members from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Novartis. The study was supported, in part, by Boehringer Ingelheim. DOI: 10.1183/09031936.00146610
J-P. Zellweger was invited by Oxford Immunotec to the annual meeting of the European Mycobacteriology Society in 2009 to give a lecture on IGRAs (travel cost and speaker's fee). DOI: 10.1183/09031936.00179310
G. Zhang. In the present study, reagents for antibody measurement were provided gratis by Phadia AB (Uppsala, Sweden). DOI: 10.1183/09031936.00029011
J. Zielinski. The ESADA study has been funded by two seeding grants from ResMed and Philips Respironics foundations (total €100,000) for establishment of the electronic data capture function. The grants have been administered via the University of Gothenburg. The EU COST Action B26 programme has provided economic support for scientific meetings and symposia, which enabled the construction of the ESADA network. DOI:: 10.1183/09031936.00046710
A.B. Zuidhof. The study was financially supported by Merck Sharpe and Dohme, Oss, the Netherlands. DOI: 10.1183/09031936.00057710
A. Zuidhof. The study was supported, in part, by Boehringer Ingelheim Pharma GmbH & Co. KG. DOI: 10.1183/09031936.00146610
S. Zuyderduyn s sponsored by a research grant from Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. DOI: 10.1183/09031936.00013111
Volume 39, 2012
A Back to top
C. Agusti. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
C. Agusti.The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
R. Akkermans. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
M. Albertini. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
J-W.C. Alffenaar has received an educational grant from Pfizer, MSD and Schering-Plough for organising symposia on antifungal treatment. The author has received research funding from Pfizer. DOI: 10.1183/09031936.00200911
I. Almendros. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
A-C. Almstrand has a pending patent on the method used in the study. DOI: 10.1183/09031936.00195610
Z. Allibhai. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
J.A. Anderson is employed by and holds stock in GlaxoSmithKline. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
M. Anderson Owns lecture fees paid for by following commercial entities (honoraria): Boehringer Ingelheim: $10,001–50,000; GSK: $1,001–5,000. The author has received royalties from Boehringer Ingelheim (in the value of $1,001–5,000) for a book on spirometry. The present study was supported, in part, by AstraZeneca. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
I.J. Armstrong has received consultancy and lecturing fees and been funded to attend conferences from Actelion, Bayer, Encysive, GSK, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00078411
P. Arvis is an employee of Bayer Schering Pharma. This study was funded by Bayer Schering Pharma. Highfield Communication Consultancy, funded by Bayer Shering Pharma, provided editorial assistance in the preparation of this manuscript. DOI 10.1183/09031936.00042111
H. Asamura has received a fee for speaking (200,000 Yen) in an educational review course held in Tokyo from Johnson and Johnson Company . The title of speaking (lymph node dissection) was, however, not related to the any product of the company. DOI: 10.1183/09031936.00027511
S. Atallah. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
V. Attali received reimbursement from Vitalair for attending a congress not related to the study. DOI: 10.1183/09031936.00153311
M. Aubier. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
N. Azimi is an employee of Bioniz. DOI: 10.1183/09031936.00099811
B Back to top
K.M. Baker This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
P.S. Bakke has, within the last 5 years, received lecture fees from the following companies: GSK, AstraZeneca, Nycomed, Pfizer, Boehringer-Ingelheim; and has received funding for taking part in the ECLIPSE study. DOI: 10.1183/09031936.00011712
F.R. Baldrick. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
P. Barbry. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for treating airway diseases. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
R.G. Barr received an unrestricted grant from Cenestra Health for supplies for an NIH-funded pilot study. DOI: 10.1183/09031936.00165410
M. Barrón. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
E.D. Bateman has participated in advisory boards and/or received consultancy fees from Actelion, Almirall, AlkAbello, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Forest, Hoffmann la Roche, GlaxoSmithKline, Merck, Morria Biopharmaceuticals, Napp Pharma, Novartis, Nycomed, Pfizer, ScheringPlough. He has received lecture fees from AlkAbello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer, Nycomed, TEVA; sponsorship for investigator-generated research from Boehringer Ingelheim; and research funding for participating in multicenter studies from Aeras, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Hoffmann la Roche, GlaxoSmithKline, Merck, Morria. Biopharmaceuticals, Novartis, Nycomed, Pfizer. He is Chair of the GINA Board and member of the Science Committee. DOI: 10.1183/09031936.00184511
E.D. Bateman has received honoraria from Nycomed for speaker activities and membership of advisory boards, and his institution has received payments for his participation in clinical trials sponsored by Nycomed. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
M-E. Bédard. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
J. Behr has received fees for speaking from Actelion, Bayer-Schering, Boehringer-Ingelheim, Encysive, GSK, Pfizer, Lilly, Nycomed, InterMune, Novartis and MSD. The author has served as consultant/advisor for Actelion, Bayer-Schering-Pharma, Lilly, Pari-Pharma, GSK, Pfizer, Optima, Gilead. He has received research grants from Actelion, Bayer-Schering, Pari-Pharma. Attending international and national congresses was sponsored by Actelion, Boehringer-Ingelheim, AstraZeneca, Bayer. DOI: 10.1183/09031936.00009112
S. Bello. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
J.A. Belperio. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
A. Berezné has received reimbursement for attending a symposium and a fee for speaking from Actelion Pharmaceuticals, and a Reimbursement for attending a symposium and A fee for speaking from France and Pfizer France. Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
E. Bergot. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
P. Berna is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
P. Bernardelli is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
L. Bertoletti. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
C.P. Bertrand is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
A. Bezjak. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
M. Bezzi. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
C. Billings has received support for equipment from Phillips Respironics, lecturing fees from Allen & Hanbury and Pfizer and been funded to attend conferences from Encysive, GSK, Lilly and Pfizer. DOI: 10.1183/09031936.00078411
E.W.M.A. Bischoff. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
K. Blake. The study was supported, in part, by a grant from GlaxoSmithKline (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00185510
E. Boedeker. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
L. Boer. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
P. Borger. The study was funded, in part, by the Novartis Research Foundation. DOI: 10.1183/09031936.00174310
I. Borget was invited to congresses by Amgen and Genzyme. DOI: 10.1183/09031936.00201210
L-P. Boulet has participated in advisory boards for AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis. He has received lecture fees from 3M, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis; sponsorship for investigator-generated research from AstraZeneca, GSK, Merck Frosst and Schering; research funding for participating in multicenter studies from Altair, Asmacure, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Pharmaxis, Schering, Wyeth; support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst. He is an adviser for the Conseil du Médicament du Québec, AETMIS, and a member of the Quebec Workmen Compensation Board Respiratory Committee. He is Chair of the Canadian Thoracic Society Respiratory Guidelines Committee and chair of GINA Guidelines Dissemination and Implementation Committee and holder of the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. He is a member of the Knowledge Translation (KT Canada) supported by the CIHR. DOI: 10.1183/09031936.00184511
T. Bourrier. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
J.M. Bradley. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
S.M. Brandenburg. This study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00193810
P.L.P. Brand. In the past 5 yrs, the author has received fees for consulting, lecturing, and research from Glaxo Smith Kline, Astra Zeneca, Merck, Boehringer Ingelheim and Nycomed. The survey and editorial assistance in the preparation of the manuscript were funded by Nycomed. DOI: 10.1183/09031936.00048911
M. Brauner. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
D. Bredenbröker is an employee of Nycomed. The study was funded by Nycomed GmbH (Konstanz, Germany). DOI: 10.1183/09031936.00096511
D. Bredenbröker is an employee of Nycomed. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
C.E. Brightling has received research grants and consultancy fees from AstraZeneca, MedImmune, GlaxoSmithKline, Novartis, Roche, and Chiesi; sponsorship to meetings from Boerhinger-Ingelheim. DOI: 10.1183/09031936.00169511
L.Brochard’s research laboratory has received research grants for specific research projects over the past five years from the following companies: Maquet (NAVA), General Electric (FRC), Covidien (PAV+), Respironics Philips (NIV), Fisher Paykel (Optiflow) and Drager (SmartCare). DOI: 10.1183/09031936.00056212
M. Brose is an employee of Nycomed. The study was funded by Nycomed GmbH (Konstanz, Germany). DOI: 10.1183/09031936.00096511
M. Brose is an employee of Nycomed. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
C. Brouillard. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
C. Broussard Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
S.M. Brown. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
B. Brunekreef received a research grant from the Center of Indoor Air Research in the mid-1990s. DOI: 10.1183/09031936.00001112
G.G. Brusselle has, within the last 5 yrs, received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer and UCB; the author is a member of advisory boards for AstraZeneca, GlaxoSmithKline, Novartis and UCB. DOI: 10.1183/09031936.00138110
A.S. Buist received funding for the BOLD study Operations Center and/or other research from unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca, ALTANA, Novartis, Merck, Chiesi, Schering Plough and Sepracor. ASB has served on advisory boards for GlaxoSmithKline, ALTANA, Schering Plough, Merck, Novartis, Pfizer, and Sepracor.ASB has participated in COPD workshops funded by AstraZeneca and GlaxoSmithKline. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
P.S.Burge has developed the Oasys system for the analysis of serial measurements of PEF in the diagnosis of occupational asthma. He makes this freely available to all via the website www.occupationalasthma.com. He has never received any money related to this. He is an unpaid member of other groups making related evidence-based guidelines (BOHRF for occupational asthma and SIGN/BTS for asthma). He is an expert witness in legal cases related to occupational asthma. DOI: 10.1183/09031936.00096111
F. Burgos has received an unrestricted grant from Boheringer-Pfizer, and has stocks to the value of €1,500 in Linkcare Health Solutions SL. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
P. Burney has acted as a consultant for GSK and contributed to courses or symposia supported by Astra-Zeneca, Boehringer-Ingelheim and Pfizer. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
G. Bussone Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
C Back to top
J. Cadranel has received fees for speaking and consulting from AstraZeneca, Boehringer-Ingelheim, and Roche (< US$5000/year); travel to the ASCO and/or IASLC congress was funded by AstraZeneca, Boehringer-Ingelheim, Merck Serono and Roche. DOI: 10.1183/09031936.00201210
J. Cadranel has received speaker and consultancy fees from Pfizer. DOI: 10.1183/09031936.00162311
P.M.A. Calverley has advised GSK, Nycomed Novartis,,Bayer and Boehringer Ingelheim on the design and conduct of clinical trials. In addition, the author has spoken at meetings supported by AstraZeneca and all the above except Bayer. He has acted as an expert witness for Nycomed/Forest in connection with the roflumilast regulatory submission. The study was funded by GSK (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
P.M.A. Calverley has advised GSK, Nycomed, Boehringer Ingelheim and Roche about study design and conduct. He has sat on advisory boards convened by these companies, and by AstraZeneca, Bayer and Novartis. He has spoken at meetings supported in whole or in part by GSK, Nycomed, AstraZeneca and Boehringer Ingelheim. He has acted as an expert witness for Forest/Nycomed. He has no shares in any company or any connections with the tobacco industry. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
D. Capener is part funded by an unrestricted educational grant from Bayer. DOI: 10.1183/09031936.00078411
C. Carré is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
W.D. Carroll has received fees for performing research, giving presentations, and consultancy from GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Teva, and Nycomed. The author has received sponsorship and support to attend respiratory meetings from GlaxoSmithKline, ALK-Abelló, Merck Sharp & Dohme and Nycomed. The survey and editorial assistance in the preparation of the manuscript were funded by Nycomed. DOI: 10.1183/09031936.00048911
L. Castillo. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
B. Celli has received consulting fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; speaking fees from Altana, AstraZeneca, Boehringer-Ingelheim and GlaxoSmithKline; and grant support from Boehringer-Ingelheim and GlaxoSmithKline. The division that the author heads has received grant funding from GlaxoSmithKline, Boehringer Ingelheim, Almirall and Pfizer. In addition, the author has received payments for speaking at symposia and attending advisory boards for GlaxoSmithKline, Boheringer Ingelheim, Almirall, Dey Pharmacautical, Astra Zeneca and Pfizer. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
I. Cerveri has received fees for speaking from AstraZeneca, Boeringher, Glaxo, Merk and Novartis. DOI: 10.1183/09031936.00061611
K.K. Chana. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
J. Chapron. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
E. Chevalier is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
B. Chevalier. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
D. Crénesse. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
B.C.J. Cho. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
C. Chouaid has received fees for attending scientific meetings, speaking, organizing research, or consulting from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman la Roche, Lilly and Amgen. DOI: 10.1183/09031936.00201210
S.H. Choudhri is an employee of Bayer HealthCare and also hold Stock in Bayer AG. This study was funded by Bayer Schering Pharma. Highfield Communication Consultancy, funded by Bayer Shering Pharma, provided editorial assistance in the preparation of this manuscript. DOI 10.1183/09031936.00042111
A. Churg has been the recipient of research grants in excess of $1,500,000 from AstraZeneca R&D and $300,000 from GlaxoSmithKline. DOI: 10.1183/09031936.00121611
D.M. Cirillo has received diagnostic kits for free from Becton Dickinson, Hain, and Cephaid for clinical evaluation. D.M. Cirillo has been an invited speaker at the European Society of Mycobacteriology (ESM) 2011. DOI: 10.1183/09031936.00203811
E. Clini has received funds for research from Boheringer Ingelheim Italia. DOI:10.1183/09031936.00217111
H.R. Collard is a consultant for Actelion, FibroGen, and Gilead and receives funds for research from Genentech. DOI: 10.1183/09031936.00050911
R. Condliffe has received honoraria for lecturing from Actelion and GSK, has sat on advisory boards for Actelion and Bayer and has received conference funding from Actelion, GSK, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00078411
U. Costabel has received fees for lectures at symposia and consulting on IPF from Boehringer Ingelheim, Gilead and InterMune. DOI: 10.1183/09031936.00009112
C.M. Costello. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
V. Cottin has received fees for speaking from Intermune, Boehringer Ingelheim, and Actelion, and has participated as investigator to clinical trials sponsored by Intermune, Boehringer, and Actelion, and as member of the steering committee of a clinical trial sponsored by Boehringer Ingelheim. DOI: 10.1183/09031936.00009112
V. Cottin has received fees for speaking and has participated as investigator to clinical trials sponsored by from Intermune. DOI: 10.1183/09031936.00217111
B. Coudert has received reimbursement for attending a symposium, a fee for speaking, funds for research or funds for a member of board of expertise from Roche Laboratories France. DOI: 10.1183/09031936.00201210
M. Coupe is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
H.O. Coxson received $4,800 in the years 2006–2010 for serving on the steering committee for the ECLIPSE project for GSK. In addition, the author was the co-investigator on two multicentre studies sponsored by GSK and has received travel expenses to attend meetings related to the project. He has three contract service agreements with GSK to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc to measure changes in lung volume in subjects with severe emphysema. He was the co-investigator on a Canadian Institutes of Health–Industry (Wyeth) partnership grant. He has received a fee for speaking at a conference and related travel expenses from AstraZeneca (Australia). He is currently the recipient of a GSK Clinical Scientist Award. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
J-L. Cracowski has received unrestricted research grants from Pfizer and Actelion, and has been a consultant for Actelion. DOI: 10.1183/09031936.00155411
B. Crestani. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
A.A. Cruz has participated on advisory boards for AstraZeneca and Merck. He has received lecture fees from AstraZeneca, GlaxoSmithKline, Merck, Novartis and Mantecorp; sponsorship for investigator-generated research from GlaxoSmithKline, Novartis; and research funding for participating in multicenter studies from AstraZeneca, GlaxoSmithKline, Novartis, Nycomed and Eurofarma. He has received support for the production of educational materials from GlaxoSmithKline, Merck, Novartis, LIBBS. He has received governmental support as Scientist of the Brazilian Research Council (CNPq) and is a member of the Board of Directors of the Global Initiative for Asthma (GINA) and Allergic Rhinitis and its Impact on Asthma (ARIA) and of the Planning Group of the Global Alliance against Chronic Respiratory Diseases. DOI: 10.1183/09031936.00184511
D Back to top
S.M. Danilov is the sole proprietor of Mono-ACE (Chicago, IL, USA) and has agreements with several companies for the supply of mAbs to ACE. The angiotensin-converting enzyme-targeting antibody used in the present study is manufactured by Mono-ACE. DOI: 10.1183/09031936.00187310
E. Dansin has received consultancy fees (less than USD 10,000) from Roche. DOI: 10.1183/09031936.00201210
P. Dartevelle has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. DOI: 10.1183/09031936.00008912
M. Dassaud is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
C. Davies has received conference funding from Pfizer. DOI: 10.1183/09031936.00078411
J. de Blic. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
M-P. Debray. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
M. Dehoux. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
J.C. de Jongste received a speakers fee from GSK, and performed research that was financially supported by Aerocrine and GSK. All payments went to his department. DOI 10.1183/09031936.00151010
P. Delaval. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
F. de Pablo. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
A. Deschildre has relationships with drug companies including GSK, MSD and Novartis. Relationships include consultancy and membership of scientific advisatory boards. Travel to ERS and ATS congresses was funded by GSK, to AAAAI by ALK. DOI: 10.1183/09031936.00185310
H. Dib Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
J. Dippon. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
J. Duran-Cantolla. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
C. Disdier Received fees and travel grant from Boheringer. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
L.E. Donnelly has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pfizer, all of whom market treatments for treating airway diseases. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
Q. Dornic. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
G.C. Dungan II has received consulting for research design fees from Fisher and Paykel Healthcare, Ltd. NZ and research funding provided by Fisher and Paykel Healthcare, Ltd NZ – for product validation study. DOI: 10.1183/09031936.00093811
M. Dupont is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
J. Duran-Cantolla. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
E. Durán-Tauleria. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
X. Duval. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
R.A. Dweik. This author’s institution has received grants from Novartis, Gilead, and Actelion. DOI 10.1183/09031936.00067011
E Back to top
J.J. Egan. This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
J.J. Egan. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
J.J. Egan. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
J.S. Elborn. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
C.A. Elliot has sat on advisory boards for, received consultancy and lecturing fees from and been funded to attend conferences from Actelion, Bayer, Encysive, GSK, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00078411
G. Engström is a full-time employee of AstraZeneca R&D and received stocks ownership as part of the bonus system in the AstraZeneca. The present study was supported, in part, by AstraZeneca. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
M. Ennis. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
R. Ehmann. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
C. Ernen was supported by an educational grant from Bayer Vital. DOI 10.1183/09031936.00098411
A. Ernst has received consulting fees from Pulmonx Inc., and presented results of the VENT study at a FDA hearing. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
A. Ernst has received consulting fees from Uptake Medical. This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
A.M.V. Evelein. The author’s study was part-funded by GlaxoSmithKline, The Netherlands. The funding agencies did not have any role in the study design, data collection, analysis and interpretation of data, or in the writing of the article and the decision to submit it for publication. DOI: 10.1183/09031936.00188310
F Back to top
L. Fabbri reports having served as a consultant to Nycomed, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche and Pfizer; having been paid lecture fees by Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, Roche and Pfizer; and having received grant support from Nycomed, Abbott, AstraZeneca, Boehringer Ingelheim, Menarini, Novartis, Schering Plough, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Italian Ministry of Health, and Italian Ministry for University and Research. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
S. Fandos. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
H. Fargeau is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
R. Farré. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
P.S. Fenwick. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
G.T. Ferguson has received consulting fees from Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline and Novartis; speaking fees from Boehringer-Ingelheim, GlaxoSmithKline and Pfizer; and grant support from Boehringer-Ingelheim, Forrest, GlaxoSmithKline and Novartis. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
M. Ferrer. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
J.H. Ficker has received a research grant from Emphasys Inc. for his department and for his study team.The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
J.M. FitzGerald has received advisory boards and speakers fees from AstraZeneca, GSK, Merck, BI, Novartis and Nycomed. He has received fees or grants paid and used for research from GSK, BI, Wyeth, Genentech, Topigen, Canadian Institute for Health Research, Medimmune, Pharmaxis, Novartis and AllerGen NCE. DOI: 10.1183/09031936.00184511
A. Fischer serves as a consultant for Actelion Pharmaceuticals, and is a member of the speaking bureau for Actelion Pharmaceuticals and Gilead Pharmaceuticals. DOI: 10.1183/09031936.00041411
P. Foccoli. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
K. Forsman-Semb is a full time employee of AstraZeneca R&D and received stocks/shares in the Astra Zeneca to the value of $5,001–10,000. The present study was supported, in part, by AstraZeneca. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
M. Fric is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
G. Friedel. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
U. Friedrich owns the dog obedience school where the dog training was performed and receives salaries for training dogs for various civil applications. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
E. Frija-Orvoen received reimbursement from Vitalair for attending a congress not related to the study. DOI: 10.1183/09031936.00153311
G Back to top
S. Gaine has received honoraria from many of the pharmaceutical companies involved with pulmonary hypertension, for speaking and advisory boards, including Actelion, GSK, Lung Rx, and Pfizer. He has received research support from Actelion and Pfizer. AstraZeneca has funded his travel to the ATS congress. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
B. Galdiz. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
G. Garcia has received fees for lecture from Chiesi, MSD and Novartis. Travel to the ERS congress was funded by MSD, and travel to the ATS congress by GSK. DOI: 10.1183/09031936.00019911
J. Garcia-Aymerich. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
S. Gasparini. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
S. Gasparini. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
C. Geltner. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
M. Gerhardsson de Verdier is a full-time employee of AstraZeneca R&D and received stocks ownership as part of the bonus system in the AstraZeneca. The present study was supported, in part, by AstraZeneca. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
P.G. Gibson has received funds for preparing educational material, speaking in an educational symposium, and related travel from GlaxoSmithKline, Pharmaxis, Novartis, AstraZeneca, and Boerhinger Ingelheim. DOI: 10.1183/09031936.00022011
L. Giovanni-Chami. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
B. Girerd has received research support or attended conferences organised by companies including Actelion, Bayer, GSK and Pfizer. DOI: 10.1183/09031936.00185011
T. Gislason received funding for the BOLD study in Iceland from GlaxoSmithKline and AstraZeneca. TG has participated in COPD workshops funded by AstraZeneca, Pfizer and GlaxoSmithKline. TG has received travel funding for ERS by AstraZeneca and Pfizer. DOI 10.1183/09031936.00002711
C. Godet has received speaker and consultancy fees from Pfizer and Gilead. DOI: 10.1183/09031936.00162311
U.M. Goehring is an employee of Nycomed. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
X. Gonzalez is an employee of Spiration, Inc. (acquired by Olympus Corporation of the Americas, June 2010), but is not a stockholder in Olympus. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
M.H. Gottfried has received research grant support from Uptake Medical and Aeris Therapeutics. This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
J. Gottlieb. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
A. Greenough has held grants and received honoraria for giving lectures and advising various ventilator manufacturers. DOI: 10.1183/09031936.00066511
R.R. Grunstein. The author’s department has received funding in the past 5 yrs from Fisher-Paykel Healthcare for sponsored research and equipment grants from Philips Respironics and ResMed. He is a scientific advisor to DiagnoseIT, which received funding from the Australian Dept of Industry to complete this study. DOI: 10.1183/09031936.00093811
L. Guillevin has relationships with drug companies including Actelion, CSL Behring, GSK and Roche. In addition to being investigator in trials involving Actelion, relationships include consultancy service and membership of scientific advisory boards. Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
H Back to top
T. Haahtela has received fees for speaking or consultation from Abdi Ibrahim, ALK-Abello, Orion Pharma, MSD, Novartis and Nycomed; advisory board fees from Orion Pharma and Merck Sharp & Dohme (MSD); and lecture fees from ALK/Abello, AstraZeneca, MSD, Meda Oy and Orion Pharma. DOI: 10.1183/09031936.00184511
N. Hamilton has received consultancy and lecturing fees and been funded to attend conferences from Actelion, Encysive, GSK and Pfizer. DOI: 10.1183/09031936.00078411
D. Hartl has received funding from the Novartis Foundation.
D. Haverstock is an employee of Bayer Healthcare. This study was funded by Bayer Schering Pharma. Highfield Communication Consultancy, funded by Bayer Shering Pharma, provided editorial assistance in the preparation of this manuscript. DOI 10.1183/09031936.00042111
S.L. Hazen is the scientific founder of Cleveland Heart Lab (CHL), has received research grant support from Abbott Laboratories, Cleveland Heart Lab (CHL), Esperion, Liposcience; and/or has received honoraria and consulting fees from Abbott Laboratories, Cleveland Heart Lab (CHL), Merck, Lilly, LipoScience, and Pfizer. DOI 10.1183/09031936.00067011
I.H. Heijink. This study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00193810
L. Hendeles. In February 2009, the author received a consulting fee from Monaghan Medical, manufacturer of the Aerochamber, to present a lecture to Forrest Laboratories on use of valved holding chambers and a travel grant to attend a pharmacy meeting. In April 2009, Forrest Laboratories, distributor of the Aerochamber, paid a lecture fee and travel expenses for the author to give a lecture to its salesforce. The study was supported, in part, by a grant from GlaxoSmithKline (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00185510
G.A. Heresi G.A.H. has received a board fee from Lung Rx United Therapeutics; his institution has received grants from Gilead Sciences Research Scholars Program and from Bayer HealthCare Pharmaceuticals. DOI 10.1183/09031936.00067011
L. Hernández. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
F.J.F. Herth has received fees for speaking from AstraZeneca, GlaxoSmithKline, Pfizer, Boehringer, Roche, Lilly, Nycomed and Medupdate. The fees were all below €1,000 and unrelated to the trial. He has also received funds for research from the Federal Ministry of Education and Research and German Center of Lung Research. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
F.J.F. Herth. has received fees below €1,000 for speaking from AstraZeneca, GlaxoSmithKline, Pfizer, Boehringer, Roche, Lilly, Nycomed and Medupdate This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
R. Hervàs. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
J. Hetzel Payment for speaking about the use of cryoprobes in bronchology from ERBE GmbH, Tuebingen, Germany; ERBE also provided funding for both the presented trail (€10 per patient) and provision of the cryoprobes. DOI 10.1183/09031936.00033011
M. Hetzel In 2009, M. Hetzel received a fee of €1000 from ERBE , Germany for speaking about the use of cryoprobes in bronchology. DOI 10.1183/09031936.00033011
C. Hill has received conference funding from Pfizer and fees for lecturing from GE. DOI: 10.1183/09031936.00078411
N. Hill has received research grants >€10,000, and consulting fees >€1,000 and <€5,000 from Philips Respironics. DOI: 10.1183/09031936.00056111
M.M. Hoeper has received honoraria for speaking at conferences and/or consultations from Actelion, Bayer, Gilead, GSK, Lilly, LungRx, Novartis and Pfizer. DOI: 10.1183/09031936.00092311
S. Hoette’s travel to the ATS conference in 2010 and ERS congress in 2010 was funded by Bayer. DOI: 10.1183/09031936.00019911
E.A. Hoffman has received consulting fees from Roche Pharmaceuticals, Sanofie-Aventis and Astra Zeneca. The author is a founder and shareholder of VIDA Diagnostics, a company commercialising software developed for lung image analysis at the University of Iowa. He has patents and an interest in Vida Diagnostics. DOI: 10.1183/09031936.00165410
P. Hofman. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
D. Holmes-Higgin is an employee and stakeholder of Pulmonx Inc. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
M.D. Holmes. The angiotensin-converting enzyme-targeting antibody used in the present study is manufactured by Mono-ACE (Chicago, IL, USA). DOI: 10.1183/09031936.00187310
R. Hooper had travel and accommodation at the 2009 ERS Congress funded by Boehringer Ingelheim. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
A. Hope. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
P. Hopkins This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
N.S. Hopkinson has been an investigator in studies of airway valves (Emphasys) and airway bypasses (EASE trial). DOI: 10.1183/09031936.00217411
K. Howell. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
M. Humbert has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, the author’s relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00039811
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00019911
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer, Chiesi, GSK, Lilly, MSD, Novartis, Nycomed, Pfizer, Stallergenes, TEVA and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00185011
M. Humbert has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. DOI: 10.1183/09031936.00008912
M. Humbert has relationships with drug companies including Actelion, Astrazeneca, BayerSchering, Chiesi, GSK, Lilly, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
J. Hurdman is part funded as a clinical research fellow by an unrestricted educational grant from Actelion and has received funding to attend conferences from Actelion, GSK and Pfizer. DOI: 10.1183/09031936.00078411
D. Hwang. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
I Back to top
M.I. Illie. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
D. Israel-Biet. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
J Back to top
X. Jaïs has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. DOI: 10.1183/09031936.00008912
H. Janssens has received incidental consultancy fees from Teva Pharma, AstraZeneca, Philips Respironics, Vectura and Ablynx, and has received research grants from Philips Respironics and AstraZeneca. Travel to the ERS Congress was partly funded by Teva Pharma. DOI: 10.1183/09031936.00020512
C.R. Jenkins is employed by the Woolcock Institute of Medical Research. The Institute receives funding for its ongoing education and research programmes from AstraZeneca and GlaxoSmithKline and conducts clinical trials for these and other pharmaceutical companies under contract. The author receives no monies directly through these sources. She undertakes research through the Co-operative Research Centre for Asthma, a collaborative research programme funded jointly by the Australian Government and Industry partners, but receives no personal funding. In the last 3 years, she has received reimbursement for Advisory Board Membership, consultancy and speakers fees from Altana, AstraZeneca, GlaxoSmithKline, Hunter Immunology, Novartis, Nycomed and Tyrian Diagnostics. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
H. Ji has received consultant fees from AstraZeneca and Innovation Center China (ICC). DOI: 10.1183/09031936.00010111
Z-C. Jing has relationships with drug companies including Actelion, Bayer Schering, Pfizer and United Therapeutics, in addition to being an investigator in trials sponsored by these companies; relationships include consultancy services and membership of scientific advisory boards. DOI 10.1183/09031936.00072911
A. Jithoo received a scholarship from the South African Thoracic Society which was funded by GSK and an academic prize from AstraZeneca. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
P.W. Jones has received consulting fees from Almirall, AstraZeneca, GlaxoSmithKline, Novartis, Roche and Spiration; speaking fees from AstraZeneca and GlaxoSmithKline; and grant support from GlaxoSmithKline. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
P.W. Jones has received consulting fees from Spiration Inc. in some years, up to US$5,000 per year. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
M. Josefson is an employer of AstraZeneca (Mölndal, Sweden). DOI:10.1183/09031936.00195610
K Back to top
S.M. Kawut has served on advisory panels, clinical trial steering committees and grant review committees for Gilead, Bayer, Pfizer and Actelion. The author has received lecture fees from Gilead and Actelion. DOI: 10.1183/09031936.00108111
S.M. Kawut received significant grant funding from Pfizer for an investigator-initiated trial in COPD. DOI: 10.1183/09031936.00165410
M.P. Keane has received research funding from GlaxoSmithKline, travel to ERS congress was funded by Pfizer and travel to ATS congress was funded by AstraZeneca. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
S. Keshavjee. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
S. Kesten is an employee of Uptake Medical. This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
D.G. Kiely has sat on advisory boards for, received consultancy and lecturing fees from and been funded to attend conferences from Actelion, Bayer, Encysive, GSK, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00078411
D.S. Kim is a consultant (steering committee) for Behringer-Ingelheim for the BIBF clinical trial for IPF and is principal investigator for the BUILD-III trial. DOI: 10.1183/09031936.00050911
S-W. Kim. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
A. Koarai has received a fellowship from Pfizer. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
A. Kocabas This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
M. Koopman. The author’s study was part-funded by GlaxoSmithKline, The Netherlands. The funding agencies did not have any role in the study design, data collection, analysis and interpretation of data, or in the writing of the article and the decision to submit it for publication. DOI: 10.1183/09031936.00188310
G.H. Koppelman has received a research grant from GSK (less than €5,000, paid to the author’s institution) and has spoken at an annual Dutch conference for Paediatricians on asthma organised by an independent committee (GSK; €900, paid to the author’s institution). DOI: 10.1183/09031936.00094511
S. Krüger has received honoraria for speaking at symposia organised on behalf of BRAHMS AG. DOI: 10.1183/09031936.00179911
F. Kruesmann is an employee of Bayer Schering Pharma. This study was funded by Bayer Schering Pharma. Highfield Communication Consultancy, funded by Bayer Shering Pharma, provided editorial assistance in the preparation of this manuscript. DOI 10.1183/09031936.00042111
P. Kuna has received fees for speaking at company sponsored symposia of Schering Plough. This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Editorial support was funded by Merck Sharp & Dohme Corp. DOI: 10.1183/09031936.00020310
R.L. Kunka is a former employee of GlaxoSmithKline (Research Triangle Park, NC, USA). The study was supported, in part, by a grant from GlaxoSmithKline. DOI: 10.1183/09031936.00185510
L Back to top
Y. Lacasse. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
J. Lacronique. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
M. Ladanyi has served on an advisory panel to Astra-Zeneca (Canada) and has spoken at a meeting organised by Genzyme. DOI: 10.1183/09031936.00010111
C. Lafine Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
J.J. Lafitte has received reimbursement for attending symposia at the following congresses: SPLF, Marseille, 2010 and ASCO, Chicago, 2010 and San Francisco, 2009. DOI: 10.1183/09031936.00190310
C. LaForce received compensation from Schering, GSK, Astra Zeneca, Boehringer Ingleheim, Novartis, Alcon, Sunovion and Medimmune for administration of clinical trials in the past 5 years, including the study described in this manuscript. This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Editorial support was funded by Merck Sharp & Dohme Corp. DOI: 10.1183/09031936.00020310
D. Lardinois. The study was funded, in part, by the Novartis Research Foundation. DOI: 10.1183/09031936.00174310
A.B. Lasierra. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. The author received speaking honoraria (€250) from BRAHMS, the manufacturer of the MR-proADM assay, at the National Clinical Laboratory Spanish Congress 2010. DOI: 10.1183/09031936.00080411
J. Lausmaa has a pending patent on the method used in the study. DOI: 10.1183/09031936.00195610
P. Leblanc. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
K. Lebrigand. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
R. Lebtahi. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
D.J. Lederer is a steering committee member for Intermune’s ASCEND trial of pirfenidone for IPF. The author is co-investigator in clinical trials for IPF sponsored by Gilead and Boehringer-Ingelheim. He has served on advisory boards for Gilead in 2010 and 2011. DOI: 10.1183/09031936.00108111
S. Leduc is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
P. Lepper has received speaker fees from Bayer HealthCare. DOI 10.1183/09031936.00098411
S. Leroy. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
S. Leroy. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
M. Levy has accepted sponsorship from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Trinity-Cheisi, Merck Sharpe and Dohme, Merck, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, TEVA, Schering Plough for attending conferences. He has accepted lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Cheisi and Alk-Abello. He has been on advisory boards or provided consultancy for GlaxoSmithKline, Schering Plough, Merck Sharp and Dohme, Cheisi, Altana Pharma, Ranbaxy, AstraZeneca, TEVA and Novartis. He has had research grants from Boehringer Ingelheim, Pfizer, GSK. He is a member of the ADMIT Group, which receives an unrestricted educational grant from MEDA pharmaceuticals. Data Safety Monitoring Board (DSMB) for the FORWARD Study n° CCD-0906-PR-0016. DOI: 10.1183/09031936.00184511
C. Lindberg is a full time employee of Astra Zeneca and holds stocks in the company. The present study was supported, in part, by AstraZeneca. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
M. Lopez. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
E. Lopez de Santamaria. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
M Back to top
J.D. Maclay has received an educational travel grant from GSK to attend the BTS. DOI: 10.1183/09031936.00124811
W. MacNee has been reimbursed for travel by GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Pfizer for attending conferences. The author has received honoraria from GlaxoSmithKline, AstraZeneca and Pfizer for participating as a speaker in scientific meetings. He serves on advisory boards for GlaxoSmithKline and Pfizer. He also serves as a consultant for Pfizer. Research grants to support work carried out in his laboratory comes from Pfizer, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00124811
W. MacNee has been reimbursed for travel by GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Pfizer for attending conferences. The author has received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings. He serves on advisory boards for GlaxoSmithKline and Pfizer, and serves as a consultant for Pfizer. Research grants to support work carried out in his laboratory come from Pfizer and GlaxoSmithKline. DOI: 10.1183/09031936.00047111
F. Maltais received fees for speaking at conferences sponsored by Boehringer Ingelheim, Pfizer and GlaxoSmithKline. He served on an advisory board for GlaxoSmithKline and Boehringer Ingelheim. He received research grants for participating in multicenter trials sponsored by GlaxoSmithKline, Boehringer Ingelheim, Altana Pharma, Merck, AstraZeneca, Nycomed and Novartis. He received unrestricted research grant from Boehringer Ingelheim and GlaxoSmithKline. He holds a CIHR/GSK research chair on COPD. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511 DOI 10.1183/09031936.00059511
A. Mantovani has received travel funds from Sigma-Tau company to attend meetings on PTX3. DOI: 10.1183/09031936.00198111
B. Marcet. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
B. Mari. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
N.S. Marshall has recently completed an investigator-initiated trial funded by Fisher & Paykel. DOI: 10.1183/09031936.00093811
J.J. Martín-Villasclaras. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
M.A. McBurnie received funding for the BOLD study Operations Center and/or other research from unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca, ALTANA, Novartis, Merck, Chiesi, Schering Plough and Sepracor. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
B. McCullagh has received a fellowship grant from Actelion Pharmaceuticals. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
V.M. McDonald has been reimbursed for participation in symposia funded by AstraZeneca, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00022011
M.C. McKinley. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
P. McLoughlin. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
R. Menendez. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
R. Mehta is an employee of GlaxoSmithKline (Research Triangle Park, NC, USA). The study was supported, in part, by a grant from GlaxoSmithKline. DOI: 10.1183/09031936.00185510
F. Mentré. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
E.O. Meltzer has received grant/research support from the following companies: Alcon, Amgen, Alexza, Astellas, AstraZeneca, Boehringer Ingelheim, Capnia, Genentech, GSK, MAP Pharmaceuticals, Meda, Merck, Novartis, Sanofi-Aventis, Schering-Plough, Sepraco and Teva. E.O. Meltzer has been a consultant for: Abbot, Alcon, Amgen, AstraZeneca, Boehringer Ingelheim, Capnia, Genentech, GSK, Greer, Johnson & Johnson, MAP Pharmaceuticals, Meda, Merck, Novartis, Sanofi-Aventis, Schering-Plough, Sepraco and Wyeth. E.O. Meltzer has also been a speaker for: AstraZeneca, Alcon, Genentech, GSK, Meda, Merck, Novartis, Sanofi-Aventis, Schering-Plough and Sepraco. This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Editorial support was funded by Merck Sharp & Dohme Corp. DOI: 10.1183/09031936.00020310
J-F. Michiels. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
N. Miglino. The study was funded, in part, by the Novartis Research Foundation. DOI: 10.1183/09031936.00174310
J. Milot. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
E. Mincholé. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
M. Miravitlles has participated as speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: Boehringer Ingelheim, Bayer Schering Pharma, Pfizer, Novartis, AstraZeneca. M. Miravitlles has been a consultant for Boehringer Ingelheim; Bayer Schering Pharma, Pfizer, AstraZeneca and Novartis. This study was funded by Bayer Schering Pharma. Highfield Communication Consultancy, funded by Bayer Shering Pharma, provided editorial assistance in the preparation of this manuscript. DOI 10.1183/09031936.00042111
P. Mismetti. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
J.P. Mitchell is a full time employee of Trudell Medical International, a manufacturer of spacer devices that are the topic of the Correspondence. DOI: 10.1183/09031936.00210911
T. Mojgan. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
J. Molema. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
C. Moreilhon. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
F. Morin received funding for travel to the ASCO and/or IASLC congress from Roche, Lille, Sanofi-Aventis, Pierre Fabre and Merck Serono. DOI: 10.1183/09031936.00201210
I. Monnet. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
M. Monreal. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
J.M. Monserrat. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
D. Montani has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00019911
D. Montani has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, the author’s relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00039811
L. Mouthon has relationships with drug companies including Actelion, CSL Behring, Cytheris, GSK, LFB biotechnologies, Lilly, Octapharma and Pfizer. In addition to being investigator in trials involving Actelion, CSL Behring, LFB biotechnologies and Pfizer, relationships include consultancy service and membership of scientific advisory boards or DMC. Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
D. Montani has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. DOI: 10.1183/09031936.00008912
M. Munavvar. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
N Back to top
R. Naeije has received reimbursements for attending symposiums speaker fees and fees for consulting from Actelion. Pfizer, Bayer Healthcare, United Therapeutics and LungRX, a fee for organising education from Pfizer, funds for research from Actelion and Pfizer, and funds for a member of staff from Pfizer. DOI: 10.1183/09031936.00166211
S.D. Nathan has received research funding and is on the speakers’ bureau and has consulted for Actelion, Gilead and United Therapeutics. DOI: 10.1183/09031936.00175511
S. Nava has received travel grants, speaking fees and a consulting honorarium from the following companies. ResMed: travel grants and honorarium for a scientific board; Philips Respironics: speaking fees; Fisher and Paykel: travel grants; Weiman: travel grants. DOI: 10.1183/09031936.00056111
D. Navajas. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
A.S. Nayak, either through her role at the University of Illinois at Chicago or personally, has received grants, honorarias, or educational support from the following Pharmaceutical companies: Astra Zeneca, Sanofi Aventis Pharmaceuticals, Schering-Plough Research Institut, Sepraco, Teva, UCB Pharma and Merck Research Laboratories. A.S. Nayak has also received honoraria from the above pharmaceutical companies for speaking at meetings sponsored by these company and for sitting on company advisory boards. This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Editorial support was funded by Merck Sharp & Dohme Corp. DOI: 10.1183/09031936.00020310
A.G. Nicholson. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
V. Ninane has received reimbursement for attending a symposium on bronchial valve treatment of emphysema by Olympus Inc. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
U. Nihlén is a full-time employee of AstraZeneca R&D and received stocks ownership as part of the bonus system in the AstraZeneca. The present study was supported, in part, by AstraZeneca. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
H. Nolte is currently an employee of Merck Sharp & Dohme. This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Editorial support was funded by Merck Sharp & Dohme Corp. DOI: 10.1183/09031936.00020310
M. Noppen. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
M. Noppen. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
I. Noth has received honoraria for speaking for GSK speakers’ bureau, PILOT CME function and other vendors, and Pfizer speakers’ bureau. He has clinical trial contracts with Intermune, Actelion, Centacor, GSK, NHLBI and Asthmatx. I. Noth has also received honoraria for acting on an advisory board for GSK, Intemune, and DSMB for celgene. DOI: 10.1183/09031936.00099910
I. Noth has received honoraria for speaking for GSK speakers’ bureau, PILOT CME function and other vendors, and Pfizer speakers’ bureau. He has clinical trial contracts with Intermune, Actelion, Centacor, GSK, NHLBI and Asthmatx. I. Noth has also received honoraria for acting on an advisory board for GSK, Intemune, and DSMB for celgene. DOI: 10.1183/09031936.00099910
O Back to top
D.S. O’Callaghan has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00019911
D.E. O’Donnell has received research funding from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed and Pfizer; and has served on speakers bureaus, consultation panels and advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Pfizer. The study was funded by Nycomed GmbH (Konstanz, Germany). DOI: 10.1183/09031936.00096511
D.E. O’Donnell has served on advisory boards for Boehringer Ingelheim, Pfizer, GSK, Novartis and Nycomed, has received lecture fees from Boehringer Ingelheim, Astra Zeneca, Pfizer and GSK, and has received industry-sponsored grants from Boehringer Ingelheim, GSK and Merck Frost Canada and from Novartis and Pfizer. DOI: 10.1183/09031936.00205211
A-C. Olin has a pending patent on the method used in the study. DOI: 10.1183/09031936.00195610
K. Olsson has received speaker honoraria from Pfizer. DOI: 10.1183/09031936.00092311
L. O’Toole has been funded to attend conferences by Actelion. DOI: 10.1183/09031936.00078411
S.R. Ott received lecture fees from MSD, Bayer, and ResMed, received travel grants from Astra Zeneca, Bayer, and Novartis and is a member of national Advisory Boards of Pfizer and Bayer. DOI 10.1183/09031936.00098411
P Back to top
M. Pai is a consultant to the Bill & Melinda Gates Foundation (BMGF). BMGF had no involvement in this publication. The author was involved in developing the WHO policy on serological assays, and was also involved in conducting systematic reviews of TB serological tests. DOI: 10.1183/09031936.00070611
X. Palazzi is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
C.C. Patterson was employed as a biometrician by Gallaher in Belfast for two years in 1977–1979 but has had no subsequent contact with this or any other tobacco company. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
S. Pedersen has received fees for speaking from GlaxoSmithKline and Nycomed and consulting fees from GlaxoSmithKline, Meda, AstraZeneca, Neolab and Nycomed. DOI: 10.1183/09031936.00184511
V. Pepin received honoraries in 2008 ($2,000) for speaking at seminars sponsored by GlaxoSmithKline (GSK) and in 2010 ($1,500) for serving on an advisory board for GSK. She is also a co-investigator on a project funded by GSK’s Collaborative Innovative Research Fund ($184,044). The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
R. Perroncel is an employee and stockholder by Bayer Healthcare Pharmaceuticals which manufactures drugs for the treatment of AECB. This study was funded by Bayer Schering Pharma. Highfield Communication Consultancy, funded by Bayer Shering Pharma, provided editorial assistance in the preparation of this manuscript. DOI 10.1183/09031936.00042111
J-P. Pignon received educational unrestricted grants from Sanofi and Roche for meta-analysis projects. DOI: 10.1183/09031936.00201210
M. Pletz has received fees for speaking from Pfizer, Astra Zeneca, Bayer, Gilead and MSD; travel to the ECCMID congress was funded by Pfizer. The author is a member of the advisory boards of Pfizer and Merck. DOI 10.1183/09031936.00098411
M.I. Polkey has received either personally or through his institution money for consulting and for research into the topic of skeletal muscle weakness and COPD (but not critical care myopathy) from GSK, Novartis, AZ and Chiesi. DOI: 10.1183/09031936.00090011
D.S. Postma. This study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00193810
M. Pottier received reimbursement from Vitalair for attending a congress not related to the study. DOI: 10.1183/09031936.00153311
D.B. Price has consultant arrangements with Altana, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Pfizer, Sandoz and Teva. The author or his research team has received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer and Teva. He has spoken for Almirral, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Pfizer and Teva. He has shares in AKL Ltd which produces phytopharmaceuticals. He is the sole owner of Research in Real Life Ltd. DOI: 10.1183/09031936.00200411
S. Provencher. The present study was supported by an unrestricted educational grant from Boehringer Ingelheim and Pfizer (Canada). The sponsor (Boehringer Ingelheim and Pfizer) was not involved in the study design, data collection, analysis or interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI 10.1183/09031936.00059511
Q Back to top
S. Quenet. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
E. Quoix has acted as a speaker in symposiums and served in advisory boards (Roche and AstraZeneca). DOI: 10.1183/09031936.00201210
R Back to top
K.F. Rabe. Although not employed by the European Respiratory Society, the author regards his function as an officer of that organisation as an interest that he wishes to state. The trials analysed in the study under discussion were funded by Nycomed. DOI: 10.1183/09031936.00162911
J. RamÃrez. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
A. Ramsay was involved in developing the WHO policy on serological assays, and was also involved in conducting systematic reviews of TB serological tests. DOI: 10.1183/09031936.00070611
A. Regent Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
M. Reynaud-Gaubert. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
G. Riely was a compensated consultant for AstraZeneca and Boehringer-Ingelheim. DOI: 10.1183/09031936.00010111
M.I. Restrepo participated in advisory boards for Theravan, Forest Laboratories, Johnson & Johnson and Novartis. He has acted as aonsultant for Theravan and Pfizer (Wyeth). DOI: 10.1183/09031936.00166811
A.M. Reynolds. The angiotensin-converting enzyme-targeting antibody used in the present study is manufactured by Mono-ACE (Chicago, IL, USA). DOI: 10.1183/09031936.00187310
P.N. Reynolds. The angiotensin-converting enzyme-targeting antibody used in the present study is manufactured by Mono-ACE (Chicago, IL, USA). DOI: 10.1183/09031936.00187310
V. Richard is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
M.L. Rivera. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
K. Robbe-Sermesant. The study was funded indirectly by AstraZeneca (via a grant to SP2A). DOI: 10.1183/09031936.00070511
J. Roca has stocks to the value of €3,500 in Linkcare Health Solutions SL. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
N. Roger. The study was funded, in part, by an unrestricted grant from Boheringer-Pfizer. DOI: 10.1183/09031936.00168010
A. Rosell. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
M.J. Rosen is an employee of the American College of Chest Physicians (ACCP), and has received honoraria for organizing and teaching at the ACCP Pulmonary Board Review Course. DOI: 10.1183/09031936.00189211
M. Roth. The study was funded, in part, by the Novartis Research Foundation. DOI: 10.1183/09031936.00174310
M.A. Ruiz. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
R.E.K. Russell. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
S Back to top
I. Sabroe has received honoraria for lecturing from Astra-Zeneca, GSK and Triniti-Chiesi and been funded to attend conferences by Actelion, Astra-Zeneca and GSK. He receives financial support from GSK for an educational meeting he runs. Work in his lab is funded by a GSK/BBSRC CASE studentship. DOI: 10.1183/09031936.00078411
C. Sadowsky. The study was funded, in part, by the Novartis Research Foundation. DOI: 10.1183/09031936.00174310
M. Saetta has received honoraria from Farmaindustria, AstraZeneca, GlaxoSmithKline, Abbott Labs, Boehring Ingelheim and Merck Sharpe & Dome. In addition the author has received industry -sponsored grants from GlaxoSmithKline, AstraZaneca, Nycomed and Chiesi Farmaceutici. DOI: 10.1183/09031936.00135711
J. Sagert. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
R. Saggar has received speaker and consulting fees in the past from Actelion Pharmaceuticals, United Therapeutics and Gilead Sciences. DOI: 10.1183/09031936.00166211
M. Sands. The study was funded in part by an unrestricted research grant from Actelion. CXCR7 inhibitors were kindly provided by M.E. Penfold at ChemoCentryx Inc. DOI: 10.1183/09031936.00044911
B.M. Sanner has served as a medical advisor and has received travel grants and honoraria for lectures from Weinmann, Germany. DOI 10.1183/09031936.00052611
L. Savale has relationships with drug companies including Actelion, Novartis and Pfizer. In addition to being investigator in trials involving these companies, relationships include consultancy service. DOI: 10.1183/09031936.00019911
T.R.J. Schermer has received unrestricted fees or grants for their department used for research, education, equipment, salaries, etc. from the Netherlands Asthma Foundation, Netherlands Organisation for Health Research and Development, NutsOhra Fund, GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, which did not interfere with any study with regards to design, data collection, analyses, manuscript submission in any way. DOI: 10.1183/09031936.00088011
T.R.J. Schermer. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
V Schlünssen has received a fee for speaking at a scientific meeting by GlaxoSmithKline Pharma A/S in 2011. DOI: 10.1183/09031936.00096111
B.C. Schock. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
U.J. Schoepf is a consultant for and receives research support from Bayer, Bracco, GE, Medrad and Siemens. DOI: 10.1183/09031936.00088711
L. Seijo. The author’s institution received reimbursement from Spiration Inc. for expenses related to the present study including evaluation, treatment, hospitalisation and follow-up of patients enrolled in the current investigation. The institution’s nurse coordinator was reimbursed for time dedicated to data collection, etc. The author has received no consulting fees, stipend or reimbursement for his participation in the study. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
P. Sephton has received funding to attend conferences from Actelion and GSK and a fee for speaking from the Pulmonary Hypertension Association (UK). DOI: 10.1183/09031936.00078411
P.L. Shah The host institutions (Royal Brompton Hospital and the Chelsea and Westminster Hospital) have been reimbursed for clinical trial expenses undertaken by P.L. Shah for Asthmatx, Boheringer-Ingelheim, Broncus, Olympus, and PneumRx. DOI 10.1183/09031936.00033011
P.L Shah has received funding from Asthmatx for the RISA trial (Royal Brompton Hospital reimbursed for clinical trial expenses) and the AIR2 trial (Chelsea & Westminster Hospital reimbursed for clinical trial expenses), Boehringer Ingelheim for the RECOVER trial (Chelsea & Westminster Hospital reimbursed for clinical trial expenses) and the REMEDY trial (Chelsea & Westminster Hospital reimbursed for clinical trial expenses), Broncus and Asthmatx for the EASE trial (Royal Brompton Hospital reimbursed for clinical trial expenses), Olympus for the IBV investigator study (Royal Brompton Hospital reimbursed for clinical trial expenses), and PneumRX for an RCT with RePneu coils (Royal Brompton Hospital and Chelsea & Westminster Hospital reimbursed for clinical trial expenses). The author has received sponsorship from Cook Medical, ERBE, Olympus, PneumRX and Superdimension for a bronchoscopy course at Imperial College London. The author has received consultancy fees from Olympus. The author has received lecture fees from Novartis. DOI: 10.1183/09031936.00217411
J-Y. Shih has received honoraria from AstraZeneca and Roche for talks. DOI: 10.1183/09031936.00043511
O.A. Shlobin serves as a speaker for United Therapeutics and Actelion Pharmaceuticals. DOI: 10.1183/09031936.00175511
A. Simonds has received research grants, support for a member of staff and reimbursement to attend a symposium from ResMed Ltd. DOI: 10.1183/09031936.00056212
G. Simonneau has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00019911
G. Simonneau has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00185011
G. Simonneau has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. DOI: 10.1183/09031936.00008912
G. Simonneau has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
O. Sitbon has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. He has received reimbursement for attending symposium, funds for research and fees for speaking from these companies. DOI: 10.1183/09031936.00019911
O. Sitbon has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, fees for speaking and membership of scientific advisory boards. DOI: 10.1183/09031936.00008912
G. Snell has received partial reimbursement from Uptake Medical of travel costs incurred in attending the ATS; has received 1000 euro in consulting fees. This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
T. Spencer. The study was supported, in part, by a grant from GlaxoSmithKline (Research Triangle Park, NC, USA). DOI: 10.1183/09031936.00185510
S.C. Springmeyer is an employee of Spiration, Inc. (acquired by Olympus Corporation of the Americas, June 2010), but is not a stockholder in Olympus. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
F. Stanzel This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
K. Steingart serves as co-chair of the Evidence Synthesis subgroup of Stop TB Partnership’s New Diagnostics Working Group. The author was involved in developing the WHO policy on serological assays and was also involved in conducting systematic reviews of TB serological tests. DOI: 10.1183/09031936.00070611
M.E. Strek has industry contracts for clinical trials with Intermune, GSK, Gilead and J&J. DOI: 10.1183/09031936.00099910
M.E. Strek has industry contracts for clinical trials with Intermune, GSK, Gilead and J&J. DOI: 10.1183/09031936.00099910
M. Svartengren participated in an advisory board for and received lecture fees from Heda, Sweden AB, and received <$5,000 for both. The author received an industry-sponsored grant from AstraZeneca in present project. Editorial support for the present study was funded by AstraZeneca. DOI: 10.1183/09031936.00064611
J.J. Swigris has served as a paid consultant for Actelion, Bayer, Gilead and Genentech. The author was paid by Actelion for his participation in an event designed to educate their scientific staff about idiopathic pulmonary fibrosis. DOI: 10.1183/09031936.00041411
M. Szyrach is researcher at ERBE, Tuebingen, Germany. DOI 10.1183/09031936.00033011
T Back to top
W.H.W. Tang has received research grant support and honorarium for speaker for an educational program from Abbott Laboratories. DOI 10.1183/09031936.00067011
M.C. Tamby received a grant from Pfizer. Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
M. Tamm. The study was funded, in part, by the Novartis Research Foundation. DOI: 10.1183/09031936.00174310
W.C. Tan received funding for the BOLD study Operations Center and/or other research from unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca, ALTANA, Novartis, Merck, Chiesi, Schering Plough and Sepracor. WCT has served on advisory boards for GlaxoSmithKline. WCT has participated in COPD workshops funded by GlaxoSmithKline. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
M. Taremi. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
A. Tazi. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
M. Thomas has received speaker’s honoraria for speaking at sponsored meetings from the following companies marketing respiratory and allergy products: AstraZeneca, Boehringer Ingelheim, GSK, MSD, Napp, Schering-Plough and Teva. The author has received honoraria for attending advisory panels from AstraZeneca, BI, GSK, MSD, Merck Respiratory, Schering-Plough, Teva, Abbott and Novartis. He has received sponsorship to attend international scientific meetings from: GSK, MSD and AstraZeneca. He has received funding for research projects from GSK, MSD and AstraZeneca. He held a research fellowship and is Chief Medical Advisor to Asthma UK. He is a member of the UK Department of Health Asthma Strategy Group and Home Oxygen Group. He is a member of the MHRA Respiratory and Allergy Expert Advisory Group. He is a member of the BTS SIGN Asthma guideline group. He is a member of the EAAACI Rhinosinusitis (EPOS) guideline group. DOI: 10.1183/09031936.00200411
V.Ø. Thomsen. The institute he is affiliated with, Statens Serum Institut, Copenhagen, Denmark, is highly involved in TB as a producer of BCG and tuberculin, a distributor of kits for detection of M. tuberculosis infection, and as a diagnostic and research centre. DOI: 10.1183/09031936.00203811
J.A. Tolodí. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
C. Tolosa. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
C. Tolosa. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
A. Torres. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. The author has received research grants from Pfizer and Covidien. He has participated in the advisory boards of Astellas, Sanofi-Aventis. DOI: 10.1183/09031936.00080411
M. Torres. Esteve-Teijin provided gas concentrators that were used to prepare gas mixtures. DOI: 10.1183/09031936.00185110
K. Treacy. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
S.L. Traves. This study was supported by Boehringer Ingelheim GmbH. DOI: 10.1183/09031936.00136710
M. Tsao. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
U Back to top
C.S.P.M. Uiterwaal. The author’s study was part-funded by GlaxoSmithKline, The Netherlands. The funding agencies did not have any role in the study design, data collection, analysis and interpretation of data, or in the writing of the article and the decision to submit it for publication. DOI: 10.1183/09031936.00188310
V Back to top
M. Valdés. This registry was supported by an unrestricted educational grant from Sanofi-Aventis (Spain) and Bayer Schering Pharma. The support from Bayer Schering Pharma was limited to the part of RIETE conducted outside of Spain, which accounts for a 13.39% of the total patients included in the RIETE registry. DOI: 10.1183/09031936.00058811
A. Valipour. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
A. Valipour has within the last five years received speaking fees for participiation at satellite symposia and industry sponsored events from Astra Zenecea, Boehringer Ingelheim, Novartis, and Pfizer. Furthermore travel to the ERS within the last couple of years was sponsored by Astra Zeneca and Boehringer Ingelheim. This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
A. Valipour. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
C.K. van der Ent has received unrestricted research grants from Grunenthal and GlaxoSmithKline. DOI: 10.1183/09031936.00086211
C.K. van der Ent. The author’s study was part-funded by GlaxoSmithKline, The Netherlands. The funding agencies did not have any role in the study design, data collection, analysis and interpretation of data, or in the writing of the article and the decision to submit it for publication. DOI: 10.1183/09031936.00188310
A.C. van der Gugten. The author’s study was part-funded by GlaxoSmithKline, The Netherlands. The funding agencies did not have any role in the study design, data collection, analysis and interpretation of data, or in the writing of the article and the decision to submit it for publication. DOI: 10.1183/09031936.00188310
A.J.M. van Oosterhout. This study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00193810
G.R. Van Pottelberge has received a travel grant for the European Respiratory Society Congress from Boehringer Ingelheim and the author’s travel to the EAACI congress was funded by Merck Sharp & Dohme. DOI: 10.1183/09031936.00138110
C. van Weel received unrestricted fees or grants for their department for research, education, equipment, salaries, etc. from Bayer, NovoNordisk, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis, which did not interfere with any study with regards to design, data collection, analyses, manuscript submission or whatsoever. DOI: 10.1183/09031936.00088011
C. van Weel. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
E. Vera. The study was partially funded by a 2010 grant from the Aragon Respiratory Society (SADAR) (€4,500) and the 2009 Brahms Prize from the José Luis Castaño Foundation for the Development of Clinical Biochemistry of the Spanish Society for Clinical Biochemistry and Molecular Pathology (SEQC) (€6,000). In 2009, the authors reached an agreement with Brahms Iberia S.L. by means of which they provided instrumentation and reagents for MR-proADM and, partially, PCT determinations. In February 2011, the authors received €2,500 from Brahms Iberia SL for finishing the current research. All this money was used to purchase 14 viral PCR kits and other laboratory material. The investigators did not receive any amount of money personally. The funding organizations played no role in the study design, data collection and analysis, or manuscript approval. Qiagen Sample and Assays Technologies performed free of charge the second PCR viral test (RT-PCR commercial kit, the ResPlex II Plus Panel) in Hamburg, Germany. DOI: 10.1183/09031936.00080411
J.H. Vercoulen. The present study was supported, in part, by Boehringer Ingelheim BV (Ingelheim, Germany). DOI: 10.1183/09031936.00057811
F. Vergne is an employee of Pfizer Global Research and Development. DOI: 10.1183/09031936.00102610
J-M. Vergnon has received research funds from Emphasys Inc. The study was sponsored by Emphasys Medical (now Pulmonx, Inc). DOI: 10.1183/09031936.00161611
T.J.M. Verheij. The author’s study was part-funded by GlaxoSmithKline, The Netherlands. The funding agencies did not have any role in the study design, data collection, analysis and interpretation of data, or in the writing of the article and the decision to submit it for publication. DOI: 10.1183/09031936.00188310
J. Vestbo has received fees for presenting and advising from GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer-Ingelheim, Nycomed, Novartis, Talecris, Hoffmann-La Roche and Chiesi. The author’s department holds a research grant from GlaxoSmithKline for the ECLIPSE study. In addition, his wife has previously worked for several pharmaceutical companies, including GlaxoSmithKline. In 1985, he received 267,000 Danish Kroner as an unconditional grant from the Scandinavian Tobacco Company Charity Foundation. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
W.M. Vollmer received funding for the BOLD study Operations Center and/or other research from unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca, ALTANA, Novartis, Merck, Chiesi, Schering Plough and Sepracor. WMV has served on advisory boards for Merck. WMV has participated in COPD workshops funded by Merck and GlaxoSmithKline. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
W Back to top
M. Wagner This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
B. Wallaert. Octreotide was kindly donated by Novartis Pharma. DOI: 10.1183/09031936.00113011
T. Walles. The study was funded by private financial resources of R. Ehmann, E. Boedeker and T. Walles. DOI: 10.1183/09031936.00051711
K.A. Webb received consultation fees as part of the quality assurance process for evaluation of exercise tests results reported in this study. The study was funded by Nycomed GmbH (Konstanz, Germany). DOI: 10.1183/09031936.00096511
A.U. Wells has received fees for speaking and consultancy work from Actelion and Intermune, and consultancy fees from Gilead, Centricorp and Novartis. DOI: 10.1183/09031936.00009112
T. Welte has received fees for lectures from Bayer, MSD, Astellas, Pfizer and Novartis; The author is member of the advisory board of Pfizer, Astellas and Novartis. DOI 10.1183/09031936.00098411
T. Welte has served on advisory boards for GlaxoSmithKline, ALTANA, Merck, Novartis, Pfizer. TW has participated in COPD workshops funded by Merck, AstraZeneca, Pfizer. This study was supported by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Sepracor. DOI 10.1183/09031936.00002711
T. Welte. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
V. Westeel has received reimbursement for attending meetings from Roche, Lilly and Astra-Zeneca, fees for speaking from Lilly and Roche, fees for consulting from Lilly and Roche, and funds for research from Roche. DOI: 10.1183/09031936.00190310
V. Westeel has received reimbursement for attending meetings from Roche, Lilly and Astra-Zeneca, fees for speaking from Lilly and Roche, fees for consulting from Lilly and Roche, and funds for research from Roche. DOI: 10.1183/09031936.00201210
K. Whyte has received speaker fees and travelling/accommodation expenses from Actelion Ltd. & Bayer Schering Ltd., both of these companies market pulmonary vasodilator therapies. DOI: 10.1183/09031936.00019911
J.M. Wild has received unrestricted educational grants and conference funding from GE and GSK and has advised GE Healthcare, Merck and Schering Plough on lung MRI methods. DOI: 10.1183/09031936.00078411
J. Wildhaber has received fees for performing research, giving presentations, and consultancy from GlaxoSmithKline, AstraZeneca, Merck, and Nycomed. The survey and editorial assistance in the preparation of the manuscript were funded by Nycomed. DOI: 10.1183/09031936.00048911
C. Witt This study was funded by Uptake Medical Corp. DOI 10.1183/09031936.00092411
V. Witko-Sarsat Pfizer supported the project CIRC 05066, HTAP-Ig. DOI 10.1183/09031936.00181410
J.V. Woodside Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
J.L. Wright has been the recipient of research grants in excess of $1,500,000 from AstraZeneca R&D and $300,000 from GlaxoSmithKline. DOI: 10.1183/09031936.00121611
Y Back to top
K. Yasufuku. The author’s study was supported by Elekta, Inc. DOI: 10.1183/09031936.00075811
J.C. Yates is employed by and holds stock in GlaxoSmithKline. The study was funded by GlaxoSmithKline (study code SCO30003). Editorial support, in the form of development of the draft outline, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copy editing, fact checking, referencing and graphic services was provided by D. Cutler (Gardiner-Caldwell Communications, Macclesfield, UK) and was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00194610
M.E. Yeager received an Actelion Entelligence Young Investigator Award. DOI: 10.1183/09031936.00072311
I.S. Young is a member of the UK Government’s Scientific Advisory Committee on Nutrition. Unilever Research (Colworth, UK) carried out the 8-isoprostaglandin F2α assays. DOI: 10.1183/09031936.00086011
Z Back to top
J.P. Zellweger has received fees from Oxford Immunotec for giving a lecture about IGRA tests. He has acted as a consultant for the Global Fund against AIDS, TB and Malaria. DOI: 10.1183/09031936.00203811
J.J. Zulueta. The funding for this study, including the supply of bronchial valves and funding for editorial support, was provided by Spiration Inc. (study number: CPR-01576). DOI: 10.1183/09031936.00019711
Volume 40, issue 1, July 2012
A Back to top
J. Alder is employed by Bayer HealthCare Pharmaceutical and holds stocks in the company. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI: 10.1183/09031936.00090311
I. Annesi Maesano. This study was supported by a research grant from the Epidemiological Research Group and Laboratoire Novartis (Paris, France). DOI: 10.1183/09031936.00123411
A. Anzueto has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: Astra-Zeneca, Boehringer Ingelheim, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline, Sanofi-Aventis. A. Anzueto has been a consultant for Astra-Zeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Sanofi-Aventis, Bayer-Schering Pharma. He has also been the principal investigator for research grants for the University of Texas Health Science Center (San Antonio, TX, USA) and was paid for participating in a multicentre clinical trial sponsored by: GlaxoSmithKline, Bayer-Schering Pharma, Lilly and National Institutes of Health. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI: 10.1183/09031936.00090311
P. Arvis is an employee of Bayer HealthCare. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI:10.1183/09031936.00090311
B Back to top
W.G. Boersma has received financial compensation for educational activities for the Dutch Respiratory Society. W.G. Boersma has recieved a grant from GSK for research activities performed in Medical Centre Alkmaar, Alkmaar, The Netherlands. DOI: 10.1183/09031936.00211911
L-P. Boulet Has served on advisory boards for AZ, GSK, Merck Frosst and Novartis, and received lecture fees from 3M, AZ, GSK, Merck Frosst and Novartis, sponsorship for investigator-generated research from AZ, GSK, Merck Frosst and Schering, research funding for participating in multicentre studies from Altair, Asmacure, AZ, BI, genentech, GSK, Pharmaxis, Schering and Wyeth, and support for the production of educational materials from AZ, GSK and Merck Frosst. The author is an adviser for the Conseil du Médicament du Québec and AETVIS, and a member of the Quebec Workmen Compensation Board Respiratory Committee. He is Chair of the Canadian Thoracic Society Guidelines Committee and Chair of GINA Guidelines Dissemination and Implementation Committee, and holder of the Laval University Chair on the Knowledge Translation (KT Canada), supported by CIHR. DOI: 10.1183/09031936.00053912
P-R. Burgel has received reimbursement for attending the ATS and ERS meeting, and fees for speaking or consulting from several pharmaceutical companies including AstraZeneca, Boehringer Ingelheim, Pfizer, GSK, Novartis, Nycomed and Pierre Fabre over the past 5 years. DOI: 10.1183/09031936.00022412
C Back to top
V. Cottin has received fees for speaking or consulting from Actelion, Boehringer Ingelheim, Centocor, Intermune, Lilly and Pfizer and has participated as investigator to clinical trials sponsored by Actelion, Boehringer Ingelheim and Intermune and as member of steering committee to a clinical trial sponsored by Boehringer Ingelheim. DOI: 10.1183/09031936.00070712
D Back to top
B.M. de Jong. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
X. Deng. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
E Back to top
F Back to top
M.J. FitzGerald is a member of the GINA Executive and also Chair of its Science Committee. The author is also a member of the Canadian Thoracic Society Asthma Committee, which is responsible for Canadian Asthma guidelines. He has received fees for lectures and advisory committees from AZ, GSK and Merck (all >$10,000), Nycomed, BI and Novartis (all < $10,000). He has received research grants from GSK, BI, Wyeth, Genentech, Topigen, the Canadian Institute for Health Research, Medimmune, Pharmaxis, Novartis and AllerGen NCE (all >$10,000). DOI: 10.1183/09031936.00053912
G Back to top
R. Gouvis-Echraghi. This study was supported by a research grant from the Epidemiological Research Group and Laboratoire Novartis (Paris, France). DOI: 10.1183/09031936.00123411
H Back to top
T. Haahtela has received speakers fees from Abdi Ibrahim, Astellas, AstraZeneca, Leiras, MSD, and ALK-Abello, and is on the advisory boards of MSD and Orion. DOI: 10.1183/09031936.00053912
T.L. Hackett is supported by a Canadian Lung Association/CIHR/GSK, CIHR Strategic Training Initiative in Health Research-IMPACT fellowship. DOI 10.1183/09031936.00065411
R.J. Halbert provided consulting services to the pharmaceutical industry, including the sponsor of this work. DOI: 10.1183/09031936.00141611
Y. Hatachi. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
D. Haverstock is employed by Bayer Inc., the manufacturer of moxifloxacin. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI:10.1183/09031936.00090311
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer, Chiesi, GSK, Lilly, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00097911
J Back to top
J. Just is on the advisory board for Novartis, ALK and Merck; is a speaker for AstraZeneca, Novartis, ALK, Merck and Shering-Plough; and has received grants from Novartis and Shering–Plough. This study was supported by a research grant from the Epidemiological Research Group and Laboratoire Novartis (Paris, France). DOI: 10.1183/09031936.00123411
K Back to top
S. Keshavjee has received funds for research on drug-resistant tuberculosis from the Eli Lilly Foundation through a grant to the Brigham and Women’s Hospital and Harvard Medical School. DOI: 10.1183/09031936.00169411
J.L.L. Kimpen. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
H. Kubo is a member of the Dept of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, which was funded by 11 pharmaceutical companies these are: Nippon Boehringer-Ingelheim Co. Ltd, Kyorin Phamaceutical Co. Ltd, Daiichi-Sankyo Co. Ltd, Ohtsuka Phamaceutical Co. Ltd, Taisho-Toyama Phamaceutical Co. Ltd, Abbott Japan Co. Ltd, Tanabe Mitsubishi Phamaceutical Co. Ltd, Teijin Pharma Co. Ltd, AstraZeneka Co. Ltd, GlaxoSmithKline Co. Ltd, and Ono Phamaceutical Co. Ltd. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
L Back to top
M.L. Levy has accepted sponsorship from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Trinity-Cheisi, Merck Sharpe and Dohme, Merck, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, TEVA, and Schering Plough for attending conferences. The author has accepted lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Cheisi and Alk-Abello. He has been on advisory boards or provided consultancy for GlaxoSmithKline, Schering Plough, Merck Sharp and Dohme, Cheisi, Altana Pharma, Ranbaxy, AstraZeneca, TEVA, and Novartis. He has had research grants from Boehringer Ingelheim, Pfizer and GSK. He is a member of the ADMIT Group, which receives an unrestricted educational grant from MEDA pharmaceuticals. Data Safety Monitoring Board (DSMB) for the FORWARD Study number CCD-0906-PR-0016. DOI: 10.1183/09031936.00053912
K.C. Lødrup Carlsen. One of the author’s research projects, the ECA study, has received funding from Phadia, as they supplied reagents for IgE measurements. She has also received a fee for giving a general talk on paediatric asthma from GSK. DOI: 10.1183/09031936.00226811
M Back to top
D. Montani has relationships with drug companies including Actelion, AstraZeneca, Bayer, Chiesi, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00097911
D. Moreau. This study was supported by a research grant from the Epidemiological Research Group and Laboratoire Novartis (Paris, France). DOI: 10.1183/09031936.00123411
M. Miravitlles has received fees from Bayer HealthCare for speaking at scientific meetings and for participating on advisory boards. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI:10.1183/09031936.00090311
N Back to top
R. Nagatomi .The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
H. Nishimura. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
Mattijs E. Numans. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
P Back to top
P.D. Paré has received fees (<$2000) for giving 2 talks over the last 3 years. These have been honoraria from academic institutions where he has been a visiting scientist. He have not received any fees from any commercial entity for giving talks. He has received funding of ~ <$200,000/year from various granting agencies and companies to pursue research over the last 5 years. These funds have come from the Canadian Institutes of Health Research, the NIH, the AllerGen NCE and one grant for $119,000 from Merck to do studies of lung gene expression. DOI 10.1183/09031936.00065411
R Back to top
S. Rouve. This study was supported by a research grant from the Epidemiological Research Group and Laboratoire Novartis (Paris, France). DOI: 10.1183/09031936.00123411
S Back to top
T. Sasaki. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
S. Sethi has received lecture, consulting fees and research funds from Bayer, GSK and Merck. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI: 10.1183/09031936.00090311
G. Simonneau has relationships with drug companies including Actelion, AstraZeneca, Bayer, Chiesi, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00097911
O. Sitbon has relationships with drug companies including Actelion, AstraZeneca, Bayer, Chiesi, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00097911
T Back to top
M. Trajanovic is employed by Bayer Inc., and holds stocks in the company. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI:10.1183/09031936.00090311
U Back to top
C.S.P.M. Uiterwaal. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
V Back to top
C.K. van der Ent. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
A.C. van der Gugten. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
N. van Putte-Katier. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
T.J.M. Verheij. This study was funded by an unrestricted grant from Glaxo Smith Kline Netherlands, who had no role or influence on the study execution. DOI 10.1183/09031936.00175910
W Back to top
S. Wanin. This study was supported by a research grant from the Epidemiological Research Group and Laboratoire Novartis (Paris, France). DOI: 10.1183/09031936.00123411
R. Wilson has received fees for lecturing and symposia and attending advisory boards for Bayer HealthCare, and has appeared as an expert witness concerning the licensing of moxifloxacin. This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin, Germany. DOI: 10.1183/09031936.00090311
Y Back to top
M. Yamaya is a professor in the Dept of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, which was funded by 11 pharmaceutical companies these are: Nippon Boehringer-Ingelheim Co. Ltd, Kyorin Phamaceutical Co. Ltd, Daiichi-Sankyo Co. Ltd, Ohtsuka Phamaceutical Co. Ltd, Taisho-Toyama Phamaceutical Co. Ltd, Abbott Japan Co. Ltd, Tanabe Mitsubishi Phamaceutical Co. Ltd, Teijin Pharma Co. Ltd, AstraZeneka Co. Ltd, GlaxoSmithKline Co. Ltd, and Ono Phamaceutical Co. Ltd. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
H. Yasuda. The study was supported by Nippon Boehringer-Ingelheim, Co. Ltd. DOI: 10.1183/09031936.00065111
Volume 40, issue 2, August 2012
A Back to top
R.T. Abboud received payments per patient for covering the cost of the study. DOI:10.1183/09031936.00161911
A. Azuma received fees from Abbott Japan Co. Ltd and Taisho-Toyama Pharmaceutical Co. Ltd for speaking on the effects of macrolides in the lecture. DOI: 10.1183/09031936.00208011
B Back to top
E. Borroni. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
P-R. Burgel. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
C Back to top
D. Caillaud. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
P. Carré. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
D.M. Cirillo. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
P. Chanez. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
L. Coltella. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
B. Cooper has received consulting fees from Hoffmann-La Roche for providing consultation on technical aspects of the methods employed in this study and for reimbursement of attendance at meetings. DOI: 10.1183/09031936.00161911
I. Court-Fortune. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
S.C. Connor receives research funding from GlaxoSmithKline. GlaxoSmithKline provided funding for the study. DOI: 10.1183/09031936.00112411
G.F. Cope is the inventor of the SmokeScreen test and director and shareholder in the company GFC Diagnostics, which manufactures and distributes the test. DOI: 10.1183/09031936.00219011
D Back to top
P. Dal Monte. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
W. De Backer has received a scientific grant from AstraZeneca not in relation with this study. DOI: 10.1183/09031936.00072511
J. De Backer is a shareholder and director of FluidDA nv, a company that actively develops and markets part of the technology described in this paper. DOI: 10.1183/09031936.00072511
M. Decramer has been part of an Advisory Board for Boehringer-Pfizer, GSK, Nycomed, Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than €10,000 per annum. He received a research grant of €45,000 per year from AstraZeneca. DOI:10.1183/09031936.00111811; 10.1183/09031936.00161911
F.H. de Jongh. This study was financially supported by Chiesi Pharmaceutical. The EIT device was provided by CareFusion. DOI: 10.1183/09031936.00138311
E Back to top
R. Escamilla. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
F Back to top
L. Finn was a statistical consultant for Respironics in 2009. She received $1000 for her statistical analysis to compare two different types of CPAP therapy. Currently no publication has resulted from this work. DOI: 10.1183/09031936.00177411
I. Frerichs. This study was financially supported by Chiesi Pharmaceutical. The EIT device was provided by CareFusion. DOI: 10.1183/09031936.00138311
G Back to top
J. L. Griffin. GlaxoSmithKline provided funding for the study. . DOI: 10.1183/09031936.00112411
J.A. Guenette. The study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany). DOI: 10.1183/09031936.00157711
H Back to top
A.J. Hawkridge was employed fulltime by the Aeras Global TB Vaccine Foundation, MD, USA, between 2007 and 2010. Since 2010 he has continued to work part time for them as a consultant. It is possible that that organisation might benefit from an increased focus on childhood tuberculosis particularly if it brings about an increase in funding for tuberculosis vaccine research. DOI: 10.1183/09031936.00187711
K Back to top
J-I. Kadota received fees from Abbott Japan Co. Ltd and Taisho-Toyama Pharmaceutical Co. Ltd for speaking on the effects of macrolides in the lecture. DOI: 10.1183/09031936.00208011
S. Kudoh received fees from Abbott Japan Co. Ltd and Taisho-Toyama Pharmaceutical Co. Ltd for speaking on the effects of macrolides in the lecture. DOI: 10.1183/09031936.00208011
L Back to top
D.A. Lomas has received an educational grant, fees for speaking and acts as a consultant for GlaxoSmithKline. GlaxoSmithKline provided funding for the study. DOI: 10.1183/09031936.00112411
G. Lombardi. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
F. Lurmann is an employee Sonoma Technology Inc. (Petaluma, CA, USA). DOI: 10.1183/09031936.00157811
M Back to top
W.A. MacNee received funds for participation and recruitment of patients for the REPAIR study. DOI: 10.1183/09031936.00161911
W. MacNee has been reimbursed for travel by GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Pfizer for attending conferences. He has also received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings. In addition he serves on advisory boards for GlaxoSmithKline and Pfizer and serves as a consultant for Pfizer and SMB Pharmaceuticals. Research grants that support work carried out in W. MacNee’s laboratory come from SMB, Pfizer, GlaxoSmithKline and Novartis. GlaxoSmithKline provided funding for the study. DOI: 10.1183/09031936.00112411
E. Mazzola. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
M. Miedema. This study was financially supported by Chiesi Pharmaceutical. The EIT device was provided by CareFusion. DOI: 10.1183/09031936.00138311
A. Mondo. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
M Morrell has received research funding from ResMed UK in the form of equipment for a seperate randomised controlled trial up to the value of £275,000. DOI: 10.1183/09031936.00177411
O Back to top
D.E. O’Donnell has received research funding via Queen’s University from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed and Pfizer; and has served on speakers bureaus, consultation panels and advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Pfizer. DOI: 10.1183/09031936.00157711
T. Omland has received speakers' honoraria from Roche, Abbott and Otsuka of less than US$10,000. The current study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany). DOI: 10.1183/09031936.00111411
P Back to top
J-L. Paillasseur. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
M. Pascarella. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
T. Perez. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
F. Piana. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
C. Piersimoni. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
J.J. Pillow has received equipment loans for animal research from Fisher & Paykel Healthcare, Draeger Medical, CareFusion and Bunnell Incorporated. DOI: 10.1183/09031936.00020012
D.S. Postma has received funding for research from AstraZeneca, GSK and Nycomed. The author’s travel to ERS or ATS conferences has been partially funded by AstraZeneca, GSK, Chiesi and Nycomed. She has acted as a consultant to AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and TEVA. DOI: 10.1183/09031936.00011211
M.I. Polkey My institution has received research grants from the EU (IMI Proactive initiative) and GlaxoSmithKline for studies relating to physical activity monitoring in COPD. DOI: 10.1183/09031936.00113611
R Back to top
A. Rames is an employee of Hoffman La-Roche. DOI: 10.1183/09031936.00161911
J.H.Riley is an employee and shareholder of the GlaxoSmithKline. GlaxoSmithKline provided funding for the study. DOI: 10.1183/09031936.00112411
N. Roche. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
C. Russo. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
S Back to top
C. Scarparo. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
P.A. Shaw is an employee of GlaxoSmithKline. GlaxoSmithKline provided funding for the study DOI: 10.1183/09031936.00112411
R.A. Stockley has acted as an advisor to Roche Pharmacueticals in the design and delivery of the REPAIR study as well as being one of the PIs involved in the study delivery. In addition he has acted as an advisor to Baxter, Kamada and Talecris all of whom have treatments used in the management of Alpha-1-antitrypsin deficiency and has lectured for Talecris and received non-commercial grant funding from them. DOI: 10.1183/09031936.00161911
B. Stoel’s institution has received consulting fees from Roche, Talecris, Baxter, BioClinica and CSL Behring. The institution had grants for STW (Dutch technology foundation) project from BioClinica, Medis specials, Roche and Talecris; and received compensation for lectures from Talecris. DOI: 10.1183/09031936.00161911
C.J. Smith received A salary during this period that was supported by a grant from GlaxoSmithKline. DOI: 10.1183/09031936.00113611
J. Stolk. Funds received for participation and recruitment of patients for the REPAIR study and funds received for consultancy for Roche, not exceeding a total of €40,000 over a five-year period. DOI: 10.1183/09031936.00161911
T Back to top
R. Tal-Singer is an employee of GlaxoSmithKline. GlaxoSmithKline provided funding for the study. DOI: 10.1183/09031936.00112411
J. Tamaoki received fees from Abbott Japan Co. Ltd and Taisho-Toyama Pharmaceutical Co. Ltd for speaking on the effects of macrolides in the lecture. DOI: 10.1183/09031936.00208011
H. Takizawa received fees from Abbott Japan Co. Ltd and Taisho-Toyama Pharmaceutical Co. Ltd for speaking on the effects of macrolides in the lecture. DOI: 10.1183/09031936.00208011
I. Tillie-Leblond. This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer. DOI 10.1183/09031936.00228511
E. Tortoli. The authors are grateful to Cepheid for providing, 50% discounted, Xpert reagents used for non-routine tests. DOI: 10.1183/09031936.00176311
U Back to top
B.K. Ubhi has received Grants for Research Awards from Murray Edwards College, this has been used to pay for attendance to the 2nd Metabolomics Symposium in Australia (2010). He has also received an Overseas Travel Award from the Royal Society of Chemistry (RSC) for travel to Metabomeeting in Helsinki 2011. GlaxoSmithKline provided funding for the study. DOI: 10.1183/09031936.00112411
V Back to top
A.H. van Kaam. This study was financially supported by Chiesi Pharmaceutical. The EIT device was provided by CareFusion. DOI: 10.1183/09031936.00138311
M.B. van Veenendaal. This study was financially supported by Chiesi Pharmaceutical. The EIT device was provided by CareFusion. DOI: 10.1183/09031936.00138311
W Back to top
P.A.B. Wark has received honoraria for speaking from GSK, AstraZeneca and Boehringer Ingelheim, and has acted on advisory boards for Novartis and AstraZeneca. DOI: 10.1183/09031936.00202311
K.A. Webb. The study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany). DOI: 10.1183/09031936.00157711
W. Windisch was reimbursed by Breas Medical AB (Molnlycke, Sweden) for attending the annual ERS conferences between 2001 and 2005 and by Werner and Müller Medizintechnik, Germany, for attending the annual German conferences on home mechanical ventilation between 2001 and 2007. The author has also received the following speaking fees: 2000 Euro in 2005, 3000 Euro in 2008, 5000 Euro in 2010 and 3000 Euro in 2011 from Dräger Medical, Germany; 2000 Euro in 2005, 1000 Euro in 2006, 1000 Euro in 2008, 750 Euro in 2009 and 4000 Euro in 2010 from Heinen und Löwenstein, Germany; 1000 Euro in 2005 and 1500 Euro in 2007 from Werner und Müller Medizintechnik; 750 Euro in 2006, 2007, 2008 and 2009, 500 Euro in 2010, and 1500 Euro from VitalAire, Germany, respectively; 1000 Euro in 2006, 1000 Euro in 2007, 2000 Euro in 2008 and 3500 Euro in 2009 from Respironics, USA; 500 Euro in 2006 and 500 Euro in 2007 from Weinmann, Germany; 1750 Euro in 2008, 1750 Euro in 2009 and 2500 Euro in 2010 from ResMed, Germany; 500 Euro in 2008 from MPV Truma, Germany; 1000 Euro in 2009 from Covedien, France; 1500 Euro in 2010 from Linde, Germany; 1500 Euro from Siare, Italy. W. Windisch has received the following funds for research: research grant from Respironics, USA, in 2008 (100,000 USD) and 60,000 Euro for 2009 and 2010, respectively; 310,000 Euro from Breas (1999–2009) and 75,000 Euro for 2010. DOI:10.1183/09031936.00152411
Y Back to top
M. Yamaya is a Professor of Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine which was funded by 11 pharmaceutical companies, including Abott Japan, Co., Ltd and Taisho Toyama Pharmaceutical Co., Ltd. DOI: 10.1183/09031936.00208011
Volume 40, issue 3, September 2012
A Back to top
J.M. Antó. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
B Back to top
J.A. Barberà. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
J. de Batlle. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
A. Batra has received research grants from McNeil AB, Pfizer, GlaxoSmithKline and Sanofi Aventis, and advisory board honoraria from GlaxoSmithKline and Sanofi. The author’s study was funded by McNeil AB, Sweden. DOI: 10.1183/09031936.00155811
E. Balcells. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
M. Benet. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
I. Blanco. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
E. Borroni.Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
C Back to top
A.M. Cabibbe. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
M.J. Castillo-Palma. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
D. M. Cirillo. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
V. Cottin has received fees for speaking from Actelion and Pfizer, and has participated as investigator to clinical trials sponsored by Actelion and Pfizer. DOI:10.1183/09031936.00093111
V. Cottin has received fees for speaking from InterMune, Boehringer Ingelheim, and Actelion. He has participated as an investigator to clinical trials sponsored by InterMune, Boehringer, and Actelion, and also as member of the steering committee to a clinical trial sponsored by Boehringer Ingelheim. DOI: 10.1183/09031936.00001612
J-F. Cordier received reimbursement for attending a symposium, fee for speaking, fee for organising education, fees from consulting from Pfizer, GlaxoSmithKline, Actelion, Lilly. DOI:10.1183/09031936.00093111
J-F. Cordier has received reimbursement for attending a symposium, fees for speaking, fees for organising education and fees for consulting from Pfizer, GlaxoSmithKline, Actelion, and Lilly. DOI: 10.1183/09031936.00001612
D Back to top
C.P. Denton has received fees for lecturing and consultancy from Roche, Pfizer, Actelion, SanofiAventis, Medimmune and GSK. DOI: 10.1183/09031936.00163911
D. Donaire-Gonzalez. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
E Back to top
P. Escribano-Subias. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
F Back to top
L. Fattorini. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
J.J. Ferrer. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
P. Fesler developed and holds licensing rights for the software package used to analyse pressure decay. DOI: 10.1183/09031936.00134111
G Back to top
J. Garcia-Aymerich. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
M. Gomberg-Maitland reports that the University of Chicago has received grants from Acetlion, Gilead, GlaxoSmithKline, Medtronic, Novartis, and United Therapeutics for clinical trial research. She serves as a consultant on DSMBs, Steering Committees and Clinical Events Committees for Acetlion, Gilead, Ikaria, Medtronic, Pfizer, and United Therapeutics. She has received honoraria for CME symposium and education from ABcomm, Heathmatters CME, and Medscape. DOI: 10.1183/09031936.00094112
M.A. Gómez-Sanchez has received funds for research from Actelion, Bayer Schering, Gilead, Lilly Icos, Pfizer and United Therapeutics. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
H Back to top
J.M. Hopkin. WD & HO Wills (tobacco manufacturers) provided in 1978 J.M. Hopkin and the MRC Human Genetics Unit, Edinburgh, with an automatic smoking machine to allow studies into the mutagenicity of cigarette smoke; the results were freely published as Hopkin & Evans in Nature 1979 (279, 241), Nature 1980 (283, 388), Br J Cancer 1984 (49, 333). J.M. Hopkin is a founder and director of Allerna Therapeutics, a university start-up company developing an siRNA therapeutic for asthma. DOI: 10.1183/09031936.00043311
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI:10.1183/09031936.00093111
M. Humbert has relationships with drug companies including Actelion, Aires, Astrazeneca, Bayer, BMS, GSK, Merck, Novartis, Nycomed, Pfizer, Stallergènes, TEVA and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00094112
J Back to top
C. Jimenez Lopez-Guarch. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
M.K. Johnson has received speaker fees from Pfizer. The present study was funded by Actelion UK. DOI: 10.1183/09031936.00196611
X. Jais has relationships with drug companies including Actelion, Pfizer, GlaxoSmithKline, Lilly, Bayer. In addition to being investigator in clinical trials involving these companies, relationships include reimbursement for attending symposium and fees for speaking. DOI: 10.1183/09031936.00093111
K Back to top
S. Konstantinides has received lecture and consulting fees from Boehringer Ingelheim and Bayer Healthcare, and lecture fees from Roche Diagnostics. DOI 10.1183/09031936.00216811
L Back to top
H. Lauri is employed by McNeil AB, Sweden. The author’s study was funded by McNeil AB, Sweden. DOI: 10.1183/09031936.00155811
P. Laveneziana. The research seminar was sponsored by the ERS with the financial support of an unrestricted grant from Boehringer-Ingelheim (Italy) and Pfizer (Italy). DOI: 10.1183/09031936.00041212
K.E. Lewis has received an educational grant from GlaxoSmithKline (GSK) for £9000; has received speaker and consultancy fees from GSK, AstraZeneca and MSD; and previous travel to the ATS congress was funded by AstraZeneca and GSK. DOI: 10.1183/09031936.00043311
Y. Ling. The present study was funded by Actelion UK. DOI: 10.1183/09031936.00196611
W-T.N. Lee has received unrestricted research support and travel grants from Pfizer. The present study was funded by Actelion UK. DOI: 10.1183/09031936.00196611
M Back to top
T.M. Maher has received an academic-industry research grant from GSK. He has received fees for consultancy or acting as part of advisory boards from Boehringer Ingelheim, GSK, Sanofi-Aventis, Actelion and Phillips Respironics. DOI: 10.1183/09031936.00163911
K. Mann has received speaker fees from McNeil AB and Pfizer, and research grants from McNeil AB. The author’s study was funded by McNeil AB, Sweden. DOI: 10.1183/09031936.00155811
P. Mantegani. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
M. Mendez. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
D.P. Miller is an employee of ICON Late Phase & Outcomes Research. ICON receives research funding from pharmaceutical companies, and has provided ongoing statistical analysis support for the REVEAL study, which is funded by Actelion. . DOI: 10.1183/09031936.00094112
P.Miotto. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
G. B. Migliori. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
P. Morales. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
R.M. Muellenbach has received lecture fees from Novalung GmbH and Maquet GmbH. DOI: 10.1183/09031936.00006012
O Back to top
M. Orozco-Levi. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
P Back to top
P. Palange. The research seminar was sponsored by the ERS with the financial support of an unrestricted grant from Boehringer-Ingelheim (Italy) and Pfizer (Italy). DOI: 10.1183/09031936.00041212
A.J. Peacock has received speakers fees, honoraria to attend advisory boards, travel grants and unrestricted research support from Actelion, Bayer, Lilly, Pfizer, GSK and United Therapeutics, and gave evidence at the Inquest held into the death. The present study was funded by Actelion UK. DOI: 10.1183/09031936.00196611
R. Perfekt is employed by McNeil AB, Sweden. The author’s study was funded by McNeil AB, Sweden. DOI: 10.1183/09031936.00155811
J. Pepke-Zaba has received honoraria for lecturing from Bayer, Actelion, Pfizer, and GSK, and is on advisory boards for Actelion, Pfizer, Bayer, GSK, United Therapeutics, and Eli Lilly. The present study was funded by Actelion UK. DOI: 10.1183/09031936.00196611
R Back to top
E. Reeves is a member of ERS staff. DOI: 10.1183/09031936.00105912
A. Roman. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
I. Romieu. The present study was supported in part by an unrestricted educational grant from Novartis Farmacèutica, Spain. DOI: 10.1183/09031936.00116911
S Back to top
J. Segovia has received funds for research and a fee for consulting from Actelion. The REHAP registry is sponsored by an unrestricted educational grant from Bayer Schering Pharma. DOI: 10.1183/09031936.00101211
K. Sheares has received, in the past 5 years, honoraria for lecturing or consulting from Actelion, and educational/travel grants to attend scientific symposia and conferences from Actelion, Encysive, GlaxoSmithKline, Pfizer, Lung Rx and United Therapeutics. The present study was funded by Actelion UK. DOI: 10.1183/09031936.00196611
G. Simonneau has relationships with drug companies including: Actelion, Bayer Schering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00093111
R.A. Stockley has received non-commercial grant funding from Talecris and lectured at symposia sponsored by Talecris who are suppliers of augmentation therapy for AAT deficiency. DOI: 10.1183/09031936.00162811
T Back to top
P. Tønnesen has received speaker fees, consultant and advisory board honoraria and research grants from several pharmaceutical companies, including McNeil AB, who produce and/or market drugs for smoking cessation. The author’s study was funded by McNeil AB, Sweden. DOI: 10.1183/09031936.00155811
E. Tortoli. Hain Lifescience (Nehren, Germany) provided the GenoType® MTBDRsl assay that was used in the present study. DOI: 10.1183/09031936.00164111
V Back to top
D. Valeyre has benefited from travel and accommodation for the ERS, ATS, CPLF meetings, the Milan meeting on rare diseases and the Berlin AIR meeting from, respectively, GSK, BI, Nycomed, Mundipharma, Actelion and Intermune. He has participated in scientific boards on IPF sponsored by Actelion and Intermune. He has been a member of steering committees on IPF trials supported by Intermune and Actelion. DOI: 10.1183/09031936.00025212
Volume 40, issue 4, October 2012
A Back to top
E. Alfaro-Moreno. This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
A. Agusti has received honoraria for speaking at meetings and participating in advisory boards from Almirall and Forest Inc., and has received funding for research from Almirall. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
M. Arzt has received unrestricted grant support from Philips Home Healthcare Solutions, Resmed and the German Foundation for Cardiac Research (Deutsche Stiftung für Herzforschung). M. Arzt is the holder of an endowed professorship from the Free State of Bavaria at the University of Regensburg that was donated by Philips Home Healthcare Solutions and Resmed. M. Arzt has previously received lecture fees from AstraZeneca, Covidien, Philips Home Healthcare Solutions and Resmed. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
B Back to top
E.D. Bateman has received payment for consulting and advisory board involvement from Almirall and Forest, and his institution has performed contract research for Almirall. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
J.L. Bernheim has been retained as an expert witness (affidavit and cross-examination) by the lawyers of a British Columbia (Canada) fatally ill patient challenging the Crown’s right to deny her assisted dying. DOI: 10.1183/09031936.00182611
F. Berteletti is a member of ERS staff. DOI: 10.1183/09031936.00117012
F. Blasi. The European Forum for TB Innovation is supported through an unrestricted grant from Otsuka SA (Geneva, Switzerland) to the ERS. DOI: 10.1183/09031936.00080212
D. Bonderman. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
C. Brightling has received research funding from Novartis, MedImmune, AstraZeneca, Roche and Chiesi; consultancy fees from Genentech, Roche, MedImmune, Novartis and AstraZeneca; and support to attend scientific international meetings from Boerhinger-Ingelheim. DOI: 10.1183/09031936.00142811
D. Bumbacea has received funding from Ewopharma travel to one Global IGRA Symposium. DOI: 10.1183/09031936.00000712
C Back to top
C. Caracta is an employee of Forest Research Institute, Inc. and is a stockowner and has received stock options from Forest Laboratories, Inc. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
D Back to top
B. Degano. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
M. Delcroix has received fees for serving as an investigator, speaker, consultant or steering committee member for ActelionPharmaceuticals Ltd, Aventis Pharmaceuticals, Bayer Schering Pharma, Eli Lilly, Encysive, Gilead (Myogen), GlaxoSmithKline, Nippon Shinyaku, Novartis, Pfizer and United Therapeutics; educational grants from Actelion, GlaxoSmithKline, Pfizer and Therabel; and research grants from Actelion Pharmaceuticals Ltd, Encysive and GlaxoSmithKline. M Delcroix is holder of the Actelion Chair for Pulmonary Hypertension and of the GlaxoSmithKline Chair for Research and Education in Pulmonary Vascular Pathology at the Catholic University of Leuven. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
M. Delcroix is holder of the Actelion chair for Pulmonary Hypertension and of the GSK chair for Research and Education in pulmonary vascular pathology at the Katholieke Universiteit Leuven (Leuven, Belgium). This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
G. de Miquel is an employee of Almirall SA. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
R. Dumitrascu. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
E Back to top
M. Efficace is an employee of Actelion Pharmaceuticals. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
J.S. Elborn consulted once for AstraZeneca and spoke at a meeting. He received travel support from AstraZeneca to attend the ATS in 2011. The author’s study was funded by AstraZeneca. DOI: 10.1183/09031936.00194611
N. Entwistle is employed by AstraZeneca and as part of their annual performance bonus payment has received shares in AstraZeneca. The author’s study was funded by AstraZeneca. DOI: 10.1183/09031936.00194611
F Back to top
K. Forsman-Semb was a full-time employee at AstraZeneca when this study was conducted, and owns stocks to an estimated value of £3000 in AstraZeneca. The author’s study was funded by AstraZeneca. DOI: 10.1183/09031936.00194611
G Back to top
N. Galiè has served as a consultant and received lecture fees from Actelion Pharmaceuticals Ltd, Pfizer, GlaxoSmithKline, Eli Lilly and Bayer Schering Pharma. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
E. Garcia Gil is an employee of Almirall SA. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
R. Giorgino was previously an employee of Actelion Pharmaceuticals Ltd. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
D. Goletti has received a grant from Cellestis to go to a scientific meeting in Croatia in 2009, a partial travel reimbursement from A.D.A to go to the ATS meeting in Canada in 2008, and her institution has received a grant from Oxford Immunotec as part of the salary for a laboratory technician in 2007. DOI: 10.1183/09031936.00000712
K. Gunawardena is a former employee of AstraZeneca, and holds some shares given as part of the employment package. The author’s study was funded by AstraZeneca. DOI: 10.1183/09031936.00194611
H Back to top
C. Hecker. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
M.M. Hoeper has received speaker and/or consultant fees from Actelion, Bayer, Encysive, Gilead, GSK, Lilly, Novartis and Pfizer. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
D. Horeau-Langlard has received a fee from Actelion pharmaceuticals (France) for speaking about pulmonary hypertension, and they also funded travel to the congress. DOI: 10.1183/09031936.00182711
K. Häussinger has received fees exceeding €5,000 for consulting from Karl Storz GmbH. DOI: 10.1183/09031936.00142811
P. Hiemstra. The Department of Pulmonology at Leiden University Medical Center, and thereby P. Hiemstra as a staff member of the department, has received research grants from GlaxoSmithKline and Boehringer Ingelheim. DOI: 10.1183/09031936.00142811
M.M. Hoeper has received speaker and/or consultant fees from Actelion, Bayer, Encysive, Gilead, GSK, Lilly, LungRx, Novartis and Pfizer. DOI: 10.1183/09031936.00141211
J.M. Hohlfeld’s institution (Fraunhofer Institute for Toxicology and Experimental Medicine) received funding for the performance of the EvA study. DOI: 10.1183/09031936.00142811
M. Humbert has relationships with drug companies including Actelion, Bayer Schering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00141211
M. Humbert has relationships with drug companies including Actelion, BayerSchering, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI 10.1183/09031936.00159911
I Back to top
M.G. Ison has received funds from ViraCor for a study comparing TSPOT to Quantiferon TB In Tube and has received funds from ViraCor as a consultant on assays needed for the transplant community. DOI: 10.1183/09031936.00000712
J Back to top
X. Jaïs has received speaker and/or consultant fees from Actelion, GSK, Lilly and Pfizer. DOI: 10.1183/09031936.00141211
P.W. Jones has received consultancy fees and chaired advisory boards for Almirall. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
K Back to top
K. Karlócai has received fees for speaking from Actelion and Bayer; travel and participation to ERS and Euroecho was funded by Actelion. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
I. Koper. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
M. Kurzyna has received honoraria for speaking and consulting from Actelion, AOP Orphan, Bayer-Schering, GSK and Pfizer. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
L Back to top
R. Lamarca is an employee of Almirall SA. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
I.M. Lang has received an educational grant from Actelion Pharmaceutical industries; has received speaker fees from Actelion, Bayer, Glaxo, United Therapuetics, AOP Orphan and Pfizer. I.M. Lang has been a recipient of a tobacco-related research grant of the state of California. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
R. Luigart. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
L. Lüthje. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
M Back to top
P. Macdonald has received speaker fees from Actelion and Pfizer for educational talks on pulmonary hypertension. He has received consultancy fees from Pfizer as a member of its Australian Revatio Advisory Board. He received an educational grant from Actelion to organise the 2nd Asian Pulmonary Artery Hypertension Experts Meeting held in 2006. DOI: 10.1183/09031936.00141211
N. Marchetti has received speaker’s fees (<$2,000) for giving educational talks at grand rounds and at local hospitals. DOI: 10.1183/09031936.00169311
J. Marks-Konczalik has been funded by AstraZeneca for attendance of ERS symposia and was employed by AstraZeneca until November 2010. The author’s study was funded by AstraZeneca. DOI: 10.1183/09031936.00194611
B. Meyns. This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
G.B. Migliori. The European Forum for TB Innovation is supported through an unrestricted grant from Otsuka SA (Geneva, Switzerland) to the ERS. DOI: 10.1183/09031936.00080212
D. Montani has relationships with drug companies including Actelion, AstraZeneca, Bayer Schering, GSK, Lilly, Novartis and Pfizer. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI 10.1183/09031936.00159911
P. Muñoz has received advisory board and conference honoraria from Pfizer, MSD, Novartis, Astellas and Biomerieux, and research funds from Novartis and Astellas. DOI: 10.1183/09031936.00000712
O Back to top
K.M. Olsson has received reimbursement for attending a conference from Pfizer and has received a speaker honorarium from Actelion Pharmaceuticals. DOI: 10.1183/09031936.00141211
P Back to top
D. Parr works as an independent consultant to Talecris Biopharmaceuticals and Hoffmann-La Roche, receiving consultancy fees and support to attend conferences, with travel and accommodation, amounting to approximately $20,000. Future commitments uncertain, since Talecris now merged with Grifols. He has received lecture fees from Talecris amounting to approximately $2,000, financial support from Boehringer Ingelheim to attend conferences amounting to approximately $3,000, and lecture fees from Chiesi amounting to approximately $300. D. Parr has received financial support for conference attendance and fees for consulting and presenting on issues on chronic obstructive pulmonary disease and α1 antitrypsin deficiency from the following pharmaceutical companies: Talecris Biotherapeutics, Boehringer Ingelheim, Hoffmann-La Roche, Chiesi. D. Parr’s wife is an employee of Grifols. DOI: 10.1183/09031936.00142811
A. Peacock has received honoraria for speaking from Actelion, Bayer, Eli Lilly, GSK, Novartis, Pfizer and United Therapeutics; assistance with travel to major conferences and unrestricted educational grants to support non-pharma research from Actelion, Bayer, Eli Lilly, GSK, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00141211
J. Perrett was previously an employee of AstraZeneca and holds £10,000 worth of shares as part of the company’s employee bonus scheme. The author’s study was funded by AstraZeneca. DOI: 10.1183/09031936.00194611
A. Prasse has received funding from Sanofi Aventis and Pfizer for consultancy and funding for research from Stromedix. Lecture fees have been paid by Novartis. A. Prasse has received reimbursement for attending a symposium by Boehringer Ingelheim, Novartis, Chiesi and AstraZeneca. DOI: 10.1183/09031936.00142811
Q Back to top
R. Quarck. This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
R Back to top
K.F. Rabe has been consulting, participated in advisory board meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceutical, Forest Labs, Pfizer, Novartis, Nycomed, MSD and GSK. K.F. Rabe holds no stock or other equities in pharmaceutical companies. DOI: 10.1183/09031936.00117012
K.F. Rabe has been consulting, participated in advisory board meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceutical, Pfizer, Novartis, Altana Pharma, Nycomed, MSD and GSK. K.F. Rabe holds no stock or other equities in pharmaceutcial companies. The Department of Pulmonology at Leiden University Medical Center and thereby K.F. Rabe as head of the department has received grants from Altana Pharma, Novartis, Bayer, AstraZeneca, Pfizer, MSD, Exhale Therapeutics, Boehringer Ingelheim, Roche and GSK in the years 2001–2011. DOI: 10.1183/09031936.00142811
L.B. Reichmann. The European Forum for TB Innovation is supported through an unrestricted grant from Otsuka SA (Geneva, Switzerland) to the ERS. DOI: 10.1183/09031936.00080212
A. Ronisz. This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
S Back to top
R. Segarra is an employee of Almirall SA. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
R. Schulz. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
C. Schum. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
G. Simonneau has served as a consultant for Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli Lilly, Pfizer, United Therapeutics and Novartis, and received lecture fees and grants from Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli Lilly and Pfizer. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
D. Singh has received lecture fees, research grants, consultancy fees and support for conference attendance from various pharmaceutical companies including AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingelheim and Roche. DOI: 10.1183/09031936.00142811
D. Singh has received lecture fees, research grants, consultancy fees and support for conference attendance from various pharmaceutical companies including AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Roche, Novartis, Cipla, Almirall and Merck. This study was funded by Almirall, SA, Barcelona, Spain, and Forest Laboratories, Inc, NY, USA. DOI: 10.1183/09031936.00225511
A.R. Smyth runs twice yearly educational meetings for the cystic fibrosis team sponsored by Forest Labs. He has has received consultancy fees from Novartis and sits on an advisory board for REMPEX. DOI: 10.1183/09031936.00042012
A. Stein. The author’s study was supported by a research grant from Respironics. DOI: 10.1183/09031936.00176711
T Back to top
N. Theodoropoulos has received funds from ViraCor for a study comparing TSPOT to Quantiferon TB In Tube. DOI: 10.1183/09031936.00000712
A. Torbicki served as a consultant for Actelion, Eli Lilly, GlaxoSmithKline and mondoBIOTECH and received speaker’s honoraria from Bayer Schering, Eli Lilly, United Therapeutics and Sanofi Aventis He has conducted research supported by Actelion, Bayer Schering, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, mondoBIOTECH and Pfizer. The author’s study was sponsored by Actelion Pharmaceuticals and Nippon Shinyaku. DOI: 10.1183/09031936.00137511
A. Torbicki has served as a consultant for Actelion, Eli Lilly, GlaxoSmithKline, mondoBIOTECH; received speakers’ honoraria from Bayer Schering, Eli Lilly, United Therapeutics and Sanofi Aventis; and conducted research supported by Actelion, Bayer Schering, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, mondoBIOTECH and Pfizer. DOI: 10.1183/09031936.00141211
A. Torres has received speaking fees from Astellas, MSD and Pfizer, and research grants from Pfizer and Covidien. The author is on the advisory boards of Astellas, MSD and Sanofi Pasteur. DOI: 10.1183/09031936.00168811
V Back to top
D. Valeyre is an investigator and/or member of steering committee in trials on IPF (INSPIRE, BUILD 1, CAPACITY, BUILD III, BIBF, MUSIC) and on sarcoidosis (Centocor) and received support for transportation and accommodation for ATS, ERS and CPLF meetings from companies including GSK, AstraZeneca, Boehringer-Ingelheim, Nycomed, and others. DOI : 10.1183/09031936.00210711
D. Van Raemdonck. This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
P. Venge and family are the owners of Diagnostics Development, a P&M Venge AB company. DOI: 10.1183/09031936.00142811
C.D. Vizza has received educational grants, fees for speaking and fees for consulting from Actelion, Pfizer, United Therapeutics, GSK and Lilly. DOI: 10.1183/09031936.00141211
W Back to top
B. Ward is a member of ERS staff. DOI: 10.1183/09031936.00117012
J.P. Wisnivesky is a member of the research board of EHE International, he has received lecture honorarium from Novartis Pharmaceutical, and was awarded a research grant from GlaxoSmithKline to conduct a COPD study. DOI 10.1183/09031936.00176911
M. Wynants. This study was supported by research grants from Pfizer and from the Belgian Funds for Cardiac Surgery. DOI: 10.1183/09031936.00197511
Volume 40, issue 5, November 2012
A Back to top
V.K.T. Alagappan is an employee of Novartis. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
M. Arzt received an unrestricted grant support from Resmed (Martinsried, Germany), Philips Home Healthcare Solutions (Murrysville, PA, USA) and the German Foundation for Cardiac Research (Deutsche Stiftung für Herzforschung). DOI 10.1183/09031936.00172211
B Back to top
D. Banerji is an employee of Novartis and holds stocks in the company. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712E. Baraldi has received lecture fees from GlaxoSmithKline, Merck Sharp & Dohme, Abbott, Valeas, and Chiesi (each up to $1,000). DOI 10.1183/09031936.00185511
A. Binder. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
E. Bergot has relationships with drug companies including Actelion and Lilly as a member of the scientific advisory boards. DOI: 10.1183/09031936.00188611
A. Bourdin declares being investigator in trials from Actelion, United Therapeutics, Boeringher, Bayer, Astra-Zeneca, Centocor, Gilead, Novartis, Chiesi and GSK; has received funds for research from GSK. DOI: 10.1183/09031936.00188611
P.L. Brand has received support in the last 5 years for research, lecturing, consulting, and attending conferences from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, and Nycomed. DOI: 10.1183/09031936.00191511
C.E. Brighting has received research grants and consultancy fees from AstraZeneca, MedImmune, GlaxoSmithKline, Novartis, Roche, and Chiesi; sponsorship to meetings from Boerhinger-Ingelheim. DOI: 10.1183/09031936.00228611
M. de Bruijne. The densitometric measurements reported in this paper were supported by an unrestricted grant from AstraZeneca R&D, Sweden. M. de Bruijne received unconditional research funding from AstraZeneca R&D DOI: 10.1183/09031936.00207911
C Back to top
V. Cottin has received fees for speaking from Actelion, Boeringer Ingelheim, GSK, and Pfizer. He has participated as investigator to clinical trials sponsored by Actelion, Boeringer Ingelheim, GSK, and Pfizer, and has served on advisory boards from Actelion, Bayer, Boeringer Ingelheim, Intermune, Lilly, Novartis. DOI: 10.1183/09031936.00188611
D Back to top
K. Dheda. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
A. Dirksen has received a research grant of approximately 100,000 Euros (for nurse and PhD assistance) from AstraZeneca for the Danish Lung Cancer Screening Trial. The densitometric measurements reported in this paper were supported by an unrestricted grant from AstraZeneca R&D, Sweden. DOI: 10.1183/09031936.00207911
G.C. Donaldson The clinical trial of tiotropium was funded by Boehringer Ingelheim. DOI: 10.1183/09031936.00180811
F.M. Ducharme In the past 5 years, the author has received research funds or fees for consulting from Merck Frosst Inc, Merck Canada, Novartis and Takada (formerly Nycomed). DOI: 10.1183/09031936.00096912
F Back to top
A.Fléchon has received fees for speaking for Pfizer and travelling to ASCO with Pfizer. DOI 10.1183/09031936.00048212
I. Frachon has relationships with drug companies including Actelion, Bayer, GSK, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include travel reimbursements to congresses or symposia. DOI: 10.1183/09031936.00188611
G Back to top
N. Gallagher is an employee of Novartis and holds stocks in the company. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
E. Grunig has received honoraria for consultations and/or speaking at conferences from Actelion, Bayer, Gilead, GSK, Lilly, Miltenyi, Novartis, Pfizer and Rotex Medica, and funding for clinical trials by Actelion, Bayer, GSK, Encysive, Lilly, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00021712
J. Grigg revived consultancy fees of £1,000 from Novartis and £1,300 from GlaxoSmith Kline. DOI: 10.1183/09031936.00195711
M. Gosman. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
M. Guazzi. In the past 5 years, the author has received fees for speaking and consulting from Pfizer and Merck. DOI: 10.1183/09031936.00039012
H Back to top
A. Hardy. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
A. Haripersad. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
J. Hébert has served as a consultant for GlaxoSmithKline, Novartis, Merck, Talecris, CSLBehring, as a speaker for GlaxoSmithKline, Merck, Novartis, Talecris, CSL Behring, and has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Talecris, CSLBehring, Shire, Johnson and Johnson, and Circassia. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
P.S. Hiemstra has received research grants from Boehringer Ingelheim, Centocor and Galapagos. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
M. Humbert has relationships with drug companies including Actelion, AstraZeneca, Bayer, Chiesi, GSK, Lilly, MSD, Novartis, Nycomed, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and a member of scientific advisory boards. DOI: 10.1183/09031936.00188611
J.R. Hurst The clinical trial of tiotropium was funded by Boehringer Ingelheim. DOI: 10.1183/09031936.00180811
I Back to top/p>
J Back to top
X. Jaïs has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188611
K Back to top
E. Kerwin has served on speaker panels or advisory boards for AstraZeneca (MAP Pharma), Dey Laboratories, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck (Schering Plough), Pfizer, Sanofi Aventis, Sunovion, Targacept, Teva Labs and UCB Pharma. He has conducted clinical research trials for fifty pharmaceutical companies, including Novartis and Boehringer Ingelheim. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
H.A.M. Kerstjens has acted as a consultant to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Novartis, and received grants from AstraZeneca, GlaxoSmithKline, Nycomed, Boehringer Ingelheim and Novartis. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
S. Kraus. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
L.I.Z. Kunz. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
L Back to top
N. Lamblin has relationships with drugs companies including Actelion, AstraZeneca, Bayer, Boehringer, GlaxoSmithKline, Lilly, MSD, Novartis, Pfizer, Sanofi-Aventis, and Servier. These relationships are limited to fees for speaking and consultancy. DOI: 10.1183/09031936.00188611
T.S. Lapperre has received a fee for speaking of €788 from GlaxoSmithKline. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
A.L. Lazaar is an employee of GlaxoSmithKline and owns shares in the company. DOI: 10.1183/09031936.00051012
P. Lo. The densitometric measurements reported in this paper were supported by an unrestricted grant from AstraZeneca R&D, Sweden. DOI: 10.1183/09031936.00207911
Y. Lu is an employee of Novartis. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
M Back to top
C. Martin is an employee of Novartis. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
R. Meldau. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
D. Montani has relationships with drug companies including AB Science, Actelion, BayerSchering, GSK, Novartis, Pfizer and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188611
L. Mottay. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
N Back to top
R. Naeije has received educational, travel and research grants from Actelion, Pfizer, Bayer Healthcare and United Therapeutics. DOI: 10.1183/09031936.00021712
C. Nwokoro received the British Lung Foundation Travel award to the ERS, £750, funded by Allen and Hanburys. DOI: 10.1183/09031936.00195711
O Back to top
T. Overend is an employee of Novartis. The study was sponsored by Novartis Pharma AG. DOI: 10.1183/09031936.00040712
P Back to top
J.H. Pedersen. The densitometric measurements reported in this paper were supported by an unrestricted grant from AstraZeneca R&D, Sweden. DOI: 10.1183/09031936.00207911
J.G. Peter. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
C. Pison has relationships with drug companies including AB Sciences, Actelion, AstraZeneca, Aventis, Bayer, Boerhinger Ingelheim, Emphasis, Gensyme, GSK, LFB Lilly, MSD, Novartis, Nutricia-Danone, Nycomed, Pfizer, Pulmonx, Roche, Shering-Plough, Theratechnologies Inc., United Therapeutics, Wyeth. In addition to being an investigator in trials involving these companies, relationships include consultancy service and member of scientific advisory boards for Actélion, LFB, Theratechnologies and Nutricia. DOI: 10.1183/09031936.00188611
M.I. Polkey has received payment for lecturing or consulting on aspects of muscle dysfunction and or physical activity from Novartis, Chiesi and GSK. His institution has received payment or received grants from GSK, AZ, Lilly, the MRC, NIHR and the EU. DOI: 10.1183/09031936.00170111
D.S. Postma has acted as a consultant to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed, Chiesi and TEVA, and received grants from AstraZeneca, GlaxoSmithKline, Nycomed and Chiesi. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
G. Prévot has relationships with drug companies including Actelion, GSK, Lilly, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy and membership of scientific advisory boards. DOI: 10.1183/09031936.00188611
R Back to top
M. Reynaud-Gaubert has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Astellas Pharma, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships also include consultancy. DOI: 10.1183/09031936.00188611
S Back to top
O. Sanchez has relationships with drug companies including Actelion, AstraZeneca, Boeringher Ingelheim, GSK, Pfizer and Vitalaire. Relationships include fees for speaking, consultancy, and reimbursement for attending congresses. DOI: 10.1183/09031936.00188611
T.A.R. Seemungal The clinical trial of tiotropium was funded by Boehringer Ingelheim. DOI: 10.1183/09031936.00180811
S. Siddiqui has received speaker fees and travel reimbursement from the American Thoracic Society in 2011, and funding for research in small airways disease from Chiesi and the European Union. DOI: 10.1183/09031936.00228611
D-J. Slebos was reimbursed for all trial-related expenses for NCT00391612 by Broncus Technologies USA, for NCT01220908 by PneumRx Inc. USA, and for NCT01101958 by Pulmonx USA. DOI: 10.1183/09031936.00219111
S.B. Shaker. The densitometric measurements reported in this paper were supported by an unrestricted grant from AstraZeneca R&D, Sweden. DOI: 10.1183/09031936.00207911
G. Simonneau has relationships with drug companies including Actelion, Bayer, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and a member of scientific advisory boards. DOI: 10.1183/09031936.00188611
O. Sitbon has relationships with pharmaceutical companies including Actelion, Bayer HealthCare, GlaxoSmithKline, Lilly, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. DOI: 10.1183/09031936.00188611
J.B. Snoeck-Stroband. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
A. Stenzinger has received a fee for counseling/advising the pharmaceutical company Pfizer regarding EML4-ALK diagnostics in lung cancer but this is entirely unrelated to the research presented in this paper. He is currently fully funded by a Postdoctoral Fellowship of the University of Heidelberg Medical Faculty (Heidelberg, Germany). DOI: 10.1183/09031936.00219211
P.J. Sterk. The author’s institute has received an unrelated, public–private grant from the Innovative Medicines Initiative that includes the manufacturer and financial co-sponsor of the Glucold Study (GSK). In addition, the author’s has received investigator-initiated, unrestricted grants for ongoing clinical and experimental studies from GSK. The present study was funded, in part, by GSK. DOI: 10.1183/09031936.00169711
L. Savale has relationships with drug companies including Actelion, BayerSchering, GSK, Pfizer. In addition to being investigator in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. DOI: 10.1183/09031936.00188611
L.T. Skovgaard The densitometric measurements reported in this paper were supported by an unrestricted grant from AstraZeneca R&D, Sweden. DOI: 10.1183/09031936.00207911
T Back to top
G. Theron. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
N.H.T. ten Hacken has received a research grant from Chiesi. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
W. Timens. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
V Back to top
J-L. Vachiéry has received educational, travel and research grants from Actelion, Pfizer, Bayer Healthcare and United Therapeutics. DOI: 10.1183/09031936.00021712
M. van den Berge has received a research grant from GlaxoSmithKline. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
R. van Zyl-Smit. In the present study, Alere supplied the ELISA and LAM strip-tests free of charge but they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. DOI: 10.1183/09031936.00201711
J.M Vonk. The study was sponsored, in part, by GlaxoSmithKline. DOI: 10.1183/09031936.00169711
W Back to top
J.A. Wedzicha The clinical trial of tiotropium was funded by Boehringer Ingelheim. DOI: 10.1183/09031936.00180811
Volume 40, issue 6, December 2012
B Back to top
T.T. Bauer The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
J. Beauregard. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
E.H. Bel received in behalf of the department of Respiratory Medicine grants for research, money for consultancies, participation in advisory boards, and speaking at symposia from EU-IMI, GSK, Novartis, Actelion, PDL-Pharma, Merck, Shering Plough, Cambridge Antigen Technology, Aerocirne and Nycomed. DOI 10.1183/09031936.00195211
H.M. Boezen. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
T.D. Bradley. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
A.O. Bron is working in the Asthma Centre Davos as lung physician. The Dutch Asthma Centre Davos is financially supported by the patient association, Vereniging Nederland Davos. DOI 10.1183/09031936.00195211
O.C. Burghuber The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
C Back to top
K-H. Carlsen The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
U. Costabel The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
D Back to top
S-E. Dahlén The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
M. Decramer has been part of advisory boards for Boehringer, Pfizer, GSK, Nycomed, Altana and Novartis. He has performed consulting work for Boehringer, Pfizer, GSK, AstraZeneca and Dompé. He also received lecture fees from these companies. All of the above amounted to less than €10,000 per annum. He received a research grant of €45,000 per year from AstraZeneca. Writing and editorial assistance was funded by Novartis Pharma AG (Basel, Switzerland). M. Fedele (Novartis, East Hanover, NJ, USA) provided editorial and writing assistance. DOI: 10.1183/09031936.00048912
M.H.G. de Greef. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
O. Dumas. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
E Back to top
S. Ewig has received fees for speaking and funds for research from Thermofisher. DOI: 10.1183/09031936.00150211
F Back to top
R. Farre. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
H Back to top
K. Haeussinger The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
J.E. Hartman. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
G. Hedlin The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
S. Heintzbergen. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
P.S. Hiemstra and the Department of Pulmonology (LUMC) have received research grants from GlaxoSmithKline and Boehringer Ingelheim. DOI: 10.1183/09031936.00192611
A. Huerta has received a fee for speaking from Novartis Pharma. DOI: 10.1183/09031936.00150211
J Back to top
V. Jobin. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
K Back to top
F. Kauffmann. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
R.J. KIimoff has received lecture honoraria from OSR Medical Inc., VitalAire Inc. and GSK. He has received research funds from OSR Medical Inc. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
K. Klooster. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
G.H. Koppelman has received a fee for speaking from GSK (money to institution). DOI: 10.1183/09031936.00064312
L Back to top
C. Lange has participated in immunodiagnostic studies where test kits have been provided free of charge by the companies Cellestis and/or Oxford Immunotec. DOI: 10.1183/09031936.00214611
P. Lange has received a fee for speaking, organising education, research and symposia and consulting, and has been involved with following medical companies: AstraZeneca, GSK, Nycomed, Pfizer, Boehringer-Ingelheim, Novartis, UCB, Norpharma. The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
R. Leigh has received consulting and speakers’ fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis during the past 24 months. The University of Calgary has also received research funding from AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, MedImmune, Novartis and Pharmaxis to conduct industry-sponsored clinical studies during this time period. None of these studies relate in any way to the content of the current manuscript. DOI: 10.1183/09031936.00197211
N. Le Moual. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
M Back to top
W. MacNee has been reimbursed for travel by GlaxoSmithKline, Zambon, AstraZeneca, Boehringer Ingelheim, Pfizer and Micromet for attending conferences. WM has received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings. WM serves on advisory boards for GlaxoSmithKline, Pfizer, Almirall, Amgen, Bayer and Micromet. WM serves as a consultant for Pfizer and SMB Pharmaceuticals. Research grants to support work carried out in WM’s laboratory comes from SMB, Pfizer, Ceremedix GlaxoSmithKline and Novartis. The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
S. Maio The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
J. Monserrat. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
N Back to top
R. Nadif. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
L. Nicod The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
P Back to top
I. Pin. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
D.S. Postma received research funding from AstraZeneca, GSK and Chiesi. Travel to ERS or ATS has been partially funded by AstraZeneca, GSK, Chiesi and Nycomed. D.S. Postma has acted as a consultant to Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and TEVA. DOI: 10.1183/09031936.00064312
R Back to top
K.F. Rabe has been consulting, participated in advisory board meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceutical, Forest Labs, Pfizer, Novartis, Nycomed, MSD, and GSK. DOI: 10.1183/09031936.00192611
Prof. Rabe holds no stock or other equities in pharmaceutical companies
J. Riedler The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
J. Rigau. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
L.H. Rijssenbeek-Nouwens is working in the Asthma Centre Davos as lung physician and is fellow at the Academic Medical Centre, University of Amsterdam. The Dutch Asthma Centre Davos is financially supported by the patient association, Vereniging Nederland Davos. LR has received travel funding to the ERS and ATS from Novartis and Nycomed. DOI 10.1183/09031936.00195211
S Back to top
T.A.R. Seemungal has received funding for attending internationals meetings at the ERS and ATS within the past 5 years from GSK and AstraZeneca. He has also received speaker fees at meetings organised by AstraZeneca, GSK and Boehringer Ingelheim. Speaker fees have always been less than US$5,000 per year. Writing and editorial assistance was funded by Novartis Pharma AG (Basel, Switzerland). M. Fedele (Novartis, East Hanover, NJ, USA) provided editorial and writing assistance. DOI: 10.1183/09031936.00048912
S. Sethi has received institutional research funding from Bayer and Sanofi Aventis, and has received honoraria for speaking and consulting from Bayer, GlaxoSmithKline, Novartis, Pfizer and Sanofi Aventis. DOI: 10.1183/09031936.00136412
D.L. Sherrill The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
D-J. Slebos was reimbursed for all trial related expenses for NCT01220908 and 01328899 by PneumRx Inc., USA. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
V. Siroux. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
P.J. Sterk has received a public-private grant by the Innovative Medicines Initiative (IMI). DOI: 10.1183/09031936.00192611
R. Stevenson The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
G.W. Sybrecht The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
T Back to top
N.H.T. ten Hacken. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
P. Tønnesen The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
A. Torres has received research grants from Pfizer and Covidien. He has participated in the advisory boards of Astellas and Sanofi-Aventis. DOI: 10.1183/09031936.00150211
V Back to top
R. Varraso. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
G. Viegi The ERS/ELF spriometry events (2004–2009) were supported by unrestricted financial funding from Boehringer Ingelheim GmbH and Pfizer. DOI 10.1183/09031936.00111910
W Back to top
J.A. Wedzicha has received honoraria for lectures or attending advisory boards from Novartis, GSK, Boehringer, Pfizer, AstraZeneca, Bayer, Nycomed Takeda, Almirall, Chiesi. J.A. Wedzicha’s institution has received research grant funding from GSK, Nycomed Takeda, Chiesi, Novartis and AstraZeneca. Writing and editorial assistance was funded by Novartis Pharma AG (Basel, Switzerland). M. Fedele (Novartis, East Hanover, NJ, USA) provided editorial and writing assistance. DOI: 10.1183/09031936.00048912
Z Back to top
J-P. Zock. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
Volume 41, issue 1, January 2013
B Back to top
J. Beauregard. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
E.H. Bel received in behalf of the department of Respiratory Medicine grants for research, money for consultancies, participation in advisory boards, and speaking at symposia from EU-IMI, GSK, Novartis, Actelion, PDL-Pharma, Merck, Shering Plough, Cambridge Antigen Technology, Aerocirne and Nycomed. DOI 10.1183/09031936.00195211
H.M. Boezen. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
T.D. Bradley. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
A.O. Bron is working in the Asthma Centre Davos as lung physician. The Dutch Asthma Centre Davos is financially supported by the patient association, Vereniging Nederland Davos. DOI 10.1183/09031936.00195211
D Back to top
M. Decramer has been part of advisory boards for Boehringer, Pfizer, GSK, Nycomed, Altana and Novartis. He has performed consulting work for Boehringer, Pfizer, GSK, AstraZeneca and Dompé. He also received lecture fees from these companies. All of the above amounted to less than €10,000 per annum. He received a research grant of €45,000 per year from AstraZeneca. Writing and editorial assistance was funded by Novartis Pharma AG (Basel, Switzerland). M. Fedele (Novartis, East Hanover, NJ, USA) provided editorial and writing assistance. DOI: 10.1183/09031936.00048912
M.H.G. de Greef. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
O. Dumas. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
E Back to top
S. Ewig has received fees for speaking and funds for research from Thermofisher. DOI: 10.1183/09031936.00150211
F Back to top
R. Farre. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
H Back to top
J.E. Hartman. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
S. Heintzbergen. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
P.S. Hiemstra and the Department of Pulmonology (LUMC) have received research grants from GlaxoSmithKline and Boehringer Ingelheim. DOI: 10.1183/09031936.00192611
A. Huerta has received a fee for speaking from Novartis Pharma. DOI: 10.1183/09031936.00150211
J Back to top
V. Jobin. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
K Back to top
F. Kauffmann. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
R.J. KIimoff has received lecture honoraria from OSR Medical Inc., VitalAire Inc. and GSK. He has received research funds from OSR Medical Inc. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
K. Klooster. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
G.H. Koppelman has received a fee for speaking from GSK (money to institution). DOI: 10.1183/09031936.00064312
L Back to top
C. Lange has participated in immunodiagnostic studies where test kits have been provided free of charge by the companies Cellestis and/or Oxford Immunotec. DOI: 10.1183/09031936.00214611
R. Leigh has received consulting and speakers’ fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis during the past 24 months. The University of Calgary has also received research funding from AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, MedImmune, Novartis and Pharmaxis to conduct industry-sponsored clinical studies during this time period. None of these studies relate in any way to the content of the current manuscript. DOI: 10.1183/09031936.00197211
N. Le Moual. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
M Back to top
J. Monserrat. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
N Back to top
R. Nadif. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
P Back to top
I. Pin. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
D.S. Postma received research funding from AstraZeneca, GSK and Chiesi. Travel to ERS or ATS has been partially funded by AstraZeneca, GSK, Chiesi and Nycomed. D.S. Postma has acted as a consultant to Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and TEVA. DOI: 10.1183/09031936.00064312
R Back to top
K.F. Rabe has been consulting, participated in advisory board meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceutical, Forest Labs, Pfizer, Novartis, Nycomed, MSD, and GSK. DOI: 10.1183/09031936.00192611
Prof. Rabe holds no stock or other equities in pharmaceutical companies
J. Rigau. This study was funded by l'Association Pulmonaire du Québec and by an operating grant from the Canadian Institutes of Health Research through its University Industry Program (UI-14909) in partnership with Respironics Inc., ResMed Inc., and Tyco Healthcare. DOI: 10.1183/09031936.00060311
L.H. Rijssenbeek-Nouwens is working in the Asthma Centre Davos as lung physician and is fellow at the Academic Medical Centre, University of Amsterdam. The Dutch Asthma Centre Davos is financially supported by the patient association, Vereniging Nederland Davos. LR has received travel funding to the ERS and ATS from Novartis and Nycomed. DOI 10.1183/09031936.00195211
S Back to top
T.A.R. Seemungal has received funding for attending internationals meetings at the ERS and ATS within the past 5 years from GSK and AstraZeneca. He has also received speaker fees at meetings organised by AstraZeneca, GSK and Boehringer Ingelheim. Speaker fees have always been less than US$5,000 per year. Writing and editorial assistance was funded by Novartis Pharma AG (Basel, Switzerland). M. Fedele (Novartis, East Hanover, NJ, USA) provided editorial and writing assistance. DOI: 10.1183/09031936.00048912
D-J. Slebos was reimbursed for all trial related expenses for NCT01220908 and 01328899 by PneumRx Inc., USA. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
S. Sethi has received institutional research funding from Bayer and Sanofi Aventis, and has received honoraria for speaking and consulting from Bayer, GlaxoSmithKline, Novartis, Pfizer and Sanofi Aventis. DOI: 10.1183/09031936.00136412
V. Siroux. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
P.J. Sterk has received a public-private grant by the Innovative Medicines Initiative (IMI). DOI: 10.1183/09031936.00192611
T Back to top
N.H.T. ten Hacken. Measurements were supported by an unrestricted loan of the accelerometers by McRoberts BV, The Netherlands. DOI: 10.1183/09031936.00072112
A. Torres has received research grants from Pfizer and Covidien. He has participated in the advisory boards of Astellas and Sanofi-Aventis. DOI: 10.1183/09031936.00150211
V Back to top
R. Varraso. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
W Back to top
J.A. Wedzicha has received honoraria for lectures or attending advisory boards from Novartis, GSK, Boehringer, Pfizer, AstraZeneca, Bayer, Nycomed Takeda, Almirall, Chiesi. J.A. Wedzicha’s institution has received research grant funding from GSK, Nycomed Takeda, Chiesi, Novartis and AstraZeneca. Writing and editorial assistance was funded by Novartis Pharma AG (Basel, Switzerland). M. Fedele (Novartis, East Hanover, NJ, USA) provided editorial and writing assistance. DOI: 10.1183/09031936.00048912
Z Back to top
J-P. Zock. The present study was sponsored by Merck Sharp & Dohme. DOI: 10.1183/09031936.00197611
Volume 41, issue 2, February 2013
B Back to top
P. Bilan. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
A. Bilstein is an employee of bitop AG, Witten, who is produced and distributed the ectoine. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
C. Brightling has received research funding from MedImmune, AstraZeneca, GlaxoSmithKline, Novartis, Roche and Chiesi; has consulted for MedImmune, AstraZeneca, GlaxoSmithKline, Novartis, Roche and Chiesi and has received travel funding to attend international meetings from Boehringer-Ingelheim. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
M. Busk has received reimbursement for attending a symposium and a fee for speaking from GlaxoSmithKline. DOI: 10.1183/09031936.00059712
C Back to top
J.P. Capone. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
J. Corren has acted as a principal investigator for Medimmune and AstraZeneca. The author acted as a speaker, consultant and principal investigator for Genentech, who is developing another anti-IL-13 antibody, lebrikizumab, for the treatment of asthma. DOI: 10.1183/09031936.00124212
P.G. Cox. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
D Back to top
C. Delvecchio. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
R.M. du Bois has, in the last five years, served as a paid consultant, study steering committee member, or chairman of a steering committee for Actelion, Bayer, Boehringer Ingelheim, Genzyme, InterMune and Novartis, and has received fees for lecturing from Actelion, Boehringer Ingelheim, GlaxoSmithKline and InterMune. DOI: 10.1183/09031936.00115112
M. Dury. The author’s study was supported by ImThera Medical, Inc., San Diego, CA, USA. DOI 10.1183/09031936.00042412
E Back to top
R. Eberhardt This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
L. Ek This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
F Back to top
R. Faggioni is a full-time employee of MedImmune. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
J.H. Ficker has received educational grants from Emphasys, Uptake Medical and Pulmonx for his institution; he has received fees for consulting from Uptake Medica. This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
G Back to top
G. Geba is a former employee of MedImmune LLC. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
A. Giesler . The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
J. Grigg is a member of a Novartis advisory board (2011 to date). DOI: 10.1183/09031936.00160412
D. Gompelmann has received reimbursement for travelling costs for scientific congress. This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
H Back to top
F.J.F. Herth This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
C. Heiss. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
S. Hartl has received research grants exceeding €100,000 from Böhringer, GSK, Torrex Chiesi and Nycomed as part of the Ludwig Botzmann Institute of COPD and respiratory epidemiology, and has received speakers fees from Böhringer and Nycomed, less than €5,000. DOI 10.1183/09031936.00021812
I Back to top
C.G. Irvin receives speaker fees from Merck for approved educational programmes only, has grants from the American Lung Association and National Institutes of Health, and receives book royalties from Up-to-Date. DOI: 10.1183/09031936.00115212
J Back to top
Y.M.W. Janssen-Heininger has received funding for my research from the National Institutes of Health, grants R01 HL060014, R01 HL 079331, and R01 HL 085464. DOI: 10.1183/09031936.00115212
K Back to top
C. Kell is a full-time employee of MedImmune. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
A. Kelsall. The authors study was sponsored by GSK. DOI: 10.1183/09031936.00190111
S. Keymel. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
M. Kelm. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
U. Krämer has received a research grant from bitop AG, Witten, who produced and distributed the ectoine. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
M. Kroker. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
J. Krutmann acts as a consultant for bitop AG. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
L Back to top
I.M. Lang has received speaker’s fees and/or educational grants from Actelion, GSK, United Therapeutics, Bayer and AOPOrphan Pharma, has acted in advisory boards for Actelion, GSK, Pfizer, Lilly, Servier and Astra Zeneca, and has received a fellowship grant from the US Tobacco Research fund in 1991. DOI: 10.1183/09031936.00049312
B. Lengelé. The author’s study was supported by ImThera Medical Inc., San Diego, CA, USA. DOI 10.1183/09031936.00042412
M Back to top
R.D. May is a full-time employee of MedImmune and holds shares and share options in AstraZeneca. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
N.A. Molfino is a full-time employee of MedImmune and owns stocks from Astra Zeneca. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
R.D. Murdoch is an employee of, and holds stock in, GSK who provided financial support for the conduct of the study in the form of an unrestricted grant. The authors study was sponsored by GSK. DOI: 10.1183/09031936.00190111
G.B. Mwenge. The author’s study was supported by ImThera Medical Inc., San Diego, CA, USA. DOI 10.1183/09031936.00042412
N Back to top
P. Nair. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
R. Niven has, in the last 5 years, received financial support to attend international conferences from GSK, Novartis and Boehringer Ingelheim. He has received fees for attending advisory boards or speaking at meetings for the following: GSK, Astra Zeneca, Novartis, Chiesi and Vectura Ltd. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
O Back to top
C. Oh is a full-time employee of MedImmune. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
P Back to top
H. Peuschel. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
A. Paunel-Görgülü. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
E. Piper is a full-time employee of MedImmune. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
K. Poon is a full-time employee of MedImmune. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
W.M. Powley is an employee of, and holds stock in, GSK who provided financial support for the conduct of the study in the form of an unrestricted grant. The authors study was sponsored by GSK. DOI: 10.1183/09031936.00190111
R Back to top
K. Radford. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
D. Rodenstein. The author’s study was supported by ImThera Medical Inc., San Diego, CA, USA. DOI 10.1183/09031936.00042412
P. Rombaux. The author’s study was supported by ImThera Medical Inc., San Diego, CA, USA. DOI 10.1183/09031936.00042412
S Back to top
B. Schmidt has received speakers’ fees and support from the following companies: Uptake Medical USA and PulmonX USA. This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
S. Seghrouchni. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
D. She is a full-time employee of MedImmune and has AstraZeneca stocks. The author’s study was funded by MedImmune. DOI: 10.1883/09031936.00223411
D-J. Slebos received speakers’ fees from Broncus Technologies USA, PneumRx Inc. USA and Pulmonx USA and was reimbursed for all trial related expenses for NCT00391612 by Broncus Technologies USA, for NCT01220908 by PneumRx Inc. USA, and for NCT01101958 by Pulmonx USA. This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
J.A. Smith is an inventor on a patent describing a novel method for the automated detection of cough, owned by the University Hospital of South Manchester and licensed to Vitalograph Ltd. The authors study was sponsored by GSK. DOI: 10.1183/09031936.00190111
N. Spitale. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
J. Steven. The present study was funded, in part, by a Firestone Institute–GlaxoSmithKline Research Award. Full 2 was obtained from J. Berger (Merck Frosst, Montreal, QC, Canada). DOI: 10.1183/09031936.00145009
H. Summer. The authors study was sponsored by GSK. DOI: 10.1183/09031936.00190111
K. Sunger. The authors study was sponsored by GSK. DOI: 10.1183/09031936.00190111
U. Sydlik. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
U Back to top
K. Unfreid received a research grant from bitop AG. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
V Back to top
C. Vancheri has, in the last five years, served as a paid consultant or advisory board member for Boehringer Ingelheim and Intermune, and has received fees for lecturing from Novartis, Boehringer Ingelheim, Intermune, Chiesi and Menarini. DOI: 10.1183/09031936.00115112
W Back to top
M. Wagner has received an educational grant and clinical research grant from Pulmonx International and speaker fees from Pulmonx International. This study was sponsored by Pulmonx. Writing assistance was provided by Archimed Medical Communication AG, Zofingen, Switzerland. DOI 10.1183/09031936.00015312
M. Weissenberg. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
J. Windolf. The authors study was supported by bitop AG (Witten, Germany). DOI: 10.1183/09031936.00132211
Y Back to top
R. Yusen has served as an expert witness in legal cases, performed funded research and performed consulting that involve venous thromboembolism. However, these have not specifically addressed the main topic of the author’s paper (sPESI), and the author therefore does not view this as a conflict of interest. DOI: 10.1183/09031936.00225011
Volume 41, issue 3, March 2013
A Back to top
J.K. Airaksinen This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
M.J. Al. The Erasmus University, Institute for Medical Technology Assessment, where the author is employed, has received funding for designing and conducting cost-effectiveness studies of COPD drugs from multiple pharmaceutical companies (Boehringer Ingelheim, Nycomed, Pfizer). M.J. Al does not own stock of any pharmaceutical company. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
B Back to top
M-M. Balp is employed by Novartis Pharma AG. The study was sponsored by Novartis. DOI: 10.1183/09031936.00224911
E.D. Bateman. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
K-M. Beeh has received compensation for serving on advisory boards for AstraZeneca, Boehringer Ingelheim, Cytos, Pfizer, Revotar, Novartis and other pharmaceutical companies. He has participated as speaker in scientific meetings or courses organised and financed by pharmaceutical companies (AstraZeneca, Boehringer, Novartis, Pfizer, Takeda) in 2006–2011. The institution where K-M. Beeh is currently employed has received compensation for design and performance or participation in single- or multi-centre clinical trials in 2006–2011 from multiple companies (Almirall, Altana, AstraZeneca, Boehringer Ingelheim, Cytos, Fujisawa, GSK, Medapharma, Merck Sharp & Dohme, Novartis, Pfizer, Revotar Biopharmaceuticals). The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI: 10.1183/09031936.00027212
S.W. Blume is an employee of United BioSource Corporation, which consults Novartis Pharma AG, and a range of other pharmaceutical manufacturers, some of which have products for cystic fibrosis. The study was sponsored by Novartis. DOI: 10.1183/09031936.00224911
D. Bowles. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI: 10.1183/09031936.00027212
J.M. Bradley received some reimbursement for attending and presenting this data at the European Respiratory Society 2010 Congress and also consultancy fees of £1000 from Novartis Pharma AG. The study was sponsored by Novartis. DOI: 10.1183/09031936.00224911
A.S. Buist has been a member of advisory boards for Merck, GSK, Schering Plough, Novartis, Sepracor and Forrest. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
P. Burney has received speaker’s fees from Pfizer & Boehringer Ingleheim. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
C Back to top
D.C. Cole is a tenured professor, with consultancies on environmental health to public health units but none on respiratory or fungal disorders or their treatment. DOI 10.1183/09031936.00226911
M.J.T. Crobach. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
D Back to top
M. Decramer has been part of Advisory Board for Boehringer-Pfizer, GSK, Nycomed, Altana. He has performed consulting work for Boehringer-Pfizer and GSK. He also received lecture fees from these companies. All of the above amounted to less than 10,000 euro per annum. He received a research grant of 45,000 euro/year from AstraZeneca. DOI: 10.1183/09031936.00135412
D.W Denning holds founder shares in F2G Ltd, a University of Manchester spin-out company and has received grant support from F2G as well as the Fungal Research Trust, the Wellcome Trust, the Moulton Trust, The Medical Research Council, The Chronic Granulomatous Disease Research Trust, the National Institute of Allergy and Infectious Diseases, National Institute of Health Research and the European Union, AstraZeneca and Basilea. He currently or previously acted as an advisor/consultant to F2G, Basilea, Vicuron (now Pfizer), Pfizer, Schering Plough (now Merck), Nektar, Daiichi, Astellas, Gilead, York Pharma and Lab21. He has been paid for talks on behalf of Merck, Astellas, Novartis, Merck, Dainippon and Pfizer. DOI 10.1183/09031936.00226911
A. Dolsma. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
M. Durian. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
E Back to top
O. Eickelberg received lecture fees and consulting honoraria from InterMune, Roche, and Bayer. He has also received research grant support from Roche and Bayer. DOI: 10.1183/09031936.00173012
J.S. Elborn is a member of advisory boards for Novartis, Bayer, Vertex and Aptalis. He has received travel grants for himself or CF team members from Novartis, Gilead, Forest, Solvay and Astra-Zeneca. He is a speaker for Novartis, Vertex and Bayer. The study was sponsored by Novartis. DOI: 10.1183/09031936.00224911
P.L. Enright. About 4–6 years ago, the author was paid by Pfizer a total of about $30,000 to review the quality of spirometry tests done for a study of varenicline to prompt smoking cessation in patients with COPD. Pfizer sells varenicline for smoking cessation, which may be prompted by spirometry tests done to detect COPD. Pfizer and BIPI also sell anticholinergic inhalers which are commonly prescribed for patients with COPD. Screening for mild COPD is likely to increase the number of adults who are prescribed an inhaler, while using peak flow to exclude clinically significant COPD (in place of relying exclusively on respiratory symptoms to make the diagnosis) may reduce the number. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
F Back to top
L.M. Faber. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
P.A. Frith has received over the past 5 years educational grants and consultancy honoraria from Boehringer Ingelheim, Nycomed, Novartis and GlaxoSmithKline, as well as travel support to attend TSANZ from GSK, Novartis, Nycomed and to attend the ERS congress from Novartis, Nycomed and Boehringer Ingelheim, none of whom stands to gain financially from this publication. He is an unpaid council member and Chair of the COPD Committee for the Australian Lung Foundation, which formulates educational support and guideline papers relating to COPD diagnosis and management, pulmonary rehabilitation and training for a wide range of health professional groups. DOI 10.1183/09031936.00021412
G Back to top
M. Gappa declares that her institution has received an unrestricted grant (€18.000) to support ongoing research projects and technical support from ndd Medical technologies. DOI: 10.1183/09031936.00069712.
J.M. Graf von der Schulenburg has received an unrestricted grant from Boehringer-Ingelheim to estimate the cost of COPD in Germany. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI: 10.1183/09031936.00027212
S. Gillespie. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
K.M. Godfrey has acted as a consultant to Abbott Nutrition and Nestle Nutrition, and has received reimbursement for speaking at an Abbott Nutrition Conference on Pregnancy Nutrition and Later Health Outcomes and at a Nestle Nutrition Institute Workshop. The author is part of an academic consortium that has received research funding from Abbott Nutrition, Nestec and Danone. DOI: 10.1183/09031936.00171712
L. Gote has received honorary for lectures from Resmed, Respironics, Weinmann and Breas. He has received reimbursement for attending a symposium from Weinmann and Respironics and is member of the advisory board from Weinmann. He is a steering group member of the European Sleep Apnea Database (ESADA), which has received founding from Resmed and Respironics. He is a principal investigator in studies sponsored by Respironics and Apnex. DOI: 10.1183/09031936.00226711
H Back to top
H. Hakovirta This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
J. Hedner received fees for speaking from GmbH, Respironics and Resmed. DOI: 10.1183/09031936.00226711
H.Y. Helenius This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
B.I. Hiddinga. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
H.M.A. Hofstee. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
D. Honeybourne is a member of advisory boards for Novartis, Bayer and Vertex. He has received travel grants for himself or CF team members from Chiesi, Novartis, Gilead, Bayer, Forest and Solvay. The study was sponsored by Novartis. DOI: 10.1183/09031936.00224911
M. Hoogendoorn. The Erasmus University, Institute for Medical Technology Assessment where the author is employed, has received funding for designing and conducting cost-effectiveness studies of COPD drugs from multiple pharmaceutical companies (Boehringer Ingelheim, Nycomed, Pfizer). M. Hoogendoorn does not own stock of any pharmaceutical company. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
M. Humbert has served on speaker's bureaus and consultation panels for Actelion, Bayer Schering, GlaxoSmithKline, Novartis, Pfizer and United Therapeutics. DOI 10.1183/09031936.00223611
M.V. Huisman reports having received research grants from GSK and Actelion; and has given presentations and has been consulting for Bayer, Boehringer Ingelheim and Pfizer. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
JBack to top
J.R. Jalonen This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
D.P. Jenkins has received fees for lectures and honoraria for educational events from Bayer, GSK and Actelion. DOI: 10.1183/09031936.00058112
A. Jithoo was awarded the South African Thoracic Society GlaxoSmithKline Pulmonology Research Fellowship in 2004. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
KBack to top
M. Kajossari. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
E.S. Kentala This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
G.G. King has received various travel sponsorships from Boehringer Ingelheim, Pfizer, AstraZeneca and GlaxoSmithKline for travel and accommodation to attend international, local and interstate meetings that include Pharmaceutical Industry sponsored meetings and independent Society Scientific meetings. A proportion of G.G. King’s research work is conducted at the Woolcock Institute of Medical Research, which receives unrestricted grants from Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline, Pharmaxis and which also has current and past consultancy agreements with Pfizer, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline. G.G. King provides consultancy services related to asthma and COPD, which include sitting on advisory boards and providing talks at local and national meetings. His research group receives a proportion of the grants and monies that arise from those companies, as part of a general allocation of those funds for research purposes across all research groups of the Woolcock Institute of Medical Research. His research group is supported from competitive grants arising from local research foundations, the National Health & Medical Research Council of Australia, Cooperative Research Centre for Asthma and Airways and The Australian Lung Foundation. DOI: 10.1183/09031936.00069712.
T. Klemola. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
M. Königshoff has received travel reimbursement for activities at ERS conferences and has received lecture fees from Intermune. DOI: 10.1183/09031936.00173012
L Back to top
T.T. Laitio This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
G. Labots. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
P. Laveneziana has received a Marie Curie International Re-integration Grant (IRG), FP7-PEOPLE-2010-RG and a PFIZER Investigator-Initiated Research (IIR) Grant. DOI 10.1183/09031936.00223611
K.A. Leino This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
P. Lange received during the last five years pharmaceutical company grants from GSK in 2010 and 2011, Boehringer-Ingelheim and Almirall in 2012 via his home institution, and also participated in speaking activities, industry advisory committee, or other related activities sponsored by Almirall, Boehringer-Ingelheim, Novartis, GSK, AstraZeneca, Pfizer, Mundipharma, UCB during the period 2008-2012. However, I declare not to have conflicts of interest to disclose regarding the contents of this editorial. DOI: 10.1183/09031936.00153512
J. Lungershausen is an employee of Boehringer Ingelheim, the manufacturer of tiotropium. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
MBack to top
K. Malmström. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
L.P. Malmberg has received fees for speaking from AstraZeneca, GlaxoSmithKline and Orion Pharma; has received funds for research from Orion Pharma; and travel to the ERS Congress was funded by GlaxoSmithKline and Orion Pharma. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
M.J. Mäkelä has received fees for lectures from Orion Pharma, GlaxoSmithKline, MSD and AstraZeneca. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
B.J. Marsland has received travel reimbursement for activities at ERS conferences and an ERS Marie Curie Fellowship supported a post-doctoral fellow in his laboratory. DOI: 10.1183/09031936.00173012
E. Mayer has received speaking and consulting fees from Actelion and Bayer Pharma. DOI: 10.1183/09031936.00058112
F. Mejza. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
C.F. Melissant. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
B.U. Monz is an employee of Boehringer Ingelheim, the manufacturer of tiotropium. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
NBack to top
S. Nava has received travel grants, speaking fees and consulting honorarium from the following companies: ResMed travel grants and honorarium for a scientific board, Respironics Philips speaking fees, Fisher and Paykel travel grants, Weiman travel grants. DOI: 10.1183/09031936.00173212
PBack to top
A. Pelkonen has received fees for lectures from Orion Pharma, GlaxoSmithKline, MSD and AstraZeneca. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
M.J. Pietilä This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
J.J. Pillow research has benefited from extended equipment loans from Care Fusion. DOI: 10.1183/09031936.00069712.
A. Pleuvry is a Director and shareholder in Oncalex, an independent consultancy, with no specific financial interest in respiratory or fungal disorders. DOI 10.1183/09031936.00226911
O. Polo This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
R. Polosa has received payment for developing educational presentations (including service on speakers’ bureaus) from Pfizer. DOI: 10.1183/09031936.00073312
D.S. Postma The University of Groningen has received money for D.S. Postma in the form of an unrestricted educational grant for research from AstraZeneca, Chiesi and GSK. Travel to ERS and/or ATS conferences has been partially funded by AstraZeneca, Chiesi, GSK and Nycomed. Fees for consultancies were given to the University of Groningen by AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and TEVA. DOI: 10.1183/09031936.00170912.
D. Price has consultant arrangements with Almirral, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Meda, Novartis, Napp, Nycomed, Pfizer, Sandoz and Teva. He or his research team have received grants and support for research in respiratory disease from the following organisations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, and Teva. He has spoken for: Almirral, AstraZeneca, Activaero, Boehringer. He is affiliated with Optimum Patient Care Ltd and Research in Real Life Ltd, Cambridge, UK. DOI: 10.1183/09031936.00153512
R Back to top
O.T. Raitakari This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
F. Ratjen has acted as consultant to Inspire Inc, Vertex , Novartis, Bayer, Talecris, CSL Behring, Roche and Gilead; all for cystic fibrosis related activities. He is principle investigatorI for a grant from Novartis, a principle investigator on a study sponsored by Inspire, and has been involved in the development of a Speaker’s bureau for Genenetech Inc., as well as given talks within Genentech program. F. Ratjen has also given a talk sponsored by Pari. DOI: 10.1183/09031936.00069712.
P. Robinson has provided ongoing advice to Ecomedics regarding the development of a new Nitrogen based inert gas washout device, but does not have any commercial interests in the device. As part of this advice he has received reimbursement for travel to attend a seminar in Bern, Switzerland. DOI: 10.1183/09031936.00069712.
M.P.M.H. Rutten-van Mölken. The Erasmus University, Institute for Medical Technology Assessment, where the author is employed, has received funding for designing and conducting cost-effectiveness studies of COPD drugs from multiple pharmaceutical companies (Boehringer Ingelheim, Nycomed, Pfizer). M.P.M.H. Rutten-van Mölken has received speaker fees and compensation for serving on advisory boards for GSK, Boehringer Ingelheim, Pfizer, Nycomed and Novartis. The author does not own stock of any pharmaceutical company. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
S Back to top
T.M. Salo was reimbursed for travel to the EHRA Europace from Biotronic. This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
S. Sarna. Funding for the study was provided by Merck Research Laboratories (IISP ID number 33902). DOI: 10.1183/09031936.00173411
H. Scheinin This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
H. Schmidt is an employee of Boehringer Ingelheim, the manufacturer of tiotropium. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
T. Similowski has received research funding from Novartis France, Maquet France, and Pierre Fabre; and has served on advisory boards for AstraZeneca corporate, Boehringer Ingelheim France, Nycomed France, Nycomed corporate, Novartis France and Pierre Fabre; and has served on consultation panels for Pierre Fabre and Rox biomedical; and has served on speaker's bureaus for MSD France, Medapharma, Hamilton, Pfizer France and AstraZeneca France; and has received honoraria for manuscript preparation for Boehringer Ingelheim France and for translating documents for Synapse biomedical Atrostim. DOI 10.1183/09031936.00223611
G. Simonneau has served on speaker's bureaus and consultation panels for Actelion, Bayer Schering, GlaxoSmithKline, Novartis, Pfizer and United Therapeutics. DOI 10.1183/09031936.00223611
O. Sitbon has received research funding from Actelion, GlaxoSmithKline, Bayer HealthCare, Pfizer and Lilly; and has served on advisory boards for Actelion, Lilly and Pfizer; and has served on consultation panels for Actelion, GlaxoSmithKline, Pfizer, Lilly and United Therapeutics; and has served on speaker's bureaus for Actelion, GlaxoSmithKline, Bayer HealthCare, Pfizer, Lilly and United Therapeutics. DOI 10.1183/09031936.00223611
J.B. Soriano received during the last five years pharmaceutical company grants from GSK in 2011 and Chiesi in 2012 via his home institution, and also participated in speaking activities, industry advisory committee, or other related activities sponsored by Almirall, Boehringer-Ingelheim, Pfizer, Chiesi, GSK, and Novartis during the period 2008-2012. However, I DECLARE NOT TO HAVE CONFLICTS OF INTEREST TO DISCLOSE REGARDING THE CONTENTS OF THIS EDITORIAL. DOI: 10.1183/09031936.00153512
M. Studnicka has received funds for research in the past 5 years: Astra-Zeneca € 19.000, Boehringer-Ingelheim € 60.000,GSK € 13.000, MSD € 5000, Novartis € 3500. Fees for speaking or reimbursement for attending a symposium in the past 5 years: Astra-Zeneca € 2.500, Boehringer-Ingelheim € 5.000, GSK € 1.500, Novartis € 2.500, Nycomed € 5.000. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
TBack to top
W.C Tan has received unrestricted educational grants for the Canadian Obstructive Lung Disease (COLD) study operations from Astrazeneca, GlaxoSmithKline, Boehringer Ingelheim and Pfizer; and participated in speaking activities in workshops funded by Boehringer-Ingelheim , GSK and Telacris. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
N.C. Thomson has participated in advisory boards and/or received consultancy fees from Asmacure, Boston Scientific, Chiesi and Respivert. He has received lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline and Novartis; industry-sponsored grant funding from Aerovance, Asthmatx, AstraZeneca, Centocor, GlaxoSmithKline, MedImmune, Novartis, and Synairgen for participating in clinical trials; and travel to the ERS congress was funded by Novartis and Nycomed. DOI: 10.1183/09031936.00073312
UBack to top
E.F. Ullmann. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
K.T. Utriainen This study has been funded by GE Healthcare Finland. DOI 10.1183/09031936.00227611
VBack to top
M van den Berge has received research grants from GlaxoSmithKline and AstraZeneca, and a fee for speaking from Takeda. DOI 10.1183/09031936.00170912
L.M.A. Vingerhoets. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
M.J.M. de Vreede. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
C. Vogelmeier gave presentations at symposia sponsored by: AstraZeneca, Boehringer, Chiesi, GlaxoSmithKline, Janssen-Cilag, Novartis, Nycomed, Pfizer and Talecris. The author received fees for consulting from: AstraZeneca, Boehringer, GlaxoSmithKline, Janssen-Cilag, Mundipharma, Novartis, Nycomed, Talecris. The author’s study was financially supported by Boehringer Ingelheim International GmbH. DOI 10.1183/09031936.00027212
W.M. Vollmer was Director of the Burden of Obstructive Lung Disease (BOLD) Operations Center, funding for which included unrestricted educational grants to the Kaiser Permanente Center for Health Research from Boehringer Ingelheim, Pfizer, ALTANA, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi, and Merck. Dr. Vollmer also receives some research support from Novartis for his work on a study of medication adherence in COPD. In addition, the author works for a large managed care organization whose operations may eventually be affected by the results of this study. The author’s study was funded by ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, GlaxoSmithKline Pulmonary Research Fellowship, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Schering-Plough, Sepracor, Polpharma, Ivax Pharma Poland, Pliva Kraków, Adamed, Linde Gaz Polska, Lek Polska, Tarchomińskie Zakłady Farmaceutyczne Polfa, Starostwo Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie, Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin, Agroplon, United Laboratories and Air Liquide Healthcare. DOI: 10.1183/09031936.00132011
Z
W. Zondag. This study was partially supported by an unrestricted research grant from GSK, the Netherlands. GSK had no influence in designing and writing the protocol, collection of data, performing the analysis of the study results and writing of the manuscript. DOI 10.1183/09031936.00030412
This page was updated on 15 March 2024